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Abstract 
The development of new chemical reactions is equally as important as the applications of the 
resulting products, which is often the development of medicinal agents. The two parts of the work 
disclosed herein explore synthetic chemistry from each of these angles. Part I of this work has 
involved the design and synthesis of novel drug compounds for African sleeping sickness, Chagas 
disease and leishmaniasis, which are neglected tropical diseases caused by the respective 
trypanosomal parasites T. brucei, T. cruzi and Leishmania. These diseases call for rapid methods 
of drug discovery such as drug repurposing and high-throughput screening, and the latter strategy 
has previously identified WEHI-0086109 (14a) as an anti-T. brucei agent (IC50/SI = 2.50 μM/48). 
In this work, structure-activity relationships of 14a were established, with an attention to 
physiochemical properties (MW, ClogP, H-bonding). Many of the resulting novel benzothiazolyl-
thiophenamides exhibited antitrypanosomal activity (up to IC50 = 0.32 μM) and selectivity (up to 
SI > 130) against the surrogate species, T. b. brucei. The derivative 32b was found to surpass 14a 
when subjected to the human infective species, T. b. rhodesiense (IC50/SI = 5.04 μM/13, 32b vs. 
8.96 μM/3, 14a) and deemed suitable for further development, informed by the newly-established 
structure-activity information. In regard to Chagas disease and leishmaniasis, the existing 
antiparasitic drug nitazoxanide was identified as a suitable candidate for repurposing, given its 
known activity against T. cruzi and leishmania. A series of ferrocenyl and cymantrenyl 
derivatives of nitazoxanide were designed, considering the well-established power of 
organometallic moieties to exert antiparasitic action via production of reactive oxygen species. 
Two ferrocenyl derivatives, 56a and 65a, were the first of a novel class of organometallic drug 
compounds to be synthesised. Though these were found to be inactive against both species of 
trypanosome, it was proposed that the cymantrenyl derivatives are worth pursuing as 
antileishmanial agents in the future due to their comparative electron-withdrawing character.  
Part II of this work is derived from the knowledge that potent, selective drug compounds and 
other chemical agents require new synthetic routes to complex, sp3-rich and stereodefined 
molecular scaffolds. This work began with efforts to harness synthetically powerful aziridine and 
allene building blocks en route to such scaffolds, and ultimately led to the discovery of the 
divergent, palladium-catalysed reactivity of an enantioenriched allenyloxazolidinone system 
previously developed within our group. This allenyl building block was found to undergo Pd(0)-
catalysed cross-coupling with boronic acids to form chiral 1,3-dienes bearing a pendant nitrogen 
atom, or enantioenriched 5-vinyloxazolidinones,  where this divergency could be tightly 
controlled by a single switch in additive (K2CO3 to AcOH). The reactions proceeded in good to 
excellent yields (up to 99%) with high stereoselectivity for the E isomer (up to > 99:1) and were 
shown to proceed with complete enantioretention of the amino acid-derived chiral substituent. 
The scope of these processes were shown to accommodate aryl-, heteroaryl-, vinyl- and – in the 
case of the 1,3-dienes – alkylboronic acids, as well as a range of chiral alkyl substituents on the 
allenyloxazolidinone. The 5-vinyloxazolidinones are the most complex of this class reported to 
date and it was reasoned that these may serve as enantioenriched analogues of the structurally 
similar oxazolidinone class of antibiotics (eg. linezolid). The chiral 1,3-dienes presented a unique 
opportunity to utilise the highly valuable intramolecular Diels–Alder reaction, which is limited 
by a lack of synthetic routes to complex and stereodefined 1,3-diene substrates such as those 
developed herein. The 1,3-dienes were found to undergo a one-pot N-alkylation and 
intramolecular Diels–Alder reaction with a dienophile under relatively mild conditions to give 
densely functionalised, stereodefined isoindoline scaffolds in fair yield and diastereoselectivity 
(55%, 10:3:1 dr, 64b). The absolute stereochemistry of the system 64b was determined via a 
combination of 1D NOE techniques and computational methods, and rationalised by an exo 
transition state. Furthermore, these isoindoline systems are structurally and stereochemically 
similar to the bioactive cytochalasin group of natural products, leaving the allenyloxazolidinone 
system a highly versatile building block for the pursuit of complex and medicinally-relevant 
molecular architectures.  
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1.1 Introduction 
 
1.1.1 Neglecting Diseases in Medicinal Chemistry 
 
The field of synthetic chemistry harvests many fruits, including materials, chemical agents and 
new drug compounds for battling disease. The allocation of funds for particular diseases is 
governed by the interests of the providing body, and often reflects the needs of the general 
population of a certain region. As a result, ‘lifestyle diseases’ (obesity, type II diabetes, heart 
disease and diseases linked to alcohol and smoking) often dominate lists of categorical spending 
in Australia1 and the US,2 as do prominent diseases such as cancer. In a global sense, it is 
inevitable that certain diseases affecting developing countries and populations, become neglected. 
This has been the case for neglected tropical diseases (NTDs), which affect tropical and 
subtropical regions across 149 countries spanning mainly Asia, South America and sub-Saharan 
Africa.3 The finances required for research and development into these diseases is derived 
primarily from public funding, followed by philanthropic funding (notably the Bill & Melinda 
Gates Foundation (BMGF)) and private companies.4  Fortunately, research funding for neglected 
diseases has increased in recent years and hit record heights in 2017,4,5 with speculation that 
successful research efforts in regard to the Ebola crisis between 2014 and 2016 served as positive 
reinforcement for investors.5  
 
As of 2019, twenty NTDs are officially recognised by the World Health Organisation (WHO) 
(Figure 1.1),3 caused by viruses, bacteria or parasites (protozoa, helminths (worms) and 
ectoparasites such as lice and fleas). The first line of defence is often preventative measures, such 
as improving hygiene, sanitation and water quality, controlling populations of vector species that 
transmit the diseases, production of vaccines or antivenoms where possible, and donating drug 
treatments to developing countries. From a synthetic chemistry perspective, defence against 
NTDs involves the design and synthesis of novel drug compounds with high potency and low 
toxicity. There is often a focus on one class of causative agent (eg. protozoa), as the higher 
incidence of genetic crossover can lead to broad-spectrum drug compounds. For example, a 
proteasome inhibitor has been developed by Novartis as a novel treatment for African sleeping 
sickness, Chagas disease and leishmaniasis, with nanomolar in vitro efficacy against all three 
causative parasites.6 Furthermore, this is a welcomed example of a private company investing in 
NTD research and contributing to the steadily growing artillery of funding for combatting 
neglected diseases. Our group is similarly interested in these three trypanosomal diseases, with a 
particular focus on African sleeping sickness and medicinal organometallic chemistry.  
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Figure 1.1. List of NTDs officially recognised by the WHO3 with an illustration of their global distribution. 
The areas most affected by three trypanosomal diseases have been shown. aFigure appropriated from 
Uniting to Combat Neglected Tropical Diseases. https://unitingtocombatntds.org (accessed October 1, 
2019). bData obtained from WHO. https://www.who.int/gho/map_gallery/en/ (accessed October 1, 2019). 
 
 
1.1.2 African sleeping sickness, Chagas disease and Leishmaniasis 
 
African sleeping sickness (human African trypanosomiasis),7 Chagas disease (American 
trypanosomiasis)8 and leishmaniasis9 comprise an unholy trinity of trypanosomal infections. 
Trypanosomes (Fig. 1.2) are protozoan (single-celled, eukaryotic) parasites of the class 
Kinetoplastea. Their distinctive, tail-like flagellum propels them through solution in a corkscrew-
like motion, giving rise to the Greek-derived name (trypano (borer), soma (body)). Two of the 
causative trypanosomes are of the genus Trypanosoma. T. brucei is transmitted via the tsetse fly 
to cause sleeping sickness, and T. cruzi is transmitted via the triatomine, or ‘kissing’ bug, to cause 
Chagas disease (as discovered by Dr Carlos Chagas in 1909)10 (Fig. 1.2). Leishmaniasis occurs 
upon infection of one of the twenty (at least) human infective trypanosomes of the genus 
Leishmania, transmitted via female phlebotamine sandflies (Fig. 1.2). 
 
Reported Cases of African 
Sleeping Sickness in 2018b 
 
            > 500 (T. b. gambiense) 
 
            > 10 (T. b. rhodesiense) 
Endemic NTDs/Countrya 
 
 
 
    1     2      3     4     5      6    7+ 
      
 
Reported Cases of 
Leishmaniasis in 2016b 
 
            > 5 000 (cutaneous) 
 
            > 1 000 (visceral) 
Estimated Cases of Chagas  
Disease, 2006 - 2009b 
 
                   > 1 000 000  
 
 
African sleeping sickness × Buruli ulcer × Chagas disease × cysticercosis × Dengue and Chikungunya × echinococcosis × fascioliasis 
×  Guinea-worm disease × leishmaniasis × leprosy × lymphatic filariasis × mycetoma and deep mycoses × onchocerciasis × rabies × 
scabies and other ectoparasites × schistosomiasis × snakebite envenoming × soil-transmitted helminthiasis × trachoma × yaws 
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Figure 1.2. A. Tsetse fly taking a blood meal. Credit: Martin Dohrn/Science Photo Library. B. SEM of T. 
brucei. Credit: Michael Smith, LSHTM. C. Triatomine bug taking a blood meal. Credit: Glenn Seplak. D. 
Blood smear showing stained T. cruzi cells (dark purple). Credit: CarolinaTM Microscope Slides. E. Slide 
showing stained T. cruzi cells accumulating in cardiac muscle. Credit: Peter Anderson/PEIR Digital 
Library. F. Phlebotamine sandfly taking a blood meal. Credit: Ray Wilson. G. SEM of L. mexicana. Credit: 
Richard Wheeler. 
The incidence of sleeping sickness is restricted to sub-Saharan Africa, the habitat of the tsetse fly. 
Human infection can arise from two subspecies: T. b. gambiense is the predominant of the two 
and affects the central west of Africa, while T. b. rhodesiense affects southeast Africa. A third 
subspecies exists (T. b. brucei), though this infects wild and domestic animals (nagana disease) 
and not humans.7a Chagas disease was similarly restricted to South America, until population 
migration allowed it to creep up to the US and Canada in recent years, with cases surfacing in 
parts of Europe.8b The life cycles of T. brucei and T. cruzi are similar: both involve transmission 
of the metacyclic trypomastigote form of the parasite to humans, through the bite of the tsetse fly 
(sleeping sickness) or in the faeces of the triatomine bug (Chagas disease), as either vector takes 
a blood meal (Fig. 1.3). Once in circulation, T. brucei multiply as bloodstream trypomastigotes 
to bring about itching, headaches, fever and the swelling of organs and lymph nodes in stage I, 
sometimes leaving a trypanosomal chancre (inflammatory reaction at the site of the bite).7a During 
stage II, T. brucei penetrate the central nervous system (CNS) to disrupt the sleep/wake cycle and 
cause a characteristic sleeping sickness and neuropsychiatric disorders, the exact mechanism of 
which is still under debate.7a,11 As for Chagas disease, T. cruzi cells multiply in cells or tissue as 
amastigotes, after having entered the bite wound or mucosal membranes of the victim. Symptoms 
range from fever, oedema (swelling from fluid retention) and myocarditis (inflammation of 
cardiac muscle, less common) in the acute phase (4–8 weeks) to digestive conditions and heart 
failure in the chronic phase, which is often symptomless.8a  
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Figure 1.3. Life cycle of T. brucei (African sleeping sickness), T. cruzi (Chagas disease) and Leishmania 
(leishmaniasis). Artwork produced by the author.  
The life cycle of Leishmania differs in that it exploits the defence mechanisms of the human host. 
When an infected sandfly takes a blood meal, it injects promastigote Leishmania into the 
bloodstream of a victim, and these are engulfed by human macrophages (Fig. 1.3). Here, the 
promastigotes transform into amastigotes and multiply, before the macrophage lyses and releases 
Leishmania amastigotes to infect other cells throughout the body. Based on which cells the 
promastigotes infect, and the species of Leishmania, the disease can manifest in different forms. 
Visceral leishmaniasis (or “kala-azar”) is the most severe as it affects the internal organs, causing 
swelling of the liver and spleen, along with persistent fever, weight loss and anaemia.9  This is 
almost exclusively caused by L. donovani and L. infantum, with most cases occurring in Brazil, 
east Africa, India and Bangladesh.12,13 Cutaneous leishmaniasis is the most common form of the 
disease, resulting from infection by a range of other Leishmania species including L. major.9a 
This largely urban phenomenon occurs mostly in South America, the Mediterranean basin and 
the Middle East,13 leaving victims with significant skin lesions - mostly ulcers. Lesions caused 
by species such as L. major, L. tropica and L. mexicana usually heal by themselves within a year, 
but often leave permanent scars, and the social stigma associated with the condition can be 
severely debilitating. Upon infection by species such as L. braziliensis,  cutaneous leishmaniasis 
can develop into mucocutaneous leishmaniasis, a highly disfiguring disease which destroys the 
mucosal membranes of the nose, mouth and throat. Though only a small fraction of those infected 
with Leishmania will develop the disease, factors such as malnutrition and coinfection with HIV 
can dramatically increase the likelihood of disease progression. 
 6 
1.1.3 Diagnosis and Treatment of Trypanosomal Diseases 
 
Given the severity of trypanosomal infections, it is imperative that diagnosis is rapid in order to 
proceed with treatment. If left untreated, sleeping sickness leads to coma and death within three 
years (T. b. gambiense) and weeks to months (T. b. rhodesiense),7a and visceral leishmaniasis is 
similarly fatal in over 95% of cases.9b In contrast, victims entering the chronic phase of Chagas 
disease can go without symptoms for much of their lives, while T. cruzi quietly accumulate in 
digestive and heart muscles (as seen in Fig. 1.1E) and bring on sudden death via heart failure or 
cardiac arrythmia in later years.8a This phase can therefore go unnoticed, though diagnosis 
involves a combination of assessing the likelihood of exposure and identifying the presence of 
antibodies to T. cruzi.8a The acute phase of Chagas disease is much more straightforward to 
diagnose, as T. cruzi can be readily observed by analysing a blood smear (as seen in Fig. 1.1D).8a 
The characteristic skin lesions and mucosal damage associated with the cutaneous leishmaniases 
allows a largely symptoms-based diagnosis. Visceral leishmaniasis requires diagnostic biopsies, 
as Leishmania amastigotes can often be detected in tissue smears of bone marrow and the spleen.9a 
Sleeping sickness is perhaps the most complex of the three diseases to diagnose. While T. b. 
rhodesiense can be detected by analysing a blood smear from a victim, the comparatively low 
density of T. b. gambiense in the bloodstream calls for serological methods of diagnosis, which 
normally requires a fine needle aspiration biopsy of the cervical lymph node (located in the 
neck).7a Determining the stage of sleeping sickness requires analysis of the cerebrospinal fluid to 
detect whether the trypanosomes have entered the CNS,  and a lumbar puncture (spinal tap) is 
necessary.7a Despite the danger and invasiveness of this procedure, determining the stage of 
sleeping sickness is crucial, given that the appropriate treatments are radically different for each, 
and treatments for stage II in particular can be highly toxic. While multiple drugs exist for each 
trypanosomal disease, many are species and/or stage-specific, which often leaves one suitable 
treatment per disease scenario. This is especially challenging in the shadow of antimicrobial 
resistance, which has been reported for virtually all current drug treatments.14 Furthermore, the 
development of vaccines is unlikely, as these species (namely T. brucei) are known to exhibit 
antigenic variation, through which they change the antigenic character of their surface 
glycoproteins to evade the human immune system.15 This adds to the pressure of the existing 
cabinet of antitrypanosomal agents, many of which are highly toxic to the patient they are 
administered to. 
 
There are currently five main drugs recommended for the treatment of sleeping sickness, with a 
sixth being distributed for use in 2019,16 and a seventh in phase III clinical trials.17 Recommended 
treatments for stage I of the disease are pentamidine (T. b. gambiense) and suramin (T. b. 
rhodesiense) (Fig. 1.4). While the mechanism of action is not fully understood, pentamidine is 
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known to bind to trypanosomal DNA and RNA, and its therapeutic selectivity relies on selective 
transportation into trypanosomal cells.18 Suramin is known to bind to human low-density 
lipoprotein, which is taken up by T. brucei cells as a source of sterols. Once inside, the drug 
inhibits trypanosomal enzymes involved in metabolic pathways: the anionic state of suramin in 
vivo is thought to allow it to selectively bind to cationic trypanosomal enzymes, which exhibit a 
higher isoelectric point than human enzymes.18
  
 
Figure 1.4. Recommended drug treatments for stage I of African sleeping sickness showing dosage,7a 
toxicity (adverse side effects)7a and mechanism of action.  
 
Treatment of stage II sleeping sickness requires highly lipophilic drugs to penetrate the blood-
brain barrier (BBB) and reach trypanosomes in the CNS (Fig. 1.5). For many years, melarsoprol 
remained the only treatment capable of doing this, however this arsenic-based prodrug is 
infamously toxic. Manufactured as a solution in propylene glycol (due to its lipophilicity), this 
“arsenic in antifreeze” is highly painful to administer, with thrombophlebitis (blood clots from 
vein inflammation) commonly observed at the injection site.7a More alarmingly is the occurrence 
of encephalopathic symptoms (brain damage), which occurs in up to 10% of patients, and roughly 
half of these patients die (6%, roughly 1 in 15).19 Fortunately, melarsoprol is highly trypanocidal, 
as the active metabolite melarsen oxide is thought to bind to sulfhydryl groups of multiple T. 
brucei enzymes to inhibit their function in metabolic pathways and cause rapid cell lysis.18 The 
selectivity of melarsoprol hinges on selective transportation into trypanosomal cells, while human 
cells suffer the toxicity of any drug molecules left behind.18 Although melarsoprol remains the 
only treatment for stage II T. b. rhodesiense infection, safer options have since been developed 
for other disease scenarios. Until 2019, the only new drug introduced for treating sleeping 
sickness in roughly fifty years was eflornithine (Fig. 1.5). Effective against stage II T. b. 
gambiense, eflornithine is trypanostatic: after binding irreversibly to ornithine decarboxylase 
(ODC) in place of ornithine, it shuts down polyamine synthesis, inhibiting cell proliferation and 
rendering them vulnerable to the host immune system.20 Though ODC is present in humans, its 
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regeneration is much more rapid than in trypanosomes, allowing therapeutic selectivity.20 It has 
been found21 that eflornithine is more effective when used in combination with the 
nitroheterocyclic drug, nifurtimox, and NECT (nifurtimox-eflornithine combination therapy) was 
added to the WHO list of essential medicines in 2009,22 given it was the only safe alternative to 
melarsoprol in treating stage II T. b. gambiense infection. This changed in late 2018, when another 
nitroheterocyclic drug, fexinidazole, was approved in the Democratic Republic of Congo (DRC)23 
(Fig. 1.5). Critically, fexinidazole is the first orally administered treatment for sleeping sickness, 
which is an enormous improvement over the intravenous or intramuscular route of administration 
for all other treatments, and is also effective against both stages of T. b. gambiense infection. 
Acoziborole (Fig. 1.5) is in phase III clinical trials in the DRC as of 2019.17 This novel 
benzoxaborole would be administered orally as a single-dose treatment for stage I and II sleeping 
sickness, dramatically simplifying treatment regimens.17 
 
Figure 1.5. Recommended drug treatments for stage II of African sleeping sickness showing dosage,7a,24,25, 
26 toxicity (adverse side effects)7a,24,25 and mechanism of action.  
 
The two drug treatments approved to treat Chagas disease are orally administered and capable of 
completely curing the disease if administered early (during the acute phase).8a The 
nitroheterocycles, nifurtimox and benznidazole (Fig. 1.6A) are capable of multiple 
antitrypanosomal mechanisms.27 The primary mode of action is two electron reduction of the nitro 
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group by type I nitroreductase enzymes (Fig. 1.6B).28 The nitrosyl (2) and hydroxylamine (3) 
metabolites are both capable of inducing cellular damage,29 and further nitrenium metabolites (5) 
are thought to bind to trypanosomal DNA.30 Ultimately, nifurtimox degrades to a linear nitrile 
metabolite (4'),31 and benznidazole releases highly reactive glyoxal,32 both of which are thought 
to be trypanocidal. Nifurtimox is known to also undergo one electron reduction (via type II 
nitroreductases)27 to an anionic nitro radical (1) which can form reactive oxygen species (ROS, 
eg. • –O2, •OH, H2O2) via redox cycling,33 and the resulting superoxide (• –O2) in particular can 
lead to extensive damage to cellular machinery (Fig. 1.6B).34 Though trypanosomes contain 
enzymes to combat this,35 they are easily foiled by oxidative stress in comparison to human cells.36 
Both nifurtimox and benznidazole have significant drawbacks, the first being their archaic nature, 
which leaves them open to antimicrobial resistance.28a Both are contraindicated during pregnancy 
due to potential teratogenicity, carry adverse side effects (mostly gastrointestinal for nifurtimox 
and cutaneous for benznidazole), have long treatment regimens lasting 60–90 days, and are 
ineffective against the chronic phase of the disease.8a Fortunately, fexinidazole (the previously 
mentioned oral treatment for sleeping sickness) is in phase II clinical trials for the treatment of 
Chagas disease.37  
 
 
Figure 1.6. A. Recommended drug treatments for Chagas disease showing dosage,8a toxicity (adverse 
side effects)8a and mechanism of action. B. Reduction and metabolism of nifurtimox and benznidazole.27 
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choice of drug depends on type of leishmaniasis and species involved, pentavalent antimonials 
(containing SbV) are key antileishmanial agents. These are administered intravenously with 
careful monitoring, and intralesional injection (directly into the skin lesion/ulcer) is often 
recommended for cutaneous leishmaniasis.9a The mechanism of action is not well understood, 
and it is debated whether antimony-based drugs such as sodium stibogluconate and meglumine 
antimoniate are reduced to SbIII to inhibit metabolic pathways in Leishmania, or render the cells 
vulnerable to the human immune system.38 Many strains of Leishmania are resistant to 
pentavalent antimonials, and so alternative options are often sought after.9a,39 Amphotericin B is 
a natural product-derived polyene with a high affinity for ergosterol, which is an essential 
component of fungal cell walls. This makes it a highly effective antifungal agent, creating pores 
through which monovalent ions flood from the cell and lead to its death.39 Given that ergosterol 
is also present in protozoal cell walls, Amphotericin B is similarly effective against Leishmania, 
and is commonly employed for antimony-resistant strains.39 Due to the severe side effects of 
nephrotoxicity, hypokalemia, myocarditis and even death, the lengthy intravenous administration 
requires close monitoring and hospitalisation and is therefore expensive.40 Lipid formulations of 
the drug have therefore been developed, which can be administered over a shorter period of time 
due to their rapid uptake into organs, which is particularly useful for visceral leishmaniasis and 
also evades damage to the kidneys.40 The presence of ergosterol in trypanosomal cells has shown 
promise for the repurposing of other antifungals such as ketoconazole, itraconazole and 
fluconazole (which inhibit ergosterol synthesis) for the treatment of leishmaniasis in the future.40 
The final approved drug for treatment of all forms of leishmaniasis, as well as the only orally 
administered option, is miltefosine. The mechanism of this alkyl phospholipid is still under 
debate, but is accepted to result in cell apoptosis.41 The drug is contraindicated during pregnancy 
due to its potential teratogenicity, and its efficacy is variable, particularly in children.9a Treatments 
for leishmaniasis are often used in combination, sometimes with the inclusion of paromomycin 
(a protein synthesis inhibitor), which can be administered intramuscularly or as a topical ointment 
for the treatment of cutaneous leishmaniasis.9a  
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Figure 1.7. Recommended drug treatments for leishmaniasis showing dosage,9a toxicity (adverse side 
effects)9a and mechanism of action. 
 
1.1.4 The Importance of Combatting Neglected Tropical Diseases 
 
Neglected tropical diseases have plagued the world throughout civilisation and well before it. The 
demise of Mari Djata II (ruler of Mali, Africa, 1360–1374)42 was relayed to Tunisian historian, 
Ibn Khaldun, by a fellow countryman: “He told me that (Djata) had been smitten by the sleeping 
illness, a disease which frequently afflicts the inhabitants of that climate, especially the chieftains 
who are habitually affected by sleep. Those afflicted are virtually never awake or alert. The 
sickness harms the patient and continues until he perishes. He said that the illness persisted in 
(Djata's) humour for a duration of two years after which he died in the year (1374).”7b This would 
later be acknowledged as one of the first written accounts of African sleeping sickness. Chagas 
disease is similarly thought to have afflicted humans for as long as they have populated South 
America: the earliest evidence of human infective T. cruzi was found in a 9 000 year old 
Chinchorro mummy, via PCR amplification of kinetoplastid DNA sequences.8b Furthermore, 
mitochondrial DNA of L. donovani has been found in Egyptian mummies dating from 2050–1650 
BCE, implying that visceral leishmaniasis was present in ancient Egypt, and evidence of 
Leishmania parasites has been found inside prehistoric sand flies fossilised in 100 million-year-
old amber.9b Today, these diseases exist in a world with the capability to understand, control and 
even eradicate them.43 The closest NTD to eradication is Guinea-worm disease, with the number 
of new cases being reduced from 3.5 million cases in 1986 to merely 25 in 2016 (a reduction of 
> 99.9% in a decade).  As of 2019, an estimated 700 000 to 1 million new cases of leishmaniasis 
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occur annually, along with 25 000 to 65 000 deaths.44 In regard to Chagas disease, 6 to 7 million 
people are estimated to be infected with T. cruzi, mostly within Latin America.45 Control of these 
diseases is particularly challenging, as they are not confined to the habitat of the vector and are 
spreading further from their endemic areas. Chagas disease can be transmitted from mother to 
child during pregnancy, and blood samples from endemic countries must be thoroughly screened 
to avoid transmission during transfusions and transplants.8a The wide distribution and species 
diversity associated with leishmaniasis make it particularly difficult to control, and these are both 
thought to be affected by climate change and deforestation.9b In regard to sleeping sickness, 2009 
saw the number of reported cases drop below 10 000 for the first time in 50 years, with 1446 new 
cases being reported in 2017,46 and this reduction in disease burden is a testament to the 
collaborative control strategies largely driven by the WHO, many focusing on containing tsetse 
fly populations. Drug treatments are distributed by the WHO and donated by pharmaceutical 
companies such as Sanofi (pentamidine, melarsoprol, eflornithine) and Bayer AG (suramin, 
nifurtimox), which is enabled by crucial public-private partnerships.46 Critically, the development 
of new drugs such as fexinidazole and acoziborole has been made possible by organisations such 
as the Drugs for Neglected Diseases Initiative (DNDi)16,17 with funding from philanthropic 
bodies, namely the BMGF, and these collaborative initiatives make the eradication of NTDs a 
real possibility. Having said this, a small window exists for eradication, as a single epidemic has 
the potential to destroy this progress.7b Furthermore, due to the threat of antimicrobial resistance, 
the spread of disease affected regions, the dangerously high toxicity of key drug treatments and 
their complex administration, as well as the severity of the diseases themselves, it is crucial that 
drug development for NTDs is a rapid process. 
 
1.1.5 Screening Compound Libraries for New Antitrypanosomal Drugs 
 
One of the most rapid methods of identifying new drug candidates is the screening of large 
compound libraries for a suitable “hit.” This is often referred to as compound mining, or high-
throughput screening (HTS), and involves the use of automated machinery to conduct biological 
experiments on hundreds to millions of compounds at once. Both fexinidazole and acoziborole 
(the newly-developed sleeping sickness treatments), as well as GNF6702 (the broad-spectrum 
proteasome inhibitor developed by Novartis) are a testament to the success of this strategy (Fig. 
1.8). As detailed in Section 1.1.3, nitroheterocyclic drugs like nifurtimox and benznidazole have 
exhibited considerable efficacy in the treatment of trypanosomal diseases. This influenced the 
DNDi to conduct a screening of over 700 nitroheterocyclic compounds for activity against T. 
brucei in 2005, in an effort to identify a suitable candidate for the treatment of sleeping sickness.47 
From this screening, fexinidazole was identified as a hit (Fig. 1.8A). This was considered a 
rediscovery, given that this compound had been developed by Hoechst AG in the 1980s and 
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subsequently abandoned, and its in vivo antitrypanosomal activity has been previously 
established.47,48 After a partnership between the DNDi and Sanofi was established, fexinidazole 
entered stage I clinical development in 2009,47 and has now been approved for use in the DRC.23  
Given that fexinidazole is known to bind to type I nitroreductase enzymes49 and loses efficacy in 
nifurtimox-resistant cell lines,50 it is thought to share the same primary mode of action as the 
previously discussed nitroheterocyclic drugs (see Section 1.1.3), though in vivo oxidation to the 
sulfone metabolite appears to be necessary for its bioactivity.50  
 
Figure 1.8. Development of new drug treatments for African sleeping sickness discovered via three 
separate screenings (A–C) of compound libraries. 
 
Having established the necessity of a public-private partnership in seeing such initiatives through, 
a second collaboration was established between the DNDi, Anacor Pharmaceuticals Inc. (now 
owned by Pfizer) and Scynexis (now Avista Pharma). A focused library of anti-infective 
benzoxaboroles was formulated from Anacor’s expansive boron chemistry platform and, upon 
biological screening, the compound 6 was identified to be trypanostatic (Fig. 1.8B).51a This hit 
served as a novel class of antitrypanosomal agent, though other benzoxaboroles had previously 
been studied for their antifungal and anti-inflammatory properties. Investigations were then 
initiated to establish structure-activity relationships (SAR) of the scaffold, in order to guide the 
design of future generations of the drug, and these have been summarised in Figure 1.8B. With 
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careful attention to physiochemical properties, the subsequent derivatives 7 and 8 were found to 
be both orally bioavailable and able to penetrate the blood brain barrier,51b that latter of which is 
crucial for treating stage II sleeping sickness. Broadly speaking, an orally bioavailable drug 
follows Lipinski guidelines (£ 5 H-bond donors, £ 10 H-bond acceptors, MW £ 500 Da, logP £ 
5)52a and has a limited polar surface area (PSA) and number of rotatable bonds,52b and in order to 
freely diffuse across the blood brain barrier to penetrate the CNS, a drug should have a low MW 
(< 400 Da) and adequate lipophilicity/low hydrogen bonding.53 With these parameters considered, 
in addition to antitrypanosomal activity, selectivity and metabolic stability, compound 8 was 
deemed more suitable for further development.51b The final derivative was acoziborole,54 which 
entered phase I clinical trials in 2015.17 While investigations into the mode of action of 
benzoxaboroles are ongoing, the drug has been found to bind to the trypanosomal endonuclease 
CPSF355a to interrupt mRNA processing.55b 
Both fexinidazole and acoziborole have shown potential to treat other trypanosomal diseases 
outside of sleeping sickness, presumably due to the presence of the target (nitroreductases and 
CPSF3, respectively) in multiple species as a result of genetic crossover. As mentioned in Section 
1.1.1, this is an opportunity to develop broad-spectrum agents for the treatment of multiple 
trypanosomal infections, and has been capitalised upon by Novartis in their development of 
GNF6702 (10, Fig. 1.8C).6 During a HTS of over 3 million compounds, the hit 9 was found to 
inhibit the growth of both T. brucei and L. donovani, as well as T. cruzi (in subsequent assays), 
and selectivity over mammalian cells (Fig. 1.1.8C).6 Establishing the SAR of the compound with 
respect to the three species involved the synthesis of roughly 3 000 compounds (summarised in 
Fig. 1.8C), in order to guide the optimisation process. Given the bioactivity of 9 was significantly 
less for L. donovani than the other species, much of this optimisation focused on increasing 
bioavailability and potency for inhibiting L. donovani growth within mammalian macrophages. 
This led to the derivative GNF6702 (10), which exhibits nanomolar activity against the three 
causative species and translates to in vivo models, and shows high selectivity over mammalian 
cells. Critically, 10 was found to penetrate the CNS to treat stage II sleeping sickness in a murine 
model, and antileishmanial activity against L. donovani in particular allows the treatment of 
visceral leishmaniasis, the most severe form of the disease. The Genomics Institute of the Novartis 
Research Foundation (GNF) conducted rigorous investigations into the mechanism of action of 
10, where it was found that trypanosome strains resistant to this drug compound contained a 
mutation encoding the replacement of isoleucine with methionine at amino acid 29 in one 
proteasome subunit. Interestingly, the human proteasome also contains a methionine residue at 
the same position, suggesting why 10 may be non-toxic to human cells.6 Proteosomes are large 
protein complexes which degrade damaged or unneeded proteins with the aid of trypsin, 
chymotrypsin or caspase enzymes. Further investigation revealed that 10 binds non-competitively 
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to the trypanosomal proteasome to inhibit chymotrypsin-like activity and, given this is an essential 
process during the growth of trypanosomal cells, this likely explains the mechanism of 
trypanostatic action.6,56 This work unveiled both a new cellular target - the proteasome - and novel 
class of inhibitors for the treatment of all three trypanosomal diseases. 
In their efforts to identify new drug candidates for the treatment of sleeping sickness, the DNDi 
extended their screening campaigns to Australia, which led to the involvement of our group in 
the drug development process. In 2012, the organisation funded a HTS against T. b. brucei, using 
the Walter and Eliza Hall Institute (WEHI) 2003 library of roughly 87 000 compounds.57 This 
was led by Vicky Avery, from the Eskitis institute (now Discovery Biology) at Griffith 
University, and a number of highly potent and selective antitrypanosomal agents were identified. 
The screening was based on a whole cell viability assay previously developed by Sykes and 
Avery, which employs Alamar Blue, a redox indicator containing resazurin.58 In metabolically 
active cells, resazurin is converted into the fluorescent product, resofurin, where the detected 
fluorescence is proportional to the number of viable T. b. brucei cells. A whole cell protocol 
allows potential hits to function in a physiologically relevant environment, and accounts for 
multiple mechanisms of action, as well as accumulative action, which would otherwise go 
unnoticed in target-based assays.57 Many of the hits have undergone investigation to establish 
SAR, as per the development of fexinidazole and acoziborole, and this has allowed the design of 
optimised drug candidates in many cases. Interestingly, the first hit to be investigated (by the 
Baell group)59 was the very same molecule (9, Fig. 1.8C) investigated by Novartis in the 
development of GNF6702 (10). It appears that both groups conducted their work simultaneously, 
and both observed the broad-spectrum activity of this class of compounds.59,6 The Baell group has 
investigated other hits since,60,61 along with the Payne group.62 The most recent hit to be 
investigated was 11, within the Baell and Piggott groups, which was optimised for 
antitrypanosomal activity against both T. brucei and T. cruzi and lead to the SAR-informed design 
of the highly potent and selective derivative 12 (Fig. 1.9).63 The University of Wollongong has 
also participated in the investigation of these hits, with the Keller group establishing a preliminary 
SAR of the hit 13.64 Our group has been investigating the hit WEHI-0086109 (14a, Fig. 1.9) in 
order to establish SAR, conducting investigations over three structural components of the novel 
thiazolyl-benzothiophenamide scaffold (Fig. 1.9), and this has comprised the first part of this 
project. 
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Figure 1.9. Investigation of selected hits arising from the 2012 T. brucei screening led by Avery.  
 
1.1.6 Incorporating Organometallic Fragments into Existing Drug Scaffolds 
 
Another rapid method of drug discovery with demonstrated success in regard to NTDs is the 
repurposing of existing drugs. As discussed in Section 1.1.3, multiple trypanosomal diseases have 
benefited from this approach, namely the repurposing of nifurtimox (Chagas disease) for the 
treatment of sleeping sickness, and the use of azole antifungals such as ketoconazole for the 
treatment of leishmaniasis. Given the toxicity and metabolic profiles of these drugs are 
preestablished, their direct repurposing can fast track them through clinical trials.65 Having said 
this, synthetically modifying an existing drug before repurposing is often necessary, and the 
incorporation of organometallic moieties in particular has emerged as a powerful strategy in the 
search for new drug treatments for NTDs.66 The primary reason for this is the enabling of metal-
specific modes of action, which can enhance the bioactivity of the parent drug and evade 
mechanisms of antimicrobial resistance. As per nitroheterocyclic drugs like nifurtimox, 
organometallic moieties containing redox active metal centres are often capable of producing 
ROS. Perhaps the most notable example is the ferrocene moiety, which readily produces hydroxyl 
radicals via a Fenton reaction with H2O2, and  undergoes facile one electron oxidation to the toxic 
ferrocenium cation, which can generate additional ROS (Fig. 1.10).67 The redox potential for this 
process is known to vary with the electronic character of the attached substituents,68 and this 
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allows tuning for maximal biological activity, given the physiological redox potential range spans 
from approximately –1 mV to +1 mV.69 The biology of many protozoan species such as T. cruzi 
are highly adapted to high and carefully balanced levels of ROS, which are involved in cellular 
processes such as signalling pathways.70 By introducing additional ROS, redox active drugs can 
disrupt this balance, inducing oxidative stress and bringing about cellular death. Parasitic 
mechanisms of combatting this stress (superoxide dismutase, catalase and peroxidase enzymes) 
are both distinct and limited in comparison to those of human cells,71 which allows for therapeutic 
selectivity when using oxidative stress as a drug target. The lipophilicity of the ferrocene moiety 
can also promote its uptake into relevant cellular compartments such as the digestive vacuole of 
parasites,72 and may also allow drug compounds to cross the BBB for the treatment of stage II 
sleeping sickness. Generally speaking, organometallic moieties allow vast structural diversity 
(including ligand coordination modes, Fig. 1.10) inaccessible to purely organic structures.   
 
Figure 1.10. Selected classes of organometallic drug compounds, showing the redox activity of the 
ferrocenyl moiety. 
 
The first example of this design strategy was the development of ferrocifens, which are ferrocenyl 
analogues of tamoxifen, an estrogen receptor agonist/antagonist used for the treatment of breast 
cancer (Fig. 1.11).72,73 The similarly high ROS concentration in cancer cells allows ferrocifens to 
induce oxidative stress as per parasitic cells, enhancing the existing bioactivity of the parent 
drug.72 The most successful drug of this design strategy has been the antimalarial compound, 
ferroquine, a ferrocenyl analogue of chloroquine (Fig. 1.11). Developed by Biot in the 1990s,74 
ferroquine exploits the need for Plasmodium to take up haemoglobin as a source of amino acids. 
Once the Plasmodium cell has taken up the iron-containing bait, the chloroquine-like skeleton 
carries out its usual mode of action, by interfering with the normal digestion of haemoglobin 
within the digestive vacuole, while the ferrocene moiety generates ROS to enhance antimalarial 
activity.72 As of 2019, ferroquine is undergoing phase II clinical trials.75 
Figure 1.11. Ferrocenyl derivatives of tamoxifen (anticancer drug) and chloroquine (antimalarial). 
FeII
+ e–
H2O2 OH + OH
– e–
Fenton reaction (other oxidation 
mechanisms are also possible)
FeIII ROS
reduction
Drug Drug
Ru
Cl
Cl N N Drug
Drug
Cr
CO
OC
OC
tricarbonylchromium
complex
ruthenium ‘piano stool’
complex
ferrocenyl
drug compound
ferrocenium 
ion
Cl N
HN N
Cl N
HN
Fe
N
Fe
O
N
O
N
tamoxifen ferrocifen chloroquine ferroquine
 18 
In regard to NTDs, many potential drug candidates have emerged using similar design strategies, 
and our group published a review of these in 2015 (Med. Chem. Commun. 2015, 6, 1230–1243, 
DOI: 10.1039/c5md00174a, see appendix for full article).66a Multiple research groups have 
produced additional examples in recent years, notably the Gasser group, who have developed 
organometallic derivatives of monepantel,76 oxamniquine77 and mefloquine78 for the treatment of 
helminth-based NTDs. While formulating the aforementioned review, our group was particularly 
influenced by the work of the Klahn group, who designed and evaluated ferrocenyl and 
cyrhetrenyl analogues of nifurtimox for the treatment of Chagas disease (Fig. 1.12).79 The group 
had rationalised that maintaining the 5-nitrofuryl pharmacophore would retain the existing mode 
of action of nifurtimox (bioreduction by nitroreductase enzymes to form cytotoxic metabolites 
and ROS), while the added organometallic moiety would enhance the antitrypanosomal activity 
by generating additional ROS. While the potency of the ferrocenyl derivatives against T. cruzi 
(12.3, 18.3 μM) was comparable to that of nifurtimox (19.8 μM), the cyrhetrenyl analogues were 
up to fifty-fold more potent (0.4 μM, 3.7 μM). It was proposed that the increase in potency was 
due to the electron withdrawing character of the cyrhetrene moiety, rendering the nitro group 
electron deficient and therefore more easily reduced, while the converse is true for the electron 
donating ferrocene moiety (Fig. 1.12). Furthermore, conjugation between the nitro group and 
organometallic unit was found to be essential for bioactivity, 79b though it could not be ruled out 
that increased lipophilicity alone may have been responsible for the higher potency of the 
organometallic analogues. The authors have investigated related systems since,80 and our group 
has been inspired by this work. We endeavoured to investigate the incorporation of similar 
organometallic units in other existing drug scaffolds for the treatment of trypanosomal NTDs, 
with a focus on comparing and contrasting the electronic character of the organometallic moiety. 
 
 
Figure 1.12. Ferrocenyl and cyrhetrenyl derivatives of nifurtimox developed by the Klahn group, 
showing bioactivity against T. cruzi. 
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different disease targets. With these factors considered, we identified nitazoxanide, a 
nitrothiazolide prodrug, as a suitable candidate (Fig. 1.13A). This relatively new drug is taken 
orally, exhibits broad-spectrum antiparasitic activity, and is currently approved for the treatment 
of infection by a wide range of parasites including the protozoa Cryptosporidium, Giardia and 
Entamoeba histolytica.81 It is also being repurposed for the treatment of influenza, having 
completed phase III clinical trials in April 2019.82 Nitazoxanide itself is a prodrug, which is 
rapidly hydrolysed to the active form, tizoxanide, in vivo (Fig. 1.13A). While this drug has many 
known modes of action, the generally accepted mechanism of antiprotozoal activity is in the 
inhibition of the pyruvate:ferrodoxin oxidoreductase (PFOR) enzymes that play a critical role in 
anaerobic energy metabolism.83 In 2009, nitazoxanide was found to exhibit low micromolar 
bioactivity against T. cruzi (18.74 μM) and L. mexicana (8.18 μM),84 and the benzothiazole 
analogue (or benzologue) of nitazoxanide has since been found to be even more potent (4.89 μM, 
T. cruzi and 1.35 μM, L. mexicana, Fig. 1.13A).85 The scaffold of nitazoxanide is comprised of a 
5-nitrothiazole fragment and a salicylate fragment joined by an amide bond, and this presented 
the opportunity to introduce organometallic moieties at multiple positions, in a facile manner. Not 
only is the nitro group of nifurtimox known to be important for its bioactivity,83 but the drug has 
also been found to produce ROS in Leishmania cells.86 It therefore seemed reasonable to replace 
the entire salicylate component with an organometallic unit to preserve the PFOR-mediated mode 
of action (as well as the generation of ROS by the nitro group), while the organometallic unit 
could produce additional ROS (Fig. 1.13B). This would allow the comparing and contrasting of 
organometallic moieties with different electronic character, and the effect of this on the bioactivity 
of the nitro group, as in the work of the Klahn group.79 Furthermore, the importance of 
conjugation between the nitroheterocyclic and organometallic components observed by the Klahn 
group could be investigated in these analogues, by exchanging the amide for an imine linker (Fig. 
1.13B). The function of nitazoxanide as a prodrug presented a second opportunity to introduce an 
organometallic unit via an ester linkage, in exchange for the acetyl group. Upon hydrolysis in 
vivo, this should release the active drug and the organometallic moiety (as the carboxylic acid), 
the latter of which would produce ROS as an additional mode of action (Fig. 1.13B), and is 
considered to be non-toxic to humans. This approach should allow the parent drug to carry out its 
known antitrypanosomal action without modification of the scaffold, while enhancing its 
bioactivity. Given the benzologues of nitazoxanide are known to be more potent antitrypanosomal 
agents,85 it was proposed that the corresponding benzothiazole scaffolds should also be employed. 
Upon screening the organometallic nitazoxanide analogues against T. cruzi and Leishmania, the 
success of these design strategies could be evaluated and used to inform the design of further 
derivatives. 
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Figure 1.13. A. Bioactivity of nitazoxanide and its benzothiazolide analogue against T. cruzi epimastigotes 
and L. mexicana promastigotes, showing selectivity over Vero (mammalian) cells. B. Two proposed design 
strategies to incorporate organometallic units into the structure of nitazoxanide. 
 
1.1.7 Arrival at Specific Project Aims 
 
The overall aim of this project has been to develop new antitrypanosomal drugs using robust 
methods of drug discovery, in order to add to the growing artillery of new treatments for NTDs 
(Fig. 1.14). Specifically, this involved the investigation of drug scaffolds derived from either a 
HTS (14a, Fig. 1.14A) for the treatment of sleeping sickness, or the organometallic modification 
of nitazoxanide, as repurposed drug treatments for Chagas disease and leishmaniasis (Fig. 1.14B). 
In regard to the former, the lead compound 14a could be divided into three components for 
investigation: the thiazole fragment (blue), the benzothiophene fragment (red) and the amide 
linker (green). Derivatives were to be designed to explore each of these components and 
synthesised using the synthetic strategies outlined in Figure 1.14A. Upon introducing these 
derivatives to T. b. brucei and HEK293 (human embryonic kidney) cells in a whole-cell viability 
assay, the results could be used to establish the SAR of 14a. With an attention to potency, 
selectivity and physiochemical properties, this information could inform the design of future 
generations of derivatives toward an optimised drug candidate suitable for preclinical studies. In 
regard to the latter strategy, the conceived series of type I and II nitazoxanide derivatives were to 
be synthesised, with the organometallic moieties being introduced as the carboxylic acid or 
aldehyde, using the synthetic strategies outlined in Figure 1.14B. While cyrhetrene was originally 
envisioned as the electron withdrawing organometallic moiety, it was decided to use the more 
readily commercially available cymantrene analogue (Fig. 1.14B). Upon screening the resulting 
series for bioactivity against T. cruzi and Leishmania (performed by the Avery group), using 
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nitazoxanide as a positive control, the results could be used to elucidate the reactive trends of the 
series. Specifically, this was to be focused on whether the organometallic derivatives exhibited 
greater potency than nitazoxanide, and also whether this differed between derivatives containing 
an electron donating (ferrocenyl) and electron withdrawing (cymantrenyl) moiety. This initial 
study was intended to serve as a proof of concept for the first generation of a novel class of drug 
compounds, informing the design of further derivatives. Ultimately, both methods of drug design 
(compound screening and drug repurposing) are driven toward a common goal: to discover the 
type of drug treatment that sufferers of trypanosomal NTDs are desparately in need of. This 
treatment should be potent and selective (preferably broad-spectrum), orally administered, and 
safe. As of October 2019, the work disclosed herein regarding the development of WEHI-
0086109 (14a) and its derivatives is in preparation for publication. 
 
 
Figure 1.14. Graphical summary of the conceived strategy to: A. establish structure-activity relationships 
of the lead compound 14a for the treatment of African sleeping sickness; B. develop organometallic 
derivatives of nitazoxanide for the treatment of Chagas disease and leishmaniasis. 
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1.2 Results and Discussion 
 
1.2.1 Resynthesis and Validation of WEHI-0086109: Synthetic and Analytical Protocols* 
 
While the design of derivatives of WEHI-0086109 (14a) was driven by medicinal chemistry 
principles, it was also inevitably governed by synthetic accessibility which, in turn, is influenced 
by the availability of chemical building blocks. The overall strategy for constructing the thiazolyl-
benzothiophenamide scaffold is best demonstrated in the synthesis of the lead compound 14a 
(Scheme 1.1), which was to be retested against T. b. brucei and HEK293 cells in order to confirm 
the results obtained in the original screening. The synthesis of 14a began with preparation of the 
thiazole fragment (20a), which required the bromination of 1,3-cyclohexanedione (18a) to 
facilitate the subsequent Hantzsch thiazole synthesis, both being achieved on a gram scale in good 
yield (83%, 19a and 70%, 20a). Comparison of the NMR spectrum of 20a to literature data87a 
was sufficient to confirm its formation, though diketone systems such as 19 are notorious for 
producing ambiguous NMR spectra due to keto-enol tautomerisation.87c Mass spectrometry 
analysis (ESI, positive mode) provided much clearer evidence of a successful bromination, 
producing the characteristic [M] and [M+2] signals (from 79Br and 81Br isotopes) as the 
corresponding proton adducts at m/z 191 and 193, respectively. The benzothiophene fragment 
could be accessed from cinnamic acid (21a, Scheme 1.1), which was treated with thionyl chloride 
in the presence of pyridine to give the fragment as the acyl chloride (22a) in moderate yield (45%). 
The amine and acyl chloride functionalities allowed coupling of the two fragments via a Schotten–
Baumann amidation (Scheme 1.1) to give the lead compound 14a in quantitative yield. As with 
all derivatives in this study, the purity of 14a was analysed via a combination of high field NMR 
spectroscopy and analytical HPLC, for which a protocol was developed using a C-18 column and 
MeCN/water/TFA solvent system. Any derivatives below 95% purity were repurified (via 
recrystallisation or column chromatography) or resynthesised if necessary, to ensure the accuracy 
of the results obtained from the T. b. brucei assays. With a purity of 96% (HPLC), the lead 
compound 14a was submitted to the whole-cell viability assay58 in order to confirm the bioactivity 
(IC50 = 0.44 μM) and selectivity (SI > 94) observed in the original screening, using pentamidine 
as a positive control.† The assay uses bloodstream trypomastigotes (the clinically relevant form) 
of T. b. brucei strain 427. While this is a non-human infective species, it serves as a surrogate to 
T. b. rhodesiense and T. b. gambiense (a genetically close alternative that is safer and easier to 
culture). Inclusion of the resynthesised lead 14 in this assay confirmed that it was indeed active 
against T. b. brucei, but exhibited a four-fold drop in potency (IC50 = 1.75 μM) in comparison to 
 
* Development of the synthetic route to WEHI-0086109 (14a) and preliminary syntheses were performed 
by Dr Ashraf Abdel-Megeed, The University of Wollongong. 
† Performed within the group of Prof Vicky Avery, Discovery Biology, Griffith Institute for Drug 
Discovery, Griffith University. 
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the original screening, and was half as selective (SI = 48) over HEK293 cells. The reliability of 
these results was investigated by retesting 14a in a later assay, which returned an IC50 value in a 
similar range (3.22 μM), and the potency of 14a was accepted to be the average of the two results 
(IC50 = 2.50 μM, SI = 48).  
 
 
Scheme 1.1. Synthetic strategy for preparing the scaffold of the lead compound.  
 
1.2.2 Investigation of the 3-Chloro Position of WEHI-0086109 
 
Having established a synthetic strategy for the scaffold of 14a, the design and synthesis of the 
first series of derivatives was initiated. From a synthetic chemistry perspective, perhaps the most 
obvious point of derivatisation was the 3-chloro position, which could be used as a handle in 
cross-coupling reactions to introduce aryl groups and investigate their effect on bioactivity. In 
addition to this, the ready availability of dimedone (18b, Scheme 1.1) enabled the synthesis of 
derivatives with or without a 5-gem-dimethyl group, which is commonly employed in drug 
design.88 The first derivative to be synthesised was therefore 14b (Scheme 1.1), the 5-gem-
dimethyl analogue of 14a. In order to prepare the benzothiophene fragment for cross-coupling 
reactions, the acyl chloride 22a was converted to the more robust methyl ester substrate 23 
(Scheme 1.2). While the notorious ineffectiveness of chloroaryl substrates under Suzuki–Miyaura 
conditions was considered (due to the comparatively strong C-Cl bond), it was acknowledged that 
the benzothiophene 23 may be compatible with a Pd(0) catalyst system as a result of its activated 
nature.89a Most chloroaryl systems call for a Ni(0) catalyst, which more readily undergoes 
oxidative addition due to its smaller atomic radius, which enhances its nucleophilic character.89b 
The conjugation enabled by the substrate 23, however, may facilitate an SN2-like oxidative 
addition and render oxidative addition more facile (Scheme 2.2). Having said this, the literature 
revealed the Ni(0)-catalysed cross-coupling for this very substrate, developed by the Miura 
group,90 and so the same Ni(II) precatalyst (Ni(dppe)Cl2) was employed for this work. Under 
these conditions, a variety of aryl groups were introduced to the benzothiophene fragment in good 
to excellent yields (70–88%, Scheme 2.2). Conversion to the corresponding carboxylic acids (25) 
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was achieved in good to excellent yields (77–97%) and allowed conversion of the 3-aryl 
fragments to the corresponding acyl chlorides, which were immediately coupled to the 
benzothiazoles 20 under the conditions established in Section 1.1.1, to afford the 3-aryl 
derivatives of 14a in varying yields (Scheme 1.2 and Table 1.1). As with all derivatives in this 
study, successful formation of the amide bond was inferred from the characteristic signals at 3300 
cm–1 (NH stretch) and 1650 cm–1 (CO stretch) in the infrared spectrum, as well as the broad singlet 
(NH) above 10.00 ppm and amide carbonyl signal near 190.0 ppm in the 1H and 13C NMR spectra, 
respectively. Interpretation of the NMR spectrum was largely straightforward in most cases: the 
benzothiazole or 5-gem-dimethyl benzothiazole rings generated distinctive, appropriate splitting 
patterns between 2.0 ppm and 3.0 ppm. The exception was the naphthyl derivatives 30, which 
generated benzothiazole signals that exhibited more complex splitting patterns in the 1H NMR 
spectra. A plausible explanation may be the restricted rotation of the bulky naphthyl substituent 
about the amide carbonyl, rendering the benzothiazole protons diastereotopic. Completion of this 
series entailed removal of the 3-chloro group entirely, and this was initially attempted via a proton 
transfer dechlorination with MeOH and Pd/C. After this proved unsuccessful, the desired 3-hydro 
derivatives 32 were accessed via a coupling reagent (EDC×HCl) in moderate yields (42%, 32a, 
55%, 32b) using commercially available benzo[b]thiophene-2-carboxylic acid (31) and the 
benzothiazoles 20 in the presence of catalytic DMAP (Scheme 1.2).  
 
Scheme 1.2. Synthetic strategy for the preparation of 3-substituted derivatives of the lead compound. 
Further yields are reported in Table 1.1.  
 
Upon screening the first series of derivatives against T. b. brucei, the most striking observation 
was the role of the 5-gem-dimethyl substituent in improving bioactivity (IC50 = 0.73 μM, 14b vs. 
2.50 μM, 14a and similarly 32b vs. 32a, 28b vs. 28a and 29b vs. 29a, Table 1.1). Though some 
3-aryl substituents were tolerated (see methoxyphenyl derivatives 28b and 29b), bioactivity and 
selectivity were maximised when the substituent was removed entirely (IC50/SI = 0.75 μM/> 106 
32b). The 3-position appears to plays a role in controlling selectivity over mammalian cells, in 
that a 5-gem-dimethyl substituent alone depletes selectivity (SI = 7, 14b), while simultaneous 3-
substitution replenishes this (SI = 29, 28b and > 38, 29b) with retention of bioactivity. This was 
reflected in the aforementioned derivative 29b, containing both a 5-gem-dimethyl and 3-hydro 
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substituent, which is four times as potent as the lead compound (IC50 = 0.75 μM) and twice as 
selective (SI > 106).  
 
In the absence of a known biological target for 14a, it is difficult to speculate the exact reasons 
for the observed SAR. Perhaps the compound occupies the active site of a protein, where the gem-
dimethyl group adequately fills a hydrophobic pocket, or the resulting increase in lipophilicity 
increases its uptake into relevant cellular compartments of the trypanosome. Attention to 
physiochemical properties such as lipophilicity are critical in determining the suitability of a drug 
compound, and the derivative 32b is similar to 14a in this regard. Both compounds exhibit 
parameters within Lipinski guidelines for oral bioavailability, where 32b is slightly more 
lipophilic (ClogP = 2.85)‡ than the lead compound (ClogP = 1.70). In particular, both compounds 
exhibit suitably low molecular weights (< 400 Da), PSA (59 Å2, 14a and 59 Å2, 32b)‡ and 
 
‡ Calculated using ChemDraw v. 16.0 
Table 1.1. Bioactivity against T. b. brucei 427 (IC50) and selectivity index (SI) over HEK 293 cells of 3-
substituted derivatives of the lead compound. Pentamidine was used as a positive control. 
 
 
 Compound R R'
 Yield (%) MW (gmol–1) ClogPa IC50 (μM) SI 
14a H 
 
> 99 362.85 1.70 2.50 ± 0.18b > 48 
14b Me 86 390.90 2.73 0.73 ± 0.12 7 
26a H 
 
13 404.50 3.24 > 10c - 
26b Me 58 432.56 4.28 > 10d - 
27a H 
 
47 472.50 4.12 > 10e - 
27b Me 82 500.55 5.16 Inactivef - 
28a H 
 
49 434.53 3.16 7.23 ± 1.06 3 
28b Me 35 462.58 4.20 2.91 ± 0.04 29 
29a H 
 
52 434.53 3.16 9.39 ± 1.54 2 
29b Me 44 462.58 4.20 2.21 ± 0.33 > 38 
30a H 
 
56 454.56 4.41 6.38 ± 1.10 1 
30b Me 47 482.62 5.45 > 10g - 
32a H 
 
42 328.40 1.81 > 10h - 
32b Me 55 356.46 2.85 0.75 ± 0.08 > 106 
aCalculated using ChemDraw v. 16.0. bAverage of IC50 values obtained from two separate assays (1.75 ± 
0.48 μM, 3.22 ± 0.31 μM). c77% activity at 83.3 μM. d93% activity at 39.7 µM.e17 % activity at 10.0 μM. 
f0% activity at 83.3 μM. g100% activity at 39.7 µM. h97% activity at 79.4 µM. 
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hydrogen bonding (one H-bond donor, four H-bond acceptors) required for penetration of the 
BBB, which is required for the treatment of stage II sleeping sickness.  
 
1.2.3 Investigation of the Benzothiophene Fragment of WEHI-0086109 
 
Further SAR information was pursued by synthesising substituted benzothiophene fragments and 
screening their benzothiazolyl amides (prepared via the established synthetic strategy) against T. 
b. brucei. The required acyl chloride fragments were accessed from cinnamic acids 21b–e using 
thionyl chloride and catalytic pyridine (Scheme 1.3), however the type and position of 
substituents about the benzene ring was limited by the availability of cinnamic acids and the 
underlying reaction mechanism. For example, the use of meta-substituted cinnamic acids (21d 
and e) gave a mixture of 5- and 7-substituted benzothiophenes, where selective recrystallisation 
afforded the 5-methoxy (22d) or 7-bromo (22e) regioisomer as the major isolated product 
(Scheme 1.3). The yields of these syntheses suffered as expected (29%, 22d and 7%, 22e 
respectively), though this is reflective of the literature.91 The isomerisation is a consequence of 
the free rotation within intermediate 33 in the reaction mechanism, the  cyclisation of which is 
asymmetric in the presence of a  meta-substituent (Scheme 1.3).92 The 6-substituted derivatives 
of 14a (34–35) were therefore more straightforward to synthesise, though these exhibited reduced 
bioactivity upon screening against T. b. brucei (34–35, Table 1.2). Despite this, the derivatives 
did serve to reinforce the benefit of the 5-gem-dimethyl group (IC50/SI = 2.27 μM/> 37, 34b vs. 
7.77 μM/> 11, 34a and similarly 35b vs. 35a) and subsequent derivatives were therefore 
synthesised with this unit in place. While a 5-methoxy substituent was detrimental to activity (36), 
the introduction of a 7-bromo substituent (37) led to an eight-fold increase in bioactivity (IC50 = 
0.32 μM) and a three-fold increase in selectivity (SI > 130) with respect to 14a, warranting further 
investigation of this position. This derivative exhibits similar lipophilicity (CLogP = 3.60, PSA = 
59 Å2) than the lead compound and the 3-hydro derivative 32b, though the higher MW (469.80 
gmol–1) may impact its druglikeness and potential BBB penetration.  
 
The final derivatives of this series examined the effect of replacing the entire benzothiophene 
fragment with related heterocycles. Removal of the benzene ring from the fragment (via a 
Schotten–Baumann amidation between 20b and 2-thiophenecarbonyl chloride, 40) abolished 
bioactivity (41, Table 1.2), revealing its necessity. Replacing the fragment with the structurally 
similar benzothiazole (via EDC-mediated coupling of 20b and benzothiazole-2-carboxylic acid, 
38) led to a two-fold increase in bioactivity (IC50 = 1.41 μM, 39) while maintaining selectivity (SI 
> 59). This derivative effectively serves as an analogue of 32b, where the 3-position is occupied 
by a lone pair of electrons in place of a proton.  This grants 39 an additional H-bond acceptor and 
lower degree of lipophilicity than the lead compound (CLogP = 1.91, PSA = 71 Å2), rendering it 
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slightly less suitable for BBB penetration, but a generally more suitable drug compound in terms 
of bioavailability. 
 
Scheme 1.3. Synthetic strategy for the preparation of derivatives of the lead compound in which the 
benzothiophene fragment is varied. Further yields are reported in Table 1.2. a. SOCl2, pyridine in 
chlorobenzene, reflux. b. SOCl2, DMAP (∶B in scheme) in heptane, reflux. c. 20, pyridine in toluene, 
reflux. 
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The SAR information gained from this series was particularly useful for the design of further drug 
compounds. Given the demonstrated importance of the 7-position for bioactivity and selectivity, 
preliminary work was initiated to incorporate other substituents at this position, using available 
materials. The acyl chloride 22e was converted to the corresponding methyl ester in preparation 
for the cross-coupling of aryl substituents to the 7-bromo handle (Scheme 1.4). A useful protocol 
was developed for the chemoselective cross-coupling of aryl groups to either the 7-bromo handle 
(monocoupling) or the 7-bromo and 3-chloro handles simultaneously (dicoupling). This divergent 
protocol confirmed the hypothesis (presented in Section 1.2.2) that the activated system 23 could 
facilitate palladium-catalysed C-Cl cross-coupling (Scheme 1.4), and the choice of a bidentate 
diphenylphosphinoferrocene (dppf) or PPh3 ligand appeared to play a key role in controlling 
chemoselectivity at the chloro handle. In the knowledge that a m-methoxyphenyl substituent was 
best tolerated at the 3-position (see 29b, Table 1.1), the corresponding boronic acid was chosen 
for preparation of the dicoupled fragment 43, and the resulting methoxy methyl signals were 
clearly discernible at 3.89, 3.84 and 3.77 ppm in the 1H NMR spectrum. While mass spectrometry 
clearly evidenced the formation of both structures,§ the presence of trace amounts of uncoupled 
 
§ Sodium adducts were observed at m/z 325 (42) and m/z 427 (43) via ESI (positive mode).  
Table 1.2. Bioactivity against T. b. brucei 427 (IC50) and selectivity index (SI) over HEK 293 cells of 
derivatives of the lead compound in which the benzothiophene fragment is varied.  Pentamidine was used 
as a positive control. 
 
Compound R Het Yield (%) MW (gmol-1) ClogPa IC50 (μM) SI 
14a H 
        
> 99 362.85 1.70 2.50 ± 0.18b 48 
34a H 
   
94 376.87 2.19 7.77 ± 2.01 > 11 
34b Me 94 404.93 3.23 2.27 ± 0.54 > 37 
35a H 
     
58 441.74 2.56 > 10c - 
35b Me 66 469.80 3.60 6.53 ± 0.38 > 78 
36 Me 
        
41 420.93 2.65 5.86 ± 1.74 > 14 
37 Me 
        
50 469.80 3.60 0.32 ± 0.23 > 130 
39 Me 
        
62 357.45 1.91 1.41 ± 0.17 > 59 
41 Me 
        
75 306.40 1.50 > 10d - 
aCalculated using ChemDraw v. 16.0. bAverage of IC50 values obtained from two separate assays (1.75 ± 
0.48 μM, 3.22 ± 0.31 μM). c80% activity at 79.4 µM. d94% activity at 39.7 µM.  
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starting material (and monocoupled material in the case of 43) impeded the full characterisation 
and utilisation of these building blocks, as these impurities were inseparable via column 
chromatography. Efforts were made to drive these processes to completion and consume these 
impurities and, though intriguing from a synthetic methodology perspective and worth 
investigating in future work, the pure fragments were not pursued further: more suitable strategies 
of investigating the 7-substituent would present themselves later in the project. 
 
 
Scheme 1.4. Development of a chemoselective (Cl/Br) Suzuki–Miyaura cross-coupling of the 
benzothiophene fragment, showing the activated nature of the substrate facilitating the use of a Pd(0) 
catalyst with a chloro handle. 
 
1.2.4 Investigation of the Amide Linker and Benzothiazole Fragment of WEHI-0086109 
 
Having developed an ample SAR profile for the benzothiophene fragment of the lead compound, 
similar investigations were carried out with respect to the benzothiazole fragment and amide 
linker. It was reasoned that screening of an N-alkylated derivative of 14b against T. b. brucei 
would reveal the importance of the secondary amide and, though N-methylation using a 
MeI/K2CO3 system was successful, the resulting derivative was poorly soluble in most organic 
solvents and ultimately discarded. The N-allyl derivative 44 (Scheme 1.5A) was therefore 
synthesised from the appropriate benzothiazole fragment 20c which, in turn, was prepared using 
N-allylthiourea (Scheme 1.5). The inactivity of this derivative against T. b. brucei (44, Table 1.3) 
demonstrated that the secondary amide was indeed essential for bioactivity.  
 
In regard to the benzothiazole fragment, the ketone presented itself as the most overt point of 
investigation, having already established the effect of a 5-gem-dimethyl substituent. Attempts 
were made to reduce the lead compound to the corresponding carbinol 45 using NaBH4, which 
would introduce an additional hydrogen bond donor and a stereogenic centre (Scheme 1.5B).** 
These efforts were unsuccessful using stoichiometric reducing agent, and the addition of excess 
NaBH4 returned evidence of the elimination product 46, the resulting alkenyl protons producing 
 
** The synthesis or attempted synthesis of compounds 20d, 48 and 45 were conducted as part of the Honours 
project of the author, before the commencement of this PhD program. 
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clear signals near 6.00 ppm and 6.50 ppm in the 1H NMR spectrum. This was likely a result of β-
elimination to form a stable, conjugated system during aqueous workup. Despite this, the ketone 
was found to be essential for bioactivity after its removal (via synthesis of the benzothiazole 
fragment 20d from o-chlorocyclohexanone, 47) depleted bioactivity (48, Table 1.3), implying the 
requirement of a hydrogen bond acceptor at this site of the scaffold.** Similar results (49 and 50, 
Table 1.3) were obtained when the fragment was replaced with related heterocycles (via 
amidation with the appropriate amines, Scheme 1.5C), implying that an unmodified benzothiazole 
fragment was best suited for antitrypanosomal activity.  
 
 
Scheme 1.5. Synthesis or attempted synthesis of A. N-allyl derivative; B. carbinol derivative; C. 
benzothiazolyl and thiazolyl derivatives of the lead compound. 
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1.2.5 Summary of Structure-Activity Relationships of WEHI-0086109 
 
Having investigated the three components of the thiazolyl-thiophenamide scaffold of WEHI-
0086109 (14a), the SAR with respect to T. b. brucei and HEK293 cells had been established 
(Figure 1.15). The existing thiazole fragment and secondary amide of 14a are both essential, 
where the ketone substituent is of particular importance. The only feasible change is the 
introduction of a 5-gem-dimethyl substituent, which was found to improve bioactivity, though 
simultaneous derivatisation of the benzothiophene fragment was required to maintain selectivity. 
The benzene component of the thiophene fragment proved essential, though bioactivity and 
selectivity was improved upon replacement of the entire fragment with a benzothiazole unit, and 
maximised in the presence of a 7- bromo substituent and absence of the 3-chloro handle.  
Establishing these relationships satisfied the first overarching aim of this work, but also presented 
an opportunity to use this information in the SAR-informed design of further derivatives. 
 
Figure 1.15. Summary of structure-activity relationships of  the thiazolyl-benzothiophenamide scaffold of 
WEHI-0086109 (14a) with respect to T. b. brucei and human (HEK293) cells. 
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Table 1.3. Bioactivity against T. b. brucei 427 (IC50) and selectivity index (SI) over HEK 293 cells of 
derivatives of the lead compound in which the thiazole fragment is varied.  Pentamidine was used as a 
positive control. 
 Compound Structure Yield(%) MW (gmol-1) ClogPa IC50 (μM) SI 
14a 
 
> 99 362.85 1.70 2.50 ± 0.18b 48 
44 
 
60 402.91 3.03 Inactivec - 
48 
 
64 348.86 3.28 > 10d - 
49 
 
30 344.83 3.31 > 10e - 
50 
 
49 294.77 1.71 > 10f - 
aCalculated using ChemDraw v. 16.0. bAverage of IC50 values obtained from two separate assays (1.75 ± 
0.48 μM, 3.22 ± 0.31 μM). c0 % activity at 10.0 μM. d> 50 % activity at 10.4 μM. e23 % activity at 10.0 
μM. f20 % activity at 10.0 μM.  
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1.2.6 SAR-Informed Design of Further WEHI-0086109 Derivatives 
 
With the SAR of the lead compound 14a established, the rational design of a new generation of 
derivatives was now possible. Theoretically, these would possess all of the favourable 
substitutions identified during the SAR study, including the 5-gem-dimethyl substituent, as well 
as the 3-hydro and 7-bromo substituents (i.e. 32b and 37, Scheme 1.6) and ideally exhibit additive 
bioactivity and selectivity upon biological testing.  
 
 
Scheme 1.6. SAR-informed design of further derivatives of the lead compound. 
 
Preparation of the envisioned derivative 51a required the synthesis of the appropriate 7-bromo 
thiophene fragment 53a (Scheme 1.7) in which the 3-chloro handle was absent, and this was 
achieved by the base-catalysed addition of methyl thioglycolate to the appropriate benzaldehyde 
(52a) in excellent yield (99%). After conversion to the corresponding carboxylic acid 54a, 
attempts were made to access the amide 51a via a Schotten–Baumann amidation with the amine 
20b as per previous derivatives, with no trace of the desired product. The carboxylic acid 54a was 
therefore utilised directly in the presence of various coupling reagents (EDC×HCl, DCC, HATU, 
PyBOP, CDI) with similar results, before comprehending the sheer insolubility of the product, 
which was suspected to have prevented it being carried through the workup. After modifying this 
to a simple filtration and wash, the desired derivative 51a was detected via 1H NMR and mass 
spectrometry,†† however its insolubility in most organic solvents impeded its full characterisation, 
and the derivative was not submitted for biological testing. Critically, such a poor solubility 
profile rendered 51a unsuitable as a drug compound, and this was addressed by utilising the 
bromo handle of the precursor 53a in a Suzuki–Miyaura reaction, using the conditions established 
for cross-coupling at this position in Section 1.2.3 (see Scheme 1.4) .‡‡ A 7-phenyl group was 
introduced in good yield (63%, 53c) and the corresponding derivative 51c was found to be 
tolerated upon screening against T. b. brucei and HEK293 cells (IC50/SI = 2.79 μM/> 30, 51b), 
Table 1.4). Given the druglikeness of this derivative was less than ideal (CLogP = 4.74), as was 
potential BBB penetration (MW = 432.56 gmol–1), the 7-methoxy derivative 51b was designed 
 
†† A broad singlet was observed at 13.61 ppm in the 1H NMR spectrum (amide proton) as well as [M–H]– 
and [M+2–H]– signals at m/z 433 and m/z 435, respectively, via ESI (positive mode). 
‡‡ The synthesis of 53c, 54c and 51c was performed by an undergraduate student under the supervision of 
the author. 
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to exhibit more favourable physiochemical properties (CLogP = 2.80, MW = 386.48 gmol–1). 
This derivative was accessible by a Schotten–Baumann amination via the acyl chloride, however 
its poor solubility left it operationally simpler to isolate from an EDC-mediated coupling via 
filtration (75% yield). Unfortunately, this became its downfall as, upon submission for inclusion 
in the T. b. brucei assay, 51c was unable to be accommodated due to its poor solubility (despite 
being an improvement on the 7-bromo derivative 51a).  
 
 
Scheme 1.7. Synthetic strategy for the preparation of 7-substituted derivatives of the lead compound. ND 
= not determined. 
 
 Table 1.4. Bioactivity against T. b. brucei 427 (IC50) and selectivity index (SI) over HEK 293 cells of 
derivatives of the lead compound resulting from SAR-informed design. Pentamidine was used as a positive 
control. 
 
 
Compound Structure MW (gmol-1) ClogPa IC50 (μM) SI 
14a 
 
362.85 1.70 2.50 ± 0.18b 48  
51ac 
 
435.35 3.71 - - 
51bc 
 
386.48 2.77 - - 
51c 
 
432.56 4.74 2.79 > 30 
 aCalculated using ChemDraw v. 16.0. bAverage of IC50 values obtained from two separate assays (1.75 ± 
0.48 μM, 3.22 ± 0.31 μM). cBiological activity could not be determined due to solubility issues.  
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1.2.7 Screening of WEHI-0086109 Derivatives Against T. b. rhodesiense 
 
It should be reiterated that the SAR of the lead scaffold had been established with respect to the 
non-human infective species, T. b. brucei.  In order to evaluate how the bioactivity translated to 
a more clinically relevant, human infective species, a select panel of the most promising 
derivatives developed in these series were screened against T. b. rhodesiense (Table 1.5).§§ The 
lead compound 14a was found to be almost four times less active against this strain (IC50 = 8.96 
μM) and sixteen times less selective (SI = 3). The poorly soluble 7-methoxy derivative was able 
to be accommodated by the conditions of the T. b. rhodesiense assay, exhibiting comparable 
activity to the lead compound (IC50 = 8.68 μM) with a two-fold increase in selectivity (SI = 6) 
over mammalian (L6) cells. Though all derivatives exhibited bioactivity in the low micromolar 
range, this was decreased by up to twenty-two-fold in some cases (37, Table 1.5) with respect to 
the non-human infective species, and the selectivity over mammalian cells also suffered. The 
most promising compound was the 3-hydro derivative 32b, which was almost twice as bioactive 
as the lead compound against T. b. rhodesiense (IC50 = 5.04 μM) and four times as selective (SI 
= 13), leaving this a suitable candidate for further development. 
 
Table 1.5. Bioactivity against T. b. rhodesiense STIB 900 trypomastigotes (IC50) and selectivity index (SI) 
over mammalian (L6) cells of selected derivatives of the lead compound. Melarsoprol was used as a 
positive control. 
 Compound Structure IC50 (μM) 
T. b. brucei 
SI 
HEK293 
IC50 (μM) 
T. b. rhodesiense 
SI 
L6 
14a 
    
2.50 ± 0.18a 48 8.96 ± 3.10 3 
32b 
 
0.75 ± 0.08 > 106 5.04 ± 1.21 13 
37 
 
0.32 ± 0.23 > 130 7.13 ± 2.91 4 
39 
 
1.41 ± 0.17 > 59 10.58 ± 3.18 3 
51bb 
 
- - 8.68 ± 1.27 6 
aAverage of IC50 values obtained from two separate assays (1.75 ± 0.48 μM, 3.22 ± 0.31 μM). bBiological 
activity against T. b. brucei could not be determined due to solubility issues. 
 
 
 
§§ Performed by Dr Marcel Kaiser, Swiss Tropical and Public Health Institute/University of Basel. 
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1.2.8 Synthesis of Type I Organometallic Derivatives of Nitazoxanide 
 
Having successfully made use of HTS in the development of new drug compounds for the 
treatment of sleeping sickness, focus was shifted to the alternative strategy of modifying existing 
drugs and repurposing them for the treatment of Chagas disease and leishmaniasis. As introduced 
in Section 1.1.6, the antiparasitic drug nitazoxanide is a suitable candidate in this regard, capable 
of accommodating organometallic moieties at two structural sites (i.e. type I and type II 
derivatives) to enhance its known antitrypanosomal action.84,85 The eight proposed type I 
derivatives are presented in Scheme 1.8A and, given the benzologue of nitazoxanide (17) is 
known to be more potent,85 the benzothiazolyl amides 55 were pursued first. Unfortunately, 
neither of the amidation protocols employed in the previous study (EDC-mediated coupling or 
Schotten–Baumann amidation) were successful, both returning the unreacted amine 60 and either 
carboxylic acid 59a or acyl chloride 59b. The poor solubility of the amine 60 in nonpolar organic 
solvents was noted, however this has not been reported to impede its reactivity under similar 
conditions in the literature.85 The reactivity of 60 in a condensation reaction was investigated for 
comparison, using ferrocenecarboxaldehyde (56c) (Scheme 1.8C). The imine 57a was not 
observed, neither with the use of a drying agent (MgSO4, to drive equilibrium forward), nor after 
heating the reactants in toluene (relying on the azeotropic removal of condensed water, as used 
by the Klahn group in the synthesis of related organometallic nifurtimox derivatives).79 The 
desired product 57a did present itself after the addition of an acid catalyst (H3PO4, to form the 
more reactive protonated aldehyde) to the latter conditions, albeit in low conversion (28%, 
possibly influenced by post reaction hydrolysis). This lack of reactivity is likely due to the 
electron-withdrawing nitro substituent reducing the nucleophilicity of these amine building 
blocks: similar results were obtained when employing the related nitrothiazole 61. It should be 
noted that the related organometallic nifurtimox analogues developed by the Klahn group79 
contained the reversed imine, the synthesis of which involved use of the nitroheterocycle as an 
electrophile, which is a much more electronically favourable reaction. Thankfully, the building 
block 61 was sufficiently reactive in the presence of EDC×HCl and the carboxylic acid 59a, 
affording the type I derivative 56a in good yield (75%), the first in this novel class of drug 
compounds. The 1H NMR spectrum for this derivative was sparse, bearing the signal at 8.34 ppm 
arising from the sole nitrothiazole proton, as well as the characteristic splitting pattern of the 
ferrocenyl moiety (two fine triplets and a singlet, from the symmetrically substituted and 
unsubstituted cyclopentadienyl rings, respectively) where the amide signal at 9.22 ppm was the 
main indication of a successful reaction. Ultimately, X-ray crystallography*** provided 
unambiguous confirmation of the desired structure, shown in Scheme 1.8D.  
 
*** Performed by Assoc Prof Michael Gardiner, Australian National University. 
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Scheme 1.8. A. Proposed type I organometallic derivatives of nitazoxanide. B. Attempted synthesis of 
type I benzothiazolyl ferrocenyl analogue of nitazoxanide. C. Attempted synthesis of type I ferrocenyl 
imine analogues of nitazoxanide. D. Synthesis of type I ferrocenyl amide analogue of nitazoxanide and 
crystal structure of the isolated product.  
 
In order to maintain focus on experimental design, the next priority became the selection of an 
appropriate derivative to compare and contrast with the newly synthesised derivative 56a. It was 
reasoned that the cymantrene analogue 56b would serve as an electron poor analogue of the same 
scaffold, capable of demonstrating the effect of electronic character on antitrypanosomal activity. 
In contrast to the commercially available ferrocenyl building blocks, functionalised cymantrenyl 
building blocks such as 63b require preparation from the parent compound, cymantrene 
(cyclopentadienylmanganese(I) tricarbonyl, Scheme 1.9A).93 Cymantrenecarboxylic acid (63b) 
was prepared in moderate yield (51%) via hydrolysis of the ortho-chlorobenzoyl precursor 63a, 
which was prepared in good yield (86%) via a Friedel–Crafts reaction with the corresponding 
acyl chloride 62. Aryl ketones are known to cleave readily to their corresponding carboxylic acids 
via a mixture of tert-butoxide and water, where a respective 10:3 molar ratio gives the optimal 
mixture of hydroxide, tert-butoxide and tert-butanol to carry out the cleavage mechanism 
(Scheme 1.9B).94 Ortho-chloroaryl substituents such as 63a undergo this process particularly 
smoothly due to their ability to eliminate benzyne (Scheme 1.9B).94 It was crucial that the 
presence of the carboxylic acid 63b was confirmed before any subsequent amidation reactions 
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were attempted, and this was largely possible via analysis of the 1H NMR spectrum and 
comparison with literature data.93 The absence of ortho-chloroaryl signals implied successful 
ketone cleavage, and the broad singlet at 12.96 ppm indicated the presence of the carboxylic acid 
functionality. Ultimately, the [M–H]– peak observed at m/z 247 via ESI (positive mode) provided 
reason to proceed with this building block in formation of the subsequent amides. Unfortunately, 
the desired cymantrenyl amide 56b was unable to be accessed via a coupling reagent or 
cymantrenecarbonyl chloride (Scheme 1.9B) as per the ferrocenyl analogue 56a, implying the 
cymantrenyl analogues would be even more challenging to access. 
 
Scheme 1.9. A. Synthesis of cymantrene building blocks. B. Mechanism for the cleavage of ortho-
chloroaryl ketones such as 63a. C. Attempted synthesis of a cymantrenyl derivative of nitazoxanide. 
 
1.2.9 Synthesis of Type II Organometallic Derivatives of Nitazoxanide 
While synthetic efforts toward the type I nitazoxanide derivatives afforded the first of a novel 
class of organometallic drug compounds, the reactivity of its precursors was deceiving, and 
similar challenges were to be encountered in pursuit of the type II derivatives. The four proposed 
derivatives are presented in Scheme 1.10A, and the synthetic strategy for these was the synthesis 
of the acetyl-protected parent compounds, followed by deprotection to release the free alcohol, 
with which the organometallic moiety could be coupled. As per the type I derivatives, pursuit of 
the benzothiazolyl scaffold was made a priority due to the precedent for higher potency,85 
however the same inertness of the amine 60 was observed. Given most reported syntheses of 
nitazoxanide involve a Schotten–Baumann amidation, the required acyl chloride 66b was 
prepared from acetylsalicylic acid (66a) and thionyl chloride. After varying amounts of 66a were 
detected after the reaction (via 1H NMR analysis), catalytic DMF was employed to push the 
reaction to completion in a reasonable timeframe (via formation of the highly reactive 
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chloroiminium ion 67, Scheme 1.10B), and the material was kept under an inert atmosphere and 
used immediately. Subjection of 66b to the amine 60 in the presence of Et3N did not produce the 
amide 17, and catalytic DMAP was therefore added to form the more reactive acylpyridinium 
intermediate, but neither this, nor the use of pyridine as the reaction solvent, afforded the desired 
product. The previous EDC-mediated coupling conditions were employed using both the acetyl-
protected 66a and free salicylic acid, to no avail. Finally, the conditions reported by Navarrete-
Vázquez (en route to the benzologue 17) were employed, using Et3N as the solvent with catalytic 
DMAP. 85 This gave a mixture of the desired product 17 and products of hydrolysis, where signals 
near 13.00 ppm in the 1H NMR spectrum may have arisen from salicylate hydroxyl or carboxylic 
acid functionalities. Facile hydrolysis of both the acetyl and acyl chloride functionalities was the 
suspected culprit, and it is possible that the water-miscible solvents used herein may have 
contained trace water, despite rigorous drying processes (see General Experimental, Section 
1.4.1). As a result, liberation of the acetyl group may have occurred in situ before or after 
amidation, with the former impeding amide coupling. After even nitazoxanide itself was unable 
to be accessed using a coupling reagent or a patented industrial synthesis (Scheme 1.10B),95 it 
was clear that an alternate synthetic route was necessary, in which the potential hydrolysis of the 
salicylate fragment was eliminated.  
 
 
Scheme 1.10. A. Proposed type II organometallic derivatives of nitazoxanide. B. Attempted synthesis of 
type II ferrocenyl analogues of nitazoxanide. 
 
It was reasoned that by reordering the synthesis of type II derivatives to begin with the coupling 
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prioritised, to allow direct comparison with the previously synthesised derivative 56a in 
demonstrating which derivatisation strategy (i.e. type I or II) was more effective for 
antitrypanosomal activity. The tert-butoxycarbonyl (Boc) derivative of salicylic acid  was 
therefore synthesised in preparation for the coupling reaction, in poor yield (68a, 32%). The 
conditions for the coupling of ferrocenecarboxylic acid (59a) via an ester linkage were similar to 
those employed throughout this work, and were taken from the study by Mateo-Alonso and Prato 
regarding ferrocenyl derivatives of a related system.96 The EDC-mediated coupling afforded the 
ferrocenyl fragment 69a in excellent yield (88%), though heating of the reaction to 40 °C was 
required to drive the reaction to completion, after unreacted ferrocenylcarboxylic anhydride (59d, 
a reaction intermediate) was detected and identified via comparison with literature 1H NMR 
data.97 In order to liberate the free carboxylic acid to participate in the final amide coupling, 
deprotection of the Boc group was attempted using excess trifluoroacetic acid (TFA). 
Unfortunately, this was not a selective process, and the detection of significant amounts of 
ferrocenecarboxylic acid via 1H NMR analysis indicated the ferrocenyl ester linkage had also 
been cleaved.  Reduction to 2.0 equivalents of TFA yielded similar results, as did the use of 
ytterbium(III) triflate (Yb(OTf)3), which is known to facilitate highly selective deprotection 
protocols.98 In contrast, aqueous H3PO4 was unable to cleave either functionality, and the 
synthetic strategy was modified to replace the Boc group with a more appropriate alternative.  
This came in the form of an allyloxycarbonyl (alloc) group, which was introduced to salicylic 
acid in moderate yield (67%) via an SN2 reaction with allyl bromide in neat N,N-
diisopropylethylamine (DIPEA). The formation of allyl salicylate 68b was confirmed via 
comparison with literature NMR data,99 which was crucial given the corresponding allyl ether 
(i.e. allylation at the alcohol) produces a very similar 1H NMR spectrum.99 Coupling of the 
ferrocenyl moiety was achieved in excellent yield (89%) using the previous conditions, with no 
detection of the anhydride 59d in this case. Deprotection to give the required carboxylic acid 70 
was now a chemoselective process, via formation of palladium(II) p-allyl intermediate and 
scavenging of the allyl cation by dimedone. The free carboxylic acid 70 was obtained in moderate 
yield (58%), enabling the final amidation, which gave the desired type II derivative 65a in good 
yield (71%) using EDC×HCl. As in the case of the type I derivative 56a, the success of the 
amidation was suggested by the broad singlet arising from the amide proton at 10.78 ppm, and 
the structure was unambiguously confirmed via X-ray crystallography (Scheme 1.11).††† 
 
††† Performed by Dr Christopher Richardson, University of Wollongong. 
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Scheme 1.11. A. Alternative synthetic route to type II thiazolyl ferrocenyl derivative of nitazoxanide and 
crystal structure of the isolated product.  
 
The arrival at derivatives 56a (type I) and 65a (type II) presented an opportunity to directly 
compare the effect of two strategies (type I and II) of incorporating a antitrypanosomal ferrocene 
unit into the structure of nitazoxanide. Many of the conceived derivatives were not accessible via 
the attempted synthetic routes, and alternative routes to these (and suitable analogues) will be 
discussed in Section 1.3.2. Furthermore, the synthesis of most cymantrenyl derivatives had not 
yet been attempted, and was still highly feasible. Before more derivatives were pursued, however, 
it was decided that the two analogues in hand (56a and 65a) were to be screened against T. cruzi 
and Leishmania to obtain preliminary data capable of guiding the next steps of this study.  
 
1.2.10 Screening of Type I and II Ferrocenyl Derivatives of Nitazoxanide against T. cruzi and 
Leishmania 
 
Many of the biological assays available for the screening of drug compounds against T. cruzi and 
Leishmania differ from those for T. brucei, due to the underlying differences in their life cycles. 
While T. brucei spends the majority of its time within the bloodstream of the human host as the 
trypomastigote form, both T. cruzi and Leishmania accumulate within human cells as the 
amastigote form (see Fig. 1.3, Section 1.1.2). The Avery group has therefore developed assays 
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infected with amastigotes of these trypanosomes, providing a clinically relevant model for 
determining biological activity. These are image-based assays, where the toxicity of drug 
compounds can be determined in regard to both the trypanosomes and the human host cells in the 
same assay. The bioactivity of the ferrocenyl derivatives 56a and 65a was determined using these 
assay conditions, using the parent drug nitazoxanide (³ 98%, Sigma-Aldrich) as a positive control, 
along with nifurtimox and benznidazole (T. cruzi) and Amphotericin B (L. donovani) as additional 
controls (Table 1.6). Unfortunately, neither of the ferrocenyl derivatives showed significant 
bioactivity (IC50 < 10 μM) against either species, despite being largely non-toxic to mammalian 
cells. Bioactivity in the micromolar range was observed in all cases, however this may have been 
due to the antitrypanosomal metabolite ferrocenecarboxylic acid (59a), and the inclusion of 59a 
as an additional control may confirm this suspicion in future work. Crucially, the parent drug 
nitazoxanide was found to be inactive against T. cruzi and less active against Leishmania than 
indicated in the literature,84,85 inviting analysis of the validity of these results. Both of the relevant 
literature studies involved the use of T. cruzi epimastigotes and Leishmania promastigotes in the 
biological assays, and these forms of the parasites are present in the insect vector stage of their 
life cycles (see Fig. 1.3, Section 1.1.2).9a The assay used herein employed intracellular 
amastigotes in both cases.  Furthermore, the species of Leishmania used herein was L. donovani, 
while the literature studies used L. mexicana, and the difference in both species and form of 
parasite used in this work is the first plausible explanation for the conflicting results obtained 
herein. While this discrepancy in the antitrypanosomal activity of nitazoxanide was clear with 
respect to T. cruzi (IC50 = 18.74 μM (lit.)84 vs. 0% activity at 73.26 μM (Table 1.6)), the compound 
was still found to exhibit low micromolar activity against L. donovani (IC50 = 11.20 μM), implying 
that other factors may have contributed to the inactivity of the ferrocenyl derivatives 56a and 65a 
for this species. In regard to the type I derivative 56a, a likely explanation for the observed 
inactivity is that replacement of the salicylate fragment of nitazoxanide deviates too far from the 
tolerated SAR profile, preventing this derivative from binding to its usual target. It is also possible 
that the effect of electronic character introduced in Section 1.1.6 may have influenced these 
results, in that the electron-rich ferrocenyl moiety may have increased the electron density of the 
nitro group, preventing its bioreduction in vitro. Having said this, the lack of conjugation between 
the two relevant fragments would render this electronic effect quite striking, and this could be 
further investigated via the pursuit of the electron-withdrawing cymantrenyl analogues, 
particularly those with a conjugated imine linker (57b and 58b). A likely explanation for the 
inactivity of the type II derivative 65a is the susceptibility of the ferrocenyl ester to hydrolysis, 
which is essential for bioactivity due to the release of the active drug, tizoxanide. The steric bulk 
of the ferrocenyl moiety may have prevented the cleavage of 65a in vitro, preventing the drug 
compound from binding to its biological target, or from being transported into the trypanosomal 
cell at all. In regard to the latter, the inclusion of the active drug, tizoxanide, as an additional 
 42 
control may have assisted in clarifying this hypothesis. Finally, it was noted that the iron centre 
of either derivative 56a or 65a was capable of reducing the nitro group of second drug molecule, 
however this would be highly concentration dependent, and presents implications both 
detrimental and beneficial to bioactivity. For example, while this would result in increased 
amounts of the antiparasitic ferrocenium ion, the process could also interfere with other 
mechanisms of action, or uptake into parasitic cells, if it occurred prematurely.  
There is precedent to have these compounds retested against epimastigotes of T. cruzi and 
promastigotes of L. mexicana for direct comparison with the literature, though it can also be 
argued that the assay used herein is a more clinically valid model. Both T. cruzi and Leishmania 
spend the majority of their time in the human host in the intracellular amastigote form, while the 
forms utilised in the literature are more relevant in the stage of the life cycle spent within the 
insect vector (see Fig. 1.3, Section 1.1.2).9a  Furthermore, the literature assays did not use an 
intracellular model, and therefore the ability of drugs to enter human host cells to reach 
trypanosomes may not have been taken into account. It is difficult to argue which species of 
Leishmania gives a more appropriate disease model, as L. donovani is responsible for the most 
serious form of the disease (visceral leishmaniasis), while L. mexicana causes the more common 
form (cutaneous leishmaniasis).9a Ideally, a panel of multiple species should be accommodated 
by the biological assays to encourage the development of broad-spectrum antileishmanial drugs. 
The idea of developing broad-spectrum drugs capable of treating both Chagas disease and 
leishmaniasis was an overarching theme of this project and the results obtained (Table 1.6) 
suggest that the scaffold of nitazoxanide may not be a suitable for this purpose: it appears that the 
Table 1.6.  Bioactivity (IC50) of ferrocenyl derivatives of nitazoxanide against T. cruzi (Tulahuen strain) 
amastigotes within murine (3T3) cells and L. donovani (strain: MHOM/IN/80/DD8) amastigotes within 
human (THP-1) cells. Nifurtimox and benznidazole (T. cruzi) and Amphotericin B (L. donovani) were used 
as positive controls. 
 
 
Compound Structure MW 
(gmol-1) 
ClogPa IC50 (μM) 
T. cruzi 
IC50 (μM) 
3T3 
IC50 (μM) 
L. donovani 
IC50 (μM) 
THP-1 
nitazoxanide 
 
307.28 –0.18  Inactiveb  Inactiveb 11.20 ± 0.81 > 20c 
56a 
 
357.17 0.19 > 20d Inactiveb > 20e Inactivef 
65a 
 
477.27 1.59 > 20g Inactiveb > 20h > 20i 
aCalculated using ChemDraw v. 16.0. b0% activity at 73.26 μM. c56% activity at 80.00 μM. d58% activity 
at 36.63 μM. e80% activity at 40.00 μM. f0% activity at 80.00 μM. g93% activity at 73.26 μM. h55% activity 
at 40.00 μM. i54% activity at 80.00 μM. 
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bioactivity of the drug against T. cruzi is specific to the epimastigote form of the parasite, and not 
the more clinically relevant, intracellular amastigote form (Table 1.6). While the drug is still an 
appropriate candidate for repurposing against leishmaniasis (IC50 = 11.20 μM (L. donovani)), the 
treatment of both leishmaniasis and Chagas disease may require the selection of a different 
existing drug scaffold. 
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1.3 Conclusions and Future Directions 
 
1.3.1 Conclusions 
 
The overall aim of this project has been to develop new antitrypanosomal drugs using two robust 
methods of drug discovery, in order to add to the growing artillery of new treatments for 
trypanosomal neglected tropical diseases. The first of these methods was high-throughput 
screening, from which the lead compound WEHI-0086109 (14a) was identified as a potential 
drug treatment for African sleeping sickness (IC50/SI = 2.50 μM/> 48 (T. b. brucei), Fig. 1.16A). 
Derivatisation of the scaffold of 14a allowed structure-activity relationships to be established, 
revealing that components such as the ketone and amide of 14a are essential for bioactivity and 
selectivity, while modifications such as the addition of a 5-gem-dimethyl, 3-hydro or 7-bromo 
substituent improve these. These relationships can now inform the design new generations of 
derivatives (initiated in this work) however, as it stands, the study produced a novel class of 
thiazolyl-benzothiophenamides as suitable drug treatments for African sleeping sickness. 
Critically, an attention to Lipinski guidelines (CLogP, MW, H-bond donors and acceptors) 
ensured that derivatives maintained a suitable physiochemical profile to maximise their 
druglikeness. In particular, the 3-hydro, 5-gem-dimethyl derivative 32b (Fig. 1.16A), which was 
more bioactive and selective than 14a against T. b. brucei (IC50/SI = 0.75 μM/> 106) and the 
human infective species T. b. rhodesiense (IC50/SI = 5.04 μM/13) was identified as a suitable 
candidate for further development.  
 
The second method of drug discovery utilised in this work was drug repurposing, and a series of 
organometallic derivatives of the existing antiparasitic drug nitazoxanide were designed for the 
treatment of Chagas disease and leishmaniasis. The proposed series consisted of both ferrocenyl 
and cymantrenyl derivatives, including imine analogues, however the apparent inertness of the 
required building blocks restricted this series to two derivatives (Fig. 1.16B). These each 
contained a ferrocene unit in place of the salicylate fragment (56a) or acetyl group (56b) of 
nitazoxanide, but did not show significant antitrypanosomal activity upon screening against T. 
cruzi and L. donovani in vitro. While various explanations for this were postulated (such as 
insufficient SAR profiles or resistance to in vivo hydrolysis), the observation that nitazoxanide 
itself was inactive against T. cruzi and less active against Leishmania than indicated in the 
literature84,85 invited reanalysis of the suitability of this scaffold for designing broad-spectrum 
antitrypanosomal drug treatments. This study therefore validated nitazoxanide as a suitable 
treatment for leishmaniasis (IC50 = 11.20 μM (L. donovani)), but not for Chagas disease (0% 
activity at 73.26 μM). The two ferrocenyl derivatives 56a and 65a serve as the first entries in a 
novel class of organometallic drug compounds, and it is suspected that the pursuit of their 
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cymantrene analogues in future work may lead to novel organometallic treatments for 
leishmaniasis.   
 
 
Figure 1.16. Summary of the achievements of this project. 
 
In conclusion, the overall aims for this project were met in the development of novel thiazolyl-
benzothiophenamides for the treatment of African sleeping sickness, as well as novel ferrocenyl 
derivatives of nitazoxanide informing the design of further antileishmanial agents in future work. 
The former study in particular reinforces the power of public-private partnerships in the 
development of new drug treatments for trypanosomal diseases, and both studies have utilised 
robust methods of drug discovery in pursuit of further means to eradicate neglected tropical 
diseases, which is becoming an increasing global priority.43 
 
1.3.2 Future Directions 
 
The results observed in both studies within this project have informed the next steps for 
developing antitrypanosomal drugs, with a focus on both the drug scaffolds themselves and the 
assay protocols used to determine their bioactivity. For example, the derivatives of 14a were 
found to be up to twenty-two-fold less active when tested against the human infective species T. 
b. rhodesiense, suggesting that further derivatives may need to be developed with respect to T. b. 
rhodesiense or T. b. gambiense. The same panel of derivatives should therefore undergo screening 
against the more predominant species, T. b. gambiense, before further work is initiated. The 
ultimate goal of this study is to develop a drug candidate suitable for preclinical studies, and such 
a candidate would exhibit bioactivity in the nanomolar range. The SAR of 14a established herein 
can guide the pursuit of this level of potency. In the knowledge that the 5-gem-dimethyl and 7-
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bromo substituents improve bioactivity and selectivity, a more thorough analysis focused 
exclusively on these positions would be a suitable starting point. In the suspicion that the 5-gem-
dimethyl substituent may occupy a hydrophobic binding pocket within a biological target, related 
modifications at this site can probe this further (Fig. 1.17). The necessary building blocks for ring 
expansion (71) and the introduction of chiral alkyl and aryl substituents (72) are commercially 
available. Furthermore, procedures have been reported for 5-spirocyclic building blocks such as 
73, including the 5-oxetanyl derivative 74: the oxetane moiety is a known bioisostere for the gem-
dimethyl group with more favourable druglike properties. In regard to the 7-position, it was found 
within this work that a 7-phenyl derivative was tolerated, but not as potent as the 7-bromo 
substituent, implying that non-aryl moieties should be a priority for derivatisation. Commercially 
available 3-substituted 2-fluorobenzaldehydes (75) or the corresponding pyridine analogue 77 
should give access to other 7-substituted derivatives (76 and 77) in pursuit of a drug compound 
of suitable potency for preclinical studies. 
 
 
 
Figure 1.17. Plans for further derivatisation of the scaffold of 14a in future work. 
 
Though preliminary results for the repurposing of nitazoxanide suggested that an alternative 
scaffold may be necessary for the treatment of Chagas disease, other organometallic derivatives 
from the originally proposed series may be effective in the treatment of leishmaniasis. A possible 
explanation for the lack of bioactivity of the type I ferrocenyl derivatives was proposed to be the 
electron-rich nature of the ferrocenyl unit, and this could be examined via the synthesis of the 
cymantrene analogue 56b (Fig. 1.18). Though conventional methods of amidation were 
unsuccessful, procedures accommodating sterically hindered or electron-poor amines have been 
developed, such as the generation of acyl fluorides.102 The imine analogues 58a and 58b can serve 
as a means of investigating the effect of electronic character further, however these were unable 
to be accessed via conventional methods. Other methods for the synthesis of imines involving 
metal catalysis, particularly those developed for electron-deficient amines,103 may solve this 
problem. Alternatively, interchanging of the amine and aldehyde functionalities can facilitate a 
more favourable electronic demand in the synthesis of the reversed imines 58', which may also 
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be more stable to hydrolysis, and this synthetic strategy was used for the organometallic 
nifurtimox derivatives developed by the Klahn group.79 Alternatively, the replacement of the 
imine linker with an alkene (79, accessible via ring-closing metathesis) may serve as an 
alternative route to a conjugated system. Finally, the type II cymantrene analogue 65b was not 
pursued within this preliminary work: the electron-withdrawing nature of this organometallic unit 
may render the ester moiety more susceptible to hydrolysis in vivo and bring the envisioned 
mechanism of action to fruition, supporting the field of medicinal organometallic chemistry as a 
promising strategy for the treatment of neglected tropical diseases. 
 
 
Figure 1.18. Plans to address the synthetic challenges encountered in the development of organometallic 
derivatives of nitazoxanide in future work. OM = organometallic moiety. 
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1.4 Experimental 
 
1.4.1 General Experimental 
 
All commercial reagents were used as received, unless otherwise noted. Anhydrous solvents were 
either purchased from commercial suppliers or passed over activated alumina, before being dried 
over pre-activated 3, 4 or 5 Å molecular sieves and stored under nitrogen gas. Reaction vessels 
were oven-dried (120 °C) overnight before use and all reactions were carried out under a nitrogen 
atmosphere, unless otherwise noted. Reactions were monitored via thin-layer chromatography 
(TLC) analysis using aluminium-backed silica gel sheets coated with fluorescent indicator F254 
and visualized under UV light (254 nm) and either potassium permanganate stain (1.5 g KMnO4, 
10 g K2CO3, 1.25 mL aqueous NaOH (10% v/v) in 200 mL water) or anisaldehyde stain (4 mL 
anisaldehyde, 5 mL concentrated H2SO4, 2 mL glacial AcOH in 150 mL EtOH). Column 
chromatography was performed under compressed air using flash grade silica gel (40–60 nm). 
NMR spectroscopy was conducted using a Bruker 500 (500 MHz, 1H, 125 MHz, 13C), Bruker 400 
(400 MHz, 1H, 100 MHz, 13C), Varian 500 (500 MHz, 1H, 125 MHz, 13C) or Varian 300 (300 
MHz, 1H, 75 MHz, 13C) spectrometer. For samples dissolved in CDCl3 (0.1% v/v TMS), chemical 
shifts (δ) have been reported in parts per million (ppm) and referenced to the CDCl3 signal (7.26 
ppm, 1H, 77.0 ppm, 13C) or TMS signal (0.00 ppm, 1H and 13C). Those dissolved in DMSO-d6 
have been referenced to the (CD3)2SO signal (2.50 ppm, 1H, 39.5 ppm, 13C) and those dissolved 
in acetone-d6 have been referenced to the (CD3)2CO signal (2.05 ppm, 1H, 29.9, 13C). Coupling 
constants (J) are reported in hertz (Hz). Multiplicities of NMR signals have been abbreviated as 
s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), dt (doublet of triplets), dq 
(doublet of quartets) or m (multiplet) and some denoted as app (apparent) or br. (broad). High 
resolution mass spectrometry (HRMS) was carried out using a Waters Xevo G1 QTof mass 
spectrometer. Infrared data was collected on either a Shimadzu IRAffinity-1 Miracle 10 Fourier 
transform infrared (FTIR) or Bruker Vertex 70 FTIR instrument. High-performance liquid 
chromatography (HPLC) was conducted using a Shimadzu Prominence-i LC-2030C HPLC 
system equipped with a PDA detector, under reversed-phase conditions. Purity analysis was 
conducted using a Waters SunFire C18 column at 1.0 mL/min and 25 °C, with detection at 254 
nm or 280 nm. Unless otherwise noted, analytes were eluted using a concentration gradient of 50 
– 100% solvent B in A over 10 minutes, followed by 100% B for a further 10 minutes, where A 
= water/TFA (99.9:0.1) and B = MeCN. The precatalysts Pd(dppf)Cl2×CH2Cl2104 and 
Ni(dppe)Cl2105 were prepared as per the literature. Biological assays against T. brucei/HEK293 
cells,58 T. cruzi/3T3 cells100 and L. donovani/THP-1 cells101 were performed within the group of 
Prof Vicky Avery (Discovery Biology, Griffith Institute for Drug Discovery, Griffith University) 
using their previously reported methods. The T. b. rhodesiense assay was performed by Dr Marcel 
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Kaiser (Swiss Tropical and Public Health Institute/University of Basel) using his previously 
reported method.106 See appendix for NMR spectra of novel compounds.  
 
1.4.2 Building Blocks for Derivatives of WEHI-0086109 (14a) 
 
Synthesis of 2-bromocyclohexane-1,3-dione (19a): 
 
A suspension of 1,3-cyclohexanedione (2.99 g, 26.67 mmol, 1.0 equiv.) in CH2Cl2 (12 mL) was 
stirred at 0 °C and Br2 (1.4 mL, 27.18 mmol, 1.0 equiv.) added dropwise over 15 minutes. The 
reaction mixture was allowed to warm to room temperature and stirred for 1.5 hours before the 
precipitate was filtered and washed with a solution of toluene/CH2Cl2 (50:50). The crude product 
was recrystallised in water and EtOH to give the pure product as off-white crystals (4.21 g, 22.04 
mmol, 83%).  
 
MS(ESI) m/z: 191, [M+H]+; 193, [M+2+H]+. 1H NMR (500 MHz, CDCl3): δ 2.58 (t, J = 6.4 Hz, 
4H, CH2-CO), 1.99 (quint, J = 6.4 Hz, 2H, CH2) ppm. The signal arising from the CH(Br) proton 
was not detected, presumably due to rapid keto-enol tautomerisation. 13C NMR (125 MHz, 
CDCl3/DMSO-d6, 95:5): δ 99.8 (CH2, 2´CH2-CO), 33.6 (br., CH, CH(Br)), 20.4 (CH2, CH2) ppm. 
The signal arising from the CO carbons could be detected at approximately 191.1 ppm, and a 
second signal at 175.0 ppm (presumably arising from the CO or =C-OH carbon of the enol 
tautomer), but these were too broadened to report. Apart from the aforementioned discrepancies, 
the NMR data match that previously reported.87a 
 
Synthesis of 2-bromo-5,5-dimethylcyclohexane-1,3-dione (19b): 
 
A suspension of dimedone (3.00 g, 21.40 mmol, 1.0 equiv.) in CH2Cl2 (40 mL) was stirred at 0 
°C and Br2 (1.1 mL, 21.34 mmol, 1.0 equiv.) added dropwise over 15 minutes. The reaction 
mixture was allowed to warm to room temperature and stirred for 2 hours before the precipitate 
was filtered and washed with cold Et2O to leave the pure product as an off-white powder (4.70 g, 
21.40 mmol, > 99%).    
 
MS(ESI) m/z: 219, [M+H]+; 221, [M+2+H]+.1H NMR (500 MHz, CDCl3/DMSO-d6, 95:5): δ 
6.52 (br. s, 1H, CH(Br)), 2.46 (s, 4H, CH2-CO), 1.10 (s, 6H, CH3) ppm. 13C NMR (125 MHz, 
CDCl3/DMSO-d6, 95:5): δ 181.3 (br., CO or =C-OH), 98.6 (CH, CH(Br) or =C-Br), 47.1 (CH2, 
O
O
O
O
Br
OH
O
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CH2Cl2, 0°C - r.t.
1.5 h
O
O
O
O
Br
OH
O
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CH2Cl2, 0°C - r.t.
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2´CH2-CO), 31.8 (QC, C(CH2)2, 27.8 (CH3, 2´CH3) ppm. The signal at 98.6 ppm was 
significantly downfield from that observed in the literature (66.6 ppm) and may have arisen from 
the =C-Br carbon of the enol tautomer. Similarly, the signal at 181.3 ppm was comparatively 
upfield (lit. 193.0 ppm) and may therefore have arisen from the CO or =C-OH carbon of the enol 
tautomer. Apart from these discrepancies, the NMR data match that previously reported.87b 
 
Synthesis of 2-amino-5,6-dihydrobenzo[d]thiazol-7(4H)-one (20a): 
 
A solution of 2-bromocyclohexane-1,3-dione (4.00 g, 20.94 mmol, 1.0 equiv.), thiourea (1.63 g, 
21.41 mmol, 1.0 equiv.) and pyridine (1.8 mL, 22.30 mmol, 1.0 equiv.) in MeOH (20 mL) was 
heated at reflux for 4 hours. The precipitate was filtered and washed with cold MeOH to leave 
the pure product as yellow crystals (2.46 g, 14.62 mmol, 70%).  
 
1H NMR (500 MHz, DMSO-d6) δ 8.09 (s, 2H, NH2), 2.67 (t, J = 6.2 Hz, 2H, CH2-C-N), 2.36 (t, 
J = 6.0 Hz, 2H, CH2-CO), 1.98 (app. quint, J = 6.3 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, 
DMSO-d6) δ 189.5 (QC, CO), 173.5 (QC, C-NH2), 168.1 (QC, C-N), 118.5 (QC, C-CO), 36.8 
(CH2, CH2-C-N), 26.7 (CH2, CH2-CO), 22.5 (CH2, CH2) ppm. The NMR data match that 
previously reported.107a 
 
Synthesis of 2-Amino-5,5-dimethyl-5,6-dihydrobenzo[d]thiazol-7(4H)-one (20b): 
 
A solution of 2-bromo-5,5-dimethylcyclohexane-1,3-dione (3.85 g, 17.57 mmol, 1.0 equiv.), 
thiourea (1.34 g, 17.60 mmol, 1.0 equiv.) and pyridine (5.7 mL, 70.62 mmol, 4.0 equiv.) in EtOH 
(20 mL) was heated at reflux for 18 hours. The solution was concentrated by half and then diluted 
with water and a saturated aqueous solution of NaHCO3 added. The precipitate was filtered and 
washed with cold water, then MeCN, to leave the pure product as an off-white solid (1.45 g, 7.39 
mmol, 42%). 
 
1H NMR (500 MHz, CDCl3): δ 5.83 (s, 2H, NH2), 2.67 (s, 2H, CH2-C-N), 2.39 (s, 2H, CH2-CO), 
1.12 (s, 6H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 190.8 (QC, CO), 173.2 (C-NH2), 165.8 
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(QC, C-N), 120.6 (QC, C-CO), 51.4 (CH2, CH2-CO), 41.2 (CH2, CH2-N), 34.9 (QC, C(CH3)2), 
28.5 (CH3, 2´CH3) ppm. The NMR data match that previously reported.107b 
 
Synthesis of 2-(allylamino)-5,6-dihydrobenzo[d]thiazol-7(4H)-one (20c):  
 
A solution of 2-bromocyclohexane-1,3-dione (0.201 g, 1.05 mmol, 1.0 equiv.), N-allylthiourea 
(0.122 g, 1.05 mmol, 1.0 equiv.) and pyridine (85 μL, 1.05 mmol, 1.0 equiv.) in MeOH (10 mL) 
was heated at reflux for 17 hours. After removing the solvent in vacuo, the crude material was 
subjected to column chromatography (MeOH/CH2Cl2, 4:96) to give the pure product as a pale 
yellow solid (0.150 g, 0.72 mmol, 69%). 
 
Mp 105–106 °C. HRMS-ESI (m/z): [M+H]+ calcd for C10H13N2OS, 209.0743; found, 209.0743. 
FTIR v"max (cm-1): 3190 (br., w, NH), 3086 (br., w, =CH2), 2941 (m, CH2), 1638 (s), 1583 (s), 
1521 (s), 1377 (s), 1187 (s), 991 (s), 534 (s). 1H NMR (500 MHz, CDCl3): δ 7.67 (br. s, 1H, NH), 
5.91 – 5.83 (m, 1H, =CH), 5.32 (d, J = 17.1 Hz, 1H, =CH2), 5.24 (d, J = 10.2 Hz, 1H, =CH2), 3.93 
(d, J = 5.1 Hz, 2H, CH2-N), 2.75 (t, J = 6.1 Hz, 2H, CH2-CO), 2.50 (t, J = 6.4 Hz, 2H, CH2-C-N), 
2.11 (app. quint, J = 6.2 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 190.7 (QC, CO), 
175.0 (QC, C-NH2), 167.5 (QC, C-N), 132.0 (CH,=CH), 119.9 (QC, C-S), 118.1 (CH2 =CH2), 
48.4 (CH2, CH2-N), 37.1 (CH2, CH2-CO), 27.3 (CH2, CH2-C-N), 22.8 (CH2) ppm.  
 
Synthesis of 4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine (20d):108a** 
 
A solution of 2-chlorocyclohexanone (1.02 g, 7.69 mmol, 1.0 equiv.) and thiourea (0.580 g, 7.62 
mmol, 1.0 equiv.) in EtOH (10 mL) was heated at reflux until 2-chlorocyclohexanone could no 
longer be detected by TLC analysis (Rf = 0.74, EtOAc/hexane, 70:30). The solvent was removed 
in vacuo to leave the crude product as the hydrochloride salt. This was washed with Et2O to 
remove unreacted 2-chlorocyclohexanone and agitated in aqueous NH3 (2.0 M)  to give the free 
base, which was filtered and washed with water to give the pure product as off-white crystals 
(1.03 g, 6.68 mmol, 87%). 
 
 1H NMR (500 MHz, CDCl3): δ 5.75 (br. s, 2H, NH2), 2.53 – 2.45 (m, 4H, CH2-C-S and CH2-C-
N), 1.75 (br. s, 4H, 2´CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 165.6 (QC, C-NH2), 144.3 (QC, 
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C-N), 117.4 (QC, C-S), 26.1 (CH2), 23.3 (CH2), 23.0 (CH2), 22.7 (CH2) ppm. The NMR data 
match that previously reported.108b 
 
General procedure for the synthesis of 3-chlorobenzo[b]thiophene-2-carbonyl chloride and its 6-
substituted derivatives:91a 
 
To a suspension of the appropriate cinnamic acid (1.0 equiv.) in chlorobenzene (typically 
approximately 1.0 M) was added thionyl chloride (5.0 equiv.), followed by pyridine (10 mol%), 
dropwise at room temperature. The reaction mixture was heated at reflux for 3 days before being 
filtered through a pad of celite and the filtrate concentrated in vacuo. The crude material was 
dissolved in hot hexane and any undissolved material filtered. The filtrate was left to cool to room 
temperature, allowing the pure product to recrystallise and be collected by filtration. After 
comparing the 1H NMR spectra with literature data (if available), the reactive acyl chlorides were 
used promptly, as is commonly practiced in the literature. 
 
3-Chlorobenzo[b]thiophene-2-carbonyl chloride (22a): 
 
Yellow crystals, 45%.  1H NMR (500 MHz, CDCl3): δ 8.01 (d, J = 7.9 Hz, 1H, HetCH), 7.85 (d, 
J = 7.9 Hz, 1H, HetCH), 7.62 (app. t, J = 7.2 Hz, 1H, HetCH), 7.55 (app. t, J = 7.3 Hz, 1H, HetCH) 
ppm. The NMR data match that previously reported.91c 
 
3-Chloro-6-methylbenzo[b]thiophene-2-carbonyl chloride (22b): 
 
Yellow crystals, 46%. 1H NMR (500 MHz, CDCl3): δ 7.86 (d, J = 8.4 Hz, 1H, HetCH), 7.61 (s, 
1H, HetCH), 7.35 (d, J = 8.4 Hz, 1H, HetCH), 2.53 (s, 3H, Me) ppm. The NMR data match that 
previously reported.91c 
 
6-Bromo-3-chlorobenzo[b]thiophene-2-carbonyl chloride (22c): 
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Yellow crystals, 41%. 1H NMR (300 MHz, CDCl3): δ 8.03 (d, J = 1.2 Hz, 1H, HetCH), 7.88 (d, 
J = 8.8 Hz, 1H, HetCH), 7.66 (dd, J = 8.7, 1.5 Hz, 1H, HetCH) ppm. The NMR data match that 
previously reported.91a 
 
3-Chloro-5-methoxybenzo[b]thiophene-2-carbonyl chloride (22d): 
 
Purified via recrystallisation in CH2Cl2. Yellow crystals, 29%. 1H NMR (500 MHz, CDCl3): δ 
7.72 (d, J = 8.9 Hz, 1H, HetCH), 7.34 (d, J = 2.1 Hz, 1H, HetCH), 7.27 (dd, J = 6.5, 2.1 Hz, 1H, 
HetCH), 3.94 (s, 3H, OMe) ppm. The NMR data match that previously reported.91d 
 
7-Bromo-3-chlorobenzo[b]thiophene-2-carbonyl chloride (22e): 
 
Purified via recrystallisation in heptane with minimal CH2Cl2. Pale yellow crystals, 7%. 1H NMR 
(300 MHz, CDCl3): δ 7.99 (d, J = 8.2 Hz, 1H, HetCH), 7.77 (d, J = 7.6 Hz, 1H, HetCH), 7.45 
(app. t, J = 7.9 Hz, 1H, HetCH) ppm.  
 
Synthesis of methyl 3-chlorobenzo[b]thiophene-2-carboxylate (23a): 
 
A solution of 3-chlorobenzo[b]thiophene-2-carbonyl chloride (0.212 g, 0.92 mmol, 1.0 equiv.) 
was heated at reflux in MeOH overnight. After removing the excess MeOH in vacuo, the crude 
material was recrystallized in EtOH to give the pure product as pale yellow needles (0.196 g, 0.86 
mmol, 93%).  
 
1H NMR (500 MHz, CDCl3): δ 7.98 (d, J = 7.8 Hz, 1H, HetCH), 7.83 (d, J = 7.8 Hz, 1H, HetCH), 
7.59 – 7.46 (m, 2H, HetCH), 3.97 (s, 3H, OMe) ppm. 13C NMR (75 MHz, CDCl3): δ 161.7 (QC, 
CO), 138.6 (QC, HetC), 137.0 (QC, HetC), 128.2 (CH, HetCH), 127.5 (QC, HetC), 125.4 (CH, 
HetCH), 123.8 (CH, HetCH), 122.7 (CH, HetCH), 52.5 (CH3, OMe) ppm. The NMR data match 
that previously reported.109 
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General procedure for the Ni(0)-catalysed synthesis of cross-coupled 3-arylbenzo[b]thiophene-
2-carboxylates:90 
 
Methyl 3-chlorobenzo[b]thiophene-2-carboxylate (1.0 equiv.), the appropriate arylboronic acid 
(1.5 equiv.), Ni(dppe)Cl2 (5 mol%) and K3PO4 (2.0 equiv.) were heated at 120 °C in toluene in a 
capped reaction vial for 18 hours. If methyl 3-chlorobenzo[b]thiophene-2-carboxylate could still 
be detected via TLC analysis (Rf = 0.28, EtOAc/hexane, 5:95) after this time, a further portion of 
arylboronic acid and Ni(dppe)Cl2 was added and the reaction continued for a further 18 hours to 
consume starting material and enable purification. The reaction mixture was diluted with CH2Cl2 
and filtered, before the solvents were removed in vacuo. The crude material was subjected to 
column chromatography (EtOAc/hexane, 5:95, unless otherwise specified) to give the pure 
product.  
 
Methyl 3-phenylbenzo[b]thiophene-2-carboxylate (24a): 
 
White crystals, 80%. 1H NMR (300 MHz, CDCl3): δ 7.89 (d, J = 8.1 Hz, 1H, HetCH), 7.74 – 
7.26 (m, 9H, HetCH and ArCH), 3.79 (s, 3H, OMe) ppm. 13C NMR (75 MHz, CDCl3): δ 162.9 
(QC, CO), 144.2 (QC, HetC), 140.4 (QC, HetC), 140.0 (QC, HetC), 134.5 (QC, HetC), 129.6 
(CH, 2´ArCH), 128.1 (CH, ArCH), 128.0 (CH, 2´ArCH), 127.8 (QC, ArC), 127.2 (CH, HetCH), 
125.3 (CH, HetCH), 124.8 (CH, HetCH), 122.5 (CH, HetCH), 52.2 (CH3, OMe) ppm. The NMR 
data match that previously reported.90 
 
Methyl 3-(4-(trifluoromethyl)phenyl)benzo[b]thiophene-2-carboxylate (24b): 
 
A further portion of 4-(trifluoromethyl)phenylboronic acid (1.5 equiv.) and Ni(dppe)Cl2 (2.5 
mol%) was added after 18 hours to push the reaction to completion, however an inseparable 
mixture (10:90) of starting material and product was obtained after purification. Eluent: 
EtOAc/hexane (1:99). Pale yellow crystals, 70%. 1H NMR (500 MHz, CDCl3): δ 7.87 (d, J = 8.1 
Hz, 1H, HetCH), 7.74 (d, J = 8.0 Hz, 2H, ArCH or HetCH), 7.51 (d, J = 8.0 Hz, 2H, ArCH or 
HetCH), 7.46 (d, J = 8.3 Hz, 2H, ArCH or HetCH), 7.35 (app. t, J = 7.6 Hz, 1H, HetCH), 3.77 (s, 
SMeO
O
Cl
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3H, OMe) ppm. 13C NMR (125 MHz, CDCl3): δ 162.6 (QC, CO), 142.3 (QC, HetC), 140.5 (QC, 
HetC), 139.5 (QC, HetC), 138.3 (QC, ArC), 130.13 (CH, 2´ArCH), 130.12 (q, J = 32.5 Hz, QC, 
C-CF3), 128.5 (QC, HetC), 127.4 (CH, HetCH), 125.1 (CH, HetCH), 125.0 (q, J = 3.7 Hz, CH, 
2´ArCH), 124.2 (q, J = 272.2 Hz, QC, CF3), 124.1 (CH, HetCH), 122.6 (CH, HetCH), 52.2 (CH3, 
OMe) ppm. The NMR data match that previously reported.90 
 
Methyl 3-(4-methoxyphenyl)benzo[b]thiophene-2-carboxylate (24c): 
 
Eluent: EtOAc/hexane (10:90). White solid, 88%. 1H NMR (300 MHz, CDCl3): δ 7.88 (d, J = 8.0 
Hz, 1H, HetCH), 7.59 (d, J = 8.2 Hz, 1H, HetCH), 7.48 (app. t, J = 7.5 Hz, 1H, HetCH), 7.38 – 
7.34 (m, 4H, HetCH and ArCH), 7.03 (d, J = 8.5 Hz, 2H, ArCH), 3.89 (s, 3H, OMe), 3.80 (s, 3H, 
OMe) ppm. 13C NMR (75 MHz, CDCl3): δ 163.0 (QC, CO), 159.5 (QC, C-OMe), 144.1 (QC, 
HetC), 140.4 (QC, HetC), 140.2 (QC, HetC), 131.0 (CH, 2´ArCH), 127.2 (CH, HetCH), 126.5 
(QC, ArC), 125.4 (CH, HetCH), 124.7 (CH, HetCH), 122.5 (CH, HetCH), 113.5 (CH, HetCH), 
55.2 (CH3, OMe), 52.1 (CH3, OMe) ppm. The NMR data match that previously reported.90 
 
Methyl 3-(3-methoxyphenyl)benzo[b]thiophene-2-carboxylate (24d): 
 
A further portion of 3-methoxyphenylboronic acid (0.5 equiv.) and Ni(dppe)Cl2 (5 mol%) was 
added after 18 hours to push the reaction to completion. White solid, 84%. Mp 126 – 127 °C. 
HRMS-ASAP (m/z): [M+H]+ calcd for C17H15O3S, 299.0736, found, 299.0737. FTIR v"max (cm-
1): 2944 (br., vw), 1723 (s, CO), 1226 (vs, OMe), 756 (s), 737 (s). 1H NMR (500 MHz, CDCl3): 
δ 7.89 (d, J = 8.1 Hz, 1H, HetCH), 7.58 (d, J = 8.2 Hz, 1H, HetCH), 7.48 (app. t, J = 7.9 Hz, 1H, 
ArCH or HetCH), 7.41 (app. t, J = 7.9 Hz, 1H, ArCH or HetCH), 7.36 (app. t, J = 7.9 Hz, 1H, 
ArCH or HetCH), 7.05 – 6.98 (m, 2H, ArCH), 6.96 (br. s, 1H, ArCH), 3.85 (s, 3H, OMe), 3.80 
(s, 3H, OMe) ppm. 13C NMR (125 MHz, CDCl3): δ 162.8 (QC, CO), 159.2 (QC, C-OMe), 143.9 
(QC, HetC), 140.3 (QC, HetC), 140.0 (QC, HetC), 135.8 (QC, HetC), 129.0 (CH, ArCH or 
HetCH), 127.9 (QC, ArC), 127.2 (CH, ArCH or HetCH), 125.3 (CH, ArCH or HetCH), 124.8 
(CH, ArCH or HetCH), 122.4 (CH, ArCH or HetCH), 122.1 (CH, ArCH or HetCH), 115.2 (CH, 
ArCH), 113.6 (CH, ArCH), 55.2 (CH3, OMe), 52.2 (CH3, OMe) ppm.90 
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Methyl 3-(naphthalen-1-yl)benzo[b]thiophene-2-carboxylate (24e): 
 
A further portion of 1-naphthylboronic acid (1.5 equiv.) and Ni(dppe)Cl2 (5 mol%) was added 
after 18 hours to push the reaction to completion. Eluent: EtOAc/hexane (10:90). White solid, 
79%. 1H NMR (500 MHz, CDCl3): δ 8.05 – 7.91 (m, 3H, ArCH or HetCH), 7.61 (app. t, J = 7.1 
Hz, 1H, ArCH or HetCH), 7.54 – 7.43 (m, 3H, ArCH or HetCH), 7.40 (d, J = 8.4 Hz, 1H, ArCH 
or HetCH), 7.33 (app. t, J = 7.1 Hz, 1H, ArCH or HetCH), 7.30 – 7.23 (m, 2H, ArCH or HetCH), 
3.65 (s, 3H, OMe) ppm. 13C NMR (125 MHz, CDCl3): δ 162.3 (QC, CO), 142.5 (QC, HetC), 
140.6 (QC, HetC), 140.4 (HetC), 133.5 (QC, ArC or HetC), 132.6 (QC, ArC or HetC), 132.2 (QC, 
ArC or HetC), 129.5 (QC, ArC or HetC), 128.5 (CH, ArCH or HetCH), 128.3 (CH, ArCH or 
HetCH), 127.3 (CH, ArCH or HetCH), 127.2 (CH, ArCH or HetCH), 126.1 (CH, ArCH or 
HetCH), 125.9 (CH, ArCH or HetCH), 125.49 (CH, ArCH or HetCH), 125.47 (CH, ArCH or 
HetCH), 125.2 (CH, ArCH or HetCH), 124.8 (CH, ArCH or HetCH), 122.5 (CH, ArCH or 
HetCH), 52.2 (CH3, OMe) ppm. The NMR data match that previously reported.90 
 
General procedure for the synthesis of 7-substituted benzothiophenyl-2-methyl esters:110a 
 
To a suspension of the appropriate 3-substituted-2-fluorobenzaldehyde in DMF (typically 
approximately 2.0 M) was added methyl thioglycolate (1.1 equiv.) and K2CO3 (4.0 equiv.) and 
the reaction mixture stirred vigorously at 70 °C overnight. After removing the solvent in vacuo, 
the crude material was washed with water and extracted with EtOAc. The organic layer was dried 
with sodium sulfate, filtered and concentrated in vacuo to give the pure product.  
 
Methyl 7-bromobenzo[b]thiophene-2-carboxylate (53a): 
 
Beige crystals, 99%. 1H NMR (500 MHz, CDCl3): δ 8.13 (s, 1H, HetCH), 7.82 (d, J = 8.0 Hz, 
1H, HetCH), 7.59 (d, J = 7.6 Hz, 1H, HetCH), 7.29 (app. t, J = 7.8 Hz, 1H, HetCH), 3.96 (s, 3H, 
OMe) ppm. The NMR data match that previously reported.110a  
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Methyl 7-methoxybenzo[b]thiophene-2-carboxylate (53b):  
 
Red needles, 72%. 1H NMR (500 MHz, CDCl3): δ 8.05 (s, 1H, HetCH), 7.48 (dd, J = 8.0, 0.6 Hz, 
1H, HetCH), 7.36 (app. t, J = 7.9 Hz, 1H, HetCH), 6.87 (d, J = 7.4 Hz, 1H, HetCH), 4.01 (s, 3H, 
OMe), 3.94 (s, 3H, OMe) ppm. The NMR data match that previously reported.110b 
 
Synthesis of methyl 7-phenylbenzo[b]thiophene-2-carboxylate (53c):‡‡  
 
Methyl 7-bromobenzo[b]thiophene-2-carboxylate (302 mg, 1.11 mmol, 1.0 equiv.), 
phenylboronic acid (268 mg, 2.20 mmol, 2.0 equiv.), Pd(dppf)Cl2×CH2Cl2 (91 mg, 0.11 mmol, 10 
mol%) and K2CO3 (305 mg, 2.21 mmol, 2.0 equiv.) were heated at 95 °C in a mixture of 
dioxane/water (80:20, 6 mL). After 12 hours, the reaction mixture was filtered and the precipitate 
washed with EtOAc, followed by CH2Cl2. The solvents were removed in vacuo to leave the crude 
material, which was subjected to column chromatography (EtOAc/hexane, 10:90) to give the pure 
product as white crystals (187 mg, 0.70 mmol, 63%).  
 
1H NMR (400 MHz, CDCl3): δ 7.87 (dd, J = 7.2, 1.9 Hz, 1H, HetCH), 7.73 – 7.70 (m, 2H, 
HetCH), 7.54 – 7.42 (m, 5H, ArCH), 3.94 (s, 3H, OMe) ppm. The NMR data match that 
previously reported.110c 
 
General procedure for the basic hydrolysis of methyl benzo[b]thiophene-2-carboxylates to 
carboxylic acids: 
 
A solution of the methyl ester in dioxane (typically approximately 0.2 M) was stirred at room 
temperature with aqueous NaOH (2.0 equiv) in a capped vial overnight. If the methyl ester could 
still be detected via TLC analysis after this time, a further portion of aqueous NaOH was added 
and the reaction continued until the starting material could no longer be detected via TLC analysis. 
The reaction was quenched with aqueous HCl (3.0 equiv), then water. The product was extracted 
with ethyl acetate and the combined organic extracts washed with brine, before being dried with 
MgSO4. The solvents were removed in vacuo to leave the pure carboxylic acid.  
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3-Phenylbenzo[b]thiophene-2-carboxylic acid (25a): 
 
White crystals, 95%. 1H NMR (500 MHz, DMSO-d6): δ 8.07 (d, J = 8.1 Hz, 1H, HetCH), 7.55 – 
7.38 (m, 9H, ArCH and HetCH) ppm. 13C NMR (125 MHz, DMSO-d6): δ 163.3 (QC, CO), 142.3 
(QC, HetC), 139.7 (QC, HetC), 139.4 (QC, HetC), 134.2 (QC, ArC or HetC), 129.7 (CH, 
2´ArCH), 128.0 (CH, 2´ArCH), 127.9 (CH, ArCH or HetCH), 127.2 (CH, ArCH or HetCH), 
125.1 (CH, ArCH or HetCH), 124.6 (CH, ArCH or HetCH), 122.9 (CH, ArCH or HetCH) ppm. 
The NMR data match that previously reported.90 
 
3-(4-(Trifluoromethyl)phenyl)benzo[b]thiophene-2-carboxylic acid (25b): 
 
A further portion of aqueous NaOH (2.0 equiv.) was required to consume the starting material. 
Crude material was subjected to column chromatography (MeOH/CH2Cl2, 10:90) to remove 
unreacted methyl 3-chlorobenzo[b]thiophene-2-carboxylate from the previous step. White 
crystals, 77%. 1H NMR (500 MHz, DMSO-d6): δ 13.36 (br. s, 1H, OH), 8.11 (d, J = 8.2 Hz, 1H, 
HetCH), 7.86 (d, J = 8.0 Hz, 2H, ArCH), 7.65 (d, J = 7.9 Hz, 2H, ArCH), 7.57 (app. t, J = 7.4 Hz, 
1H, HetCH), 7.45 – 7.40 (m, 2H, HetCH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 163.1 (QC, 
CO), 140.6 (QC, HetC), 139.5 (QC, HetC), 139.3 (QC, HetC), 138.8 (QC, ArC or HetC), 138.7 
(QC, ArC or HetC), 130.7 (CH, 2´ArCH), 128.4 (q, J = 31.8 Hz, QC, C-CF3), 127.5 (CH, HetCH), 
125.5 (CH, HetCH), 125.3 (q, J = 272.1 Hz, QC, CF3), 124.9 (q, J = 3.7 Hz, CH, 2´ArCH), 124.4 
(CH, HetCH), 123.1 (CH, HetCH) ppm. The NMR data match that previously reported.90 
 
3-(4-Methoxyphenyl)benzo[b]thiophene-2-carboxylic acid (25c): 
 
White crystals, 93%. 1H NMR (500 MHz, DMSO-d6): δ 8.06 (d, J = 8.1 Hz, 1H, HetCH), 7.53 
(app. t, J = 7.5 Hz, 1H, HetCH), 7.47 (d, J = 8.0 Hz, 1H, HetCH), 7.41 (app. t, J = 7.5 Hz, 1H, 
HetCH), 7.34 (d, J = 8.5 Hz, 2H, ArCH), 7.05 (d, J = 8.5 Hz, 2H, ArCH), 3.83 (s, 3H, OMe) ppm. 
13C NMR (125 MHz, DMSO-d6): δ 163.4 (QC, CO), 159.0 (QC, C-OMe), 142.1 (QC, HetC), 
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139.9 (QC, HetC), 139.3 (QC, HetC), 131.0 (CH, 2´ArCH), 129.2 (QC, ArC), 127.2 (CH, 
HetCH), 126.1 (QC, HetC), 125.0 (CH, HetCH), 124.6 (CH, HetCH), 122.8 (CH, HetCH), 113.4 
(CH, 2´ArCH), 55.1 (CH3, OMe) ppm. The NMR data match that previously reported.90 
 
3-(3-Methoxyphenyl)benzo[b]thiophene-2-carboxylic acid (25d): 
 
A further portion of aqueous NaOH (0.5 equiv.) was required to consume the starting material. 
White crystals, 97%. Mp 206 – 208 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C16H12O3SNa, 
307.0399; found, 307.0406. FTIR v"max (cm-1): 2972 (br., w, OH), 1684 (s, CO), 1242 (s), 1034 
(s), 728 (vs). 1H NMR (500 MHz, DMSO-d6): δ 8.07 (d, J = 8.1 Hz, 1H, HetCH), 7.54 (app. t, J 
= 7.4 Hz, 1H, ArCH or HetCH), 7.48 – 7.36 (m, 3H, ArCH and HetCH), 7.06 – 7.00 (m, 1H, 
ArCH or HetCH), 6.98 – 6.91 (m, 2H, ArCH), 3.78 (s, 3H, OMe) ppm. 13C NMR (125 MHz, 
DMSO-d6): δ 163.2 (QC, CO), 158.8 (QC, C-OMe), 142.0 (QC, HetC), 139.7 (QC, HetC), 139.3 
(QC, HetC), 135.6 (CH, ArCH or HetCH), 129.8 (QC, ArC), 129.0 (CH, ArCH or HetCH), 127.2 
(QC, HetC), 125.1 (CH, ArCH or HetCH), 124.6 (CH, ArCH or HetCH), 122.8 (CH, ArCH or 
HetCH), 121.9 (CH, ArCH), 115.3 (CH, ArCH), 113.4 (CH, ArCH), 55.07 ppm. 
 
3-(Naphthalen-1-yl)benzo[b]thiophene-2-carboxylic acid (25e):  
 
White crystals, 92%. 1H NMR (500 MHz, DMSO-d6): δ 13.08 (br. s, 1H, OH), 8.14 (d, J = 8.2 
Hz, 1H, ArCH or HetCH), 8.04 – 8.02 (m, 2H, ArCH or HetCH), 7.63 (app. t, J = 7.6 Hz, 1H, 
ArCH or HetCH), 7.55 – 7.50 (m, 2H, ArCH or HetCH), 7.46 (d, J = 6.9 Hz, 1H, ArCH or 
HetCH), 7.37 (app. t, J = 7.6 Hz, 1H, ArCH or HetCH), 7.32 – 7.26 (m, 2H, ArCH or HetCH), 
7.03 (d, J = 8.1 Hz, 1H, ArCH or HetCH) ppm. 13C NMR (125 MHz, DMSO-d6): δ 163.1 (QC, 
CO), 140.5 (QC, HetC), 140.3 (QC, HetC), 139.5 (QC, HetC), 133.1 (QC, ArC or HetC), 132.5 
(QC, ArC or HetC), 131.7 (QC, ArC or HetC), 131.4 (QC, ArC or HetC), 128.3 (CH, ArCH or 
HetCH), 128.1 (CH, ArCH or HetCH), 127.3 (CH, ArCH or HetCH), 127.2 (CH, ArCH or 
HetCH), 126.3 (CH, ArCH or HetCH), 125.9 (CH, ArCH or HetCH), 125.4 (CH, ArCH or 
HetCH), 125.2 (CH, ArCH or HetCH), 125.0 (CH, ArCH or HetCH), 124.6 (CH, ArCH or 
HetCH), 123.0 (CH, ArCH or HetCH) ppm. The NMR data match that previously reported.90 
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7-Bromobenzo[b]thiophene-2-carboxylic acid (54a): 
 
White solid, 98%. 1H NMR (400 MHz, DMSO-d6): δ 13.70 (br. s, 1H, OH), 8.26 (s, 1H, HetCH), 
8.05 (dd, J = 8.1, 0.9 Hz, 1H, HetCH), 7.77 (dd, J = 7.7, 0.9 Hz, 1H, HetCH), 7.44 (app. t, J = 7.8 
Hz, 1H, HetCH) ppm. The NMR data match that previously reported.110a 
 
7-methoxybenzo[b]thiophene-2-carboxylic acid (54b): 
 
White solid, 98%. 1H NMR (400 MHz, DMSO-d6): δ 13.47 (br. s, 1H, OH), 8.09 (s, 1H, HetCH), 
7.59 (dd, J = 8.1, 0.9 Hz, 1H, HetCH), 7.42 (app. t, J = 7.9 Hz, 1H, HetCH), 7.07 (dd, J = 8.0, 0.8 
Hz, 1H, HetCH), 3.97 (s, 3H, OMe) ppm. The NMR data match that previously reported.111 
 
7-Phenylbenzo[b]thiophene-2-carboxylic acid (54c):‡‡  
 
White solid, yield not determined. 1H NMR (400 MHz, DMSO-d6): δ 13.50 (br. s, 1H, OH), 8.20 
(s, 1H, HetCH), 8.03 (dd, J = 7.2, 1.9 Hz, 1H, HetCH), 7.74 – 7.71 (m, 2H, ArCH), 7.61 – 7.46 
(m, 5H, HetCH and ArCH) ppm. The NMR data match that previously reported.111 
 
1.4.3 Derivatives of WEHI-0086109 (14a) 
 
General procedure for the synthesis of WEHI-0086109 (14a) derivatives via a Schotten–Baumann 
Amidation: 
 
Where required, the appropriate acyl chloride was freshly prepared from the corresponding 
carboxylic acid. To a solution of the carboxylic acid in dioxane (typically approximately 0.04 M) 
was added thionyl chloride (5.0 equiv.) and the reaction mixture heated at reflux overnight, before 
the solvents and excess thionyl chloride were removed in vacuo to leave the acyl chloride, which 
was used immediately. A solution of the acyl chloride (1.0 equiv.), the appropriate benzothiazole 
amine fragment (1.0 equiv.) and pyridine (1.5 equiv.) in toluene (typically approximately 0.05 M 
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with respect to the acyl chloride) was heated at reflux overnight, or until the starting materials 
could no longer be detected via TLC analysis. The solvent was removed in vacuo before the 
residue was washed with aqueous HCl (2.0 M) and extracted with CH2Cl2, before the organic 
layer was dried with MgSO4 and concentrated in vacuo. If required, the crude material was 
subjected to either column chromatography or recrystallisation (detailed below) to give the pure 
carboxamide. In some cases, a small analytical sample of high purity was obtained (detailed 
below) for the purpose of biological testing. 
 
3-Chloro-N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-carboxamide 
(14a): 
 
Yellow solid, > 99%. Mp 223 – 226 °C. HRMS-ESI (m/z): [M+Na]+ calcd for 
C16H11ClN2O2S2Na, 384.9843; found, 384.9839. FTIR v"max (cm-1): 3366 (m, NH), 1662 (s, CO), 
1654 (vs, CO-NH), 1537 (s), 1522 (s), 1374 (s), 1299 (s), 771 (s). 1H NMR (500 MHz, CDCl3): 
δ 10.48 (br. s, 1H, NH), 7.97 – 7.95 (m, 1H, HetCH), 7.91 – 7.89 (m, 1H, HetCH), 7.60 – 7.54 
(m, 2H, HetCH), 2.97 (app. t, J = 6.2 Hz, 2H, CH2-CO), 2.63 – 2.61 (m, 2H, CH2-C-N), 2.23 
(app. quint, J = 6.3 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 192.5 (QC, CO), 163.6 
(QC, C-N), 162.0 (C-NH), 158.2 (QC, CO-NH), 139.0 (QC, HetC), 136.6 (QC, HetC), 129.7 
(QC, HetC), 128.6 (CH, HetCH), 126.2 (QC, HetCH), 126.0 (CH, HetCH), 123.7 (CH, HetCH), 
123.0 (CH, HetCH), 121.6 (QC, HetC), 37.8 (CH2, CH2-C-N), 26.9 (CH2, CH2-CO), 23.0 (CH2, 
CH2) ppm. HPLC: tR 8.86 min, 96% purity at 254 nm. Eluted using a concentration gradient of 0 
– 100% solvent B in A over 15 minutes. 
 
3-Chloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (14b): 
 
Purified via column chromatography (EtOAc/hexane, 30:70). Brown solid, 86%. An analytical 
sample was obtained via recrystallisation in CH2Cl2 layered with hexane and used for biological 
testing. Mp 178 – 179 °C. HRMS-ESI (m/z): [M–H]– calcd for C18H14ClN2O2S2, 389.0191; found, 
389.0179 FTIR v"max (cm-1): 3325 (vw, NH), 1658 (s, CO), 1543 (s), 1514 (s), 1366 (s), 1289 (s), 
885 (m), 740 (s). 1H NMR (400 MHz, CDCl3): 7.95 (dd, J = 7.0, 1.8 Hz, 1H, HetCH), 7.90 
(dd, J = 6.9, 1.5 Hz, 1H, HetCH), 7.60 – 7.53 (m, 2H, HetCH), 2.80 (s, 2H, CH2-CO), 2.47 (s, 
CH2-C-N), 1.13 (s, 6H, CH3) ppm. The signal arising from the NH proton could be detected at 
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approximately 10.50 ppm, but was too broadened to report. 13C NMR (100 MHz, CDCl3): δ 192.1 
(QC, CO), 162.3 (QC, C-N), 162.2 (QC, C-NH), 158.2 (QC, CO-NH), 139.0 (QC, HetC), 136.6 
(QC, HetC), 129.7 (QC, HetC), 128.6 (CH, HetCH), 126.0 (CH, HetCH), 125.0 (QC, HetC), 
123.7 (CH, HetCH), 123.0 (CH, HetCH), 121.6 (QC, HetC), 51.8 (CH2, CH2-C-N), 40.9 (CH2, 
CH2-CO), 35.1 (QC, C(CH3)2, 28.4 (CH3, 2´CH3) ppm. HPLC: tR 8.40 min, 99% purity at 254 
nm.  
 
N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-3-phenylbenzo[b]thiophene-2-carboxamide 
(26a): 
 
Purified via column chromatography (EtOAc/hexane, 50:50), off-white solid, 13%. Mp 247 – 250 
°C. HRMS-ESI (m/z): [M–H]– calcd for C22H15N2O2S2, 403.0580; found, 403.0568. FTIR v"max 
(cm-1): 3343 (m, NH), 1661 (s, CO), 1528 (s), 1506 (vs), 1371 (s), 1287 (s), 1217 (s), 743 (s). 1H 
NMR (500 MHz, CDCl3): δ 7.94 (d, J = 8.1 Hz, 1H, HetCH), 7.67 – 7.64 (m, 3H, ArCH and 
HetCH), 7.53 – 7.48 (m, 4H, ArCH and HetCH), 7.39 (app. t, J = 7.5 Hz, 1H, ArCH or HetCH), 
2.70 (t, J = 6.1 Hz, 2H, CH2-CO), 2.52 (t, J = 6.2 Hz, 2H, CH2-C-N), 2.05 (app. quint, J = 6.2 Hz, 
2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 192.5 (QC, CO), 163.6 (QC, C-N), 162.2 (QC, 
C-NH), 160.1 (QC, CO-NH), 140.6 (QC, HetC), 140.2 (QC, HetC), 140.0 (QC, HetC), 132.7 
(QC, ArC or HetC), 131.9 (QC, ArC or HetC), 130.0 (CH, ArCH), 129.9 (CH, 2´ArCH), 129.7 
(CH, 2´ArCH), 127.6 (CH, HetCH), 125.6 (QC, HetC), 125.3 (CH, HetCH), 125.2 (CH, HetCH), 
122.7 (CH, HetCH), 37.7 (CH2, CH2-C-N), 26.7 (CH2, CH2-CO), 22.9 (CH2, CH2) ppm. HPLC: 
tR 8.86 min, 96% purity at 254 nm. 
 
N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-3-phenylbenzo[b]thiophene-2-
carboxamide (26b): 
 
Synthesised with the addition of catalytic DMAP (10 mol%). Purified via recrystallisation in 
toluene. Yellow crystals, 58%. Mp 229 – 230 °C. HRMS-ESI (m/z): [M–H]– calcd for 
C24H19N2O2S2, 431.0893; found, 431.0895. FTIR v"max (cm-1): 3329 (w, NH), 1654 (s, CO), 1512 
(s), 1370 (m), 1292 (m). 1H NMR (400 MHz, CDCl3): δ 9.41 (br. s, 1H, NH), 7.94 (d, J = 8.0 Hz, 
1H, HetCH), 7.69 – 7.63 (m, 3H, ArCH and HetCH), 7.59 – 7.46 (m, 4H, ArCH and HetCH), 
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7.44 – 7.35 (m, 1H, ArCH or HetCH), 2.52 (s, 2H, CH2-CO), 2.36 (s, 2H, CH2-C-N), 0.99 (s, 6H, 
CH3) ppm. 13C NMR (100 MHz, CDCl3): δ 192.1 (QC, CO), 162.5 (QC, C-N), 162.1 (QC, C-
NH), 160.1 (QC, CO-NH), 140.6 (QC, HetC), 140.2 (QC, HetC), 140.1 (QC, HetC), 132.8 (QC, 
ArC or HetC), 131.9 (QC, ArC or HetC), 130.0 (CH, ArCH), 129.9 (CH, 2´ArCH), 129.7 (CH, 
2´ArCH), 127.6 (CH, HetCH), 125.3 (CH, HetCH), 125.2 (CH, HetCH), 124.4 (QC, HetC), 122.7 
(CH, HetCH), 51.7 (CH2, CH2-C-N), 40.7 (CH2, CH2-CO), 34.8 (QC, C(CH3)2), 28.3 (CH3, 
2´CH3) ppm. HPLC: tR 9.70 min, > 99% purity at 254 nm. 
 
N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-3-(4-
(trifluoromethyl)phenyl)benzo[b]thiophene-2-carboxamide (27a): 
 
Purified via column chromatography (EtOAc/hexane, 50:50), off-white solid, 47%. Mp 271 – 272 
°C. HRMS-ESI (m/z): [M+H]+ calcd for C23H16F3N2O2S2, 473.0600; found, 473.0603. FTIR v"max 
(cm-1): 3377 (vw, NH), 1643 (m, CO), 1490 (m), 1279 (s), 1162 (m), 1121 (s), 1066 (vs), 736 
(m). 1H NMR (500 MHz, CDCl3): δ 10.02 (br. s, 1H, NH), 7.92 (d, J = 8.1 Hz, 1H, ArCH), 7.83 
(d, J = 7.8 Hz, 2H, ArCH), 7.57 (d, J = 8.2 Hz, 2H, ArCH), 7.54 – 7.50 (m, 2H, ArCH), 7.43 (app. 
t, J = 7.5 Hz, 1H, ArCH), 2.60 (t, J = 5.9 Hz, 2H, CH2-C-N), 2.49 (t, J = 6.3 Hz, 2H, CH2-CO), 
1.99 (app. quint, J = 6.1 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 192.2 (QC, CO), 
162.71 (QC, C-N or C-NH), 162.69 (QC, C-N or C-NH), 160.2 (QC, CO-NH), 140.2 (QC, HetC), 
139.3 (QC, HetC), 139.0 (QC, HetC), 136.7 (QC, HetC), 131.9 (QC, ArC), 131.4 (q, J = 32.5 Hz, 
QC, C-CF3), 130.3 (CH, 2´ArCH), 127.8 (CH, HetCH), 126.3 (q, J = 3.3 Hz, 2´CH-C-CF3), 
125.7 (CH, HetCH), 124.7 (CH, HetCH), 123.8 (q, J = 272.6 Hz, QC, CF3), 122.8 (CH, HetCH), 
125.6 (QC, HetC), 37.7 (CH2, CH2-CO), 26.4 (CH2, CH2-C-N), 22.8 (CH2) ppm. HPLC: tR 9.03 
min, 97% purity at 254 nm. 
 
N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-3-(4-
(trifluoromethyl)phenyl)benzo[b]thiophene-2-carboxamide (27b): 
 
Purified via column chromatography (EtOAc/hexane, 30:70). Off-white solid, 82%. An analytical 
sample was obtained via recrystallisation in EtOAc layered with hexane and used for biological 
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testing.  Mp 228 – 229 °C. HRMS-ESI (m/z): [M+H]+ calcd for C25H20F3N2O2S2, 501.0913; 
found, 501.0917. FTIR v"max (cm-1): 3374 (m, NH), 1666 (vs, CO), 1513 (vs), 1328 (s), 1177 (s), 
1065 (s), 751 (m). 1H NMR (500 MHz, CDCl3): δ 10.43 (br. s, 1H, NH), 7.94 (d, J = 8.2 Hz, 1H, 
ArCH or HetCH), 7.84 (d, J = 8.1 Hz, 2H, ArCH or HetCH), 7.58 (d, J = 8.1 Hz, 2H, ArCH or 
HetCH), 7.56 – 7.50 (m, 2H, ArCH or HetCH), 7.47 – 7.40 (m, 1H, ArCH or HetCH), 2.31 (s, 
2H, CH2-CO), 2.30 (s, 2H, CH2-C-N), 0.87 (s, 6H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 
191.9 (QC, CO), 162.9 (QC, C-NH), 161.5 (QC, C-N), 160.0 (QC, CO-NH), 140.2 (QC, ArC), 
139.3 (QC, ArC), 139.2 (QC, ArC), 136.9 (QC, HetC), 131.6 (QC, ArC), 131.5 (q, J = 32.5 Hz, 
QC, C-CF3) 130.4 (CH, 2´ArCH), 127.8 (CH, HetCH), 126.4 (q, J = 3.5 Hz, CH, 2´CH-C-CF3), 
125.8 (CH, HetCH), 124.8 (CH, HetCH), 124.4 (QC, S-C-CO), 123.8 (q, J = 271.3 Hz, QC, CF3), 
122.8 (CH, HetCH), 51.7 (CH2, CH2-CO), 40.3 (CH2-C-N), 34.8 (QC, C(CH3)2), 28.2 (CH3, 
2´CH3) ppm. HPLC: tR 10.00 min, 98% purity at 254 nm. 
 
3-(4-Methoxyphenyl)-N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (28a): 
 
Purified via recrystallisation in MeOH with minimal CH2Cl2. Yellow solid, 49%. Mp 241 – 242 
°C. HRMS-ESI (m/z): [M+Na]+ calcd for C23H18N2O3S2Na, 457.0651; found, 457.0677. FTIR 
v"max (cm-1): 3337 (m, NH), 1663 (s, CO), 1654 (s, CO-NH), 1507 (s), 1288 (s), 748 (s). 1H NMR 
(500 MHz, CDCl3): δ 9.32 (br. s, 1H, NH), 7.91 (d, J = 8.2 Hz, 1H, HetCH), 7.51 – 7.48 (m, 2H, 
HetCH), 7.42 (d, J = 8.5 Hz, 2H, ArCH), 7.38 (app. t, J = 7.6 Hz, 1H, HetCH), 7.17 (d, J = 8.5 
Hz, 2H, ArCH), 3.94 (s, 3H, OMe), 2.72 (t, J = 6.1 Hz, 2H, CH2-CO), 2.51 (t, J = 6.4 Hz, 2H, 
CH2-C-N), 2.05 (app. quint, J = 6.3 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 192.4 
(QC, CO), 163.7 (QC, C-N), 162.2 (QC, C-NH), 160.8 (QC, CO-NH or C-OMe), 160.2 (QC, CO-
NH or C-OMe), 140.7 (QC, HetC), 140.3 (QC, HetC), 140.0 (QC, HetC), 131.8 (QC, ArC), 131.1 
(CH, 2´ArCH), 127.5 (CH, HetCH), 125.7 (QC, HetC), 125.2 (CH, 2´HetCH), 124.4 (QC, 
HetC), 122.7 (CH, HetCH), 115.5 (CH, 2´ArCH), 55.5 (CH3, OMe), 37.8 (CH2, CH2-C-N), 26.8 
(CH2, CH2-CO), 23.0 (CH3, 2´CH3) ppm. HPLC: tR 8.50 min, > 99% purity at 254 nm. 
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N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-3-(4-
methoxyphenyl)benzo[b]thiophene-2-carboxamide (28b): 
 
Purified via recrystallisation in MeOH/CH2Cl2. Yellow crystals, 35%. Mp 261 – 262 °C. HRMS-
ESI (m/z): [M–H]– calcd for C25H22N2O3S2, 461.0999; found, 461.0982. FTIR v"max (cm-1): 3330 
(m, NH), 1654 (s, CO), 1513 (s), 1369 (s), 1288 (vs), 749 (m). 1H NMR (500 MHz, CDCl3): δ 
9.34 (br. s, 1H, NH), 7.93 (d, J = 8.3 Hz, 1H, HetCH), 7.52 – 7.50 (m, 2H, HetCH), 7.44 – 7.37 
(m, 3H, ArCH and HetCH), 7.18 (d, J = 8.2 Hz, 2H, ArCH), 3.95 (s, 3H, OMe), 2.60 (s, 2H, CH2-
CO), 2.38 (s, 2H, CH2-C-N), 1.04 (s, 6H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 192.1 (QC, 
CO), 162.5 (QC, C-N), 162.2 (QC, C-NH), 160.8 (QC, CO-NH or C-OMe), 160.1 (QC, CO-NH 
or C-OMe), 140.7 (QC, HetC), 140.4 (QC, HetC), 140.0 (QC, HetC), 131.8 (QC, ArC), 131.1 
(CH, 2´ArCH), 127.5 (CH, HetCH), 125.2 (CH, 2´HetCH and QC, HetC), 124.4 (QC, HetC), 
122.7 (CH, HetCH), 115.5 (CH, 2´ArCH), 55.5 (CH3, OMe), 51.8 (CH2, CH2-C-N), 40.8 (CH2, 
CH2-CO), 34.9 (QC, C(CH3)2), 28.3 (CH3, 2´CH3) ppm. HPLC: tR 9.55 min, > 99% purity at 254 
nm. 
 
3-(3-Methoxyphenyl)-N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (29a): 
 
Purified via recrystallisation in MeOH with minimal CH2Cl2. Yellow crystals, 52%. Mp 233 – 
234 °C. HRMS-ESI (m/z): [M+H]+ calcd for C23H19N2O3S2, 435.0837; found, 435.0852. FTIR 
v"max (cm-1): 3336 (m, NH), 1654 (vs, CO), 1515 (vs), 1366 (s), 1345 (s), 1279 (s), 744 (vs). 1H 
NMR (500 MHz, CDCl3): δ 9.18 (br. s, 1H, NH), 7.93 (d, J = 8.1 Hz, 1H, HetCH), 7.59 (app. t, 
J = 7.9 Hz, 1H, ArCH or HetCH), 7.53 – 7.49 (m, 2H, ArCH or HetCH), 7.39 (app. t, J = 7.6 Hz, 
1H, ArCH or HetCH), 7.18 (d, J = 8.1 Hz, 1H, ArCH or HetCH), 7.08 (d, J = 7.4 Hz, 1H, ArCH 
or HetCH), 7.02 (s, 1H, ArCH), 3.88 (s, 3H, OMe), 2.75 (t, J = 6.2 Hz, 2H, CH2-CO), 2.53 (t, J 
= 6.5 Hz, 2H, CH2-C-N), 2.08 (app. quint, J = 6.3 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, 
CDCl3): δ 192.5 (QC, CO), 163.8 (QC, C-N), 162.1 (QC, C-NH), 160.6 (QC, CO-NH or C-OMe), 
159.9 (QC, CO-NH or C-OMe), 140.7 (QC, HetC), 140.1 (QC, HetC), 139.8 (QC, HetC), 134.0 
(QC, ArC or HetC), 132.1 (QC, ArC or HetC), 131.2 (CH, ArCH or HetCH), 127.6 (CH, ArCH 
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or HetCH), 125.7 (QC, HetC), 125.3 (CH, ArCH or HetCH), 125.2 (CH, HetCH), 122.6 (CH, 
ArCH or HetCH), 121.7 (CH, ArCH or HetCH), 116.0 (CH, ArCH or HetCH), 115.1 (CH, ArCH 
or HetCH), 55.5 (CH3, OMe), 37.8 (CH2, CH2-C-N), 26.9 (CH2, CH2-CO), 23.0 (CH2, CH2) ppm. 
HPLC: tR 8.57 min, > 99% purity at 254 nm.  
 
N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-3-(3-
methoxyphenyl)benzo[b]thiophene-2-carboxamide (29b): 
 
Purified via column chromatography (EtOAc/hexane, 30:70), off-white solid, 54%. An analytical 
sample was obtained via recrystallisation in CH2Cl2 layered with hexane and used for biological 
testing.  Mp 182 – 184 °C. HRMS-ESI (m/z): [M–H]– calcd for C25H21N2O3S2, 461.0999; found, 
461.0963. FTIR v"max (cm-1): 3316 (w, NH), 1653 (s, CO), 1508 (vs), 1369 (s), 1287 (s), 1225 (s), 
1157 (s), 1032 (s), 698 (s). 1H NMR (400 MHz, CDCl3): δ 9.18 (br. s, 1H, NH), 7.95 – 7.93 (m, 
1H, HetCH), 7.59 (dd, J = 8.5, 7.4 Hz, 1H, ArCH or HetCH), 7.54 – 7.50 (m, 2H, ArCH or 
HetCH), 7.41 – 7.37 (m, 1H, ArCH or HetCH), 7.19 (ddd, J = 8.4, 2.6, 1.0 Hz, 1H, ArCH or 
HetCH), 7.09 (ddd, J = 7.5, 1.6, 1.0 Hz, 1H, ArCH or HetCH), 7.01 (dd, J = 2.6, 1.6 Hz, 1H, 
ArCH), 3.88 (s, 3H, OMe), 2.65 (s, 2H, CH2-CO), 2.40 (s, 2H, CH2-C-N), 1.06 (s, 6H, CH3) ppm. 
13C NMR (100 MHz, CDCl3): δ 192.1 (QC, CO), 162.33 (QC, C-N or C-NH), 162.30 (QC, C-N 
or C-NH), 160.6 (QC, CO-NH or C-OMe), 159.9 (QC, CO-NH or C-OMe), 140.7 (QC, HetC), 
140.1 (QC, HetC), 139.8 (QC, HetC), 134.1 (QC, ArC or HetC), 132.2 (QC, ArC or HetC), 131.2 
(CH, ArCH or HetCH), 127.6 (CH, ArCH or HetCH), 125.3 (CH, ArCH or HetCH), 125.2 (CH, 
ArCH or HetCH), 124.5 (QC, HetC), 122.7 (CH, ArCH or HetCH), 121.7 (CH, ArCH or HetCH), 
115.9 (CH, ArCH or HetCH), 115.1 (CH, ArCH or HetCH), 55.5 (CH3, OMe), 51.8 (CH2, CH2-
C-N), 40.9 (CH2, CH2-CO), 34.9 (QC, C(CH3)2), 28.3 (CH3, 2´CH3) ppm. HPLC: tR 9.57 min, 
97% purity at 254 nm. 
 
3-(Naphthalen-1-yl)-N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (30a): 
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Purified via recrystallisation in MeCN. Off-white needles, 56%. Mp 246 – 248 °C. HRMS-ESI 
(m/z): [M–H]– calcd for C26H17N2O2S2, 453.0737; found, 453.0718. FTIR v"max (cm-1): 3337 (w, 
NH), 1648 (s, CO), 1507 (vs), 1369 (s), 1269 (s), 773 (s). 1H NMR (400 MHz, CDCl3): δ 8.75 
(br. s, 1H, NH), 8.18 (dd, J = 8.3, 1.3 Hz, 1H, ArCH or HetCH), 8.08 – 7.97 (m, 2H, ArCH or 
HetCH), 7.76 (dd, J = 8.3, 6.9 Hz, 1H, ArCH or HetCH), 7.66 (dd, J = 7.0, 1.3 Hz, 1H, ArCH or 
HetCH), 7.58 (app. quint, J = 4.1 Hz, 1H, ArCH or HetCH), 7.52 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H, 
ArCH or HetCH), 7.41 – 7.40 (m, 2H, ArCH or HetCH), 7.28 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H, 
ArCH or HetCH), 7.16 – 7.14 (m, 1H, ArCH or HetCH), 2.75 – 2.61 (m, 2H, CH2-CO), 2.49 (dd, 
J = 7.6, 5.7 Hz, 2H, CH2-C-N), 2.08 – 2.02 (m, 2H, CH2) ppm. 13C NMR (100 MHz, CDCl3): δ 
192.5 (QC, CO), 163.7 (QC, C-N), 161.7 (QC, C-NH), 159.7 (QC, CO-NH), 140.8 (QC, HetC), 
140.7 (QC, HetC), 138.3 (QC, HetC), 134.1 (QC, ArC or HetC), 133.6 (QC, ArC or HetC), 131.88 
(QC, ArC or HetC), 130.85 (CH, ArCH or HetCH), 130.1 (QC, ArC or HetC), 128.9 (CH, ArCH 
or HetCH), 128.3 (CH, ArCH or HetCH), 127.71 (CH, ArCH or HetCH), 127.67 (CH, ArCH or 
HetCH), 127.2 (CH, ArCH or HetCH), 125.9 (CH, ArCH or HetCH), 125.7 (QC, ArC or HetC), 
125.4 (CH, ArCH or HetCH), 125.3 (CH, ArCH or HetCH), 125.2 (CH, ArCH or HetCH), 122.7 
(CH, ArCH or HetCH), 37.7 (CH2, CH2-C-N), 26.9 (CH2, CH2-CO), 22.9 (CH2, CH2) ppm. 
HPLC: tR 9.41 min, > 99% purity at 254 nm. 
 
N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-3-(naphthalen-1-
yl)benzo[b]thiophene-2-carboxamide (30b): 
 
Purified via recrystallisation in MeCN. Pale brown crystals, 47%. Mp 264 – 265 °C. HRMS-ESI 
(m/z): [M–H]– calcd for C28H21N2O2S2, 481.1050; found, 481.1039. FTIR v"max (cm-1): 3310 (m, 
NH), 1658 (s, CO), 1512 (vs), 1366 (s), 1295 (s), 1224 (s), 784 (vs). 1H NMR (400 MHz, CDCl3): 
δ 8.92 (br. s, 1H, NH), 8.17 (d, J = 8.1 Hz, 1H, ArCH or HetCH), 8.05 – 7.99 (m, 2H, ArCH or 
HetCH), 7.77 – 7.73 (m, 1H, ArCH or HetCH), 7.65 (d, J = 6.7 Hz, 1H, ArCH or HetCH), 7.59 – 
7.50 (m, 2H, ArCH or HetCH), 7.41 – 7.40 (m, 2H, ArCH or HetCH), 7.30 – 7.26 (m, 1H, ArCH 
or HetCH), 7.16 (d, J = 8.1 Hz, 1H, ArCH or HetCH), 2.55 (app. dd, J = 23.8, 17.1 Hz, 2H, CH2-
CO), 2.35 (s, 2H, CH2-C-N)), 1.01 (d, J = 9.6 Hz, 6H, CH3) ppm. 13C NMR (100 MHz, CDCl3): 
δ 192.1 (QC, CO), 162.2 (QC, C-N or C-NH), 162.0 (QC, C-N or C-NH), 159.7 (QC, CO-NH), 
140.70 (QC, HetC), 140.66 (QC, HetC), 138.4 (QC, HetC), 134.1 (QC, ArC or HetC), 133.5 (QC, 
ArC or HetC), 131.9 (QC, ArC or HetC), 130.8 (CH, ArCH or HetCH), 130.1 (QC, ArC or HetC), 
128.8 (CH, ArCH or HetCH), 128.2 (CH, ArCH or HetCH), 127.7 (CH, ArCH or HetCH), 127.6 
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(CH, ArCH or HetCH), 127.1 (CH, ArCH or HetCH), 125.8 (CH, ArCH or HetCH), 125.4 (CH, 
ArCH or HetCH), 125.3 (CH, ArCH or HetCH), 125.2 (CH, ArCH or HetCH), 124.4 (QC, ArC 
or HetC), 122.7 (CH, ArCH or HetCH), 51.7 (CH2, CH2-C-N), 40.8 (CH2, CH2-CO), 34.9 (QC, 
C(CH3)2), 28.3 (CH3, CH3), 28.2 (CH3, CH3) ppm. HPLC: tR 10.43 min, > 99% purity at 254 nm. 
 
3-chloro-6-methyl-N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (34a): 
 
Yellow solid, 94%. An analytical sample was obtained via recrystallisation in CH2Cl2 layered 
with hexane and used for biological testing. Mp 226 – 227 °C. HRMS-ESI (m/z): [M–H]– calcd 
for C17H12ClN2O2S2, 375.0034; found, 375.0019. FTIR v"max (cm-1): 3345 (m, NH), 1641 (vs, CO), 
1506 (s), 1366 (m), 1317 (m), 1271 (m), 896 (m), 808 (s), 608 (vs). 1H NMR (500 MHz, CDCl3): 
δ 10.40 (br. s, 1H, NH), 7.82 (d, J = 8.3 Hz, 1H, HetCH), 7.68 (s, 1H, HetCH), 7.36 (d, J = 8.3 
Hz, 1H HetCH), 2.96 (t, J = 6.1 Hz, 2H, CH2-CO), 2.62 (t, J = 6.6 Hz, 2H, CH2-N), 2.53 (s, 3H, 
Me) 2.22 (app. quint, J = 6.3 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 192.5 (QC, 
CO), 163.7 (QC, C-N), 162.0 (QC, C-NH), 158.3 (QC, CO-NH), 139.6 (QC, HetC), 139.4 (QC, 
HetC), 134.5 (QC, HetC), 128.5 (QC, HetC), 128.0 (CH, HetCH), 126.2 (QC, HetC), 123.4 (CH, 
HetCH), 122.7 (CH, HetCH), 121.5 (QC, HetC), 37.8 (CH2, CH2-C-N), 27.0 (CH2, CH2-CO) 23.0 
(CH2, CH2), 21.9 (CH3, Me) ppm. HPLC: tR 7.90 min, 97% purity at 254 nm. 
 
3-chloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-6-
methylbenzo[b]thiophene-2-carboxamide (34b): 
 
Yellow solid, 94%. An analytical sample was obtained via recrystallisation in CH2Cl2 layered 
with hexane and used for biological testing. Mp 219 – 220 °C. HRMS-ESI (m/z): [M+H]+ calcd 
for C19H18ClN2O2S2, 405.0493; found, 405.0508. FTIR v"max (cm-1): 3370 (m, NH), 2953 (w), 
1661 (s, CO), 1647 (s), 1514 (vs), 1362 (s), 1277 (s), 889 (s), 810 (s). 1H NMR (500 MHz, 
CDCl3): δ 7.83 (d, J = 8.4 Hz, 1H, HetCH), 7.69 (s, 1H, HetCH), 7.37 (dd, J = 8.4, 0.8 Hz, 1H, 
HetCH), 2.83 (s, 2H, CH2, CH2-CO), 2.53 (s, 3H, Me), 2.48 (s, 2H, CH2-C-N), 1.15 (s, 6H, CH3) 
ppm. The signal arising from the NH proton could be detected at approximately 10.50 ppm, but 
was too broadened to report. 13C NMR (125 MHz, CDCl3): δ 192.1 (QC, CO), 162.3 (QC, C-N 
or C-NH), 162.2 (QC, C-N or C-NH), 158.3 (QC, CO-NH), 139.6 (QC, HetC), 139.4 (QC, HetC), 
134.5 (QC, HetC), 128.4 (QC, HetC), 128.0 (CH, HetCH), 124.9 (QC, HetC), 123.4 (CH, 
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HetCH), 122.7 (CH, HetCH), 121.6 (QC, HetC), 51.8 (CH2, CH2-C-N), 41.0 (CH2, CH2-CO), 
35.1 (QC, C(CH3)2), 28.4 (CH3, 2´CH3) , 21.9 (CH3, Me) ppm. HPLC: tR 9.14 min, 97% purity 
at 254 nm. 
 
6-bromo-3-chloro-N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (35a): 
 
Purified via recrystallization in toluene.Yellow solid, 58%. Mp 256 – 257. HRMS-ESI (m/z): 
[M–H]– calcd for C16H9BrClN2O2S2, 438.8983; found, 438.8987. FTIR v"max (cm-1): 3355 (m, 
NH), 1650 (vs, CO), 1532 (s), 1308 (m), 809 (s), 602 (s). 1H NMR (400 MHz, CDCl3): δ 10.35 
(br. s, 1H, NH), 8.06 (dd, J = 1.7, 0.5 Hz, 1H, HetCH), 7.80 (dd, J = 8.7, 0.6 Hz, 1H, HetCH), 
7.66 (dd, J = 8.7, 1.7 Hz, 1H, HetCH), 2.97 (t, J = 6.2 Hz, 2H, CH2-CO), 2.64 – 2.61 (m, 2H, 
CH2-C-N), 2.23 (app. quint, J = 6.3 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 192.5 
(QC, CO), 163.5 (QC, C-N), 161.8 (QC, C-NH), 157.9 (QC, CO-NH), 140.1 (QC, HetC), 135.4 
(QC, HetC), 130.2 (QC, HetC), 129.8 (CH, HetCH), 126.3 (QC, HetC), 125.6 (CH, HetCH), 
124.8 (CH, HetCH), 123.4 (QC, HetC), 121.4 (QC, C-Br), 37.8 (CH2, CH2-CO), 26.9 (CH2, CH2-
C-N), 23.0 (CH2, CH2) ppm. HPLC: tR 8.26 min, > 99% purity at 254 nm. 
 
6-bromo-3-chloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-
yl)benzo[b]thiophene-2-carboxamide (35b): 
 
Purified via recrystallization in toluene. Yellow solid, 66%. Mp 199 – 200 °C. HRMS-ESI (m/z): 
[M–H]– calcd for C18H13BrClN2O2S2, 466.9296; found, 466.9283. FTIR v"max (cm-1): 3354 (m, 
NH), 1656 (vs, CO), 1538 (s), 1518 (s), 1363 (s), 608 (s). 1H NMR (500 MHz, CDCl3): δ 8.06 
(d, J = 1.6 Hz, 1H, HetCH), 7.79 (d, J = 8.7 Hz, 1H, HetCH), 7.65 (dd, J = 8.7, 1.7 Hz, 1H, 
HetCH), 2.82 (s, 2H, CH2-CO), 2.48 (s, 2H, CH2-C-N), 1.15 (s, 6H, CH3) ppm. The signal arising 
from the NH proton could be detected at approximately 10.40 ppm, but was too broadened to 
report. 13C NMR (125 MHz, CDCl3): δ 192.1 (QC, CO), 162.1 (QC, C-N or C-NH), 162.0 (QC, 
C-N or C-NH), 157.8 (QC, CO-NH), 140.1 (QC, HetC), 135.4 (QC, HetC), 135.4 (QC, HetC), 
130.2 (QC, HetC), 129.8 (CH, HetCH), 125.6 (CH, HetCH), 125.1 (QC, HetC), 124.8 (CH, 
HetCH), 123.4 (QC, HetC), 121.3 (QC, C-Br), 51.8 (CH2, CH2-CO), 40.9 (CH2, CH2-C-N), 35.1 
(QC, C(CH3)2), 28.4 (CH3, 2´CH3) ppm. HPLC: tR 9.41 min, 98% purity at 254 nm. 
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3-chloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-5-
methoxybenzo[b]thiophene-2-carboxamide (36): 
 
Synthesised with the addition of catalytic DMAP (10 mol%). Crude material extracted with 
EtOAc and subjected to additional wash with aqueous NaOH (1.0 M) before drying. Purified via 
recrystallisation in CH2Cl2 layered with hexane. Pale yellow solid, 41%. Mp 211 – 214. HRMS-
ESI (m/z): [M+H]+ calcd for C19H18ClN2O3S2, 421.0442; found, 421.0461. FTIR v"max (cm-1): 
3359 (w, NH), 1666 (s, CO), 1506 (vs), 1361 (s), 1277 (s), 1209 (vs), 1022 (m), 896 (s), 828 (m), 
740 (m). 1H NMR (500 MHz, CDCl3): δ 7.75 (d, J = 8.9 Hz, 1H, HetCH), 7.29 (s, 1H, HetCH), 
7.22 (d, J = 8.8 Hz, 1H, HetCH), 3.94 (s, 3H, OMe), 2.82 (s, 2H, CH2-CO), 2.48 (s, 2H, CH2-C-
N), 1.15 (s, 6H, CH3) ppm. The signal arising from the NH proton could be detected at 
approximately 10.50 ppm, but was too broadened to report. 13C NMR (125 MHz, CDCl3): δ 192.1 
(QC, CO), 162.3 (QC, C-N or C-NH), 162.2 (QC, C-N or C-NH), 158.8 (QC, C-OMe), 158.2 
(QC, HetC), 137.7 (QC, HetC), 131.7 (QC, HetC), 130.5 (QC, HetC), 124.9 (QC, HetC), 123.9 
(CH, HetCH), 120.7 (QC, HetCH), 120.2 (CH, HetCH), 104.1 (CH, HetCH), 55.7 (CH3, OMe), 
51.8 (CH2, CH2-C-N), 40.9 (CH2, CH2-CO), 35.1 (QC, C(CH3)2), 28.4 (CH3, 2´CH3) ppm. 
HPLC: tR 8.31 min, 96% purity at 254 nm. 
 
7-bromo-3-chloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-
yl)benzo[b]thiophene-2-carboxamide (37): 
 
Purified via recrystallisation in MeOH with minimal CH2Cl2. Brown crystals, 50%. Mp  220 – 
221 °C. HRMS-ESI (m/z): [M–H]– calcd for C18H13BrClN2O2S2, 466.9296; found, 466.9276.  
FTIR v"max (cm-1): 3354 (w, NH), 2957 (w), 1652 (vs, CO), 1514 (s), 1365 (s), 1280 (s), 888 (m). 
1H NMR (400 MHz, CDCl3): δ 10.39 (br. s, 1H, NH), 7.93 (dd, J = 8.2, 0.9 Hz, 1H, HetCH), 7.73 
(dd, J = 7.7, 0.9 Hz, 1H, HetCH), 7.45 (app. t, J = 7.9 Hz, 1H, HetCH), 2.83 (s, 2H, CH2-CO), 
2.49 (s, 2H, CH2-C-N), 1.16 (s, 6H, CH3) ppm. 13C NMR (100 MHz, CDCl3): δ 192.1 (QC, CO), 
162.2 (QC, C-N or C-NH), 162.0 (C-N or C-NH), 158.0 (QC, CO-NH), 140.6 (QC, HetC), 137.4 
(QC, HetC), 131.2 (CH, HetCH), 131.1 (QC, HetC), 127.3 (CH, HetCH), 125.0 (CH, HetCH), 
122.8 (CH, HetCH), 121.8 (QC, HetC), 116.5 (CH, HetCH), 51.8 (CH2, CH2-C-N), 40.8 (CH2, 
CH2-CO), 35.0 (QC, C(CH3)2, 28.4 (CH3, 2´CH3) ppm. HPLC: tR 9.63 min, 96% purity at 254 
nm. 
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N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)thiophene-2-carboxamide (41): 
 
Purified via column chromatography (EtOAc/hexane, 40:60), pale yellow solid, 75%. Mp 254 – 
256 °C. HRMS-ESI (m/z): [M+H]+ calcd for C14H15N2O2S2, 307.0569; found, 307.0586. FTIR 
v"max (cm-1): 3361 (vw, NH), 1653 (s, CO), 1533 (s), 1507 (s), 1363 (s), 1352 (s), 1275 (vs), 727 
(vs). 1H NMR (500 MHz, CDCl3): δ 10.02 (br. s, 1H, NH), 7.76 (dd, J = 3.8, 1.2 Hz, 1H, HetCH), 
7.69 (dd, J = 4.9, 1.2 Hz, 1H, HetCH), 7.19 (dd, J = 5.0, 3.8 Hz, 1H, HetCH), 2.74 (s, 2H, CH2-
CO), 2.47 (s, 2H, CH2-N), 1.13 (s, 6H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 192.0 (QC, 
CO), 163.4 (QC, C-N), 161.8 (QC, C-NH), 158.9 (QC, CO-NH), 135.8 (QC, HetC), 133.4 (CH, 
HetCH), 130.6 (CH, HetCH), 128.4 (CH, HetCH), 124.5 (QC, HetC), 51.8 (CH2, CH2-C-N), 40.8 
(CH2, CH2-CO), 35.1 (QC, C(CH3)2, 28.4 (CH3, 2´CH3) ppm. HPLC: tR 5.97 min, > 99% purity 
at 280 nm. 
 
N-allyl-3-chloro-N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (44): 
 
Synthesised using acetone in place of toluene. Purified via column chromatography 
(EtOAc/hexane, 40:60). Off-white crystals, 60%. An analytical sample was obtained via further 
column chromatography in MeOH/CH2Cl2 (2:98). Mp 127 – 129. HRMS-ESI (m/z): [M+Na]+ 
calcd for C19H15ClN2O2S2, 425.0156; found, 425.0167. FTIR v"max (cm-1): 1646 (vs, CO), 1523 
(m), 1452 (m), 1369 (s), 1230 (s), 920 (m), 748 (vs). 1H NMR (500 MHz, CDCl3): δ 7.92 – 7.90 
(m, 1H, HetCH), 7.87 – 7.86 (m, 1H, HetCH), 7.57 – 7.52 (m, 2H, HetCH), 5.93 – 5.86 (m, 1H, 
=CH), 5.14 (d, J = 10.4 Hz, 1H, =CH), 5.02 (d, J = 17.2 Hz, 1H, =CH), 4.96 (d, J = 5.7 Hz, 2H, 
CH2-N), 2.97 (t, J = 6.1 Hz, 2H, CH2-CO), 2.61 (t, J = 6.5 Hz, 2H, CH2-C-N), 2.22 (app. quint, J 
= 6.3 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 193.0 (QC, CO), 163.4 (QC, C-N, C-
NH or CO-NH), 163.1 (QC, C-N, C-NH or CO-NH), 162.9 (QC, C-N, C-NH or CO-NH), 137.6 
(CH, HetCH), 135.2 (CH, HetCH), 131.6 (CH, =CH), 127.34 (QC, HetC), 127.31 (CH, HetCH), 
126.6 (QC, HetC), 125.8 (CH, HetCH), 122.9 (CH, HetCH), 122.8 (CH, HetCH), 121.6 (QC, 
HetC), 118.3 (CH2, =CH2), 51.3 (CH2, CH2-N), 37.9 (CH2, CH2-N), 27.1 (CH2, CH2-CO), 23.1 
(CH2, CH2) ppm. HPLC: tR 9.60 min, 98% purity at 254 nm. 
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3-chloro-N-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-carboxamide (48):** 
 
Purified via recrystallization in EtOH. Orange crystals, 64%. An analytical sample was obtained 
via recrystallisation in CHCl3 layered with hexane and used for biological testing. Mp 212 – 213 
°C. HRMS-ESI (m/z): [M+H]+ calcd for C16H13ClN2OS2, 349.0231; found, 349.0248. FTIR v"max 
(cm-1): 3381 (w, NH), 1646 (m), 1538 (m), 1507 (m), 1292 (s), 759 (s). 1H NMR (400 MHz, 
CDCl3): δ 7.92 – 7.88 (m, 1H, HetCH), 7.87 – 7.83 (m, 1H, HetCH), 7.56 – 7.49 (m, 2H, HetCH), 
2.75 – 2.71 (br. m, 2H, CH2-C-N), 2.71 – 2.66 (br. m, 2H, CH2-C-S), 1.90 – 1.84 (br. m, 4H, CH2) 
ppm. The signal arising from the NH proton could be detected at approximately 10.30 ppm, but 
was too broadened to report. 13C NMR (100 MHz, CDCl3): δ 158.2 (QC, C-NH), 154.7 (QC, CO-
NH), 144.2 (QC, CH2-C-N), 138.6 (QC, HetC), 136.8 (QC, HetC), 130.8 (QC, HetC), 128.0 (CH, 
HetCH), 125.7 (CH, HetCH), 123.9 (QC, CH2-C-S), 123.5 (CH, HetCH), 122.9 (CH, HetCH), 
120.8 (QC, HetC), 26.2 (CH2, CH2-C-N), 23.2 (CH2, CH2-C-S), 23.0 (CH2, CH2), 22.9 (CH2, 
CH2) ppm. HPLC: tR 9.29 min, > 99% purity at 254 nm. 
 
N-(benzo[d]thiazol-2-yl)-3-chlorobenzo[b]thiophene-2-carboxamide (49): 
 
Synthesised using commercially available 2-aminobenzothiazole, using acetone in place of 
toluene. Purified via recrystallisation in dioxane. Pale yellow solid, 30%. Mp 257 – 258 °C (lit. 
265 – 267 °C).112 HRMS-ESI (m/z): [M+H]+ calcd for C16H10ClN2OS2, 344.9918; found, 
344.9930. FTIR v"max (cm-1): 3374 (m, NH), 1651 (w), 1527 (vs), 1275 (vs), 893 (m), 758 (s). 1H 
NMR (500 MHz, DMSO-d6): δ 13.48 (br. s, 1H, NH), 8.12 (d, J = 7.6 Hz, 1H, HetCH), 7.96 (d, 
J = 7.6 Hz, 2H, HetCH), 7.64 – 7.58 (m, 3H, HetCH), 7.49 (app. t, J = 7.5 Hz, 1H, HetCH), 7.35 
(app. t, J = 7.5 Hz, 1H, HetCH) ppm. The mp, IR and 1H NMR data match that previously 
reported, with the exception of the signals from the heteroaromatic protons region being reported 
as one multiplet in the literature.112 13C NMR (125 MHz, DMSO-d6): δ 165.4 (br., QC, C-NH and 
CO-NH), 137.6 (QC, HetC), 136.7 (QC, HetC), 132.3 (br., QC, HetC), 128.1 (br., QC, HetC), 
128.0 (CH, 2´HetCH), 127.0 (CH, HetCH), 125.0 (CH, HetCH), 123.9 (CH, HetCH), 123.4 (CH, 
HetCH), 122.8 (CH, HetCH), 122.7 (QC, HetC), 122.6 (CH, HetCH), 115.6 (br., QC, HetC) ppm. 
HPLC: tR 9.10 min, 99% purity at 254 nm. 
 
 
 
SNH
O
S
N
Cl
SNH
O
S
N
Cl
 73 
3-chloro-N-(thiazol-2-yl)benzo[b]thiophene-2-carboxamide (50): 
 
Synthesised using commercially available 2-aminothiazole, using acetone in place of toluene. 
Purified via recrystallisation in EtOH. Pale yellow solid, 49%. Mp 200 – 201 °C. HRMS-ESI 
(m/z): [M+H]+ calcd for C12H8ClN2OS2, 294.9761; found, 294.9771. FTIR v"max (cm-1): 3382 (w, 
NH), 1647 (m, CO), 1534 (vs), 1316 (s), 1271 (m), 891 (m), 764 (s), 717 (s). 1H NMR (500 MHz, 
DMSO-d6/CDCl3, 95:5): δ 13.12 (br. s, 1H, NH), 8.10 (dd, J = 6.6, 1.9 Hz, 1H, HetCH), 7.93 (dd, 
J = 6.6, 2.3 Hz, 1H, HetCH), 7.62 – 7.56 (m, 2H, HetCH), 7.54 (d, J = 4.1 Hz, 1H, =CH-N), 7.21 
(d, J = 4.1 Hz, 1H, =CH-S) ppm. 13C NMR (125 MHz, DMSO-d6/CDCl3, 95:5): δ 164.5 (br., QC, 
C-NH), 163.7 (br., QC, CO-NH), 137.3 (QC, HetC), 136.5 (QC, HetC), 132.2 (br., CH, CH-N), 
129.8 (br., QC, HetC), 127.7 (CH, HetCH), 125.8 (CH, HetCH), 123.4 (CH, HetCH), 122.6 (CH, 
HetCH), 121.8 (QC, HetC), 112.5 (CH, CH-S) ppm. HPLC: tR 7.26 min, 99% purity at 254 nm. 
 
N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-7-phenylbenzo[b]thiophene-2-
carboxamide (51c):‡‡ 
 
Off-white solid, 60%. An analytical sample was obtained by heating in MeOH/CH2Cl2 (50:50) 
and adding hexane dropwise to induce recrystallisation. This sample was used for biological 
testing. Mp 313 – 314 °C. HRMS-ESI (m/z): [M–H]– calcd for C24H19N2OS2, 431.0893; found, 
431.0894. FTIR v"max (cm-1): 3248 (w, NH), 1664 (m), 1632 (s, CO), 1536 (m), 1506 (s), 1377 (s), 
1286 (vs), 1204 (m), 752 (m), 697 (vs). 1H NMR (500 MHz, CDCl3): δ 9.82 (br. s, 1H, NH), 8.10 
(s, 1H, HetCH), 7.90 (d, J = 7.4 Hz, 1H, HetCH), 7.71 (d, J = 7.1 Hz, 2H, HetCH), 7.58 – 7.45 
(m, 5H, ArCH), 2.77 (s, 2H, CH2-CO), 2.47 (s, 2H, CH2-C-N), 1.13 (s, 6H, CH3) ppm. 13C NMR 
(125 MHz, CDCl3): δ 192.1 (QC, CO), 163.1 (QC, C-N), 161.9 (QC, C-NH), 159.5 (QC, HetC), 
141.1 (QC, HetC), 139.5 (QC, HetC or ArC), 139.4 (QC, HetC or ArC), 137.3 (QC, HetC or 
ArC), 135.2 (QC, HetC), 129.1 (CH, 2´ArCH), 128.58 (CH, HetCH or ArCH), 128.55 (CH, 
HetCH or ArCH), 128.0 (CH, 2´ArCH), 127.3 (CH, HetCH), 126.3 (CH, HetCH), 124.7 (CH, 
HetCH), 124.6 (QC, HetC), 51.8 (CH2, CH2-CO), 40.8 (CH2, CH2-C-N), 35.1 (QC, C(CH3)2, 28.4 
(CH3, 2´CH3) ppm. HPLC: tR 9.22 min, > 99% purity at 280 nm. 
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General procedure for the synthesis of WEHI-0086109 (14a) derivatives via EDC Coupling: 
 
A suspension of the benzothiophenyl carboxylic acid (1.00 equiv.), the appropriate thiazole amine 
fragment (1.05 equiv.) and DMAP (20 mol%) in CH2Cl2 (0.05 M with respect to the carboxylic 
acid) was stirred at room temperature. To this was added EDC×HCl (1.2 equiv.) and the reaction 
mixture stirred at room temperature under a nitrogen atmosphere. After 24 hours, the reaction 
mixture was cooled to 0 °C and quenched with aqueous HCl (1.0 M). The precipitated product 
was collected by filtration and washed with cold water, followed by cold CH2Cl2, and dried under 
vacuum.  
 
N-(7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-carboxamide:(32a): 
 
Synthesised using commercially available benzothiophene-2-carboxylic acid. Off-white solid, 
42%. Mp 264 – 265 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C16H12N2O2S2Na, 351.0232; found, 
351.0251. FTIR v"max (cm-1): 3241 (w, NH), 1648 (s, CO), 1540 (s), 1375 (s), 1284 (vs), 1206 (s), 
1189 (s), 719 (vs). 1H NMR (500 MHz, DMSO-d6): δ 13.50 (br. s, 1H, NH), 8.60 (br. s, 1H, 
HetCH), 8.09 (d, J = 8.1 Hz, 1H, HetCH), 8.01 (d, J = 7.9 Hz, 1H, HetCH), 7.51 (app. dt, J = 
26.2, 7.4 Hz, 2H, HetCH), 2.91 (br. t, J = 6.2 Hz, 2H, CH2-CO), 2.52 (br. t, J = 6.2 Hz, 2H, CH2-
C-N), 2.12 (br. app. quint, J = 6.2 Hz, 2H, CH2) ppm. 13C NMR (125 MHz, DMSO-d6): δ 192.0 
(QC, CO), 163.9 (br, QC, C-N or C-NH), 163.3 (br, QC, C-N or C-NH), 161.0 (br, QC, CO-NH), 
141.2 (QC, HetC), 138.9 (QC, HetC), 136.6 (br, QC, HetC), 128.6 (CH, HetCH), 127.3 (CH, 
HetCH), 126.0 (CH, HetCH), 125.3 (CH, HetCH), 123.5 (br, QC, HetC), 123.0 (CH, HetCH), 
37.2 (CH2, CH2-C-N), 26.1 (br, CH2, CH2-O), 22.6 (CH2, CH2) ppm. HPLC: tR 6.37 min, 99% 
purity at 254 nm. 
 
N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[b]thiophene-2-
carboxamide (32b): 
 
Synthesised using commercially available benzothiophene-2-carboxylic acid. White solid, 55%. 
Mp 292 – 293 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C18H16N2O2S2Na, 379.0545; found, 
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379.0551. FTIR v"max (cm-1): 3237 (w, NH), 1664 (s), 1635 (vs, CO), 1536 (s), 1289 (s), 1207 (s), 
879 (m), 719 (s). 1H NMR (400 MHz, DMSO-d6): δ 13.51 (br. s, 1H, NH), 8.60 (br. s, 1H, 
HetCH), 8.09 (d, J = 7.9 Hz, 1H, HetCH), 8.02 (d, J = 7.6 Hz, 1H, HetCH), 7.56 – 7.47 (m, 2H, 
HetCH), 2.83 (s, 2H, CH2-CO), 2.44 (s, 2H, CH2-C-N), 1.08 (s, 6H, CH3) ppm. 13C NMR (125 
MHz, DMSO-d6): δ 191.6 (QC, CO), 163.4 (br, C-N or C-NH), 162.6 (br, C-N or C-NH, 160.8 
(br, CO-NH), 141.2 (QC, HetC), 138.9 (QC, HetC), 136.5 (br, QC, HetC), 128.6 (CH, HetCH), 
127.3 (CH, HetCH), 126.0 (CH, HetCH), 125.3 (CH, HetCH), 123.0 (CH, HetCH), 122.4 (br, 
QC, HetC), 51.1 (CH2, CH2-C-N), 34.7 (QC, C(CH3)2, 27.8 (CH3, 2´CH3) ppm. The signal arising 
from the CH2-CO carbon is obscured by the residual solvent peak, but was determined via a 
gHSQC experiment to appear at approximately 40.2 ppm. HPLC: tR 7.48 min, > 99% purity at 
254 nm. 
 
N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-7-methoxybenzo[b]thiophene-2-
carboxamide (51b): 
 
Off-white solid, 75%. Mp 305 – 309 °C (with decomp.). HRMS-ESI (m/z): [M–H]– calcd for 
C19H17N2O3S2, 385.0686; found, 385.0698. FTIR v"max (cm-1): 3228 (w, NH), 1716 (m), 1639 (m), 
1542 (m), 1301 (s), 1272 (s), 1098 (vs), 712 (vs). 1H NMR (400 MHz, DMSO-d6): δ 13.48 (br. 
s, 1H, NH), 8.58 (br. s, 1H, HetCH), 7.60 (d, J = 7.9 Hz, 1H, HetCH), 7.45 (app. t, J = 7.9 Hz, 
1H, HetCH), 7.11 (d, J = 7.8 Hz, 1H, HetCH), 3.99 (s, 3H, OMe), 2.83 (s, 2H, CH2-CO), 2.44 (s, 
2H, CH2-C-N), 1.08 (s, 6H, CH3) ppm. 13C NMR (125 MHz, DMSO-d6): δ 191.7 (QC, CO), 
163.6 (br., QC, C-N), 162.3 (br., QC, C-NH), 161.1 (br., QC, CO-NH), 153.9 (QC, HetC), 140.5 
(QC, HetC), 136.9 (br., QC, HetC), 130.0 (QC, HetC), 129.0 (CH, HetCH), 127.0 (CH, HetCH), 
122.3 (br., QC, HetC), 118.3 (CH, HetCH), 107.2 (CH, HetCH), 55.9 (CH3, OMe), 51.1 (CH2, 
CH2-C-N), 34.8 (QC, C(CH3)2) 27.9 (CH3, 2´CH3) ppm. The signal arising from the CH2-CO 
carbon is obscured by the residual solvent peak, but was determined via a gHSQC experiment to 
appear at approximately 40.0 ppm. HPLC: tR 7.59 min, 99% purity at 254 nm. 
 
Synthesis of N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)benzo[d]thiazole-2-
carboxamide (39): 
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The required carboxylic acid was prepared from commercially available ethyl benzothiazole-2-
carboxylate using the procedure reported by Mecinović.113 A suspension of the carboxylic acid 
(80.5 mg, 0.45 mmol, 1.00 equiv.), the amine (92.5 mg, 0.47 mmol, 1.05 equiv.) and DMAP (6.5 
mg, 0.05 mmol, 10 mol%) in CH2Cl2 (5 mL) was cooled to 0 °C with stirring. To this was added 
EDC×HCl (110.1 mg, 0.57 mmol, 1.30 equiv.) and the reaction mixture warmed to room 
temperature to stir under a nitrogen atmosphere. After 3 days, the reaction mixture was diluted 
with water and the organic layer extracted with CH2Cl2 before being dried with MgSO4, filtered 
and concentrated in vacuo. The crude residue was subjected to column chromatography 
(MeOH/CH2Cl2, 2:98) to give the pure product as off-white crystals (100.5 mg, 0.28 mmol, 62%).  
 
Mp 216 – 217 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C17H15N3O2S2Na, 380.0498; found, 
380.0517. FTIR v"max (cm-1): 3360 (vw, NH), 1653 (CO), 1506 (vs), 1369 (vs), 1287 (s), 1037 
(m), 893 (s), 759 (s). 1H NMR (400 MHz, CDCl3): δ 10.74 (br. s, 1H), 8.15 – 8.13 (m, 1H, 
HetCH), 8.04 – 8.02 (m, 1H, HetCH), 7.64 – 7.55 (m, 2H, HetCH), 2.85 (s, 2H, CH2-CO), 2.50 
(s, 2H, CH2-C-N), 1.16 (s, 6H, CH3) ppm. 13C NMR (100 MHz, CDCl3): δ 192.1 (QC, CO), 162.5 
(QC, CH2-C-N), 161.9 (QC, C-NH), 160.0 (QC, CO-NH), 157.5 (QC, CO-C=N), 152.5 (QC, 
HetC), 137.7 (QC, HetC), 127.8 (CH, HetCH), 127.5 (CH, HetCH), 125.1 (QC, CH2-CO-C-S), 
125.0 (CH, HetCH), 122.6 (CH, HetCH), 51.8 (CH2, CH2-C-N), 41.0 (CH2, CH2-CO), 35.1 (QC, 
C(CH3)2), 28.4 (CH3, 2´CH3) ppm. HPLC: tR 7.46 min, > 99% purity at 254 nm. 
 
1.4.4 Building Blocks for Organometallic Derivatives of Nitazoxanide 
 
Synthesis of tert-butyl salicylate (68a):114a 
 
 
 
To a solution of H2SO4 (0.55 mL, 10 mmol, 1.0 equiv.) in CH2Cl2 (40 mL) was added MgSO4 
(4.88 g, 40 mmol, 4.0 equiv.) and the mixture stirred for 15 minutes using a large stir bar to break 
up the resulting aggregate. To this was added salicylic added (1.39 g, 10 mmol, 1.0 equiv.) 
followed by t-BuOH (4.8 mL, 50 mmol, 5.0 equiv.) and the mixture stirred for 18 hours. The 
reaction was quenched with a saturated aqueous solution of NaHCO3 (75 mL) and stirred until 
the MgSO4 had dissolved. The organic layer extracted with CH2Cl2, washed with brine and dried 
with MgSO4 before being filtered and concentrated in vacuo to give the product as a colourless 
oil (0.626 g, 3.22 mmol, 32%).  
 
1H NMR (400 MHz, CDCl3): δ 11.08 (s, 1H, OH), 7.79 (dd, J = 8.0, 1.8 Hz, 1H, ArCH), 7.41 
(ddd, J = 8.7, 7.2, 1.8 Hz, 1H, ArCH), 6.96 (dd, J = 8.4, 1.2 Hz, 1H, ArCH), 6.84 (ddd, J = 8.2, 
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7.2, 1.2 Hz, 1H, ArCH), 1.62 (s, 9H, t-BuCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 169.7 (QC, 
CO), 161.7 (QC, C-OH), 135.0 (CH, ArCH), 130.0 (CH, ArCH), 118.7 (CH, ArCH), 117.4 (CH, 
ArCH), 113.7 (QC, ArC–CO2), 82.6 (QC, t-BuC), 28.0 (CH3, 3´t-BuCH3) ppm. The NMR data 
match that previously reported.114b 
 
Synthesis of allyl salicylate (68b): 
 
A solution of salicylic acid (0.505 g, 3.66 mmol, 1.0 equiv.) and DIPEA (0.76 mL, 4.34 mmol, 
1.2 equiv.) was heated at reflux in allyl bromide (8 mL) with stirring. After 8 hours, the excess 
allyl bromide was removed in vacuo and the residue dissolved in EtOAc and washed with water. 
The organic layer was dried with MgSO4 and filtered, before concentration in vacuo to give the 
crude material. This was subjected to column chromatography (EtOAc/Hexane, 2:98) to give the 
pure product (Rf  = 0.5) as a colourless oil (0.436 g, 2.45 mmol, 67%).  
 
1H NMR (500 MHz, CDCl3): δ 10.75 (s, 1H, OH), 7.88 (dd, J = 8.0, 1.8 Hz, 1H, ArCH), 7.46 
(ddd, J = 8.8, 7.2, 1.8 Hz, 1H, ArCH), 6.99 (dd, J = 8.4, 1.1 Hz, 1H, ArCH), 6.88 (ddd, J = 8.2, 
7.2, 1.2 Hz, 1H, ArCH), 6.07 – 5.99 (m, 1H, =CH), 5.43 (app. dq, J = 17.2, 1.5 Hz, 1H, =CH), 
5.33 (app. dq, J = 10.5, 1.3 Hz, 1H, =CH), 4.85 (app. dt, J = 5.7, 1.4 Hz, 2H, CH2) ppm. 13C NMR 
(125 MHz, CDCl3): δ 169.8 (QC, CO), 161.7 (QC, C-OH), 135.7 (CH, ArCH), 131.5 (CH, =CH), 
129.9 (CH, ArCH), 119.1 (CH, ArCH), 118.9 (CH2, =CH2), 117.6 (CH, ArCH), 112.3 (QC, ArC–
CO2), 65.8 (CH2, CH2) ppm. The NMR data match that previously reported.99 
 
General procedure for the synthesis of ferrocenyl esters via EDC coupling:96 
 
A solution of the O-protected salicylate (1.0 equiv.), ferrocenecarboxylic acid (1.0 equiv.) and 
DMAP (1.0 equiv.) in CH2Cl2 (0.02 M with respect to the salicylate) was stirred at room 
temperature. To this was added EDC×HCl (1.1 equiv.) and the reaction mixture stirred at 40 °C, 
with a condenser fitted. After 24 hours, the reaction mixture was diluted with EtOAc and washed 
with a saturated aqueous solution of NH4Cl, then an aqeuous 50% wt. solution of NaHCO3, before 
the organic layer was dried with MgSO4 and filtered. After concentration in vacuo, the crude 
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material was subjected to column chromatography (MeOH/CH2Cl2, 2:98) to give the pure 
product. 
 
Tert-butyl 2-(ferrocenoyloxy)benzoate (69a): 
 
Deep red crystals, 88%. Mp 127 – 128 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C22H22FeO4Na, 
429.0760; found, 429.0761. FTIR v"max (cm-1): 1736 (m, CO), 1714 (s, CO), 1445 (m), 1305 (s), 
1198 (s), 1083 (vs), 747 (s), 482 (vs). 1H NMR (400 MHz, CDCl3): δ 7.92 (dd, J = 7.8, 1.7 Hz, 
1H, ArCH), 7.54 (ddd, J = 8.1, 7.4, 1.7 Hz, 1H, ArCH), 7.30 (app. td, J = 7.6, 1.2 Hz, 1H, ArCH), 
7.16 (dd, J = 8.1, 1.0 Hz, 1H, ArCH), 4.97 (t, J = 2.0 Hz, 2H, FcCH), 4.50 (t, J = 2.0 Hz, 2H, 
FcCH), 4.35 (s, 5H, FcCH), 1.46 (s, 9H, t-BuCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 170.0 
(QC, CO-Fc), 164.3 (QC, CO-Ot-Bu), 149.8 (QC, ArC-CO2), 132.7 (CH, ArCH), 131.4 (CH, 
ArCH), 126.4 (QC, ArC-CO2Fc), 125.6 (CH, ArCH), 123.6 (CH, ArCH), 81.6 (QC, t-BuC), 71.8 
(CH, 2´FcCH), 70.7 (CH, 2´FcCH), 70.5 (QC, FcC-CO2), 70.0 (CH, 5´FcCH), 28.1 (CH3, 3´t-
BuCH3) ppm. 
 
Allyl 2-(ferrocenoyloxy)benzoate (69b): 
 
Deep red crystals, 89%. Mp 85 – 87 °C. HRMS-ESI (m/z): [M+H]+ calcd for C21H19FeO4, 
391.0627; found, 391.0637. FTIR v"max (cm-1): 1717 (vs, CO), 1196 (s), 1096 (vs), 1081 (vs), 744 
(s). 1H NMR (500 MHz, CDCl3): δ 8.03 (dd, J = 7.9, 1.7 Hz, 1H, ArCH), 7.60 (ddd, J = 8.1, 7.4, 
1.7 Hz, 1H, ArCH), 7.33 (app. td, J = 7.7, 1.2 Hz, 1H, ArCH), 7.22 (dd, J = 8.1, 1.2 Hz, 1H, 
ArCH), 5.93 – 5.85 (m, 1H, =CH), 5.31 (app. dq, J = 17.2, 1.5 Hz, 1H, =CH2), 5.18 (app. dq, J = 
10.4, 1.3 Hz, 1H, =CH2), 4.97 (t, J = 1.9 Hz, 2H, FcCH), 4.72 (app. dt, J = 5.8, 1.4 Hz, 2H, CH2), 
4.50 (t, J = 1.9 Hz, 2H, FcCH), 4.34 (s, 5H, FcCH) ppm. 13C NMR (125 MHz, CDCl3): δ 170.3 
(CO-Fc), 164.3 (QC, CO-Ot-Bu), 150.6 (QC, ArC-CO2), 133.5 (CH, ArCH), 131.9 (CH, =CH), 
131.6 (CH, ArCH), 125.7 (CH, ArCH), 124.1 (QC, ArC-CO2Fc), 124.0 (CH, ArCH), 118.6 (CH2, 
=CH2), 71.8 (CH, 2´FcCH), 70.8 (CH, 2´FcCH), 70.2 (QC, FcC-CO2), 70.0 (CH, 5´FcCH), 65.7 
(CH2, CH2) ppm. 
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Synthesis of 2-(ferrocenoyloxy)benzoic acid (70) via deprotection of 69b: 
 
To a solution of the allyl ester (401.5 mg, 1.03 mmol, 1.0 equiv.), Pd2dba3×CHCl3 (107.9 mg, 0.10 
mmol, 10 mol%) and PPh3 (57.5 mg, 0.21 mmol, 20 mol%) in CH2Cl2 (20 mL) was added 
dimedone (286.9 mg, 2.05 mmol, 2.0 equiv.) and the reaction stirred at room temperature. After 
3 hours, an acid-base extraction was performed. The carboxylate was extracted from the reaction 
mixture with a saturated aqueous solution of NaHCO3, before CH2Cl2 was added, and the mixture 
acidified with aqueous HCl (1.0 M). The carboxylic acid was then extracted with CH2Cl2 and the 
organic layer dried with MgSO4, filtered and concentrated in vacuo to give the crude material. 
This was subjected to column chromatography (Et2O/hexane, 60:40) to give the pure product as 
orange crystals (210.6 mg, 0.60 mmol, 58%).  
 
Mp 129 – 130 °C (with decomp.). HRMS-ESI (m/z): [M+H]+ calcd for C18H15FeO4, 351.0314; 
found, 351.0313. FTIR v"max (cm-1): 2960 (w, br., OH), 1726 (s, CO), 1684 (s, CO), 1266 (s), 1199 
(s), 1092 (s), 742 (s). 1H NMR (500 MHz, CDCl3): δ 8.09 (dd, J = 7.9, 1.8 Hz, 1H, ArCH), 7.62 
(ddd, J = 8.2, 7.4, 1.8 Hz, 1H, ArCH), 7.34 (app. td, J = 7.6, 1.2 Hz, 1H, ArCH), 7.24 (dd, J = 
8.1, 1.2 Hz, 1H, ArCH), 4.95 (t, J = 2.0 Hz, 2H, FcCH), 4.49 (t, J = 2.0 Hz, 2H, FcCH), 4.31 (s, 
5H, FcCH) ppm. A 1H NMR signal for the carboxylic acid proton was not observed. 13C NMR 
(125 MHz, CDCl3): δ 170.1 (QC, CO-Fc or CO2H), 169.4 (QC, CO-Fc or CO2H), 151.0 (QC, 
ArC-CO2H), 134.4 (CH, ArCH), 132.4 (CH, ArCH), 125.8 (CH, ArCH), 124.1 (CH, ArCH), 
122.9 (QC, ArC-CO2Fc), 71.8 (CH, 2´FcCH), 70.8 (CH, 2´FcCH), 70.03 (QC, FcC-CO2), 69.99 
(CH, 5´FcCH) ppm. 
 
Synthesis of 2-chlorobenzoyl cymantrene (63a):93 
 
A stirring solution of cymantrene (1.01 g, 4.95 mmol, 1.0 equiv.) in CH2Cl2 (9 mL) was cooled 
to 0 °C and o-chlorobenzoyl chloride (1.3 mL, 9.80 mmol, 2.0 equiv.) was added. Anhydrous 
AlCl3 (1.55 g, 11.63 mmol, 2.0 equiv.) was then added portionwise, while the temperature was 
maintained at 0 °C, and the reaction mixture was stirred at this temperature for 30 minutes before 
warming to room temperature to stir overnight. The reaction was then poured into ice-cold water 
and the organic layer extracted with CH2Cl2, before being washed sequentially with water, 
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aqueous 10% wt. solution of NaOH, then water, before being dried with MgSO4. After 
concentration in vacuo, the crude material was subjected to column chromatography on neutral 
alumina, where a yellow band was eluted using 100% Et2O to afford the pure product as yellow 
crystals (1.44 g, 4.20 mmol, 86%).  
 
1H NMR (500 MHz, CDCl3) δ 7.49 – 7.34 (br. m, 4H, ArCH), 5.37 (br. s, 2H, CymCH), 4.90 (br. s, 2H, 
CymCH) ppm. The 1H NMR data match that previously reported.93 
 
Synthesis of cymantrenecarboxylic acid (63b):93 
 
To a 2-necked flask under nitrogen was added KOt-Bu (4.79 g, 42.7 mmol, 10.0 equiv.), followed 
by 1,2-dimethoxyethane (40 mL) and the resulting yellow suspension stirred at room temperature, 
before water (0.22 mL, 12.39 mmol, 3.0 equiv.) was added. The cymantrenyl ketone (1.42 g, 4.13 
mmol, 1.0 equiv.) was added and the resulting deep red solution was heated at reflux for 3 hours. 
After this time, the reaction was poured into water (150 mL) and the aqueous layer, containing 
the carboxylate, was washed with Et2O. The aqueous layer was then acidified using aqueous HCl 
(2.0 M) and the carboxylic acid extracted with Et2O. The organic layer was washed with water 
and dried with MgSO4 before being filtered and concentrated in vacuo to give the crude material, 
which required a further acid-base extraction using aqueous NaOH (1.0 M) and HCl (2.0 M) to 
afford the product in adequate purity (grey powder, 0.522 g, 21.0 mmol, 51%).  
 
MS(ESI) m/z: 247, [M–H]–. 1H NMR (400 MHz, DMSO-d6): δ 12.96 (br. s, 1H, COOH), 5.60 
(t, J = 2.3 Hz, 2H, CymCH), 5.13 (t, J = 2.3 Hz, 2H, CymCH) ppm. The 1H NMR data match that 
previously reported.93 
 
1.4.5 Organometallic Derivatives of Nitazoxanide 
 
Synthesis of N-(5-nitrothiazol-2-yl)ferrocenamide (56a): 
 
 
A suspension of 5-nitro-2-aminothiazole (31.6 mg, 0.22 mmol, 1.0 equiv.), ferrocenecarboxylic 
acid (50.8 mg, 0.22 mmol, 1.0 equiv.) and DMAP (5.3 mg, 0.04 mmol, 20 mol%) in CH2Cl2 (4 
mL) was stirred at room temperature. To this was added EDC×HCl (52.1 mg, 0.26 mmol, 1.2 
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equiv.) and the reaction mixture stirred overnight. The reaction was diluted with water and the 
organic layer extracted with CH2Cl2, then washed with brine, dried with MgSO4 and filtered. 
After concentration in vacuo, the crude material was subjected to column chromatography 
(EtOAc/hexane, 40:60) to afford the product as deep red crystals (58.3 mg, 0.16 mmol, 75%). An 
analytical sample was obtained via recrystallisation in EtOH and this was used for biological 
testing.  
 
Mp 249 – 250 °C (with decomp.). HRMS-ESI (m/z): [M–H]– calcd for C14H10FeN3O3S, 
355.9798; found, 355.9807. FTIR v"max (cm-1): 3109 (vw, NH), 3073 (vw), 1673 (s, CO), 1470 (s), 
1104 (s), 819 (s). 1H NMR (500 MHz, CDCl3): δ 9.22 (br. s, 1H, NH), 8.34 (s, 1H, HetCH), 4.88 
(t, J = 1.9 Hz, 2H, FcCH), 4.61 (t, J = 1.9 Hz, 2H, FcCH), 4.28 (s, 5H, FcCH) ppm. 13C NMR 
(125 MHz, CDCl3): δ 169.1 (QC, HetC-NH), 161.1 (QC, CO), 143.5 (QC, C-NO2), 140.8 (CH, 
HetCH), 72.7 (CH, 2´FcCH), 71.2 (QC, FcC–CO), 70.4 (CH, 5´FcCH), 68.7 (CH, 2´FcCH) 
ppm. 
 
Synthesis of 2-((5-nitrothiazol-2-yl)carbamoyl)phenyl ferrocenylcarboxylate (65a):  
 
A suspension of 5-nitro-2-aminothiazole (12.9 mg, 0.09 mmol, 1.0 equiv.), the carboxylic acid 
(30.9 mg, 0.09 mmol, 1.0 equiv.) and DMAP (2.8 mg, 0.02 mmol, 20 mol%) in CH2Cl2 (2 mL) 
was stirred at room temperature. To this was added EDC×HCl (20.6 mg, 0.11 mmol, 1.1 equiv.) 
and the reaction mixture stirred for 3 hours. The reaction was diluted with water and the organic 
layer extracted with CH2Cl2, dried with MgSO4 and filtered. After concentration in vacuo, the 
crude material was subjected to column chromatography (EtOAc/hexane, 50:50) to afford the 
product as orange crystals (29.7 mg, 0.06 mmol, 71%). An analytical sample was obtained via 
recrystallisation in CHCl3 layered with hexane, and this was used for biological testing.  
 
Mp 185 – 187 °C (with decomp.). HRMS-ESI (m/z): [M–H]– calcd for C21H14FeN3O5S, 
476.0009; found, 476.0023. FTIR v"max (cm-1): 3022 (vw, NH), 1716 (s, CO), 1305 (s), 1179 (s), 
739 (vs). 1H NMR (500 MHz, CDCl3): δ 10.78 (br. s, 1H, NH), 8.22 (s, 1H, HetCH), 8.10 (dd, J 
= 7.9, 1.8 Hz, 1H, ArCH), 7.70 (ddd, J = 8.2, 7.4, 1.7 Hz, 1H, ArCH), 7.47 – 7.40 (m, 2H, ArCH), 
5.04 (t, J = 2.0 Hz, 2H, FcCH), 4.63 (t, J = 2.0 Hz, 2H, FcCH), 4.31 (s, 5H, FcCH) ppm. 13C 
NMR (125 MHz, CDCl3): δ 169.5 (QC, CH-NH), 163.1 (QC, CO-Fc or CO2H), 160.8 (QC, CO-
Fc or CO2H), 148.8 (QC, ArC-CONH), 143.8 (QC, C-NO2), 140.8 (CH, HetCH), 134.3 (CH, 
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ArCH), 131.3 (CH, ArCH), 126.4 (CH, ArCH), 123.8 (CH, ArCH), 123.6 (QC, ArC-CO2Fc), 
72.9 (CH, 2´FcCH), 70.8 (CH, 2´FcCH), 70.2 (CH, 5´FcCH), 68.2 (QC, FcC–CO) ppm. 
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2.1 Introduction and Preliminary Work 
 
2.1.1 The Importance of Reaction Development in Medicinal Chemistry 
 
The demand for more potent and selective drugs, as well as materials and chemical agents, drives 
the need for new synthetic routes to complex molecular architectures. As can be noted from the 
molecules developed in Part I, staple reactions in medicinal chemistry such as aryl cross-coupling 
and amide coupling reactions are powerful in the rapid assembly of drug libraries. While this may 
prove ideal for tackling issues in desperate need of attention, such as neglected tropical diseases, 
there is a consensus within the medicinal chemistry community to move away from such 
inherently 'flat' structures in pursuit of more complex, sp3-rich and stereodefined molecular 
scaffolds.1 By exploring new chemical space with an attention to 3D orientation and chirality, 
drug molecules can be carefully tailored to fit biological targets such as enzymes and receptors 
with a high degree of selectivity and potency. It is therefore crucial that new chemical reactions 
are continually discovered and developed as a means of pursuing molecular complexity. 
 
2.1.2 Aziridines and Allenes as Building Blocks 
 
There are a multitude of building blocks in organic synthesis that can serve as invaluable tools in 
the construction of sp3-rich and stereodefined molecular scaffolds. Two classes of building blocks 
that are of interest to the Hyland research group include strained rings (specifically aziridines) 
and allenes. Aziridines (1, Scheme 2.1A) are considered 'spring-loaded' molecules, as their 
inherent ring strain leaves them susceptible to ring-opening. Though this normally requires 
activation of the nitrogen atom via N-protection, protonation or sometimes the use of a Lewis 
acid, the ring-opening process can be harnessed to initiate diverse reaction pathways (Scheme 
2.1A). The first of these is direct nucleophilic ring-opening with heteronucleophiles or 
organometallic nucleophiles, which can be achieved with both regio- and stereoselectivity to give 
functionalised amines (2) as platforms for further reactions. Alternatively, aziridines can undergo 
spontaneous ring-opening to form 1,3-dipoles, which can undergo cycloaddition reactions to give 
direct access to complex N-heterocyclic scaffolds. This can be achieved by the use of a strong 
Lewis acid such BF3 to cleave the C–N bond or, in the case of 2-vinylaziridines, activation by 
Pd(0) to form a p-allyl intermediate. Finally, some aziridines are known to undergo C-N cleavage 
to form azomethine ylides, which can also undergo cycloaddition reactions to form N-
heterocycles. Allenes (3, Scheme 2.1B) are equally useful building blocks as their unique 
structure of two contiguous alkenes renders them more reactive than their simpler alkene 
counterparts. The high degree of unsaturation facilitates tandem, multistep reactivity, and can be 
retained in the products of cyclisation and carbometalation processes (Scheme 2.1B).2 
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Scheme 2.1. General reactivity of aziridines and allenes under Lewis acid or transition metal catalysis. 
 
Given the powerful modes of reactivity of aziridines and allenes, the purpose of this project has 
been to develop novel reactions that incorporate the two building blocks in pursuit of complex, 
medicinally-relevant N-heterocycles. A number of relevant ideas were attempted and are 
disclosed herein: though many of the conceived reactions were not fully realised, it was the 
progression of these ideas that ultimately led to the discovery of a novel series of reactions 
involving enantioenriched 5-allenyloxazolidinones, which became the focus of this project.   
 
2.1.3 Copper-Catalysed Borylative Ring-Opening of N-tosylaziridines with Allenes 
The first idea was inspired by the known reactivity of both the aziridine and allene building 
blocks, specifically with respect to the ring-opening of aziridines by organometallic nucleophiles.  
While various heteronucleophiles such as amines, alcohols and thiols can be employed to furnish 
substituted amines, the most successful of the carbon nucleophiles have been organocopper 
reagents. The utility of organocopper reagents in this field was perhaps underappreciated until 
1985, when Eis and Ganem developed an efficient procedure for the BF3-promoted ring-opening 
of unactivated aziridines by Gilman reagents (i.e. R2CuLi, Scheme 2.2).3 A few years later, 
Baldwin attempted to extend this reactivity to Lipshutz higher order cuprates (i.e. R2CuCNLi2, 
the exact structure of which is still under debate), however this study ultimately led to a highly 
valuable Lewis acid-free ring-opening of N-tosylaziridines by Gilman reagents.4 By this time, 
these reactions had found a place in natural products synthesis. For example, the enantioselective 
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synthesis of the naturally occurring carbapenem antibiotic (+)-PS-5, developed by Tanner, hinged 
on the highly regioselective ring-opening of the chiral aziridine 4 by a Gilman reagent to generate 
the enantioenriched amine 5 preceding the chiral β-lactam ring of the final product.5 The 
stereochemical aspects of these processes with respect to vinylaziridines was investigated during 
the 1990s by the groups of Sweeney and Ibuka. While Sweeney found that treatment of trans 3-
aryl-2-vinylaziridines 6 with Gilman reagents gave exclusively (E) allylamines 7,6 Ibuka found 
that treatment of related cis aziridines 8 with lower order cyanocuprates (i.e. R(CN)CuLi) 
produced exclusively (E) allylamines 9, with the trans analogues 8' giving a mixture of the 
corresponding (E) and (Z) isomers.7 
 
 
Scheme 2.2. Selected examples of aziridine ring-opening by organocuprates in previous literature.  
Despite the utility of organocopper reagents in the ring-opening of aziridines, there are some 
inherent limitations, such as the predominantly alkyl nature of the nucleophiles and the products 
formed being mostly saturated systems with limited room for further modification. More recent 
literature on organocopper reagents in regard to allenyl systems carried the potential to address 
these issues. In 2014, the Tsuji group reported the first copper-catalysed borylative allyl-allyl 
cross-coupling, using allenes and allyl phosphates (11, Scheme 2.3) to give borylated 1,5-dienes 
(12).8a The 1,5-dienes themselves are synthetically valuable and also abundant in natural products 
such as terpines, however it was the borylated organocopper intermediate 10 that presented itself 
as a potential tool to combine allene and aziridine building blocks within this project. This 
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nucleophilic species had previously been investigated by the group8b-c and is formed via a copper-
catalysed borylation reaction. Given the similarity of this intermediate to the aforementioned 
organocopper reagents, it was envisioned that this could be used as a nucleophile to ring-open an 
N-protected aziridine such as N-tosyl-2-phenylaziridine (1a, Scheme 2.3). The theoretical product 
13 would be synthetically valuable as it is highly functionalised, containing an unsaturated 
platform for further modification as well as a stereocentre arising from the aziridine (which can 
be synthesised enantiomerically pure).9 More intriguingly, this product would contain both a 
heteroatom and boronate moiety, which could undergo further cross-coupling, or a Chan–Lam 
type cyclisation to form the complex and pharmaceutically-relevant pyrrolidine scaffold 14. 
 
Scheme 2.3. Proposed idea for the copper-catalysed ring-opening of aziridines inspired by the work of the 
Tsuji group. 
The proposed reaction was attempted using the conditions outlined by the Tsuji group, with N-
tosyl-2-phenylaziridine 1a replacing the allyl phosphate 11 as the electrophile (Scheme 2.4). The 
nucleophile was generated using cyclohexylallene (3a, which in itself was synthesized via a 
Gilman reagent) and PCy3×HBF4 as the ligand. Initial results were unsuccessful, returning 
unreacted aziridine with no evidence of the desired product via 1H NMR analysis. The reaction 
conditions were modified in various ways, including heating to reflux in THF with monitoring, 
microwave-assisted heating, the introduction of a Lewis acid to further activate the aziridine, and 
even replacement of the aziridine with related systems such as 2-vinylaziridine (1b) and the 
activated 2-vinylcyclopropane 15. While none of these modifications proved successful, the 
formation of the products of protodemetalation forms of the organocopper intermediate (10b and 
10c) were detected via 1H NMR analysis and matched literature data,10 indicating that the 
nucleophile was indeed being formed, but unable to react with the aziridine. Careful attention was 
paid to the rigorous drying of reagents and solvents to ensure that the lack of reactivity was not 
simply due to quenching of the organocopper species, which is highly prone to hydrolysis.  
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Scheme 2.4. Attempted realisation of proposed ring-opening of aziridines based on the conditions used by 
the Tsuji group and synthesis of appropriate starting materials. The vinylaziridine 1b and 
vinylcyclopropane 15 had been previously prepared within the Hyland research group. 
During this time, a key publication from the Procter group emerged,11 where the organocopper 
nucleophile in question was shown to react with imines to form homoallyl amines (17, Scheme 
2.5), presenting a number of implications with respect to the idea being pursued. Firstly, the study 
showed promise that the organocopper nucleophile could indeed engage in nucleophilic addition 
to similar electrophiles in an intermolecular fashion. Furthermore, the species was shown to attack 
from the γ- rather than α-position under these conditions, implying that the theoretical product 
may contain a terminal alkene (i.e. 13b). Finally, a pre-complexed copper-N-heterocyclic carbene 
catalyst (IPrCuCl, Scheme 2.5) had been employed, which is operationally simpler to use. The 
proposed reaction was attempted using these revised conditions, however the desired product was 
still unable to be formed. In order to probe whether this was due to a lack of reactivity or a flaw 
in the reaction conditions themselves, the synthesis reported by the Procter group was repeated 
as a control experiment. The corresponding homollyl amine 17a was successfully formed from 
the appropriate imine 16a (synthesised via the condensation of aniline and benzaldehyde), albeit 
in lower yield, demonstrating that the organocopper nucleophile was indeed being formed and 
surviving long enough to react with an imine, but not with the aziridine. The final attempt to 
realise this reaction came from a key observation made by the Procter group, which was that N-
tosyl imines were unreactive due to the proposed coordination of the copper-ligand complex to 
the nitrogen and sulfonyl oxygens to form a stable adduct. This had been overcome by slowly 
adding the electrophile to a stoichiometric amount of the pre-formed copper-ligand complex: this 
approach was therefore attempted with the N-tosylaziridine, to no avail. Synthesis of an analogous 
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aziridine with a different N-protecting group was attempted (19, Scheme 2.5), but was ultimately 
unsuccessful. In light of these results, the work on this idea was directed to other synthetic 
investigations.  
 
Scheme 2.5. Attempted realisation of proposed ring-opening of aziridines using revised conditions based 
on those used by the Procter group and synthesis of appropriate starting materials.  
2.1.4 Addition of Allenylboronates to N-tosyl-2-hydroxymethylaziridine 
Drawing comparisons between the previous idea and the work of the Procter group encouraged 
the questioning of whether the reactive trends of an imine could be extended to an aziridine. This 
intuitive train of thought led to a second idea, involving the addition of an allene unit to an N-
protected 2-hydroxymethylaziridine (1c, Scheme 2.6), inspired by the similar reactivity of imine 
systems explored by Thaima and Pyne (Scheme 2.6).12 Their work involved exploiting the 
borono-Mannich (or Petasis) reaction to introduce an allenyl moiety to α-hydroxyaldehydes or 
salicaldehyde to give the respective allenyl alcohols 21 and 22, in a highly diastereoselective 
manner for 21. The borono-Mannich reaction is a multicomponent reaction combining a ketone 
(commonly an aldehyde), amine and organoboronate to form a substituted alcohol, and is highly 
useful in the synthesis of valuable amino building blocks such as α-amino acids. Thaima and Pyne 
proposed that their variation of this reaction proceeded via the imine intermediate 20 (after 
condensation of the amine and aldehyde), to which the allene moiety is delivered from pinacol 
R1
●R2
B2pin2
IPrCuCl (cat.)
KOt-Bu
THF, r.t.
18 hr
γ
R1
β
Bpin
α
CuL
10b
R2
Bpin
R1R2
NH
R3
3b 17
up to > 99%
up to > 98:2 dr
NN
Cu
Cl
i-Pr
i-Pri-Pr
i-Pr
IPrCuCl
N
PG
R3
PG
16
Procter, 2016:
Cy
●
B2pin2  (1.1 equiv.)
IPrCuCl (5 mol%)
KOt-Bu (1.0 equiv.)
THF, r.t.
18 hr
3a
1.5 equiv.
Cy
Bpin
CuL N
Ts
Ph
Bpin H
N
Ph
Ts
10a 1a
1.0 equiv.
13b
• r.t. - reflux, microwave heating
• Cu(OTf)2 (10 mol% - 1.0 equiv.)
• 1b or 15 in place of 1a
• Styrene oxide in place of 1a, r.t.
   - reflux, microwave heating
• Cs2CO3 in place of KOt-Bu
• Styrene oxide with Cs2CO3 
• Slow addition of 1a to pre-formed
  stoichiometric amount of 10a
Cy
Attempted realisation of proposed idea with revised conditions:
BpinNH
Ph
Ph
Cy
Ph H
O
aniline,
4 Å mol. sieves
Et2O, r.t. 
18 h
16a
  73%
O
3 2 Ph
LiBr (cat.)
aniline, r.t.
18
12:1 regioselectivity
for 2-attack
N
Ph
Ph• Alkyl-Br formed, with
  no ring-closure
• KOt-Bu with heat to
  promote ring-closure
Br2/PPh3
Et3N
HO
H
N
Ph
Ph
17a
(from 3a and 16a,
using Cs2CO3)
22% (9:1 dr)
N
Ph
Ph
Control:
19styrene
oxide
 102 
allenylboronate (3c) after coordination and activation by the adjacent alcohol. This prompted the 
idea that this reactivity could similarly be applied to an aziridine system if an adjacent alcohol 
was present, as in the system 1c. The product 23 would complement those formed by Thaima and 
Pyne, acting as arguably an even more versatile platform for synthesising heterocycles than the 
desired product 13 from the previously attempted idea, containing two pendant heteroatoms to 
engage in cyclisation reactions with the allenyl moiety. Furthermore, the aziridine 1c can be 
synthesised enantiomerically pure,13 allowing the development of an enantioselective variant of 
the reaction. This idea holds further advantages over the previously attempted idea, such as the 
comparatively facile conditions (bearing in mind the Petasis reaction rarely requires an air and 
moisture-free environment), the high potential for versatility (as a wide range of boronates are 
commercially available), as well as the intramolecular nature of the proposed ring-opening adding 
feasibility to the proposed reaction. Generally speaking, the 2-hydroxymethylaziridine system has 
the potential to serve as an analogue of 2-vinylaziridines, capable of undergoing similar cross-
coupling and ring-opening reactions without the need for a metal catalyst.  
 
Scheme 2.6. Proposed idea for the metal-free allenylation of aziridines inspired by the work of Thaima and 
Pyne. 
 
The reaction was attempted under the conditions used by Thaima and Pyne, with N-tosyl-2-
hydroxymethylaziridine (1c, synthesized from allyl alcohol and chloramine-T) replacing the 
aldehyde as the electrophile (Scheme 2.7). Initial results returned only unreacted aziridine, despite 
heating to reflux in MeOH and the use of microwave-assisted heating, as well as with the 
introduction of a Lewis acid to further activate the aziridine. The system did exhibit reactivity 
after the addition of an external base (intended to generate the active boronate): in the presence 
of strong bases such as KOt-Bu, the aziridine underwent an aza-Payne rearrangement to the 
corresponding epoxide 25a, which is a known process.14 The weaker base K2CO3 was therefore 
employed and, though no reaction was observed at room temperature, heating to 50 °C resulted 
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in ring-opening of the aziridine by MeOH at both the 3- and 2-positions of the aziridine to give a 
respective 2.4:1 mixture of the corresponding methoxy-substituted amino alcohols (24a:24b), 
which could be easily distinguished via the signal for the NH proton in the 1H NMR spectrum, 
appearing as either a doublet (24a) or triplet (24b). Control experiments revealed that K2CO3 was 
essential for this process (likely generating methoxide in situ) and that the reverse selectivity 
(1:2.6) was obtained in the absence of the allenylboronate. This implies that the allenylboronate 
may indeed have been coordinating to the alcohol as desired, sterically hindering the methoxide 
from attacking at the 2-position. Ring-opening of this aziridine system has been largely 
unexplored in the literature, apart from some examples involving cyano nucleophiles investigated 
by the Minakata group.15 Neither these cyano products, nor the methoxy products reported herein, 
are profound enough platforms for generating complex heterocycles. Despite this, both the ring-
opening and aza-Payne modes of reactivity prompted the development of more intriguing 
substrates for cyclisation reactions. Firstly, the K2CO3-promoted ring-opening was repeated with 
a stoichiometric amount of propargyl alcohol in THF, giving the O-propargyl amino alcohol 24c 
as a single regioisomer (resulting from attack at the less hindered 3-position), which can serve as 
a useful substrate for transition metal-catalysed cyclisation reactions with either the nitrogen or 
oxygen heteroatoms. Furthermore, the concept of the aza-Payne product serving as a more useful 
substrate than the aziridine was also considered (despite earlier experiments with the direct 
epoxide analogue, glycidol, exhibiting no reactivity with the allenylboronate). The pendant N-
tosyl amine was protected via benzylation (25b), in order to block the reverse aza-Payne 
rearrangement occurring during further reactions. A propargyl tether was also introduced (25c) 
to serve an additional purpose as a site for transition metal catalysis by π-philic transition metals 
such as gold, bearing in mind the Shi group have already investigated some gold(I)-catalysed 
cyclisations of this substrate.16 
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Scheme 2.7. Attempted realisation of proposed metal-free allenylation of aziridines and preliminary results.  
Though a small panel of promising substrates (24c, 25a and 25b) for transition metal-catalysed 
cyclisation reactions had now been established, the original goals of this idea had been lost. The 
desired C-C bond-forming reactions had given way to facile heteroatom-based reactivity and, 
more importantly, both the aziridine and allenyl moieties that were originally set out to be 
harnessed were non-existent in these systems. In regard to the N-tosyl-2-hydroxymethylaziridine 
specifically, it had become evident that a metal-free coupling reaction was not as plausible as 
originally thought: though the allenylboronate seemed to successfully coordinate to the alcohol, 
the aziridine was not a reactive enough electrophile under mild conditions. In fact, the proposed 
reaction even failed using the highly reactive Et2Zn as a catalyst, an idea that spawned from a 
related project within the Hyland group concerning the synthesis of enantioenriched 
allenyloxazolidinones. It was this related project that encouraged the setting aside of the N-tosyl-
2-hydroxymethylaziridine and related epoxide systems entirely, in favour of the aforementioned 
allenyloxazolidinones, realigning the focus of the project with its original purpose: to harness and 
combine the reactivity of allenes and aziridines. 
2.1.5 Allenyloxazolidinones as Alternative Building Blocks to Vinylaziridines 
 
Both of the previous ideas attempted to bring the allene and aziridine moieties together in an 
intermolecular fashion, however recent work within our group has produced a single building 
block containing the reactive traits of both, opening up a new approach to harnessing these 
systems in pursuit of complex heterocycles. Specifically, a highly regio- and diastereoselective 
allenylation of L-α-aminoaldehydes (26, Scheme 2.8) was developed to give allenyl alcohols 27 
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that undergo base-catalysed cyclisation to the corresponding enantioenriched 5-
allenyloxazolidinones 28.17 Subsequently, our group reported that the N-benzyl, cis analogues of 
these systems (29) can be converted in situ to 1,3-(E)-enynes 30 as substrates for dual gold-
catalyzed cycloaromatisation reactions,18 however the allenyloxazolidinone itself is an equally 
valuable building block. Given that both vinylaziridines and vinyloxazolidinones are well-
established precursors to highly complex N-heterocycles, it is surprising that the allenyl 
equivalents of these have not yet been investigated.  
 
 
Scheme 2.8. Previous work by the Hyland and Pyne groups regarding the synthesis and application of 5-
allenyloxazolidinones. aThis work was featured on the front cover of Angew. Chem. Int. Ed. (58); Angew. 
Chem. (131), the artwork for which was produced by the author, Ronald Brown (see appendix).  
 
Vinylaziridines are known to engage with transition metal catalysts such as palladium, enabling 
their participation in cross-coupling and formal cycloaddition reactions, both of which have been 
previously investigated by the Hyland group (Scheme 2.9). In 2014, our group reported the cross-
coupling of arylboronic acids to N-tosyl-2-vinylaziridine (1b) to give the corresponding aryl-
substituted sulfonamides 31, predominantly in the (Z) geometry.19 More recently, our group 
developed a protocol for the palladium-catalysed dearomative [3+2] formal cycloaddition of 
vinylaziridine 1b to 3-nitroindoles 32 to furnish the cycloadducts 33 and 33' in a highly 
diastereoselective manner, the structures exhibiting a high level of pharmaceutical relevance.20 A 
wide range of dipolaraphiles have been employed in [3+2] formal cycloaddition reactions with 
vinylaziridines in the past, including (but not limited to) alkenes, alkynes, imines and 
heterocumulenes,21 trailing back to the first example published by Alper in 2000, in which a range 
of five-memebered heterocycles (35) were accessed in a facile manner.22 
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Scheme 2.9. Selected examples of vinylaziridines in cross-coupling and cycloaddition reactions. 
 
These cycloadditions are often facilitated by the formation of a zwitterionic p-allylpalladium(II)  
intermediate formed upon cleavage of the C–N bond of the aziridine, and it has more recently 
been found that 5-vinyloxazolidinones (36, Scheme 2.10) can serve as precursors to the same 
intermediate. In 2008, the Knight group reported the first example of a palladium-catalysed [3+2] 
cycloaddition reaction of 5-vinyloxazolidinones 36a to activated alkenes 37 to give highly 
substituted pyrrolidines 38.23 An asymmetric protocol was later developed by the Ooi group in 
which their newly-developed chiral phosphine/ammonium hybrid ligand L1 allowed the synthesis 
of biologically relevant, densely functionalised pyrrolidines 39 and imidazolines 40 with a high 
degree of both enantio- and diastereocontrol.24 Generally speaking, one of the main advantages 
of the vinyloxazolidinone building block in these reactions is that they can serve as an alternate 
route to p-allyl intermediates for substrates that would otherwise be synthetically inaccessible or 
unstable in the aziridine form. This has become an important point in extending the power of 
these cycloaddition reactions from the vinylic systems to their allenyl counterparts, as there are 
currently no synthetic routes to 2-allenylaziridines. This leaves the recently developed 5-
allenyloxazolidinone building block as the key to unlocking any potential reactivity of the allenyl 
equivalents of vinylaziridines under palladium catalysis.  
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Scheme 2.10. Cycloaddition reactions of vinyloxazolidinones reported by the Knight and Ooi groups. 
 
Given the similarity of the allenyloxazolidinone scaffold to the vinyloxazolidinones used by the 
Ooi group, it was reasoned that these may also form an analogous allenylpalladium(II) 
intermediate under palladium catalysis and participate in formal cycloaddition reactions to form 
enantioenriched 5-allenylpyrrolidines (42, Scheme 2.11). The proposed [3+2] cycloaddition 
reaction was attempted using 2-benzylidenemalononitrile (37b, synthesized via a Knoevenagel 
condensation) and an N-nosyl derivative of the allenyloxazolidinone (41a). The electron-
withdrawing N-protecting group facilitates ring-opening by stabilising the resulting nitrogen 
anion, and is therefore essential for these processes. The Pd(0) source of choice was 
Pd2dba3×CHCl3, and a halide salt was also introduced as per the literature procedure, to prevent 
nitrogen coordination to the cationic Pd(II) species. After no reaction was observed in the 
presence of PPh3, a small screen of more electron-rich phosphine ligands (to promote oxidative 
addition to the allenyl moiety) was conducted, to no avail. After increasing the catalyst loading 
and heating to 80 °C, however, a new product was formed, which was isolated and revealed via 
NMR and mass spectrometry analysis to be the dimer 43. Although this was not the desired 
pyrrolidine, the dendraline structure is intriguing in itself and, more importantly, the mechanism 
of its formation provides insight into how the allenyloxazolidinone reacts under Pd(0) catalysis. 
The dimer was formed even with a molar excess (5 equivalents) of 37b present, indicating that 
the mechanism underpinning this pathway is the preferred mode of reactivity for this allenyl 
building block. Though the literature has shed some light on similar Pd(0) and Ni(0)-catalysed 
dimerisations of allenes involving proposed metalocyclic intermediates,25 another plausible 
mechanism has been proposed in Scheme 2.11. This involves the formation of an η1 Pd(II) 
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intermediate (rather than the initially expected η3 intermediate), which undergoes a migratory 
insertion to a second coordinated allenyloxazolidinone, before decarboxylation and elimination 
of Pd(II). The mechanism does not allow for the regeneration of Pd(0), making this a 
stoichiometric process, and this is supported by the isolated yield of approximately 20% of the 
dimer, which corresponds to the amount of palladium used (10 mol% of Pd2dba3×CHCl3, i.e. 20 
mol % of Pd(0)).  
 
Scheme 2.11. Attempted cycloaddition reaction and discovery of the preferred reactivity of the 
allenyloxazolidinone building block. 
 
In the suspicion that the η1 Pd(II) intermediate was forming under these conditions, looking to the 
literature gave an insight into how this intermediate may be harnessed to form a more 
synthetically valuable product. It has been known for some time that allenylcarbinols can undergo 
cross-coupling reactions with boronic acids in the presence of Pd(0) to form substituted 1,3-
dienes, which are highly valuable substrates in the Diels–Alder reaction, however the work on 
this has been limited. The first example was reported by Miyaura in 1994, generating 2-substituted 
1,3-dienes (45, Scheme 2.12) from the allenylcarbonates 44 via a similar proposed η1 Pd(II) 
intermediate.26 For two decades this methodology remained untouched, apart from one report by 
Yoshida and Ihara in 2004, allowing an alcohol to be used as the leaving group (46) and also 
utilising unsymmetrical substrates, for which the (E) products (47) were favoured.27 A few studies 
have emerged in more recent years with a focus on green chemistry. The Wu group has extended 
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the methodology to phosphinyl allenes using either an alcohol or aryl ether as the leaving group 
(48) to give the phosphinyl 1,3-dienes 49, the polar nature of the alcohol substrates allowing water 
to be used as the solvent.28 While the idea reported herein was near completion, the Lipshutz 
group published the most recent investigation using the allenes 50, which were shown to form the 
corresponding 1,3-dienes 51 at room temperature in water with the aid of micellar catalysis.29 The 
study demonstrated the versatility of the reaction, accommodating an expansive range of cross-
coupling partners including aryl, vinyl, alkynyl and alkyl groups. The conditions used in the 
aforementioned studies are milder than existing methods of preparing 1,3-dienes, including chiral 
examples (elimination reactions, enyne metathesis or rearrangement, Wittig reactions and cross-
coupling of alkenyl moieties).30 Despite this, all of the aforementioned products have been achiral, 
and many symmetrical, leaving room for molecular complexity and functionality to be introduced 
via this methodology. Having already demonstrated its ability to form the required Pd(II) 
intermediate for the generation of cross-coupled 1,3-dienes, the allenyloxazolidinone system 
presented itself an ideal candidate for this task. The resulting products would contain not only a 
2-substituted diene, but also an adjacent stereogenic centre and pendant nitrogen atom. The latter 
renders the theoretical product perfectly tailored for the intramolecular Diels–Alder (IMDA) 
reaction, which is a powerful method for generating complex multicyclic scaffolds.31 The desired 
1,3-dienes would be a welcome addition, considering synthetic routes to such complex - and 
stereodefined - substrates for the IMDA reaction are limited. The allenyloxazolidinone was 
therefore subjected to typical Suzuki–Miyaura conditions using 4-methoxyphenylboronic acid as 
the cross-coupling partner and, gratifyingly, the desired 1,3-diene 52a was furnished in 48% yield 
(76% conversion) and 9:1 (E/Z) stereoselectivity.  
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Scheme 2.12. Previous literature leading to preliminary results for the Pd-catalysed synthesis of complex 
1,3-dienes from allenyloxazolidinones.  
2.1.6 Arrival at Specific Project Aims  
This result solidified the original purpose of this project, as well as setting up its specific aims. 
The reactivity of aziridine and allene moieties had now been successfully harnessed and the 
objective for the rest of the project was to optimise this process and investigate the scope and 
mechanism, before employing the 1,3-dienes in the IMDA reaction to form highly complex N-
heterocycles (53, Scheme 2.13). While the 1,3-diene was welcomed as a promising platform for 
extending the power of the IMDA reaction to generate molecular complexity, the broader impact 
of the allenyoxazolidinone was only in its infancy. The first known mode of catalytic reactivity 
of a brand-new molecular building block had now been unearthed, paving the way for it to sit 
alongside vinylaziridines and vinyloxazolidinones as a highly valuable tool for generating 
complex and medicinally-relevant molecular scaffolds. This work was accepted for publication 
in Chemical Science in August 2019 (Chem. Sci. 2019, 10, 9051–9056, DOI: 10.1039/c9sc03215k, 
see appendix for full article). 
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Scheme 2.13. Graphical summary of project aims regarding the optimisation and utilisation of the newly-
discovered reactivity of the allenyloxazolidinone building block.  
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2.2 Results and Discussion 
 
2.2.1 Synthesis of Enantioenriched 5-Allenyloxazolidinones as Starting Materials 
 
In order to optimise the newly-established 1,3-diene synthesis and investigate the scope of this 
reaction, a series of 5-allenyloxazolidinones was required. The synthesis of these building blocks 
relied upon the procedure developed within the group by Dr Farzad Zamani, in which the allenyl 
moiety is introduced to an L-α-amino aldehyde using catalytic diethylzinc.17 The required L-α-
amino aldehydes are commercially available, however these are expensive and must be kept at 
sub-zero temperatures due to their tendency to epimerise to the racemic forms. It is therefore 
practical to synthesise these from the parent L-α-amino esters (54, Scheme 2.14) which can be 
prepared from the cheaper and readily available L-α-amino acids.* The amino esters were reduced 
to the corresponding alcohols (55) via LiAlH4, and the use of a Fieser workup to remove the 
aluminium salts was essential to maintaining yield for this transformation (see 55b). A 
TEMPO/NaOCl oxidation was then employed to furnish the corresponding aldehydes (26) in 
moderate to excellent yields. These were used immediately without further purification, due to 
their aforementioned sensitivity to epimerisation.  
 
Scheme 2.14. Synthesis of L-α-amino aldehydes. a Fieser workup not employed. b 80% conversion.  
 
In order to introduce the allenyl group, the diethylzinc-catalyzed allenylation was carried out as 
per the established procedure.17 A seminal study from the Fandrick group has revealed that the 
regioselectivity of this type of allenylation is kinetically controlled, where the addition of the 
propargylzinc intermediate 3d' to give the desired allenyl product competes with the equilibration 
of the propargyl and allenyl intermediates (Scheme 2.15).32 The diastereoselective process 
developed by the Hyland and Pyne groups is proposed to be controlled via a Cram-chelation like 
model induced by hydrogen bonding between the amide proton and carbonyl oxygen of the L-α-
amino aldehydes, which favours syn addition of the allenyl group (Scheme 2.15).17  Given that a 
moderate amount of the allenylalcohol precursors 27 were required to investigate the 1,3-diene 
 
* The synthesis of L-α-amino esters 54 was performed by Dr Farzad Zamani. 
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synthesis, the reported procedure was increased to a gram scale, where it was found that the 
diastereoselectivity suffered. The material was therefore partitioned over multiple reaction vessels 
to reduce the scale, however some optimisation (Table 2.1) was also necessary to amend this for 
the remaining substrates at scale, leading to the preference for diisopropylzinc over diethylzinc 
as the catalyst for this reaction (entry 4). The workup procedure was also modified to employ 
diethanolamine as a boron scavenger, given that the literature indicated a traditional aqueous 
workup leaves these types of allenylalcohols prone to isomerisation to the propargyl isomers (i.e. 
27').32  After subjection to column chromatography to remove any trace of this propargyl impurity, 
the allenylalcohols were immediately converted to the allenyloxazolidinone scaffolds 28 in the 
presence of NaH, where nucleophilic attack of the deprotonated syn allenylalcohols at the Boc 
carbonyl gave the trans allenyloxazolidinones 28 as the major isomer. This two-step process gave 
the desired scaffolds in moderate yields, with the alanine-derived scaffold 28b able to be isolated 
as the pure trans isomer via column chromatography.  
 
Scheme 2.15. Synthesis of enantioenriched allenyloxazolidinones from L-α-amino aldehydes, showing the 
origin of regio- and diastereoselectivity during the dialkylzinc-catalysed allenylation.  
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Table 2.1. Selected optimisation of dialkylzinc-catalysed allenylation of L-α-amino aldehydes using N-
Boc-L-leucinal (26c) as a model substrate. 
 
 
Entry Conditions 
Scale 
[mmol/26c] 
Conversion 
[%] 
dr 
[syn:anti] 
Regioselectivity 
[27c:27c'] 
  1 10 mol% Et2Zn (1.0 M/hexane) 0.95 100 3.1:1 90:10 
  2 5 mol% Et2Zn (1.0 M/hexane) 0.95 76 ND 85:15 
  3 
 
10 mol% i-Pr2Zn (1.0 M/toluene) 
 
0.95 100 4.8:1 
  4.6:1b 
82:18 
85:15b After purification: 
ND: not determined, due to poor resolution of signals in the 1H NMR spectrum of the crude reaction mixture. aDetermined 
from the 1H NMR spectrum of the material after column chromatography. All other conversion, regio- and diastereoselectivity 
data calculated from the 1H NMR spectrum of the crude reaction mixture.  
 
An N-nosyl group was then introduced to the allenyloxazolidinone scaffolds in good yields via 
nosyl chloride in the presence of NaH (Scheme 2.16). As previously mentioned, the purpose of 
this protecting group in regard to the 1,3-diene synthesis was to withdraw electron density from 
the allenyl moiety to encourage decarboxylative ring-opening, but also to stabilise the resulting 
nitrogen anion. A further advantage revealed itself in that, with the N-nosyl group present, the 
valine-derived oxazolidinone 41a was able to be purified as the pure trans diastereoisomer via 
selective recrystallization in CH2Cl2 layered with hexane. Unfortunately, the leucine- and 
phenylalanine-derived substrates could not be separated by this method, and were therefore left 
to be used as a mixture of diastereoisomers (41d-e).  
 
Scheme 2.16. N-nosylation of enantioenriched allenyloxazolidinones, showing the crystal structure of the 
product 41a (CCDC 1919153, performed by Assoc Prof Michael Gardiner, Australian National University). 
aRecrystallised from CH2Cl2/hexane to give the pure trans diastereoisomer. Yield before recrystallization: 
95% (2.8:1 dr). bDr determined after purification. 
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2.2.2 Optimisation of the Palladium(0)-Catalysed Synthesis of Chiral 1,3-Dienes and Discovery 
of a Divergence in Reactivity of 5-Allenyloxazolidinones 
 
While the ability of the N-nosyl allenyloxazolidinone scaffold 41 to react with boronic acids under 
Pd(0) catalysis to form 1,3-dienes 52 had been established, there were a number of facets of this 
process to be optimised to bring the reaction to its full potential. This included maximising the 
yield of the reaction, as well as optimising the stereoselectivity for the (E) isomer. It was also 
crucial to confirm that no racemisation occurred during the process, which was to be achieved 
through chiral HPLC analysis. Only once the optimal conditions were established could the scope 
and applications of the reaction be investigated. From the newly-synthesised series of 
allenyloxazolidinone substrates (41a-d), the optimisation process was initiated using the valine-
derived substrate 41a, given that the preliminary result was obtained using this substrate and that 
a generous amount (0.98 g) was able to be produced in one synthesis. The cross-coupling partner 
was similarly retained, with the symmetry of p-methoxyphenylboronic acid allowing ease of 
characterisation via 1H NMR spectroscopy.  
 
The first variable to be investigated was the choice of ligand in the reaction (Table 2.2). A series 
of phosphorous ligands were screened with a Tolman map33 in mind: by employing a ligand that 
is both bulky and electron-rich, or small and electron-poor (and vice versa), the search for a ligand 
with optimal steric and electronic properties could be streamlined. Interestingly, the reaction 
proceeded in the absence of an additional ligand (i.e. relying on the Pd(0)-dibenzylideneacetone 
complex to catalyse the reaction, entry 1), however the introduction of a phosphine ligand 
increased the selectivity for the E stereoisomer (entries 2 – 6). The E/Z ratio for the 1,3-diene 52a 
could be determined from the 1H NMR spectrum of the crude material, given that the signal 
arising from the internal alkene proton adjacent to the aryl group exhibited a coupling constant of 
15.6 Hz for the (E) isomer and 11.8 Hz for the (Z) isomer (Table 2.2). It should be noted that the 
remainder of the 1H NMR spectrum of 52a was consistent with the presence of a 2-substituted 
1,3-diene core, particularly the distinctive signals at 5.03 and 4.99 ppm, which were shown via a 
gHSQC experiment to arise from terminal alkene protons. Furthermore, a single band at 3255 cm-
1 in the infrared spectrum, characteristic of an N-H stretching vibration, supported the existence 
of a secondary amine. Of the phosphorus ligands, two candidates stood out in upholding both 
yield and stereoselectivity, being tert-butylphosphine (62%, 97:3, E/Z, entry 4) and 
triphenylphosphite (74%, > 95:5, E/Z, entry 6). Unfortunately, the use of both of these ligands 
left significant impurities that gave signals in the aromatic region of the 1H NMR spectrum after 
column chromatography, and the yields after further purification were poor (32% and 20%, 
respectively, after recrystallisation). Given that tert-butylphosphine was chosen for to its steric 
bulk and triphenylphosphite for its electron-poor nature, the ligand tris(2,4-di-tert-butylphenyl) 
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phosphite (L2, entry 9) was employed as it is both sterically bulky and electron-poor. This gave 
the 1,3-diene 52a in good yield and stereoselectivity (62 %, > 95:5) with no further purification 
required as in the previous examples. This, as well as being a relatively cheap ($53.90/100 G, 
Sigma-Aldrich), non-toxic and air-stable solid, left ligand L2 the optimal choice. The effect of 
other solvents was briefly investigated, however both an alternate nonpolar solvent (CH2Cl2, entry 
10) and protic solvent (MeOH, entry 11) were detrimental to the reaction yield. Before 
investigating other variables in the 1,3-diene synthesis, care was taken to elucidate what may have 
been responsible for the loss of approximately 40 % yield of 52a, despite the use of an optimal 
ligand and solvent. It is widely known that 1,3-dienes are susceptible to polymerisation, 
particularly under acidic conditions,34 and it has since been observed (via 1H NMR analysis) that 
the 1,3-dienes 52 decompose after approximately three months while stored at 0 °C. This implies 
that polymerisation may indeed be the culprit for the loss of yield, however similar results were 
obtained when conducting column chromatography at neutral pH. Additionally, the 13C NMR 
spectrum of the crude material revealed a signal at 198.4 ppm that was not consistent starting 
material or dibenzylideneacetone signals, and may have arisen from the distinctive internal allene 
carbon of a possible allenyl side product. It should be noted that ammonium salts such as Bu4NBr 
were introduced to coordinate to the nitrogen anion and prevent any potential side reactions 
arising from this, however this had no effect on the yield.  
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Table 2.2. Selected optimisation of the Pd(0)-catalysed synthesis of 1,3-diene 52a with a focus on the 
choice of  ligand, solvent and organoborate.  
 
Entry Ligand Solvent Mol% 
[L/cat.] 
Yield 52a [%] 
(E/Z) 
1 - toluene 0/10 71 (90:10)a 
2 PPh3 toluene 20/10 64 (93:7) 
3 TTMPP toluene 20/10 54 (91:9)a 
4 (t-Bu)3P×BF4 toluene 20/10 62b (97:3) 
5 dppe toluene 20/10 34 (95:5)a 
6 (PhO)3P toluene 20/10 74b (> 95:5)a 
    7c, d (PhO)3P toluene 20/10 12e (ND)f 
    8c, g (PhO)3P toluene 20/10 0 (-)f 
9 L2 toluene 20/10 62h  (> 95:5) 
 10c L2 CH2Cl2 20/10 53 
 11c L2 MeOH 20/10  42e 
TTMPP: tris(2,4,6-trimethoxyphenyl)phosphine. Dppe: 1,2-bis(diphenylphosphino)ethane. ND: not determined. aDetermined 
from the 1H NMR spectrum of the material after column chromatography. All other stereochemical ratios (E/Z) calculated 
from the 1H NMR spectrum of the crude reaction mixture. bRequired further purification after column chromatography. Yield 
after recrystallisation = 32% (entry 4), 20% (entry 6). cPerformed using a diastereomeric mixture (4.3:1, trans/cis) of the 
allenyloxazolidinone 41a containing 8% inseparable propargyl analogue, for which the yield has been adjusted. dPerformed 
using potassium p-methoxyphenyltrifluoroborate in place of the boronic acid. eCalculated from the 1H NMR spectrum of the 
crude reaction mixture using 1,2-dimethoxyethane as an internal standard. All others are isolated yields obtained after flash 
column chromatography. fPhosphonate byproduct (56a, Scheme 2.17) observed: isolated yield of 56a (entry 8) = 27% with 
respect to 20 mol% P(OPh)3 as the limiting reagent (> 95:5, E/Z); yield for entry 7 ND. gPerformed using p-
methoxyphenylboronic acid (MIDA ester) in place of the boronic acid. hRepeated average of 66%, 61% and 59% yields.  
 
In an attempt to amend the loss of yield during the ligand screening, other related boronate 
analogues were employed in the synthesis of the 1,3-diene 52a (entries 10 and 11, Table 2.2), 
returning an unprecedented result. Though trifluoroborate salts have garnered considerable 
attention for their success in cross-coupling reactions,35 the use of potassium p-
methoxyphenyltrifluoroborate in combination with triphenylphosphite as the ligand severely 
impacted the yield (12% via 1H NMR analysis, entry 7). Employing the N-methyliminodiacetic 
(MIDA) analogue gave no trace of desired product (entry 8), however both of these reactions 
afforded an intriguing byproduct.  This was isolated via column chromatography and its 1H NMR 
spectrum was very similar to that of 52a, with the signals arising from the p-methoxyphenyl 
moiety being replaced by signals resembling an unsubstituted phenyl moiety. Analysis of the 13C 
NMR spectrum revealed unexpected splitting patterns deemed to be a result of 13C–31P coupling 
and the first indication that the allenyloxazolidinone substrate had reacted with the 
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triphenylphosphite ligand. This was further supported by mass spectrometry, which revealed a 
base peak at m/z 541.1196 with a molecular formula of C26H26N2O7PS corresponding to the 1,3-
diene substituted by either a diphenyl phosphite or diphenyl phosphonate group, cross-coupled to 
the 2-position via a P–O–C or P–C linkage, respectively. The infrared spectrum directed 
assignment toward the latter (i.e. 56a), given the very strong band at 1161 cm–1 likely arising from 
stretching vibration of the phosphonate P=O.36 Similarly, a 31P NMR experiment revealed a single 
resonance 9.08 ppm, which is characteristic of this type of phosphonate signal.36 This hypothesis 
was confirmed via X-ray crystallography,† which gave unambiguous proof for the formation of a 
2-diphenylphosphonate-substituted 1,3-diene with E stereochemistry (56a, Scheme 2.17). This 
type of phosphonated 1,3-diene is intriguing, not only in terms of its application as a reaction 
substrate, but also the mechanism of its formation. The phosphonate group itself is valuable in 
that it can undergo a variety of late-stage transformations and is also a bioisostere for a 
phosphate37a or carboxylic acid37b group in medicinal chemistry. Simpler phosphonated 1,3-
dienes have been reported in the literature, though arylphosphonate examples have scarcely been 
revisited since their first appearance in the 1970s.38 The employment of related systems in the 
Diels–Alder reaction has been extensively investigated by Marchand-Brynaert and Robiette,39 
however these are limited to alkylphosphonates substituted at the terminal position of the diene. 
The 2-substituted byproduct 56a would allow the placement of a valuable triarylphosphonate 
moiety at an alternate position in Diels–Alder cycloadducts, while serving as a more complex 
precursor to enantiomerically enriched scaffolds via both inter- and intramolecular Diels–Alder 
reactions. The synthesis of these types phosphonated 1,3-dienes often relies on a Michaelis–
Arbuzov reaction between a vinyl halide and an alkylphosphite ester (Scheme 2.17). It is well 
known that arylphosphite esters are not accommodated under these conditions, due to their ability 
to form stable phosphonium salts which do not rearrange to the desired phosphonate products, as 
well as the inability of the aryl moieties to react via an SN2 mechanism during the rearrangement 
step. This has since been resolved in the development of the Hirao cross-coupling (Scheme 2.17), 
a palladium-catalysed variant of the Michaelis–Arbuzov process, though this requires the 
phosphonate moiety to be already present in the phosphorus reactant, a di-substituted phosphite 
(i.e. 57). At a glance, the formation of the byproduct 56a can be viewed as a variant of the 
Michaelis–Arbuzov which allows an arylphosphite ester to be accommodated, or as a variant of 
the Hirao cross-coupling where the coupling partner is a tri-substituted phosphite. Envisioning a 
reaction mechanism was therefore a curious task, as any plausible pathway would borrow 
mechanistic trends from both of the aforementioned reactions, as well as rationalising their 
occurrence in the absence of a halide functionality, which would normally facilitate the first step 
of both known reactions.  
 
† Performed by Assoc Prof Michael Gardiner, Australian National University.  
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Scheme 2.17. Proposed mechanism for the formation of phosphonated 1,3-diene byproduct 56a based on 
related known reactions, showing the crystal structure of the product.  
 
As shown in Scheme 2.17, the catalytic cycle for the formation of the phosphonated 1,3- diene is 
proposed to begin with an oxidative addition of the Pd(0)-ligand complex to the internal carbon 
of the allene, the unique reactivity of which eliminates the typical requirement of an alkyl or aryl 
halide. The resulting Pd(II) intermediate I was initially expected to undergo transmetalation with 
the boronate to give the desired 1,3-diene 52a, however in the presence of an unreactive boronate 
(such as a trifluoroborate salt or MIDA ester), an alternate pathway prevailed. The phosphite 
ligand can now be seen as a cross-coupling partner and is held in close proximity to the alkenyl 
coupling site, along with a carbonate anion stabilising the Pd(II) intermediate. Michaelis–
Arbuzov conditions normally require a suitable nucleophile (usually the liberated halogen) to 
cleave the O-alkyl moiety via SN2 attack, facilitated by the rearrangement of the phosphite to a 
phosphonate leaving group. In this case, not only is the aryl moiety incapable of SN2 reactivity, 
but the typical halogen nucleophile is also not present. It is therefore proposed that the carbonate 
anion is capable of undergoing a nucleophilic aromatic substitution to give the intermediate II. 
The carbonate moiety is not known for its nucleophilicity, however it has been demonstrated to 
act as a nucleophile in the literature40  and the close proximity of the reactants bound to the 
palladium centre adds to the plausibility of this mechanism. After the loss of potassium 
phenylcarbonate, the resulting intermediate II would presumably undergo immediate reductive 
elimination as per the Hirao coupling, furnishing the final product 56a and regenerating the Pd(0) 
catalyst.  
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While this phosphonate byproduct proved to be as unprecedented as it was valuable (warranting 
further investigation in future work), an even more striking discovery was made when finalising 
the optimisation of the 1,3-diene synthesis. While investigating the role of the base, a second 
product began to appear, which was found to be markedly set apart from the 1,3-dienes 52 and 
56a in its structure, formation and application. Employing other bases typically used under 
Suzuki–Miyaura conditions (entries 1 – 4, Table 2.3) saw a reduction in the yield of the 1,3-diene, 
with the emergence of a previously undetected product, which predominated as the major product 
in the presence of KOAc (entry 4) and was able to be synthesised completely chemoselectively 
with a reduced catalyst loading (entry 5). In terms of solving the structure of this new product, 
initial analysis of the NMR, mass spectrometry and infrared data was inconclusive. In the absence 
of an NH proton and existence of a methyl group, as indicated by the 1H NMR spectrum, the 
product was tentatively deemed to be the pyrrolidine 60 (Scheme 2.18A) for some time. This 
scaffold is not too dissimilar to the N-heterocycles sought after during preliminary work (see 
Section 2.1.3) and was thought to be a result of cross-coupling at an alternate position, followed 
by attack of the nitrogen anion to the allene carbon during an acidic workup (Scheme 2.18A). 
Though this hypothesis seemed to be supported by mass spectrometry and the observance of a 
single downfield 1H NMR signal thought to arise from the lone alkenyl proton, the product was 
finally confirmed via X-ray crystallography† to be strikingly different, being the 5-
vinyloxazolidinone 59a as the (E) stereoisomer (Scheme 2.18C). With this knowledge, revisiting 
the spectroscopic data allowed a much more straightforward assignment, aided by the 
characteristic C=O signal at 151.8 ppm in the 13C NMR revealing the oxazolidinone core had 
remained intact. The mass spectrometry data was initially deceiving in that a minor peak at 
439.1297 m/z corresponding to the sodium adduct of the decarboxylated form of 59a happened 
to have an identical m/z ratio and molecular formula as the sodium adduct of the pyrrolidine 60. 
Revisiting this data, however, revealed a clear [M+Na]+ base peak for the true product 59a, with 
the corresponding molecular formula. The stereochemical ratio (E/Z) of 59a was easily 
determined from the 1H NMR spectrum of the crude material, given the distinctively different 
shifts of the i-Pr methyl signals (1.03, 0.89 ppm, (E), 0.65, 0.59 ppm, (Z)).  
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Table 2.3. Selected optimisation of the divergent, Pd(0)-catalysed synthesis of 1,3-diene 52a or 5-
vinyloxazolidinone 59a and optimisation of catalyst loading for each.  
 
Entry Additive Mol%  
[L/cat.] 
Yield 52a [%] 
(E/Z)  
Yield 59a [%] 
(E/Z) 
 1a Na2CO3 20/10 43b (> 95:5) 17b (71:29) 
 2a Cs2CO3 20/10 48b (> 95:5) trace (ND) 
 3a KOt-Bu 20/10 30b (> 95:5) 0 (-) 
 4a KOAc 20/10 15b (64:36) 71b (83:17) 
5 KOAc 10/5 0 (-) 91 (95:5) 
6 AcOH 10/5 0 (-) 85 (> 95:5) 
7 AcOH 5/2.5 0 (-) 93 (> 95:5) 
8 K2CO3 10/5 74c (> 95:5) 0 (-) 
9 K2CO3 5/2.5 75 (95:5) trace (ND) 
All stereochemical ratios (E/Z) calculated from the 1H NMR spectrum of the crude reaction mixture. ND: not determined. 
aPerformed using a diastereomeric mixture (4.3:1, trans/cis) of the allenyloxazolidinone 41a containing 8% inseparable 
propargyl analogue, for which the yield has been adjusted. bCalculated from the 1H NMR spectrum of the crude reaction 
mixture using 1,2-dimethoxyethane as an internal standard. All others are isolated yields obtained after flash column 
chromatography. cRepeated average of 64%, 66%, 77% and 90% yields. 
 
Turning to the literature revealed that this result was somewhat unsurprising, as the direct addition 
of arylboronic acids to allenes under palladium(0) catalysis has been known for some time, dating 
back to the first examples reported by Oh41 and Ma42 in 2003 (Scheme 2.18B). More examples 
have followed,43 including the application of this reactivity in the synthesis of natural products.44 
These reactions are catalysed by AcOH which, after the oxidative addition of palladium to the O-
H bond, delivers a hydride to the terminal allene carbon via hydropalladation (Scheme 2.18B) to 
form the methyl group. This literature precedent implied that the analogous direct addition to 
form the 5-vinyloxazolidinone 59a was catalysed by trace AcOH rather than KOAc, and this was 
confirmed by the addition of 1.5 equivalents of AcOH as the additive, which afforded 59a in a 
chemoselective fashion (entry 6, Table 2.3 and Scheme 2.18C). The 5-vinyloxazolidinone 
scaffold 59 is synthetically attractive as its vinyloxazolidinone core is related to - but more 
complex than - those introduced in Section 2.1.5 (see Scheme 2.10), implying that this system 
may be capable of undergoing further palladium(0) catalysis to form complex N-heterocycles via 
decarboxylative cycloaddition reactions (Scheme 2.18C).  
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Scheme 2.18. A. Proposed mechanism for the formation of the pyrrolidine 60, which had been tentatively 
assigned as the structure for 59a. B. First reported examples of Pd(0)/AcOH-catalysed direct addition of 
boronic acids to allenes. C. Revised structure and mechanistic rationale for the formation of 59a and crystal 
structure of 59a (CCDC 1919154), with potential applications of this 5-vinyloxazolidinone in Pd(0)-
catalysed formal cycloaddition reactions. 
 
At this point, it was clear that the 5-allenyloxazolidinone scaffold 41 exhibited divergent 
reactivity under palladium(0) catalysis, which could be tightly controlled by a single switch in 
additive (Scheme 2.19). In the presence of K2CO3, the system forms chiral 2-substituted 1,3-
dienes which can be employed in inter- and intramolecular Diels–Alder reactions, and in the 
presence of AcOH the system gives rise to enantioenriched 5-vinyloxazolidinones, both products 
being capable of forming highly complex heterocyclic scaffolds. A brief investigation revealed 
that the 5-vinyloxazolidinone could be synthesised with a lower catalyst loading (2.5 mol%, entry 
7), while the 1,3-diene synthesis required a slightly higher loading (5 mol%, entry 8) to maintain 
stereo- and chemoselectivity (see entry 9). With this, a set of optimal conditions had now been 
established to generate both valuable products in high yield (74%, 52a, 93%, 59a) and 
stereoselectivity (> 95:5, E/Z), via a tightly controlled divergent pathway. These could now be 
used to investigate the scope of both reactions, before the applications of these two scaffolds were 
to be explored. Before these investigations were initiated, however, it was confirmed that these 
processes were proceeding with no loss of enantiomeric purity.  
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Scheme 2.19. Summary of optimal conditions for the divergent, Pd(0)-catalysed synthesis of 1,3-dienes or 
5-vinyloxazolidinones from 5-allenyloxazolidinones. 
 
2.2.3 Analysis of Enantioretention in the Newly-Established Divergent Synthesis 
 
Even before any rigorous investigation into the enantiomeric purity of the 1,3-diene and 5-
vinyloxazolidinone products, the optically active nature of both 52a ([α]D
22 +16.8 (c 0.73, CHCl3)) 
and 59a ([α]D
23 +4.42 (c 2.96, CHCl3)) gave initial confirmation that the amino acid-derived chiral 
centre had not undergone significant racemisation. In order to determine the exact degree of 
enantiorention for the two syntheses, the enantiomeric purity of a representative product was 
determined for each reaction and compared to that of the starting material. There are a number of 
ways to determine enantiomeric purity and, given the presence of a free secondary amine 
functionality in the 1,3-diene, it was initially envisioned that a chiral auxiliary could be tethered 
here (Scheme 2.20A). This would allow the resulting diastereoisomers to be analysed via 1H NMR 
analysis and indirectly reveal the enantiomeric ratio of the original product, as per the previous 
work from our group.17 The 5-vinyloxazolidinone was also planned to be analysed in the same 
fashion, after removal of the N-nosyl group via mercaptobenzoic acid.45 Unfortunately, the 1,3-
diene 52a did not react with (S)-camphorsulfonyl chloride after deprotonation by NaH, nor did it 
react with the sulfonyl chloride analogue of Mosher's acid, another chiral auxiliary, in the 
presence of Et3N and catalytic DMAP. At this point it was deemed appropriate to turn to chiral 
HPLC as a more general method of determing the enantioretention of these processes (Scheme 
2.20B). This involved the preparation of both chiral and racemic forms of the starting material 
41a. Upon analysis of 41a via chiral HPLC, the racemic form gave two peaks eluting at 21.71 
and 24.08 minutes, while the chiral analogue gave only a single peak at 24.91 minutes, indicating 
that the starting material was enantiomerically pure (> 99% ee). These very samples of chiral and 
racemic starting material were used to generate chiral and racemic analogues of the 1,3-diene 41a 
and 5-vinyloxazolidinone 59a, which were then subjected to chiral HPLC (Daicel CHIRALPAK 
IA-U column) and the chiral analogues were shown to both be enantiomerically pure (> 99% ee) 
and that both syntheses proceed with complete enantioretention (see appendix for HPLC traces). 
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Scheme 2.20. A. Attempted use of chiral auxiliaries to determine the enantiomeric purity of the chiral 1,3-
diene. a. NaH (4.0 equiv.), (S)-(+)-10-camphorsulfonyl chloride (2.0 equiv.) in THF, 0 °C, 48 h. b. (R)-(−)-
α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (1.5 equiv.), Et3N (1.5 equiv.), DMAP (10 mol%) in 
CH2Cl2, r.t. 24 h. B. Schematic of the determination of enantioretention for the 1,3-diene and 5-
vinyloxazolidinone synthesis via chiral HPLC. c. P-methoxyphenylboronic acid (1.5 equiv.), L2 (10 
mol%), Pd2dba3×CHCl3 (5 mol%), K2CO3 (1.5 equiv.) in toluene, r.t. 24 h. d. P-methoxyphenylboronic acid 
(1.5 equiv.), L2 (5 mol%), Pd2dba3×CHCl3 (2.5 mol%), AcOH (1.5 equiv.) in toluene, r.t. 24 h.  
 
2.2.4 Investigation of the Substrate Scope for the Divergent Syntheses 
 
With a set of optimal conditions established for the divergent synthesis and the enantioretentive 
nature of the process confirmed, the task was then to demonstrate the scope of boronic acids and 
5-allenyloxazolidinones that these reactions could accommodate. A small panel of 5-
allenyloxazolidinones had already been produced by this point (41a-d, Section 2.2.1), and the 
selection of a library of boronic acids was now necessary. It was important that this library was 
adequately representative, including aryl, alkenyl and alkyl examples, with examples of aryl 
groups bearing electron withdrawing, electron donating and functionalisable moieties at multiple 
positions. This would give a comprehensive insight into the limits of the reaction conditions.  
 
The scope of the 1,3-diene synthesis was investigated first. As alluded to in Section 2.1.6 (see 
Scheme 2.13), the use of a vinylboronic acid in this reaction would leave the product (61, Scheme 
2.21A) with a dendraline core capable of undergoing not only an IMDA reaction, but a diene-
transmissive IMDA reaction in which polycyclic scaffolds could be formed over sequential steps 
(Scheme 2.21A). It was therefore made a priority to employ vinylboronic acids first to give some 
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headway to this idea. The first of these to be utilised was (E)-2-tert-butylvinylboronic acid which 
afforded the desired product 61a in 31% yield as a 74:26 (E/Z) mixture, however this contained 
impurities giving rise to signals in the aryl region of the 1H NMR spectrum, which were 
inseparable even after multiple attempts at purification. This product was therefore left without 
full characterisation and (E)-styrylboronic acid was turned to instead, which returned the 
corresponding 5-vinyloxazolidinone analogue as the major product (72% yield, 83% conversion, 
92:8, E/Z) in place of the desired 1,3-diene 61b. Though this result was unexpected, vinylboronic 
acids are known to be prone to protodeboronation,46a in which case the liberated boric acid may 
have catalysed the formation of the 5-vinyloxazolidinone. At this point it was clear that the 
synthesis of 2-vinyl derivatives of the 1,3-diene platform would require specific optimisation, 
which could be carried out in future work as a separate project, along with the development of 
diene-transmissive IMDA reactions of these systems. Focus was therefore realigned to 
establishing a more straightforward substrate scope.  
 
 
Scheme 2.21. A. Envisioned route to novel polycyclic scaffolds via a sequential diene-transmissive IMDA 
reaction, then intermolecular Diels–Alder reaction, enabled by the use of vinylboronic acids in the 1,3-
diene synthesis. B. Early attempts to synthesise 2-vinyl substituted 1,3-dienes. 
 
Fortunately, the arylboronic acids were exceptionally well-tolerated in comparison (Table 2.4), 
with a range of electron-rich and electron-poor examples being accommodated by the reaction 
conditions (52a-f, Table 2.4). The ortho-substituted examples were the only notable exceptions 
to this (32%, 52c and 47%, 52f). This can be rationalised by the sterically hindered nature of these 
boronic acids, which likely impedes transmetalation,47 and is also well known to drive 
protodeboronation.46b The latter may have catalysed the formation of the corresponding 5-
vinyloxazolidinone in the case of 52c via liberated boric acid, as per the aforementioned styryl 
example. In contrast, the best performing substrates were the highly electron-poor p- and m-
nitrophenylboronic acids, which led to the highest yields (79%, 52d, 80%, 52e). This can be 
rationalised from a mechanistic perspective and will therefore be discussed in Section 2.2.5. 
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Though a small selection of functionalisable handles were able to be introduced, an ester 
functionality was surprisingly poorly tolerated (34%, 52i), however the propensity for some 
electron-poor arylboronic acids to undergo homocoupling48 and protodeboronation49 may be 
responsible for the loss of yield. The even lower yield for the p-bromo analogue (27%, 52g) is 
likely a result of competing oxidative addition of Pd(0) to the C-Br bond, however the less 
susceptible p-chloro analogue allowed a halogen functionality to be introduced in good yield 
(66%, 52h). Pleasingly, the scope was able to be extended to heteroarylboronic acids such as 
furanyl (58%, 52k) and benzo[b]thiophenyl (76%, 52l) examples and, despite the previous 
pitfalls, a vinylboronic acid was able to be accommodated while maintaining moderate yield and 
stereoselectivity (43%, 85:5, E/Z, 52m). This was achieved by employing the α-substituted 1-
phenylvinylboronic acid, providing some direction for future investigations into optimising the 
reaction for vinylboronic acids. Perhaps a more striking result was the coupling of an alkylboronic 
acid to the 5-allenyloxazolidinone, albeit in poor yield (30%, 52n). This is surprising considering 
the cross-coupling of alkyl moieties often requires alternate conditions such as a Negishi cross-
coupling with an organozinc reagent (though protocols have been developed to accommodate 
alkylboronic acids and their derivatives under Suzuki–Miyaura type conditions).50 
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Table 2.4. Substrate scope of the 1,3-diene synthesis with respect to the boronic acid and the substituent at 
the amino acid-derived stereogenic centre.  
 
 
Stereochemical (E/Z) ratio shown in parentheses and calculated from the 1H NMR spectrum of the crude reaction mixture. 
aCorresponding 5-vinyloxazolidinone 59c (Table 2.5) obtained as the major product (83%, > 95:5, E/Z). bInseparable mixture 
(86:14) of 1,3-diene 52f and dimerised starting material 43 (Scheme 2.11), respectively. Yield of 52f calculated via 1H NMR 
spectrum of the mixture. cRequired resubjection to the reaction conditions to consume starting material and enable purification. 
 
With a representative scope of aryl, alkenyl and alkylboronic acids established for the 1,3-diene 
synthesis, the small panel of 5-allenyloxazolidinones 41a-d were then utilised to probe how the 
reaction conditions tolerated other substituents at the stereogenic centre (52o-q, Table 2.4). These 
were cross-coupled with m-nitrophenylboronic acid, which had given the highest yield and 
stereoselectivity (80%, > 99:1, E/Z, 52e). While excellent stereoselectivity was maintained for 
each of these examples (> 95:5, E/Z), the yields were moderate in regard to the alanine-derived 
(47%, 52o) and phenylalanine-derived (46%, 52q) examples. While the leucine-derived example 
was a slight improvement on this (58%, 52p), the NMR spectra revealed signals from significant 
impurities inseparable by column chromatography, indicative of polymerised material. It is 
suspected that these products may be more prone to polymerisation than the valine-derived 
analogues, despite the use of pH-neutral conditions during purification.  
 
Upon investigating the scope of the 5-vinyloxazolidinone synthesis, a range of arylboronic acids 
were found to be well-tolerated, with notable differences in reactivity in comparison to the 1,3-
diene synthesis (Table 2.5). For example, though the electron-rich boronic acids furnished the 
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corresponding products in good to excellent yields (59a-c), including the sterically hindered 
ortho-substituted example (69%, 59c), the highly electron-poor nitrophenylboronic acids were 
mostly unreactive, which was in stark contrast to the scope of the 1,3-diene synthesis. Again, this 
can be explained from a mechanistic perspective and will therefore be discussed in Section 2.2.5. 
The exception to this was m-nitrophenylboronic acid (59e, 62%), where the resonance effect of 
the nitro group was less effective at the boron-substituted carbon, however this still required a 
higher catalyst loading and resubjection to the reaction conditions in order to proceed to 
completion. It should be noted at this point that other examples in the 5-vinyloxazolidinone 
synthesis required resubjection to the conditions despite high conversion, as the virtually identical 
degrees of polarity rendered these products inseparable from the starting material by column 
chromatography unless it was entirely consumed. The exact protocols, including conversion 
values, are detailed in the experimental section.  Functionalisable handles were introduced to 
these systems in a facile manner, with p-bromo (73%, 59g), p-chloro (81%, 59h) and ester (89%, 
59i) functionalities being well-tolerated by the conditions. Similarly, heteroarylboronic acids such 
as furanyl (81%, 59) and benzo[b]thiophenyl (98%, 59l) examples were also accommodated, with 
the latter providing the highest yielding example in the substrate scope, albeit requiring 
resubjection to the reaction conditions. Interestingly, while 1-phenylvinylboronic acid provided 
a suitable alkenyl example in the 1,3-diene synthesis, this afforded the corresponding 5-
vinyloxazolidinone with significant, inseparable impurities after column chromatography. 
Turning to (E)-styrylboronic acid, however, allowed the synthesis of 5-vinyloxazolidinone 59m 
in good yield, purity and excellent stereoselectivity (65%, > 99:1, E/Z). While the alkylboronic 
acid proved to be unreactive in the 5-vinyloxazolidinone synthesis, other substituents at the 
stereogenic centre were much more highly tolerated by the reaction conditions than in the 1,3-
diene synthesis, using p-methoxyphenylboronic acid as the cross-coupling partner. The alanine-
derived (80%, 59o), leucine-derived (81%, 59p) and phenylalanine-derived (79%, 59q) were 
synthesised in consistently good yields, with the diastereoisomeric nature of the starting materials 
41c and 41d giving the corresponding 5-vinyloxazolidinones 59p and 59q as the expected 
diastereoisomers, the dr of which could be increased upon purification (see Table 2.5 for details). 
This provided a fulfilling close to the investigation of the scope of the two syntheses. Through 
the 34 examples, the divergent synthesis was found to accommodate a variety of cross-coupling 
partners across a small panel of 5-allenyloxazolidinone substrates, while also revealing a 
distinctive set of trends in reactivity between the two pathways. A detailed study of the reaction 
mechanism underpinning these pathways would help elucidate the origin of these trends. 
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Table 2.5. Substrate scope of the 5-vinyloxazolidinone synthesis with respect to the boronic acid and the 
substituent at the amino acid-derived stereogenic centre.  
 
 
Stereochemical (E/Z) ratio shown in parentheses and calculated from the 1H NMR spectrum of the crude reaction mixture. 
NR: no reaction. a93% conversion. Starting material removed via recrystallisation in CHCl3/hexane following column 
chromatography. bLigand/catalyst loading increased to 10/5 mol%, respectively. cRequired resubjection to the reaction 
conditions to consume starting material and enable purification. dObtained as a mixture of diastereoisomers due to starting 
materials 41c and 41d containing a minor diastereoisomer, however dr could be increased to 15.3:1 (from 8.0:1 dr, 59p) and 
9.7:1 (from 3.2:1 dr, 59q) upon purification. 
 
2.2.5 Mechanistic Study of the Divergent Synthesis of 1,3-Dienes or 5-Vinyloxazolidinones  
 
There are many facets of the newly-developed divergent synthesis that imply a high level of 
control, such as the divergence (chemoselectivity) and stereoselectivity (E/Z), as are there reactive 
trends observed within the substrate scope that call for further explanation. All of these can be 
explained sufficiently in terms of the proposed reaction mechanism underpinning the reactions, 
which is outlined in Scheme 2.22A. The origin of divergence in reactivity of the 5-
allenyloxazolidinone 42 arises from the formation of either intermediate III or VII. During 
formation of the 1,3-diene, the Pd(0)-ligand complex likely undergoes decarboxylative oxidative 
addition to the internal allene carbon, furnishing the Pd(II) intermediate III as the (E) isomer, 
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stabilised by a carbonate anion. It is thought that this intermediate exhibits η1 rather than η3 
hapticity, which is supported both in selected literature26, 27 and by the appearance of the dimerised 
starting material 43 in the synthesis of 52c (Table 2.4) - the dendraline core of which likely forms 
via the same η1 coordination mode. Formation of the 5-vinyloxazolidinone, on the other hand, 
begins with oxidative addition of the Pd(0)-ligand complex to AcOH to give complex VI, which 
undergoes concerted hydropalladation to the allene moiety of 41 to give the Pd(II) intermediate 
VII, a process which has previously been supported by mass spectrometry studies conducted by 
Guo and Ma.51 Related work by Ma42 suggests that the (E) stereochemistry arises from facially 
selective coordination of the Pd(II)-ligand complex opposite to the substituent 'R' at the amino 
acid-derived stereogenic centre (Scheme 2.22B), and that the regioselectivity is controlled by the 
delivery of the hydride to the relatively less sterically hindered terminal allene carbon (Scheme 
2.22B).   
 
 
Scheme 2.22. A. Proposed reaction mechanism for the divergent synthesis of 1,3-dienes or 5-
vinyloxazolidinones from 5-allenyloxazolidinones. B. Facial and regioselective hydropalladation step 
responsible for the E stereochemistry in the 5-vinyloxazolidinone synthesis. C. Control experiment 
demonstrating that the 5-vinyloxazolidinone is not a precursor to the 1,3-diene.  
 
The differing relative reactivity of the electron-poor boronic acids towards the 5-
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mechanism of which differs between the two reactions. The 1,3-diene is formed in basic 
conditions, under which formation of the activated boronate IV likely initiates transmetalation.52 
It is well known that electron-poor arylboronic acids facilitate this pathway due to their increased 
Lewis acidity, and this is reflected in the high yields of the p- and m-nitrophenyl-substituted 1,3-
dienes. In contrast, formation of the 5-vinyloxazolidinone occurs in the absence of an added base 
and therefore a direct transmetalation likely occurs instead, in which the electron-poor nature of 
the nitrophenylboronic acids is no longer a benefit and renders them unreactive. Following 
transmetalation, both pathways conclude with a reductive elimination, which delivers the organic 
moiety to the 1,3-diene V or 5-vinyloxazolidinone VIII to give the final products, regenerating 
the Pd(0)-ligand complex. Critically, a control experiment showed that treatment of the 5-
vinyloxazolidinone 52a with the Pd(0)-ligand complex and K2CO3 did not lead to the 1,3-diene 
via elimination (Scheme 2.22C), indicating that the 5-vinyloxazolidinone is not a precursor to the 
1,3-diene.  
 
2.2.6 Synthetic Applications of the 1,3-Dienes and 5-Vinyloxazolidinones 
 
The two scaffolds that have emerged from this divergent synthesis can serve as highly versatile 
platforms for generating complex heterocycles, which has been the overarching aim of this 
project. While the chiral 1,3-dienes are perfectly tailored for use in the IMDA reaction to form 
highly complex and medicinally relevant polycycles, the 5-vinyloxazolidinones (which are the 
most complex systems of this class to date) are archetypal substrates for Pd(0)-catalysed 
cycloaddition reactions to form highly complex pyrrolidines, as per the literature introduced in 
Section 2.1.5. The latter reaction was attempted using the 5-vinyloxazolidinone 59a and 2-
benzenemalononitrile (37b) to form the pyrrolidine 62a, under the conditions outlined by the Ooi 
group24a with PPh3 as the ligand (Scheme 2.23). Unfortunately this saw the return of only starting 
material, even after heating to 80 °C for 12 hours. At this point it was clear that some optimisation 
was necessary for this process to be realised, presumably due to the sterically hindered nature of 
the gem-substituted alkenyl moiety. While there is adequate literature precedent for bringing this 
reaction to fruition in future work, which will be discussed in Section 3, this initial result called 
for the appreciation of the 5-vinyloxazolidinone as a useful complex heterocycle in itself. The 
scaffold 59a, including the stereochemical configuration, is structurally similar to existing 
oxazolidinone antibiotics such as linezolid, ranbezolid and, perhaps more closely, to the recently 
developed MRX-I (Scheme 2.23).53 It is therefore reasonable to propose that this class of 
compounds may serve as more complex analogues of these antibiotics, with room for further 
modification (including the addition of more appropriate N-protecting groups upon denosylation, 
as well as the presence of an unsaturated alkene moiety). The 1,3-dienes, on the other hand, 
welcomed synthetic transformations much more readily.  
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Scheme 2.23. Applications of the 5-vinyloxazolidinone scaffold 59, including the attempted Pd(0)-
catalysed cycloaddition to form pyrrolidines and structurally related existing oxazolidinone antibiotics.  
 
Perhaps the more intriguing scaffold, from a synthetic perspective, is the chiral 1,3-diene 52. Not 
only is the 1,3-diene core suitable for Diels–Alder reactivity, but the presence of a pendant amine 
allows this to occur in an intramolecular fashion, after tethering the dienophile directly to the 
scaffold via N-alkylation to give the IMDA substrates 63 (Scheme 2.24). The power of the IMDA 
reaction lies in the ability to create fused polycycles with multiple stereocentres in a single step, 
with the intramolecular nature of the process often allowing this to be achieved under mild 
conditions.31 It is therefore no surprise that this has proved an invaluable tool in the synthesis of 
complex natural products,54 however the IMDA is limited by the lack of syntheses for 1,3-dienes 
containing pendant heteroatoms. The proposed scaffold arising from an IMDA reaction with the 
1,3-diene 52 is shown in Scheme 2.24 (64). This scaffold could contain up to four stereocentres, 
three of which would be created during the IMDA reaction. The resulting scaffold is structurally 
similar to the cytochalasin group of natural products (Scheme 2.24), which are mycotocins that 
bind to actin filaments to inhibit actin polymerisation and shut down multiple cellular processes. 
Despite their toxicity, these compounds have been invaluable tools in studying the role of actin 
in cellular processes, not to mention they have been found to be involved in other biological 
mechanisms, with many showing therapeutic potential.55 As a result, the total synthesis of 
cytochalasins has been investigated for a number of years, with many syntheses hinging on IMDA 
reactions.56 Despite the aforementioned power of this reaction, the IMDA process does have its 
drawbacks, namely in the unpredictability of the stereochemical outcome. In contrast to the more 
widely studied intermolecular Diels–Alder reaction, the traditional rules regarding exo and endo 
selectivity are often disobeyed, due to the forced proximity of the diene and dienophile in an 
intramolecular system. This often leaves the stereochemistry of the products impossible to 
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predict, and it would soon become clear that this was a serious obstacle in characterising 
cycloadducts of the 1,3-diene 52.  
 
Scheme 2.24. Potential of the 1,3-diene system 52 in the intramolecular Diels–Alder (IMDA) reaction.                                                                                                                                                                                                                                                                
 
Before fully investigating the IMDA reaction, a pilot reaction was conducted using the 
benzo[b]thiophene analogue 52l, to find an appropriate set of conditions for the N-alkylation step. 
The alkylating agent of choice was ethyl 2-(bromomethyl)acrylate (66, prepared from PBr3 and 
ethyl 2-(hydroxymethyl)acrylate (65), Scheme 2.25), which would leave the tethered dienophile 
suited for a normal electron demand Diels–Alder reaction (i.e. electron-rich diene, electron-poor 
dienophile). The alkylation was performed using the acrylate 66 in the presence of Et3N (Scheme 
2.25). Analysis of the 1H NMR spectrum of the isolated product (present as a major and minor 
isomer) revealed only one alkene signal at 5.89 ppm for the major isomer, where six were 
expected in the triene 63a, immediately implying this was not present. The corresponding mass 
and molecular formula were detected via mass spectrometry,‡ however, and the presence of the 
ethyl ester moiety was clear from the characteristic 1H NMR splitting pattern. Further experiments 
(13C NMR and gHSQC) revealed no trace of either terminal alkene of 63a, implying this had 
undergone further reactivity, and the appearance of multiple sp3 methylene signals in the 1H NMR 
and 13C NMR spectra suggested that the IMDA reaction had occurred immediately after alkylation 
to furnish the cycloadduct 64a. This was an extremely promising outcome, demonstrating that 
capability of these systems to undergo a one-pot N-alkylation and IMDA reaction to form 
isoindoline scaffolds in moderate yield and diastereoselectivity, under mild conditions. The 
challenge then became to determine the stereochemical outcome of these products. There are 
many ways to achieve this, including through-space NMR experiments, analysis of coupling 
constants, comparison to computational data and X-ray crystallography. Given that through-space 
NMR experiments are generally proton-based, determining the stereochemistry of centre 'd' 
(Scheme 2.25) would be difficult, due to the ester functionality. With a diastereoisomeric ratio of 
9:1, it was reasonable to speculate that the major isomer could be selectively recrystallised and 
subjected to X-ray crystallography to determine the stereochemistry. Unfortunately, despite 
 
‡ A signal at m/z 577.1469 was detected via high resolution mass spectrometry, corresponding to a 
sodium adduct with the formula C28H30N2O6S2Na, common to both 63a and 64a.  
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numerous attempts across a myriad of solvent systems, the cycloadduct 64a could not be obtained 
as a single diastereoisomer.  
 
Scheme 2.25. Pilot reaction of the 1,3-diene 52l in a one-pot N-alkylation and IMDA reaction, showing the 
synthesis of the acrylate alkylating agent 66. 
 
Though the stereochemical outcome remained unclear, the pilot reaction had served the purpose 
of establishing a set of conditions for generating cycloadducts 64. The purpose of the next reaction 
was to prepare a sample of cycloadduct suitable for X-ray crystallography and therefore 
stereochemical determination. Though the cycloadduct 64a had been obtained in moderate yield 
(48%), the reaction had not proceeded to completion (60% conversion), even after the addition of 
multiple portions of the acrylate 66 and Et3N. It was therefore decided to employ a 1,3-diene 
bearing an alternative electron-donating group that may better drive the N-alkylation and IMDA 
reaction, such as the p-methoxyphenyl derivative 52a. In addition to this, the pilot reaction had 
been conducted on a 20 mg scale with respect to the 1,3-diene, and so 50 mg of the p-
methoxyphenyl analogue 52a was used for the next reaction, being freshly synthesised and used 
immediately. Contrary to expectations, no reaction was observed at room temperature, though the 
cycloadduct 64b was successfully isolated in 55% yield after heating for 24 hours. While this was 
an improvement on the previous reaction, three diastereoisomers were now present in a ratio of 
10:3:1, likely a consequence of temperature. As in the previous case, many efforts were made to 
selectively recrystallise the major diastereoisomer for X-ray crystallography however, with three 
isomers present, these attempts were understandably fruitless.  
 
Scheme 2.26. Reaction of the 1,3-diene 52a in a one-pot N-alkylation and IMDA reaction.  
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It had become clear that relying solely on X-ray crystallography was stalling the determination of 
stereochemistry for these cycloadducts. The culprit was the all-carbon stereocentre 'd', which 
prevented the use of NMR analysis to assign the stereochemistry of the ester substituent. The 
literature revealed a report from 1972 by Gschwend and Meier, in which a similar 1,3-diene (67, 
Scheme 2.27A) underwent a one-pot acylation and cyclisation at 0 °C using the fumarate 
derivative 68 to give the cycloadduct 69.57 If these same conditions could be used to generate the 
cycloadduct 64c from the 1,3-diene 52a, the stereocentre 'd' would have a proton substituent, 
allowing the stereochemistry to be determined via NMR analysis, with the low temperature 
potentially affording high diastereoselectivity. Moreover, the product 64c would more closely 
resemble the cytochalasin core, with the added carbonyl group constituting the required γ-lactam 
ring. Unfortunately, no reaction was observed at room temperature. This is likely due to the highly 
electron-withdrawing N-nosyl group, which renders the nitrogen anion much less nucleophilic 
than the methyl-substituted nitrogen in Gschwend and Meier's substrate 68. Nevertheless, the 
desired cycloadduct 64c was obtained upon heating, albeit in a diastereoisomeric ratio of 13:2:1 
(Scheme 2.27C). With the absolute stereochemistry of the amino acid-derived proton Ha known 
in 64c, establishing the relationship (cis or trans) between protons Ha and Hb, Hb and Hd (i.e. the 
bridgehead protons) and Hd and Hg would reveal the absolute stereochemistry of the entire system. 
Theoretically, this could be achieved via NOE experiments and the analysis of coupling constants 
in the 1H NMR spectrum, however the overlapping of several signals complicated this approach.  
For example, overlapping signals from key protons Hb and Hd were only narrowly resolved by 
using acetone-d6 as the NMR solvent, making exclusive irradiation of either difficult during 1D 
NOE experiments. It was suspected that this may have been partly responsible for the conflicting 
correlation patterns observed across the spectrum, as was the close proximity of all protons across 
the relatively small ring system. Focus was therefore shifted to the coupling constants. While the 
clear doublet of doublets arising from proton Hd revealed vicinal coupling at 13.9 Hz and 11.0 
Hz, assigning the corresponding coupling partners was virtually impossible, given that both 
adjacent protons Hb and Hg spawned complex and overlapping multiplets. Having said this, a 
series of very similar isoindoline scaffolds (70, Scheme 2.27E) was reported by Murray in 1999,58 
where the coupling constants for the bridgehead protons were between 11.1 Hz and 13.2 Hz in 
the trans conformation. From this it was inferred that, given both of the two coupling constants 
for Hc are in agreement with this range, the cycloadduct 64c is likely a trans-fused system. In 
search of confirmation, obtaining a suitable sample for X-ray crystallography was difficult: while 
the product 64c readily recrystallised in EtOH, this could not be achieved in a selective manner 
with respect to the major isomer.  
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Scheme 2.27. A. Previous work by Gschwend and Meier on the related system 69. B. Epimerisation of 
cycloadduct 69 to reveal the thermodynamically favoured product. C. Reaction of the 1,3-diene 52a in a 
one-pot N-acylation and IMDA reaction with 68, freshly prepared from monoethyl fumarate and SOCl2. D. 
Reaction mechanism for possible epimerisation of the cycloadduct 64c. E. Related system investigated by 
Murray, showing the indicative coupling constants for the trans isomer.  
 
While the absolute stereochemistry of the cycloadduct 64c remained elusive, there was a critical 
flaw in the design of this system that may have impacted the stereochemical outcome. The system 
64c contains two epimerisable centres 'd' and 'g'. Gschwend and Meier had used this to their 
advantage in regard to cycloadduct 69, deliberately equilibrating the product in NaOMe to leave 
the thermodynamically favoured product 69', showing that the reaction product 69 was, in fact, 
the kinetically favoured product (Scheme 2.27B). While this cycloadduct was formed at 0 °C, the 
product 64c was obtained by heating in the presence of pyridine, where it is possible that the 
centres 'c' and 'd' were inverted. As a result, even if the absolute stereochemistry of 64c had been 
determined, it could not be said with certainty whether this was the true product of the reaction, 
or the thermodynamically favoured product arising from epimerisation. Alternative systems such 
as 64d and 64e (Scheme 2.28) were sought after, in which the epimerisable centres were removed, 
however these syntheses were unsuccessful.  It was now becoming clear that the non-epimerisable 
systems 64a and 64b were more suitable models for stereochemical determination. 
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Scheme 2.28. Synthetic attempts to remove the epimerisable stereocentres in the scaffold 64. Acyl chlorides 
freshly prepared from the corresponding carboxylic acids and SOCl2. 
 
At this point, it was clear that the newly-developed 1,3-dienes 52 were highly valuable platforms, 
given their ability to undergo one-pot N-alkylation and IMDA cyclisation to form complex and 
medicinally relevant heterocycles. An exhaustive effort to determine the stereochemistry of these 
systems was therefore highly justified, given their synthetic value. With the aid of a computational 
chemistry collaborator Assoc Prof Haibo Yu (UOW), attempts were made to demystify the 
stereochemistry via computational methods. The lowest energy conformers of all possible 
diastereoisomers of 64a-c had been modelled using density functional theory (DFT) and the key 
chemical shifts and coupling constants were calculated using Gaussian09.59 Upon comparing 
these to the experimental data, the possible isomers were narrowed down to a small panel for all 
systems, however the margin of error did not allow a conclusive assignment in any case. 
Returning to synthetic methods as a solution, it was finally decided to perform further reactions 
on one of the existing systems to ease analysis.  By derivatising either of the systems 64a or 64b, 
the stereocentre in question could be modified to include a proton for use in through-space NMR 
experiments. The product 64b was therefore reduced to the corresponding alcohol 64f using 
LiAlH4 (Scheme 2.29A), though the overlapping of signals in the 1H NMR spectrum left the 
resulting methylene signals difficult to analyse. An O-tosyl group was then introduced to the 
alcohol for two purposes: firstly, to draw the methylene signals further downfield and allow ease 
of analysis, and to render the overall molecule more suitable for selective recrystallisation for X-
ray crystallography. Gratifyingly, upon purification of the O-tosyl derivative 64g by column 
chromatography, the major isomer was able to be selectively isolated. Though recrystallisation of 
this sample was unsuccessful, the 1D NOE data was much clearer than in previous cases and has 
been summarised in Scheme 2.29A (see appendix for 1D NOE spectra). Firstly, strong 
correlations were observed between the O-tosyl methylene protons Hf and the bridgehead proton 
Hb, immediately indicating that these were positioned on the same face (i.e. a cis-fused system). 
This left two possible isomers, 64g and 64g' (Scheme 2.29B), depending on the relationship (cis 
or trans) between protons Ha and Hb. The 1D NOE data implied that this was a trans relationship 
(i.e. 64g), due to the strong correlation between proton Hb and the methyl protons of the i-Pr 
substituent, and comparatively weak correlation between protons Ha and Hb. This inference was 
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justified via computational experiments conducted by Assoc Prof Haibo Yu, in which the 
interproton distances for the lowest energy conformers of 64g and 64g' were calculated (Scheme 
2.29B). The distance between Ha and Hb was found to be 2.3 Å in the cis conformation (64g') and 
3.0 Å in the trans conformation (64g), where the latter better supports the comparatively weak 
NOE correlation. Furthermore, the distances between proton Hb and each methyl group of the i-
Pr substituent were 3.8 Å and 4.8 Å for the cis conformation (64g'), which do not justify the 
strong NOE correlations observed, whereas the distances of 2.2 Å and 2.6 Å in the trans 
conformation (64g) do. At this point, the stereochemistry of the isoindoline system 64g, and that 
of the parent system 64b, could be assigned as per 64g in Scheme 2.29A. Due to the similarity in 
both the reaction conditions and NMR spectra, the same configuration was tentatively assigned 
for the benzo[b]thiophene analogue 64a. The stereochemical outcome can be rationalised in terms 
of the transition state TS1 (Scheme 2.29C), the exo nature of which is not uncommon in IMDA 
processes60 due to the forced conformation of an intramolecular system. Furthermore, the 
stereochemical outcome is consistent with that of the cytochalasin natural products (Scheme 
2.29C), which adds to the medicinal relevance of these structures. It is now clear that the newly 
developed 1,3-dienes 52 are capable of generating highly complex and medicinally relevant 
isoindoline scaffolds via a one-pot N-alkylation and IMDA reaction, for which the absolute 
stereochemistry can be confidently elucidated.  
 
Scheme 2.29. A. Derivatisation of the cycloadduct 64b to allow stereochemical determination, showing 
indicative NOE correlations. B. Lowest energy conformers of 64g and 64g' showing only isoindoline core 
and key protons, with key interproton distances. C. Proposed exo transition state governing the 
stereochemical outcome of products 64a and 64b. 
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2.3 Conclusions and Future Directions 
 
2.3.1 Conclusions 
 
The overarching aim of this project has been to develop novel reactions combining the reactivity 
of allene and aziridine building blocks in pursuit of complex, medicinally-relevant N-
heterocycles. Though preliminary work left a trail of various allene and aziridine substrates that 
had failed to come together as desired, this trail ultimately led to a single substrate that contained 
the reactive traits of both. The 5-vinyloxazolidinone system developed in our group was found to 
engage in reaction pathways characteristic of both allenes and strained ring systems, generating 
either 1,3-dienes or 5-vinyloxazolidinones upon reacting with boronic acids under palladium 
catalysis (Scheme 2.30). At this point, the first part of the overall aim had been achieved. The 
significance of this was that the catalytic reactivity of a completely new synthetic building block 
had been unearthed for the first time, allowing this allenyloxazolidinone scaffold to sit alongside 
its vinylaziridine and vinyloxazolidinone counterparts as an invaluable building block in synthetic 
chemistry. In order to secure the second part of the overall aim (using these products to access 
complex N-heterocycles), some more specific goals in regard to optimisation and scope were 
pursued. Here, the most striking trait of this new building block was unveiled, being the ability to 
engage in one of two different reaction pathways with complete selectivity, where this divergence 
could be tightly controlled by the switch in a single additive, i.e. K2CO3 or AcOH. Furthermore, 
both reaction pathways were shown to proceed with high stereoselectivity (E/Z) and complete 
enantioretention (> 99% ee), generating a wide range of products in mostly good to excellent 
yields. The conditions for each synthesis were found to accommodate aryl, heteroaryl, vinyl and 
(in the case of the 1,3-diene synthesis) alkylboronic acids, across a panel of allenyloxazolidinones 
derived from various amino acids. Following this, the pursuit of complex, medicinally relevant 
N-heterocycles was successfully realised in regard to both products. The 5-vinyloxazolidinones 
themselves were inherently complex, more so than any previously reported in the literature, with 
both their oxazolidinone core and stereochemical configuration leaving them potential analogues 
of existing oxazolidinone antibiotics. The chiral 1,3-dienes served as complex substrates for the 
intramolecular Diels–Alder reaction, which further highlighted the significance of their synthesis, 
in that the literature has proved that chiral 1,3-dienes with this level of complexity are inherently 
difficult to synthesise. Critically, this is also the first example of a chiral 1,3-diene arising from 
the palladium-catalysed reaction of boronic acids with allenes. Not only were these 1,3-dienes 
able to undergo a one-pot N-alkylation and cyclisation to form complex isoindoline scaffolds in 
moderate yield and diastereoselectivity, but rigorous analysis revealed that the stereochemical 
outcome, as well as the overall scaffold, resembled that of the cytochalasin natural products, 
giving these systems a high degree of medicinal relevance. Not only does this render the aims of 
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the project successfully met, but the work detailed herein has also spawned numerous 
opportunities for future work.  
 
 
 
Scheme 2.30. Summary of the achievements of this project.  
 
 
2.3.2 Future Directions 
 
The range of robust ideas this project can lead to is a testament to the synthetic versatility of these 
systems. While applications of the 1,3-dienes and 5-vinyloxazolidinones were amply 
demonstrated, both products were tailored for more compelling synthetic transformations that 
were best suited for separate investigations. In regard to the 1,3-dienes, future work would involve 
the use of 2-vinyl substituted derivatives, or trienes (61, Scheme 2.31C) in the newly established 
IMDA reaction. This would be a diene-transmissive process, allowing the resulting 1,3-dienyl 
cycloadduct 71 to undergo a subsequent Diels–Alder reaction to give the polycyclic scaffold 72. 
Specific optimisation would be required to introduce the vinyl moieties to the 5-
allenyloxazolidinone 41 in adequate chemo- and stereoselectivity (E/Z), as these were prominent 
issues under the current conditions. The generation of the corresponding 5-vinyloxazolidinone 
59m in place of the desired 1,3-diene 61b (Scheme 2.31A) was thought to be catalysed by boric 
acid, which is liberated upon protodeboronation. This known issue with vinylboronic acids can 
be overcome by using more stable boronate derivatives such as N-methyliminodiacetic acid 
(MIDA) esters (Scheme 2.29B), not to mention many commercially available vinylboronates can 
only be handled in an ester form due to their inherent instability. Tuning the current conditions to 
tolerate a MIDA ester, which may include the addition of water/alcohol to promote slow release 
of the reactive boronic acid via basic hydrolysis,61 may therefore allow vinyl moieties to be 
accommodated with high chemoselectivity for the 1,3-diene. As for the issue of E/Z selectivity, 
the observation that an α-substituted (rather than β-substituted) vinylboronate positively 
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influenced the stereochemical outcome (see 61a vs. 59m) implied that this may be key to 
controlling stereoselectivity. A more general solution, however, would be to tailor the ligand-
catalyst system for the vinylboronates: the screening of phosphorus, amine and N-heterocyclic 
carbene (NHC) ligands with a model vinylboronate may identify a suitable system for introducing 
52 in high E/Z selectivity. Once this process has been optimised, the 1,3-dienyl cycloadduct 71 
can then be subjected to Diels–Alder reactions with alkene, alkyne or imine dienophiles to give 
the polycyclic scaffold 72 (Scheme 2.31C), the stereochemical outcome of which should be easier 
to predict than the IMDA products 64, due to the tendency of intermolecular Diels–Alder 
reactions to favour the endo product. While the polycyclic scaffold 72 has a steroid like structure, 
there is no direct resemblance to any known natural products. From a medicinal chemistry 
perspective, the advantage here lies purely in structural novelty, by which other 'abiotic' or 
'artificial' scaffolds are able to delve deeper into chemical space by deviating from the limits of 
what has been synthesised in nature.62 This rationale has appeared recently in the literature as a 
new method of identifying medicinally-relevant scaffolds, and has been coined 'ChOS' 
(chemistry-oriented synthesis).63  
 
 
Scheme 2.31. A. Problems encountered while accommodating vinylboronic acids in the 1,3-diene 
synthesis. B. N-methyliminodiacetic acid (MIDA) ester derivatives proposed to address the issue of 
protodeboronation in future work. C. Summary of future work in regard to vinyl derivatives of the 1,3-
dienes developed in this project.  
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While the 1,3-dienes demonstrate clear potential for generating highly complex scaffolds in future 
work, the 5-vinyloxazolidinones can prove equally powerful under the correct conditions. While 
these systems appear to be archetypal substrates for Pd(0)-catalysed cycloaddition reactions to 
form complex pyrrolidines, this reaction did not occur under standard conditions (see Section 
2.2.6). It was suspected that the required Pd(II)-π-allyl intermediate was unreactive, or not formed 
at all, due to the sterically hindered nature of the gem-disubstituted vinyl group. This prompted 
the realisation that the 5-vinyloxazolidone itself was complex and medicinally relevant, however 
turning to the literature revealed that, while rare, examples of similar gem-disubstituted vinyl 
groups undergoing allylic substitution do exist. In 2018, Ding and Hou reported a palladium 
catalysed example (Scheme 2.32) using a Pd(OAc)2/NHC system that forms a σ-bound Pd(II) 
species rather than a π-allyl intermediate.64 This process was tailored specifically to a ketone 
nucleophile, however, from which the transition state TS2 required to tolerate the gem-
substituents could be formed. A more generally applicable protocol may be found in iridium 
catalysis, which has enriched the realm of allylic substitution over the last few decades.65 The 
active catalyst in these processes is thought resemble the iridicyclic species 73, which Stoltz has 
since found accommodates gem-disubstituted substituents in allylic substitution reactions 
(Scheme 2.32).66 In regard to the 5-vinyloxazolidinone 59, future work may involve the use of a 
similar iridium system to catalyse the desired cycloaddition to form densely functionalised 
pyrrolidines (74, Scheme 2.32). The products of both aforementioned examples resulted from 
terminal attack on the alkene, making the 7-membered 74' an additional, feasible product. 
Iridium-catalysed allylic substitutions are well known to proceed with exceptionally high regio- 
and enantioselectivity, and the enantioenriched nature of the starting material 59 may provide 
additional stereocontrol. The possibility of creating four contiguous stereocentres in the product 
74 with a high degree of stereochemical control is hugely appealing. From a medicinal chemistry 
perspective, the creation of such stereodefined, sp3-rich molecules could produce highly potent 
and selective drug molecules.  
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Scheme 2.32. Examples of palladium and iridium-catalysed allylic substitution reactions of gem-
substituted vinyl groups used to devise a plan for future work regarding the 5-vinyloxazolidinone products. 
 
With a plan of action devised for both products developed in this project, there remains one final 
result that warrants further investigation. The Pd(0)-catalysed formation of the phosphonated 1,3-
diene 56a (Scheme 2.33) during optimisation was completely unprecedented and presented the 
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as detection of the phenylcarbonate leaving group via mass spectrometry analysis, and 
computational analysis. Once the mechanism and scope have been established for simple 
substrates, this method may be extended to form complex 1,3-dienes capable of forming densely 
functionalised phosphonated heterocycles, rendering this result both distinct and complementary 
to the achievements of the rest of this project.  
 
 
 
Scheme 2.33. Plans for preliminary work required to investigate the palladium-catalysed cross-coupling 
of phosphite esters to allenes, discovered via the formation of phosphonated 1,3-diene 56a.  
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2.4 Experimental 
 
2.4.1 General Experimental 
 
All commercial reagents were used as received, unless otherwise noted. Anhydrous solvents were 
either purchased from commercial suppliers or passed over activated alumina, before being dried 
over pre-activated 3, 4 or 5 Å molecular sieves and stored under nitrogen gas. Reaction vessels 
were oven-dried (120 °C) overnight before use and all reactions were carried out under a nitrogen 
atmosphere, unless otherwise noted. Reactions were monitored via thin-layer chromatography 
(TLC) analysis using aluminium-backed silica gel sheets coated with fluorescent indicator F254 
and visualized under UV light (254 nm) and anisaldehyde stain (4 mL anisaldehyde, 5 mL 
concentrated H2SO4, 2 mL glacial AcOH in 150 mL EtOH). Column chromatography was 
performed under compressed air using flash grade silica gel (40–60 nm). NMR spectroscopy was 
conducted using a Bruker 500 (500 MHz, 1H, 125 MHz, 13C, 200 MHz, 31P) or Bruker 400 (400 
MHz, 1H, 100 MHz, 13C) spectrometer. For samples dissolved in CDCl3 (0.1% v/v TMS), 
chemical shifts (δ) have been reported in parts per million (ppm) and referenced to the CDCl3 
signal (7.26 ppm, 1H, 77.0 ppm, 13C) or TMS signal (0.00 ppm, 1H and 13C). Those dissolved in 
acetone-d6 have been referenced to the (CD3)2CO signal (2.05 ppm, 1H, 29.9, 13C). 31P NMR 
experiments were performed using triphenylphosphate (0.0485 M in (CD3)2CO) as an external 
reference. Coupling constants (J) are reported in hertz (Hz). Multiplicities of NMR signals have 
been abbreviated as s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), sext (sextet), sept 
(septet), oct (octet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of 
triplets), ddt (doublet of doublet of triplets), tt (triplet of triplets), dq (doublet of quartets) or m 
(multiplet) and some denoted as app. (apparent) or br. (broad), with quaternary carbons denoted 
as 'QC' when reporting 13C NMR signals. High resolution mass spectrometry (HRMS) was carried 
out using a Waters Xevo G1 QTof mass spectrometer. Infrared data was collected on either a 
Shimadzu IRAffinity-1 Miracle 10 Fourier transform infrared (FTIR) or Bruker Vertex 70 FTIR 
instrument and the intensities of the observed signals assigned as very weak (vw), weak (w), 
strong (s) or very strong (vs). Melting points (Mp) were obtained using a Buchi M-560 melting 
point apparatus. Optical rotation data was obtained using a JASCO P-2000 polarimeter at 589 nm 
and a 0.5 mL cell with a path length of 0.5 decimeters. Chiral high-performance liquid 
chromatography (HPLC) was conducted using a Shimadzu Nexera X2 UHPLC system equipped 
with a PDA detector, under normal-phase conditions. Fresh Pd2dba3×CHCl3 was synthesized at a 
purity of > 90% (via 1H NMR analysis) using the procedure outlined by Zalesskiy and 
Ananikov.67 The L-N-Boc-amino esters were prepared by Dr Farzad Zamani, following the 
procedure previously reported by our group.17 See appendix for NMR spectra of novel 
compounds. 
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2.4.2 Preliminary Work 
 
General procedure for the synthesis of 2-substituted aziridines: 
 
 
To a stirring solution of the appropriate alkene (2.0 equiv.) and  chloramine-T trihydrate (1.0 
equiv) in MeCN (0.5 M with respect to the alkene) was added iodine (10 mol%). The vessel was 
sealed under nitrogen gas and stirred vigorously for 3 days at room temperature. After aqueous 
workup, the pure products were isolated via column chromotography (see below). 
 
2-Phenyl-1-tosylaziridine (1a): 
 
The reaction was filtered and the filtrate concentrated by half in vacuo, before washing with 
hexane (to remove unreacted styrene) and removing MeCN in vacuo. The material was washed 
with a saturated aqueous solution of Na2S2O3, then brine, and the organic layer extracted 
with EtOAc. After drying with MgSO4, filtration and concentration in vacuo, the crude 
material was subjected to column chromatography (EtOAc/hexane, 20:80) to isolate the pure 
product (white crystals, 54%).  
 
1H NMR (500 MHz, CDCl3): δ 7.87 (d, J = 8.0 Hz, 2H, TsCH), 7.33 (d, J = 8.0 Hz, 2H, TsCH), 
7.29 – 7.21 (m, 5H, ArCH), 3.77 (dd, J = 6.8, 4.7 Hz, 1H, CH), 2.98 (d, J = 7.2 Hz, 1H, CH2), 
2.43 (s, 3H, TsCH3), 2.39 (d, J = 4.3 Hz, 1H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 144.5 
(QC, TsC), 134.92 (QC, TsC or ArC), 134.88 (QC, TsC or ArC), 129.6 (CH, 2´TsCH or 
2´ArCH), 128.4 (CH, 2´TsCH or 2´ArCH), 128.2 (CH, ArCH), 127.8 (CH, 2´TsCH or 
2´ArCH), 126.4 (CH, 2´TsCH or 2´ArCH), 40.9 (CH, CH), 35.8 (CH2, CH2), 21.5 (CH3, TsCH3) 
ppm. The NMR data match that previously reported.68 
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The reaction was diluted with CH2Cl2 and washed with water, then brine. The organic layer was 
dried with Na2SO4, filtered and concentrated in vacuo to leave the crude material, which was 
subjected to column chromatography (EtOAc/hexane, 60:40) to isolate the pure product 
(colourless oil, 24%).  
 
1H NMR (500 MHz, CDCl3): δ 7.82 (d, J = 8.0 Hz, 2H, TsCH), 7.34 (d, J = 8.0 Hz, 2H, TsCH), 
3.79 (d, J = 11.9 Hz, 1H, CH2-O), 3.55 – 3.52 (m, 1H, CH2-O), 3.02 – 2.98 (m, 1H, CH-N), 2.58 
(d, J = 7.0 Hz, 1H, CH2-N), 2.53 (br. s, 1H, OH), 2.43 (s, 3H, TsCH3), 2.29 (d, J = 4.5 Hz, 1H, 
CH2-N) ppm. 13C NMR (125 MHz, CDCl3): δ 144.7 (QC, TsC), 134.1 (QC, TsC), 129.6 (CH, 
2´TsCH), 127.8 (CH, 2´TsCH), 60.6 (CH2, CH2-O), 40.3 (CH2, CH2-N), 30.8 (CH, CH-N), 21.4 
(CH3, TsCH3) ppm. The NMR data match that previously reported.68 
 
Synthesis of cyclohexylallene (3a):69 
 
 
A 100 mL Schlenk flask charged with cyclohexylmagnesium chloride (40.5 mmol of a 2.0 M 
solution in Et2O, 1.0 equiv.) in THF (32 mL) was cooled to –84°C with stirring. To the Grignard 
was added a solution of anhydrous LiBr (804.4 mg, 9.25 mmol, 20 mol%) and anhydrous CuBr 
(405.0 mg, 2.84 mmol, 7 mol%) in THF (10 mL) via cannula and the mixture stirred at –84°C for 
20 minutes to produce the Gilman reagent. During this time, a solution of propargyl bromide (4.60 
mL, 48.42 mmol, 1.2 equiv.) in THF (5 mL) was cooled to –84°C for 15 minutes. This was taken 
up by syringe and added to the reaction over 30 minutes, after which the mixture was allowed to 
stir at –84°C for a further 30 minutes, then warmed to room temperature and stirred for 18 hours. 
The reaction was quenched with a solution of saturated aqueous NH4Cl and the organic layer 
extracted with pentane, then washed repeatedly with water and finally with brine. After drying 
with MgSO4 and filtering, the pentane was removed in vacuo. The crude material was subjected 
to column chromatography (pentane), followed by distillation to leave the pure product as a 
colourless oil (2.31 g, 18.90 mmol, 47%).  
 
1H NMR (300 MHz, CDCl3): δ 5.09 (app. q, J = 6.5 Hz, 1H, =CH), 4.68 (dd, J = 6.6, 3.2 Hz, 2H, 
=CH2), 2.04 – 1.91 (m, 1H, CyCH), 1.78 – 1.61 (m, 5H, CyCH2), 1.36 – 1.03 (m, 5H, CyCH2) 
ppm. 13C NMR (75 MHz, CDCl3): δ 207.4 (QC, =C=), 96.1 (CH, =CH), 75.4 (CH2, =CH2), 36.6 
(CH, CyCH), 33.0 (CH2, 2´CyCH2), 26.13 (CH2, CyCH2), 25.99 (CH2, 2´CyCH2) ppm. The 
NMR data match that previously reported.69 
MgCl
(1.2 equiv.)
LiBr (20 mol%)
CuBr (7 mol%)
THF, –84°C - r.t.
18 h
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Synthesis of N-benzylideneaniline (16a): 
 
 
A solution of benzaldehyde (2.20 mL, 19.94 mmol, 1.05 equiv.) and aniline (1.80 mL, 18.96 
mmol, 1.00 equiv.) in Et2O (30 mL) was stirred at room temperature with 4 Å molecular sieves 
for 18 hours. After this time, the precipitate was filtered and recrystallised in EtOH to afford the 
pure product as pale yellow needles (2.51 g, 13.85 mmol, 73%). 
 
1H NMR (500 MHz, CDCl3): δ 8.45 (s, 1H, CH=N), 7.93 – 7.86 (m, 2H, ArH), 7.47 – 7.46 (m, 
3H, ArH), 7.40 – 7.37 (m, 2H, ArH), 7.24 – 7.20 (m, 3H, ArH) ppm. 13C NMR (125 MHz, 
CDCl3): δ 160.3 (CH, CH=N), 152.1 (QC, ArC-N), 136.2 (QC, ArC), 131.3 (CH, ArCH), 129.1 
(CH, 2´ArCH), 128.8 (CH, 2´ArCH), 128.7 (ArCH, 2´ArCH), 125.9 (CH, ArCH), 120.8 (CH, 
2´ArCH) ppm. The NMR data match that provided by commercial suppliers such as Sigma 
Aldrich. 
 
Synthesis of N-((1R,2R)-2-cyclohexyl-1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)but-3-en-1-yl)aniline (17a):11 
 
A 25 mL Schlenk flask charged with IPrCuCl (4.6 mg, 0.01 mmol, 5 mol%), Cs2CO3 (56.0 mg, 
0.17 mmol, 1.0 equiv.) and B2pin2 (46.9 mg, 0.18 mmol, 1.1 equiv.) was evacuated under high 
vacuum for 1 hour, before being backfilled with nitrogen gas. THF (1.5 mL) was added and the 
mixture allowed to stir at room temperature for 20 minutes. To this was added a solution of the 
imine (30.3 mg, 0.17 mmol, 1.0 equiv.) and cyclohexylallene (35.5 mg, 0.29 mmol, 1.5 equiv.) 
in THF (1.0 mL) via cannula under nitrogen gas. After 20 hours, the reaction was filtered through 
a short pad of silica and concentrated in vacuo to give the crude material, which was subjected to 
column chromatography (EtOAc/hexane, 2:98) to give the pure product as a pale orange oil (16.1 
mg, 0.04 mmol, 22%, 89:11 dr).  
 
1H NMR (500 MHz, CDCl3): δ 7.29 – 7.10 (m, 5H, ArCH), 7.03 (app. t, J = 7.7 Hz, 2H, ArCH), 
6.54 (app. t, J = 7.3 Hz, 1H, ArCH), 6.42 (d, J = 8.0 Hz, 2H, ArCH), 5.70 (d, J = 3.6 Hz, 1H, 
NH), 4.98 (d, J = 3.6 Hz, 1H, =CH2), 4.73 (d, J = 5.0 Hz, 1H, =CH2), 2.24 (dd, J = 9.4, 5.0 Hz, 
H
O
4 Å mol. sieves
Et2O, r.t. 18 h
NH2N
BNH
OO●
B2pin2 (1.1 equiv.)
IPrCuCl (5 mol%))
Cs2CO3 (1.0 equiv.)
THF, r.t., 20 h
N
(1.5 equiv.) (1.0 equiv.)
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1H, CH-N), 1.88 – 1.78 (m, 2H, CyCH and CyCH2), 1.70 – 1.60 (m, 4H, CyCH2), 1.31 (s, 6H, 
PinCH3), 1.28 (s, 6H, PinCH3), 1.23 – 1.11 (m, 3H, CyCH2), 1.04 – 0.97 (m, 1H, CyCH2), 0.84 – 
0.74 (m, 1H, CyCH2) ppm. 13C NMR (125 MHz, CDCl3): δ 148.1 (QC, ArC), 143.7 (QC, ArC), 
134.9 (CH2, =CH2), 128.9 (CH, 2´ArCH), 127.9 (CH, 2´ArCH), 127.2 (CH, 2´ArCH), 126.1 
(CH, ArCH), 115.9 (CH, ArCH), 112.5 (CH, 2´ArCH), 83.7 (QC, 2´PinC-O), 61.4 (CH, CH-
Cy), 57.5 (CH, CH-N), 36.9 (CH, CyCH), 32.4 (CH2, CyCH2), 31.3 (CH2, CyCH2), 26.6 (CH2, 
CyCH2), 26.4 (CH2, CyCH2), 26.3 (CH2, CyCH2), 24.9 (CH3, 2´PinCH3), 24.4 (CH3, 2´PinCH3) 
ppm. The NMR data match that previously reported, including the absence of the signal for the 
B-C= carbon.11 
 
Synthesis of 2-Phenylamino-2-phenylethan-1-ol (18):70 
 
To a solvent-free mixture of styrene oxide (2.30 mL, 20.09 mmol, 1.0 equiv.) and aniline (1.80 
mL, 19.67 mmol, 1.0 equiv.) was added LiBr (88.1 mg, 1.01 mmol, 5 mol%) and the reaction 
stirred at room temperature. A further portion of LiBr (2.5 mol%) was added after 4 hours, and 
the mixture left to stir overnight. The reaction was diluted with water and the organic layer 
extracted with Et2O, dried with MgSO4 and filtered. The Et2O was removed in vacuo and the 
crude material subjected to column chromatography (EtOAc/hexane, 20:80) to leave the product 
as a deep purple oil (4.31 g, 12:1 major:minor). The viscous oil was unable to be dried adequately 
enough to obtain an accurate yield, and was used immediately in the next reaction.  
 
1H NMR (500 MHz, CDCl3): δ 7.36 – 7.28 (m, 5H, ArCH), 7.07 (app. t, J = 7.5 Hz, 2H, ArCH), 
6.66 (t, J = 7.3 Hz, 1H, ArCH), 6.54 (d, J = 8.5 Hz, 2H, ArCH), 4.43 (dd, J = 6.9, 4.2 Hz, 1H, 
CH-N), 3.85 (dd, J = 11.1, 3.8 Hz, 1H, CH2-O), 3.67 (dd, J = 10.8, 7.6 Hz, 1H, CH2-O), 3.45 (br. 
s, 2H, NH and OH) ppm. 13C NMR (125 MHz, CDCl3): δ 147.0 (QC, ArC), 134.0 (QC, ArC), 
129.1 (CH, 2´ArCH), 128.7 (CH, 2´ArCH), 127.5 (CH, ArCH), 126.7 (CH, 2´ArCH), 117.9 
(CH, ArCH), 113.9 (CH, 2´ArCH), 67.1 (CH2, CH2-O), 59.9 (CH2, CH2-N) ppm. The NMR data 
match that previously reported.71 
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General procedure for the synthesis of β-methoxy amines: 
 
A solution of the aziridine (1.0 equiv.) and K2CO3 (2.0 equiv.) in MeOH was stirred with (A) or 
without (B) pinacol allenylboronate (2.0 equiv.) at 50 °C overnight. The reaction was diluted with 
CH2Cl2 and washed with water, then brine. The organic layer was dried with MgSO4 and filtered, 
before the solvents were removed in vacuo. The major and minor isomers were separated and 
isolated via column chromatography (EtOAc/hexane, 80:20). A. 52%, 2.4:1 (major:minor). B. 
40%, 2.6:1 (major:minor).  
 
2-Tosylamino-3-methoxypropanol (24a): 
 
Pale yellow oil. Rf = 0.42 (EtOAc/hexane, 80:20). HRMS-ESI (m/z): [M+H]+ calcd for 
C11H18NO4S, 260.0951; found, 260.0957. FTIR v!max (cm-1): 3497 (br., w, OH), 3275 (br., w, NH), 
1598 (w), 1451 (w), 1323 (m), 1154 (vs), 1090 (s), 814 (s), 667 (s). 1H NMR (500 MHz, CDCl3): 
δ 7.77 (d, J = 8.1 Hz, 2H, TsCH), 7.30 (d, J = 8.0 Hz, 2H, TsCH), 5.28 (d, J = 7.7 Hz, 1H, NH), 
3.66 (dd, J = 11.4, 4.2 Hz, 1H, CH-O), 3.52 (d, J = 12.2 Hz, 1H, CH-O), 3.45 (dd, J = 9.4, 4.2 
Hz, 1H, CH2-N), 3.39 – 3.36 (m, 1H, CH-N), 3.34 – 3.30 (m, 1H, CH2-N), 3.22 (s, 3H, OMe), 
2.42 (s, 3H, TsCH3), 2.37 (br s, 1H, OH) ppm. 13C NMR (125 MHz, CDCl3): δ 143.6 (QC, TsC), 
137.4 (QC, TsC), 129.7 (CH, 2´TsCH), 127.0 (CH, 2´TsCH), 72.6 (CH2, CH2-N), 63.0 (CH2, 
CH2-O), 59.1 (CH3, OMe), 54.0 (CH, CH-N), 21.5 (TsCH3) ppm.  
 
3-Tosylamino-2-methoxypropanol (24b): 
 
Off-white solid. Rf = 0.33 (EtOAc/hexane, 80:20). Mp 100.9 – 102.1 °C. HRMS-ESI (m/z): 
[M+Na]+ calcd for C11H17NO4SNa, 282.0770; found, 282.0790. FTIR v!max (cm-1): 3462 (br., w, 
OH), 3168 (w, NH), 1596 (w), 1453 (w), 1385 (m), 1327 (s), 1163 (vs), 1045 (vs), 783 (s), 678 
●
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(s). 1H NMR (500 MHz, CDCl3): δ 7.75 (d, J = 8.1 Hz, 2H, TsCH), 7.32 (d, J = 7.9 Hz, 2H, 
TsCH), 4.93 (t, J = 6.4 Hz, 1H, NH), 3.74 – 3.71 (m, 1H, CH2-O), 3.61 – 3.58 (m, 1H, CH2-O), 
3.38 – 3.35 (m, 1H, CH-OMe), 3.35 (s, 3H, OMe), 3.19 – 3.14 (m, 1H, CH2-N), 3.06 (m, 1H, 
CH2-N), 2.43 (s, 3H, TsCH3), 2.02 (br s, 1H, OH) ppm. 13C NMR (125 MHz, CDCl3): δ 143.5 
(QC, TsC), 136.8 (QC, TsC), 129.8 (CH, 2´TsCH), 127.1 (CH, 2´TsCH), 79.3 (CH3, OMe), 61.2 
(CH2, CH2-O), 57.4 (CH, CH-OMe), 43.0 (CH2, CH2-N), 21.5 (CH3, TsCH3) ppm.  
 
Synthesis of 2-Tosylamino-3-propargyloxypropanol (24c):  
 
To an oven-dried reaction vial was added the aziridine (30.6 mg, 0.13 mmol, 1.0 equiv.), K2CO3 
(38.0 mg, 0.27 mmol, 2.0 equiv.) and propargyl alcohol (15.0 μL, 0.26 mmol, 2.0 equiv.). The 
vial was purged with nitrogen gas and MeCN (0.5 mL) added, before capping the vial under a 
nitrogen atmosphere. The reaction mixture was stirred at 50 °C for 18 hours, before being diluted 
with CH2Cl2, washed with water, then brine, and the organic layer dried with MgSO4. After 
filtration, the organic layer was concentrated in vacuo to give the crude material, which was 
subjected to column chromatography (EtOAc/hexane, 60:40) to afford the pure product as a 
colourless oil (7.7 mg, 0.03 mmol, 23%). 
 
HRMS-ESI (m/z): [M+H]+ calcd for C13H18NO4S, 306.0770; found, 306.0775. FTIR v!max (cm-1): 
3512 (br., w, OH), 3277 (m, ≡CH), 1598 (vw), 1323 (m), 1156 (vs), 1087 (s), 814 (m), 665 (s). 
1H NMR (500 MHz, CDCl3): δ 7.77 (d, J = 8.0 Hz, 2H, TsCH), 7.31 (d, J = 8.0 Hz, 2H, TsCH), 
5.16 (d, J = 7.7 Hz, 1H, NH), 4.04 (ddd, J = 18.0, 15.9, 2.2 Hz, 2H, CH2-C≡CH), 3.69 – 3.67 (m, 
1H, CH2), 3.61 (dd, J = 9.4, 4.3 Hz, 1H, CH2), 3.57 – 3.52 (m, 1H, CH2), 3.47 (dd, J = 9.4, 4.7 
Hz, 1H, CH2), 3.44 – 3.39 (m, 1H, CH-N), 2.43 (s, 3H, TsCH3 and 1H, ≡CH), 2.10 (br s, 1H, OH) 
ppm. 13C NMR (125 MHz, CDCl3): δ 143.6 (QC, TsC), 137.4 (QC, TsC), 129.8 (CH, 2´TsCH), 
127.1 (CH, 2´TsCH), 78.8 (QC, ≡C), 75.2 (CH, ≡CH), 69.6 (CH2, CH2-N), 62.7 (CH2, CH2-O), 
58.6 (CH2, CH2-C≡CH), 54.1 (CH, CH-N), 21.5 (CH3, TsCH3) ppm.  
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Synthesis of 2-(tosylamino)methyl oxirane (25a): 
 
To a solution of the aziridine (30.9 mg, 0.14 mmol, 1.0 equiv.) in THF (2 mL) was added KOt-
Bu (0.28 mmol of a 1 M solution in THF, 2.0 equiv.), followed by pinacol allenylboronate (0.05 
mL, 0.28 mmol, 2.0 equiv.), under a nitrogen atmosphere. The reaction was stirred at room 
temperature for 1 hour, before quenching with water, extracting with CH2Cl2 and the organic 
extracts washed with brine. The organic layer was dried with MgSO4 and filtered before being 
concentrated in vacuo to give the crude material. This was subjected to column chromatography 
(EtOAc/hexane, 70:30) to give the epoxide as the major product (white solid, 20.3 mg, 0.09 mmol, 
64%), with no trace of the desired β-allenyl amine. 
 
1H NMR (500 MHz, CDCl3): δ 7.75 (d, J = 8.3 Hz, 2H, TsCH), 7.32 (d, J = 7.9 Hz, 2H, TsCH), 
4.81 (t, J = 6.2 Hz, 1H, NH), 3.36 – 3.31 (m, 1H, CH2-N), 3.07 – 3.00 (m, 1H, CH-O and 1H, 
CH2-N), 2.75 (appt, J = 4.3 Hz, 1H, CH2-O), 2.63 – 2.62 (m, 1H, CH2-O), 2.43 (s, 3H, TsCH3) 
ppm. 13C NMR (125 MHz, CDCl3): δ 143.7 (QC, TsC), 136.8 (QC, TsC), 129.8 (CH, 2´TsCH), 
127.0 (CH, 2´TsCH), 50.2 (CH, CH-O), 45.1 (CH2, CH2-O), 44.3 (CH2, CH2-N), 21.5 (CH3, 
TsCH3) ppm. The NMR data match that previously reported.72 
 
General procedure for the synthesis of N-alkylated 2-(tosylamino)methyl epoxides: 
 
To a solution of the epoxide (1.0 equiv.) and K2CO3 (2.0 equiv.) in MeCN (approximately 0.1 M 
with respect to the epoxide) was added the alkyl bromide (1.2 equiv.) and the reaction stirred at 
room temperature overnight. The reaction was quenched with water and extracted with CH2Cl2 
and the organic extracts washed with brine and dried with MgSO4. After filtration and removal 
of the solvents in vacuo, the crude material was purified via column chromatography if required. 
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N-benzyl-2-(tosylamino)methyl oxirane (25b):  
 
Purified via column chromatography (EtOAc/hexane, 30:70) and obtained as a colourless oil 
(81%). HRMS-ESI (m/z): [M+Na]+ calcd for C17H19NO3SNa, 340.0978; found, 340.0992. FTIR 
v!max (cm-1): 1597 (w), 1496 (w), 1340 (s), 1155 (vs), 936 (m), 735 (s), 656 (s). 1H NMR (500 
MHz, CDCl3): δ 7.75 (d, J = 8.0 Hz, 2H, TsCH), 7.33 – 7.26 (m, 2H, TsCH and 5H, ArCH), 4.48 
(d, J = 14.7 Hz, 1H, BnCH2), 4.35 (d, J = 14.7 Hz, 1H, BnCH2), 3.32 (dd, J = 15.2, 4.7 Hz, 1H, 
CH2-N), 3.10 (dd, J = 15.2, 5.9 Hz, 1H, CH2-N), 2.85 – 2.82 (m, 1H, CH-O), 2.55 (appt, J = 4.4 
Hz, 1H, CH2-O), 2.44 (s, 3H, TsCH3), 2.22 (dd, J = 4.8, 2.6 Hz, 1H, CH2-O) ppm. 13C NMR (125 
MHz, CDCl3): δ 143.5 (QC, TsC), 136.8 (QC, ArC), 136.0 (QC, NsC), 129.8 (CH, 2´TsCH), 
128.5 (CH, 2´ArCH), 128.5 (CH, 2´ArCH), 127.9 (CH, ArCH), 127.2 (CH, 2´TsCH), 52.4 (CH2, 
BnCH2), 50.0 (CH, CH-O), 49.9 (CH2, CH2-O), 45.5 (CH2, CH2-N), 21.4 (CH3, TsCH3) ppm.  
 
N-propargyl-2-(tosylamino)methyl oxirane (25c):  
 
NMR data suggested no further purification was required. Obtained as a colourless oil (98%). 1H 
NMR (500 MHz, CDCl3): δ 7.73 (d, J = 8.3 Hz, 2H, TsCH), 7.30 (d, J = 8.0 Hz, 2H, TsCH), 4.24 
(d, J = 2.6 Hz, 2H, ≡C-CH2), 3.53 (dd, J = 14.7, 3.8 Hz, 1H, CH2-N), 3.24 (dd, J = 14.7, 5.8 Hz, 
1H, CH2-N), 3.16 – 3.13 (m, 1H, CH-O), 2.79 (app. t, J = 4.4 Hz, 1H, CH2-O), 2.62 (dd, J = 4.8, 
2.6 Hz, 1H, CH2-O), 2.42 (s, 3H, TsCH3), 2.06 (t, J = 2.5 Hz, 1H, ≡CH) ppm. 13C NMR (125 
MHz, CDCl3): δ 143.7 (QC, TsC), 135.5 (QC, TsC), 129.5 (CH, 2´TsCH), 127.5 (QC, 2´TsCH), 
76.5 (QC, ≡C), 73.9 (d, J = 4.1 Hz, CH, ≡CH), 50.3 (CH, CH-O), 48.2 (CH2, CH2-N), 44.8 (CH2, 
CH2-O), 37.8 (CH2, ≡C-CH2), 21.4 (d, J = 3.1 Hz, CH3, TsCH3) ppm. The NMR data match that 
previously reported,73 however splitting of the signals arising from the propargyl and methyl 
protons was not observed in the literature.  
 
Synthesis of 2-benzylidenemalononitrile (37b):  
 
To a solution of malononitrile (0.663 g, 10.03 mmol, 1.0 equiv.) in EtOH (5 mL) was added 
benzaldehyde (1.0 mL, 9.80 mmol, 1.0 equiv.), followed by NaOH (5 drops of an aqueous 1 M 
solution). The reaction was stirred at room temperature under a nitrogen atmosphere for 2.5 hours. 
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Upon collection of the precipitated product by filtration and washing with cold EtOH, NMR 
analysis suggested no further purification was required. Off-white solid, 74%.  
 
1H NMR (400 MHz, CDCl3): δ 7.91 (d, J = 7.4 Hz, 2H, ArCH), 7.78 (s, 1H, =CH), 7.64 (t, J = 
7.4 Hz, 1H, ArCH), 7.55 (app. t, J = 7.6 Hz, 2H, ArCH) ppm. 13C NMR (100 MHz, CDCl3): δ 
159.9 (CH, =CH), 134.6 (CH, ArCH), 130.9 (QC, ArC), 130.7 (CH, 2´ArCH), 129.6 (CH, 
2´ArCH), 113.7 (QC, C≡N), 112.5 (QC, C≡N), 82.9 (QC, =C(CN)2) ppm. The NMR data match 
that provided by commercial suppliers such as Sigma Aldrich. 
 
Isolation of N,N'-((3S,4E,8E,10S)-2,11-dimethyl-6,7-dimethylenedodeca-4,8-diene-3,10-
diyl)bis(4-methylbenzenesulfonamide) (43): 
 
A 25 mL Schlenk flask was charged with Pd2dba3×CHCl3 (6.2 mg, 6.0 μmol, 10 mol%), P(p-tolyl)3 
(3.8 mg, 12.5 μmol, 20 mol%) and benzylidenemalononitrile (11.1 mg, 72.00 μmol, 1.2 equiv.) 
and backfilled with nitrogen gas. Toluene (1 mL) was added and the solution stirred, before the 
addition of the 5-allenyloxazolidinone (21.0 mg, 59.6 μmol, 1.0 equiv.) under nitrogen gas. The 
reaction was stirred at room temperature and gradually heated to 80 °C over the first 6 hours with 
monitoring via TLC analysis, then stirred for a further 22 hours at 80 °C. The reaction mixture 
was passed through a short silica plug and eluted with acetone, and the solvents removed in vacuo 
to give the crude material. Upon column chromatography (EtOAc/hexane, 40:60), the dendraline 
dimer was isolated as a yellow gum (4.3 mg, 7.0 μmol, 23%, Rf = 0.23, EtOAc/hexane, 30:70). 
The yield was treated as approximately 20%, due to the presence of inseparable impurities 
showing signals in the aryl region of the 1H NMR spectrum. For this reason, full characterisation 
of the dimer has not been reported using this sample. The dimer was obtained again during the 
synthesis of the o-nitrophenyl substituted 1,3-diene 52f and its full characterisation as a mixture 
with 52f is reported in Section 2.4.4.  
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2.4.3 Synthesis of 5-Allenyloxazolidinone Starting Materials 
 
General procedure for the reduction of L-α-amino esters to L-α-amino alcohols: 
 
 
 
To an oven-dried Schlenk flask was added LiAlH4 (2.0 equiv.) and the vessel cooled to 0°C, 
before THF was added. To the resulting solution was added the L-α-amino ester (1.0 equiv.) 
dropwise as a solution in THF and the reaction stirred at 0 °C for 2 hours, or until the ester could 
no longer be detected via TLC analysis. A Fieser workup was employed, in which the reaction 
was diluted with Et2O and quenched by adding H2O (1 mL/g of LiAlH4) dropwise at 0°C, 
followed by an aqueous 15 % wt. solution of NaOH (1 mL/g of LiAlH4), then further H2O (3 
mL/g of LiAlH4). MgSO4 was then added and the mixture stirred before filtration of the resulting 
white solid. The filtrate was washed with brine and the organic layer extracted with EtOAc, dried 
with MgSO4 and concentrated in vacuo. The crude residue was subjected to column 
chromatography to give the pure L-α-amino alcohol.  
 
L-α-N-Boc-valinol (55a): 
 
L-α-amino ester (2.7 M in THF) added to 1.3 M solution of LiAlH4 in THF. Eluent: EtOAc/hexane 
(40:60). Colourless oil, 92%. 1H NMR (400 MHz, CDCl3): δ 4.72 (d, J = 8.1 Hz, 1H, NH), 3.69 
– 3.65 (m, 1H, CH2), 3.58 (dd, J = 10.8, 6.4 Hz, 1H, CH2), 3.41 (br. s, 1H, CH-N), 2.70 (br. s, 
1H, OH), 1.82 (app. sext, J = 6.5 Hz, 1H, i-PrCH), 1.43 (s, 9H, t-BuCH3), 0.92 (app. dd, J = 8.6, 
6.8 Hz, 6H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 156.8 (QC, CO), 79.5 (QC, t-BuC), 
64.1 (CH2, CH2), 58.0 (CH, CH-N), 29.3 (CH, i-PrCH), 28.3 (CH3, 3´t-BuCH3), 19.5 (CH3, i-
PrCH3), 18.5 (CH3, i-PrCH3) ppm. The NMR data match that previously reported.74 
 
L-α-N-Boc-alaninol (55b): 
 
L-α-amino ester (2.8 M in THF) added to 5.6 M solution of LiAlH4 in THF. A Fieser workup was 
not employed in this case. The reaction was quenched with ice and the resulting gel filtered. The 
filtrate was washed with brine and the organic layer extracted with EtOAc before drying with 
MgSO4 and concentration in vacuo to give the crude product, which was purified via column 
chromatography. Eluent: EtOAc/hexane (50:50). White solid, 39%. 1H NMR (500 MHz, CDCl3): 
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δ 4.68 (br. s, 1H, NH), 3.76 (br. s, 1H,CH-N), 3.62 (dd, J = 10.9, 3.4 Hz, 1H, CH2), 3.49 (dd, J = 
10.8, 6.2 Hz, 2H, CH2), 1.44 (s, 9H, t-BuCH3), 1.14 (d, J = 6.8 Hz, 3H, Me) ppm. 13C NMR (125 
MHz, CDCl3): δ 156.1 (QC, CO), 79.3 (QC, t-BuC), 66.3 (CH2, CH2), 48.2 (CH, CH-N), 28.2 
(CH3, 3´t-BuCH3), 17.1 (CH3, Me) ppm. The NMR data match that previously reported.74 
 
L-α-N-Boc-leucinol (55c): 
 
L-α-amino ester (2.0 M in THF) added to 4.1 M solution of LiAlH4 in THF. Eluent: EtOAc/hexane 
(40:60). Colourless oil, 95%. 1H NMR (500 MHz, CDCl3): δ 4.58 (br. s, 1H, NH), 3.70 (br. s, 
1H, CH-N), 3.65 (d, J = 10.6 Hz, 1H, CH2), 3.49 (dd, J = 9.8, 6.0 Hz, 1H, CH2), 2.60 (br. s, 1H, 
OH), 1.70 – 1.62 (m, 1H, i-BuCH), 1.44 (s, 9H, t-BuCH3), 1.32 – 1.29 (m, 2H, i-BuCH2), 0.92 
(d, J = 6.5 Hz, 6H, i-BuCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 156.6 (QC, CO), 79.6 (QC, 
t-BuC), 66.6 (CH2, CH2), 51.0 (CH, CH-N), 40.5 (CH2, i-BuCH2), 28.4 (CH3, 3´t-BuCH3), 24.8 
(CH, i-BuCH), 23.0 (CH3, i-BuCH3), 22.2 (CH3, i-BuCH3) ppm. The NMR data match that 
previously reported.74 
 
L-α-N-Boc-phenylalaninol (55d): 
 
L-α-amino ester (0.5 M in THF) added to 1.5 M solution of LiAlH4 in THF. Eluent: EtOAc/hexane 
(60:40). White solid, 77%. 1H NMR (500 MHz, CDCl3): δ 7.31 – 7.28 (m, 2H, ArCH), 7.25 – 
7.17 (m, 3H, ArCH), 4.78 (d, J = 7.6 Hz, 1H, NH), 3.87 (br. s, 1H, CH-N), 3.66 (m, 1H, CH2), 
3.54 (m, 1H, CH2), 2.84 (d, J = 7.0 Hz, 2H, BnCH2), 2.50 (br. s, 1H, OH), 1.41 (s, 3H, t-BuCH3) 
ppm. 13C NMR (125 MHz, CDCl3): δ 156.2 (QC, CO), 137.8 (QC, ArC), 129.3 (CH, 2´ArCH), 
128.5 (CH, 3´ArCH), 126.5 (CH, ArCH), 79.7 (QC, t-BuC), 64.3 (CH2, CH2),  53.7 (CH, CH-
N), 37.4 (CH2, BnCH2), 28.3 (3´t-BuCH3) ppm. The NMR data match that previously reported.74 
 
General procedure for the oxidation of  L-α-amino alcohols to of  L-α-amino aldehydes:17 
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To a solution of the L-α-amino alcohol in CH2Cl2 (1.0 equiv., typically approximately 0.1 M) was 
added a saturated aqueous solution of NaHCO3 (0.5 mL/mL of CH2Cl2). The mixture was cooled 
to 0 °C and KBr (1.0 equiv.) added, followed by TEMPO (5 mol%). The resulting suspension 
was stirred vigorously and NaOCl (1.2 equiv. of a commercial grade 0.5 M aqueous solution) was 
added dropwise over 30 minutes at 0 °C. The suspension was stirred for an additional 15 minutes 
after the addition was complete, before quenching with a saturated aqueous solution of Na2S2O3 
(0.5 mL/mL of CH2Cl2). The organic layer was extracted with CH2Cl2 and dried with MgSO4 
before filtration and concentration in vacuo to give the L-α-amino aldehyde, which was used 
without further purification. 
 
L-α-N-Boc-valinal (26a): 
 
Orange oil, 78%. 1H NMR (400 MHz, CDCl3): δ 9.65 (s, 1H, CHO), 5.08 (br. s, 1H, NH), 4.25 
(br. s, 1H, CH-N), 2.33 – 2.25 (m, 1H, i-PrCH), 1.45 (s, 9H, t-BuCH3), 1.03 (d, J = 6.9 Hz, 3H, 
i-PrCH3), 0.95 (d, J = 7.0 Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 200.2 (CH, 
CHO), 155.7 (QC, CO), 79.8 (QC, t-BuC), 64.5 (CH, CH-N), 28.9 (CH, i-PrCH), 28.1 (CH3, 3´t-
BuCH3), 18.9 (CH3, i-PrCH3), 17.4 (CH3, i-PrCH3) ppm. The NMR data match that previously 
reported.75 
 
L-α-N-Boc-alaninal (26b): 
 
Pale yellow solid, 50% (80% conversion). Mixture of L-α-amino aldehyde and unreacted alcohol 
used without further purification. 1H NMR (500 MHz, CDCl3): δ 9.48 (s, 1H, CHO), 5.25 (br. s, 
1H, NH), 4.15 (br. s, 1H, CH-N), 1.39 (s, 9H, t-BuCH3), 1.27 (d, J = 7.3 Hz, 3H, Me) ppm. 13C 
NMR (125 MHz, CDCl3): δ 199.9 (CH, CHO), 155.3 (QC, CO), 79.9 (QC, t-BuC), 55.3 (CH, 
CH-N), 28.2 (CH3, 3´t-BuCH3), 14.6 (CH3, Me) ppm. The NMR data match that previously 
reported.75 
 
L-α-N-Boc-leucinal (26c): 
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Orange oil, 83%. 1H NMR (500 MHz, CDCl3): δ 9.61 (s, 1H, CHO), 5.07 (br. s, 1H, NH), 4.27 
(br. s, 1H, CH-N), 1.80 (br. s, 1H, i-BuCH), 1.69 (br. s, 1H, i-BuCH2), 1.47 (s, 1H, i-BuCH2 and 
9H, t-BuCH3), 0.99 (d, J = 6.5 Hz, 6H, i-BuCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 199.1 
(CH, CHO), 154.1 (QC, CO), 78.3 (QC, t-BuC), 56.8 (CH, CH-N), 36.6 (CH2, i-BuCH2), 26.7 
(CH3, 3´t-BuCH3), 23.1 (CH, i-BuCH), 21.5 (CH3, i-BuCH3), 20.3 (CH3, i-BuCH3) ppm. The 
NMR data match that previously reported.75 
 
L-α-N-Boc-phenylalaninal (26d): 
 
Off-white solid, 97%. 1H NMR (400 MHz, CDCl3): δ 9.59 (s, 1H, CHO), 7.42 – 7.00 (m, 5H, 
ArCH), 5.18 (d, J = 6.9 Hz, 1H, NH), 4.38 (d, J = 6.6 Hz, 1H, CH-N), 3.14 – 3.03 (m, 2H, BnCH2), 
1.42 (s, 9H, t-BuCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 199.5 (CH, CHO), 155.5 (QC, CO), 
136.0 (QC, ArC), 129.4 (CH, 2´ArCH), 128.7 (CH, 2´ArCH), 127.0 (CH, ArCH), 80.1 (QC, t-
BuC), 60.8 (CH, CH-N), 35.4 (CH2, BnCH2), 28.3 (CH3, 3´t-BuCH3) ppm. The NMR data match 
that previously reported.75 
 
2-Step synthesis of (4S,5S)-4-isopropyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (28a): 
 
In order to reduce the scale of the reaction to maintain an acceptable diastereoisomeric ratio, a 
solution of L-N-Boc-valinal (1.88 g, 9.35 mmol, 1.0 equiv.) in toluene (9 mL) was divided into 
3´3mL aliquots (0.63 g, 3.12 mmol each) and distributed equally into 3 oven-dried reaction 
vessels under nitrogen gas and the vessels cooled to -10 °C with stirring. To each was added 
pinacol allenylboronate (0.62 mL, 3.43 mmol, 1.1 equiv.), followed by Et2Zn (0.22 mmol of a 
15% wt. solution in toluene, 7 mol%) dropwise at -10 °C. The homogenous solutions were 
transferred to a refrigerator and left at approximately 0 °C overnight. After 20 hours, the reactions 
were warmed to room temperature and diethanolamine (0.56 mL, 5.80 mmol, 2.0 equiv.) was 
added to each and the mixtures stirred for 1 hour at room temperature. Each organic layer was 
washed with brine and extracted with EtOAc, before drying with MgSO4, filtration and 
concentration in vacuo to give the crude products. These were combined and subjected to column 
chromatography (Et2O/hexane, 50:50) to give the allenyl alcohol as a deep brown oil (Rf = 0.30, 
Et2O/hexane, 50:50). The allenyl alcohol was dissolved in THF (15 mL) in an oven-dried Schlenk 
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flask and cooled to 0 °C with stirring, before NaH (60% dispersion in mineral oil, 0.623 g, 2.0 
equiv.) was added in one portion. The reaction was warmed to room temperature and stirred for 
2 hours, after which an additional portion of NaH (0.5 equiv.) was added for the reaction to 
proceed to completion. After a further 3 hours, the reaction was cooled to 0 °C and quenched with 
a saturated aqueous solution of NH4Cl. The organic layer washed with brine and extracted with 
CH2Cl2 before drying with MgSO4, filtration and concentration in vacuo to give the crude 
allenyloxazolidinone, which was subjected to column chromatography (acetone/pentane, 20:80) 
to give the pure allenyloxazolidinone as a yellow oil (0.858 g, 5.13 mmol, 55 %, 3.3:1 dr).  
 
1H NMR (500 MHz, CDCl3): δ 6.97 (s, 1H, NH, major), 6.89 (s, 1H, NH, minor), 5.34 (app. q, J 
= 6.7 Hz, 1H, =CH, major), 5.31 (app. dt, J = 8.9, 6.6 Hz, 1H, =CH, minor), 5.04 (app. ddt, J = 
8.7, 7.7, 1.1 Hz, 1H, CH-O, minor), 4.99 – 4.87 (m, 2H, =CH2, minor), 4.95 (ddd, J = 6.5, 3.0, 
1.9 Hz, 1H, =CH2, major), 4.72 (app. ddt, J = 7.3, 5.5, 1.9 Hz, 1H, CH-O, major), 3.60 (app. t, J 
= 8.0 Hz, 1H, CH-N, minor), 3.43 (ddd, J = 6.7, 5.4, 1.1 Hz, 1H, CH-N, major), 1.91 – 1.83 (m, 
1H, i-PrCH, minor), 1.74 (app. oct, J = 6.7 Hz, 1H, i-PrCH, major), 0.99 (d, J = 6.6 Hz, 3H, i-
PrCH3, minor), 0.94 (d, J = 6.7 Hz, 3H, i-PrCH3, major), 0.90 (d, J = 6.8 Hz, 3H, i-PrCH3, major), 
0.88 (d, J = 6.7 Hz, 3H, i-PrCH3, minor) ppm. 13C NMR (125 MHz, CDCl3): δ 209.8 (QC, =C=, 
minor), 208.7 (QC, =C=, major), 160.0 (QC, CO, minor), 159.3 (QC, CO, major), 90.4 (CH, 
=CH, major), 85.7 (CH, =CH, minor), 78.8 (CH, CH-O, minor), 78.6 (CH2, =CH2, major), 78.0 
(CH, CH-O, major), 77.4 (CH2, =CH2, minor), 63.5 (CH, CH-N, major), 62.6 (CH, CH-N, minor), 
32.3 (CH, i-PrCH, major), 28.7 (CH, i-PrCH, minor), 19.2 (CH3, i-PrCH3, minor), 19.0 (CH3, i-
PrCH3, minor), 17.9 (CH3, i-PrCH3, major), 17.8 (CH3, i-PrCH3, major) ppm. The NMR data 
match that previously reported.17  
 
2-Step synthesis of (4S,5S)-4-methyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (28b): 
 
A solution of L-N-Boc-alaninal (0.526 g, 3.04 mmol, 1.0 equiv.) in toluene (8 mL) in an oven-
dried Schlenk flask was cooled to 0 °C with stirring. To this was added pinacol allenylboronate 
(0.65 mL, 3.62 mmol, 1.1 equiv.), followed by Et2Zn (0.33 mmol of a 1.0 M solution in hexane, 
10 mol%) dropwise at 0 °C. The homogenous solution was stirred at 0 °C for 5 minutes before 
being transferred to a refrigerator to be left at approximately 0 °C overnight. After 20 hours, the 
reaction was quenched with a saturated aqueous solution of NH4Cl at 0 °C and warmed to room 
temperature before washing with saturated aqueous NaHCO3 and drying with Na2SO4, before 
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filtration and concentration in vacuo to give the crude product, which was subjected to column 
chromatography (EtOAc/hexane, 30:70) to give the allenyl alcohol as a yellow oil (Rf = 0.25, 
EtOAc/hexane, 30:70). The allenyl alcohol was dissolved in THF (6 mL) in an oven-dried 
Schlenk flask and cooled to 0 °C with stirring, before NaH (60% dispersion in mineral oil, 0.165 
g, 4.13 mmol, 2.0 equiv.) was added in one portion. The reaction was warmed to room 
temperature and stirred for 2 hours, after which an additional portion of NaH (1.0 equiv.) was 
added for the reaction to proceed to completion. After a further 5 hours, the reaction was cooled 
to 0 °C and quenched with a saturated aqueous solution of NH4Cl. The organic layer was washed 
with brine and extracted with CH2Cl2, dried with MgSO4, filtered and the filtrate concentrated in 
vacuo to give the crude product (2.6:1 dr). The trans isomer of the allenyl oxazolidinone was 
isolated via column chromatography (CH2Cl2/Et2O, 2:98) as a colourless oil (0.156 g, 1.12 mmol, 
37%, > 99:1 dr).  
 
1H NMR (500 MHz, CDCl3): δ 6.68 (s, 1H, NH), 5.30 (app. q, J = 6.7 Hz, 1H, =CH), 5.03 – 4.85 
(m, 2H, =CH2), 4.52 (app. tt, J = 7.0, 1.8 Hz, 1H, CH-O), 3.76 (app. p, J = 6.3 Hz, 1H, CH-N), 
1.26 (d, J = 6.3 Hz, 3H, Me) ppm. 13C NMR (125 MHz, CDCl3): δ 208.9 (QC, =C=), 159.1 (QC, 
CO), 88.8 (CH, =CH), 81.4 (CH, CH-O), 78.3 (CH2, =CH2), 53.8 (CH, CH-N), 19.7 (CH3, Me) 
ppm. The NMR data match that previously reported.17 
 
2-Step synthesis of (4S,5S)-4-isobutyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (28c): 
 
A solution of L-N-Boc-leucinal (0.205 g, 0.95 mmol, 1.0 equiv.) in toluene (2.6 mL) in an oven-
dried Schlenk flask was cooled to 0 °C with stirring. To this was added pinacol allenylboronate 
(0.19 mL, 1.05 mmol, 1.1 equiv.), followed by i-Pr2Zn (0.10 mmol of a 1.0M solution in toluene, 
10 mol%) dropwise at 0 °C. The homogenous solution was stirred at 0 °C for 3 hours before being 
transferred to a refrigerator to be left at approximately 0 °C overnight. After 18 hours, the reaction 
was quenched with a saturated aqueous solution of NH4Cl at 0 °C and warmed to room 
temperature before washing with saturated aqueous NaHCO3, extracting with EtOAc and drying 
with Na2SO4, then filtration and concentration in vacuo to give the crude product, which was 
subjected to column chromatography (EtOAc/hexane, 20:80) to give the allenyl alcohol as an 
orange oil (Rf = 0.31, EtOAc/hexane, 20:80). The allenyl alcohol was dissolved in THF (2 mL) 
in an oven-dried Schlenk flask and cooled to 0 °C with stirring, before NaH (60% dispersion in 
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mineral oil, 64.7 mg, 1.61 mmol, 2.0 equiv.) was added in one portion. The reaction was warmed 
to room temperature and stirred for 1 hour before cooling to 0 °C and quenching with a saturated 
aqueous solution of NH4Cl. The organic layer was washed with brine and extracted with CH2Cl2, 
dried with MgSO4, filtered and the filtrate concentrated in vacuo to give the crude product. This 
was subjected to column chromatography (acetone/pentane, 20:80) to give the pure 
allenyloxazolidinone as a colourless oil (0.102 g, 0.60 mmol, 63%, 4.7:1 dr). 
 
1H NMR (400 MHz, CDCl3): δ 7.12 (br. s, 1H, NH, major and minor), 5.30 (app. q, J = 6.7 Hz, 
1H, =CH, major), 5.21 (app. dt, J = 8.8, 6.5 Hz, 1H, =CH, minor), 5.04 (app. t, J = 8.9 Hz, 1H, 
CH-O, minor), 4.97 – 4.83 (m, 2H, =CH2, minor), 4.93 (app. dt, J = 6.5, 2.0 Hz, 2H, =CH2, major), 
4.56 (app. tt, J = 6.7, 1.9 Hz, 1H, CH-O, major), 3.99 – 3.93 (m, 1H, CH-N, minor), 3.73 – 3.68 
(m, 1H, CH-N, major), 1.71 – 1.57 (m, 1H, i-BuCH, major and minor), 1.52 – 1.21 (m, 2H, i-
BuCH2, major and minor), 0.92 – 0.86 (m, 6H, i-BuCH3, major and minor) ppm. 13C NMR (100 
MHz, CDCl3): δ 209.5 (QC, =C=, minor), 208.8 (QC, =C=, major), 159.6 (QC, CO, minor), 159.4 
(QC, CO, major), 89.3 (CH, =CH, major), 86.0 (CH, =CH, minor), 80.2 (CH, CH-O, major), 78.6 
(CH, CH-O, minor), 78.3 (CH2, =CH2, major), 77.3 (CH2, =CH2, minor), 56.3 (CH, CH-N, 
major), 54.0 (CH, CH-N, minor), 43.8 (CH2, i-BuCH2, major), 39.6 (CH2, i-BuCH2, minor), 24.7 
(CH, i-BuCH, major and minor), 23.4 (CH3, i-BuCH3, minor), 22.8 (CH3, i-BuCH3, major), 21.9 
(CH3, i-BuCH3, major), 21.3 (CH3, i-BuCH3, minor) ppm. The NMR data match that previously 
reported.17 
 
2-Step synthesis of (4S,5S)-4-benzyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (28d): 
 
A solution of L-N-Boc-phenylalaninal (0.418 g, 1.68 mmol, 1 equiv.) in toluene (5 mL) in an 
oven-dried Schlenk flask was cooled to -10 °C with stirring. To this was added pinacol 
allenylboronate (0.33 mL, 1.84 mmol, 1.1 equiv.), followed by i-Pr2Zn (0.13 mmol of a 1.0 M 
solution in toluene, 7.5 mol%) dropwise at -10 °C. The homogenous solution was stirred at -10 
°C for 1.5 hours before being transferred to a refrigerator to be left at approximately 0 °C 
overnight. After 20 hours, the reaction was warmed to room temperature and diethanolamine 
(0.30 mL, 3.1 mmol, 2.0 equiv.) was added and the mixture stirred for 1 hour at room temperature. 
The organic layer was washed with brine and extracted with EtOAc, before drying with MgSO4, 
filtration and concentration in vacuo to give the crude product. This was subjected to column 
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chromatography (EtOAc/hexane, 30:70) to give the allenyl alcohol as a white solid (Rf = 0.30, 
EtOAc/hexane, 30:70). The allenyl alcohol was dissolved in THF (4 mL) in an oven-dried 
Schlenk flask and cooled to 0 °C with stirring, before NaH (60% dispersion in mineral oil, 0.131 
g, 3.26 mmol, 2.0 equiv.) was added in one portion. The reaction was warmed to room 
temperature and stirred for 2.5 hours, after which an additional portion of NaH (1.0 equiv.) was 
added for the reaction to proceed to completion. After a further 2 hours, the reaction was cooled 
to 0 °C and quenched with a saturated aqueous solution of NH4Cl. The organic layer was washed 
with brine and extracted with CH2Cl2, dried with MgSO4, filtered and the filtrate concentrated in 
vacuo to give the crude product. This was subjected to column chromatography (acetone/pentane, 
20:80) to give the pure allenyloxazolidinone as a yellow oil (0.122 g, 0.57 mmol, 34%, 2.9:1 dr). 
 
1H NMR (500 MHz, CDCl3): δ 7.33 – 7.16 (m, 5H, ArH, major and minor), 6.29 (s, 1H, NH, 
major), 5.74 (s, 1H, NH, minor), 5.36 (app. dt, J = 8.6, 6.6 Hz, 1H, =CH, minor), 5.25 (app. q, J 
= 6.7 Hz, 1H, =CH, major), 5.14 (app. ddt, J = 8.9, 7.7, 1.4 Hz, 1H, CH-O, minor), 5.01 – 4.84 
(m, 2H, =CH2, major and minor), 4.73 (app. ddt, J = 6.8, 5.9, 2.0 Hz, 1H, CH-O, major), 4.15 – 
4.11 (m, 1H, CH-N, minor), 3.93 – 3.89 (m, 1H, CH-N, major), 2.91 (dd, J = 13.7, 4.6 Hz, 1H, 
BnCH2, minor), 2.88 (d, J = 6.8 Hz, 2H, BnCH2, major), 2.73 (dd, J = 13.7, 10.1 Hz, 1H, BnCH2, 
minor) ppm. 13C NMR (125 MHz, CDCl3): δ 209.6 (QC, =C=, minor), 208.6 (QC, =C=, major), 
158.5 (QC, CO, major), 158.4 (QC, CO, minor), 136.6 (QC, ArC, minor), 135.7 (QC, ArC, 
major), 129.1 (CH, 2´ArCH, major), 128.8 (CH, 2´ArCH, minor), 128.7 (CH, 2´ArCH, major 
and minor), 127.01 (CH, ArCH, major), 126.96 (CH, ArCH, minor), 89.1 (CH, =CH, major), 
85.9 (CH, =CH, minor), 78.9 (CH, CH-O, major), 78.4 (CH2, =CH2, major), 78.0 (CH, CH-O, 
minor), 77.7 (CH2, =CH2, minor), 59.0 (CH, CH-N, major), 57.2 (CH, CH-N, minor), 40.6 (CH2, 
BnCH2, major), 37.2 (CH2, BnCH2, minor) ppm. The NMR data match that previously reported.17 
 
General procedure for the N-nosylation of 5-allenyloxazolidinones: 
 
A solution of the allenyloxazolidinone in THF (typically approximately 0.2 M) was cooled to 0 
°C with stirring, before NaH (60% dispersion in mineral oil, 2.0 equiv.) was added portionwise. 
After 15 minutes, nosyl chloride (1.5 equiv.) was added portionwise at 0 °C and the reaction 
warmed to room temperature and stirred for 2 hours, or until the allenyloxazolidinone could no 
longer be detected via TLC analysis. The reaction was quenched with a saturated aqueous solution 
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of NH4Cl and extracted with EtOAc before drying with MgSO4, filtration and concentration in 
vacuo to give the crude product, which was purified via column chromatography.  
 
(4S,5S)-4-isopropyl-3-((4-nitrophenyl)sulfonyl)-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (41a): 
 
Eluent: MeOH/CH2Cl2 (2:98). Yellow solid, 95%, 2.8:1 dr. The trans diastereoisomer was 
isolated via selective recrystallization in CH2Cl2 layered with hexane (white crystals, 54%, > 99:1 
dr). The enantiopurity was determined via chiral HPLC using a Daicel CHIRALPAK IA-U 
column, hexane/isopropanol (95:5), 0.2 mL/min, 40 °C, 254 nm, single peak, tR = 24.91 min, > 
99% ee. The racemic analogue, prepared from racemic N-Boc-valinal, gave two peaks (tR = 21.71, 
24.08 min, 1:1) under the same conditions. 
 
[α]D
22 +41.4 (c 2.99, CHCl3).   Mp 125.9 – 130.9 °C. HRMS-ESI (m/z): [M+Na]+ calcd for 
C15H16N2O6SNa, 375.0621; found, 375.0625. FTIR v!max (cm-1): 3112 (w, C=CH), 2962 – 2935 
(w), 2878 (w), 1955 (w), 1767 (s, CO), 1379 (s), 1352 (s), 1179 (s), 1128 (s), 1011 (s), 855 (s), 
745 (s), 737 (s), 615 (vs). 1H NMR (400 MHz, CDCl3): δ 8.40 (d, J = 9.0 Hz, 2H, NsCH), 8.28 
(d, J = 9.1 Hz, 2H, NsCH), 5.30 (app. q, J = 6.6 Hz, 1H, =CH), 5.04 (app. t, J = 2.3 Hz, 1H, 
=CH2), 5.02 (dd, J = 2.4, 1.7 Hz, 1H, =CH2), 4.79 – 4.76 (m, 1H, CH-O), 4.35 (dd, J = 3.9, 2.5 
Hz, 1H, CH-N), 2.49 – 2.37 (m, 1H, i-PrCH), 0.97 (d, J = 7.0 Hz, 3H, i-PrCH3), 0.82 (d, J = 6.9 
Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 207.9 (QC, =C=), 151.3 (QC, CO), 151.0 
(QC, NsC), 143.3 (QC, NsC), 129.9 (CH, 2´NsCH), 124.2 (CH, 2´NsCH), 89.8 (CH, =CH), 80.3 
(CH2, =CH2), 72.9 (CH, CH-O), 66.6 (CH, CH-N), 30.4 (CH, i-PrCH), 17.5 (CH3, i-PrCH3), 14.8 
(CH3, i-PrCH3) ppm. A crystal structure for this compound was obtained (CCDC 1919153).  
 
(4S,5S)-4-methyl-3-((4-nitrophenyl)sulfonyl)-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (41b): 
 
Eluent: EtOAc/hexane (40:60). White crystals, 58%, > 99:1 dr. [α]D
23 +1.6 (c 1.10, CHCl3). Mp 
98.9 – 101.5 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C13H12N2O6SNa, 347.0308; found, 
347.0306. FTIR v!max (cm-1): 3104 (w, C=CH), 3068 (w), 3029 (w), 2990 (w), 1948 (w), 1782 (s, 
CO), 1608 (w), 1535 (s), 1362 (s), 1348 (s), 1318 (m), 1287 (m), 1172 (s), 1132 (s), 1110 (s), 
1089 (s), 854 (s), 751 (s), 616 (vs). 1H NMR (400 MHz, CDCl3): δ 8.41 (d, J = 9.0 Hz, 2H, 
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NsCH), 8.27 (d, J = 9.1 Hz, 2H, NsCH), 5.30 – 5.25 (m, 1H, =CH), 5.04 (dd, J = 2.1, 1.5 Hz, 1H, 
=CH2), 5.03 (dd, J = 2.1, 1.0 Hz, 1H, =CH2), 4.59 (app. oct, 1H, CH-O), 4.42 (app. dq, J = 6.3, 
4.1 Hz, 1H, CH-N), 1.59 (d, J = 6.3 Hz, 3H, Me) ppm. 13C NMR (125 MHz, CDCl3): δ 208.6 
(QC, =C=), 150.96 (QC, CO), 150.94 (QC, NsC), 143.3 (QC, NsC), 129.9 (CH, 2´NsCH), 124.3 
(CH, 2´NsCH), 88.1 (CH, =CH), 80.0 (CH2, =CH2), 79.1 (CH, CH-O), 58.5 (CH, CH-N), 20.1 
(CH3, Me) ppm.  
 
(4S,5S)-4-isobutyl-3-((4-nitrophenyl)sulfonyl)-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (41c): 
 
Eluent: EtOAc/hexane (20:80). Colourless oil, 93%, 4.9:1 dr (after purification). HRMS-ESI 
(m/z): [M+Na]+ calcd for C16H18N2O6SNa, 389.0778; found, 389.0796. FTIR v!max (cm-1): 3108 
(w, C=CH), 2959 – 2872 (w), 1954 (w), 1776 (vs, CO), 1607 (w), 1531 (s), 1348 (s), 1172 (vs), 
1139 (s), 1090 (s), 855 (s), 736 (s), 613 (vs). 1H NMR (500 MHz, CDCl3): δ 8.40 (d, J = 8.8 Hz, 
2H, NsCH, major and minor), 8.29 – 8.26 (m, 2H, NsCH, major and minor), 5.29 (app. q, J = 6.4 
Hz, 1H, =CH, major), 5.21 (app. dt, J = 8.8, 6.5 Hz, 1H, =CH, minor), 5.10 (app. ddt, J = 8.4, 
6.9, 1.2 Hz, 1H, CH-O, minor), 5.05 – 4.96 (m, 2H, =CH2, minor), 5.03 (dd, J = 6.6, 2.4 Hz, 2H, 
=CH2, minor), 4.74 – 4.72 (m, 1H, CH-O, major), 4.56 – 4.52 (m, 1H, CH-N, minor), 4.42 (app. 
ddd, J = 10.7, 3.4, 2.4 Hz, 1H, CH-N, major), 1.93 – 1.87 (m, 1H, i-BuCH2, major), 1.81 – 1.76 
(m, 1H, i-BuCH2, minor), 1.72 – 1.61 (m, 2H, i-BuCH and i-BuCH2, major and minor), 1.02 (d, 
J = 6.2 Hz, 3H, i-BuCH3, minor), 1.00 (d, J = 6.5 Hz, 6H, i-BuCH3, major), 0.97 (d, J = 6.2 Hz, 
3H, i-BuCH3, minor) ppm. 13C NMR (125 MHz, CDCl3): δ 210.5 (CH, =C=, minor), 208.1 (CH, 
=C=, major), 151.2 (QC, CO, minor), 151.0 (QC, CO, major), 150.9 (QC, NsC, major and minor), 
143.6 (QC, NsC, minor), 143.5 (QC, NsC, major), 129.93 (CH, 2´NsCH, minor), 129.87 (CH, 
2´NsCH, major), 124.30 (CH, 2´NsCH, minor), 124.25 (CH, 2´NsCH, major), 89.2 (CH, =CH, 
major), 84.5 (CH, =CH, minor), 80.2 (CH2, =CH2, major), 78.5 (CH2, =CH2, minor), 78.2 (CH, 
CH-O, minor), 77.23 (CH, CH-O, major), 60.7 (CH, CH-N, major), 59.8 (CH, CH-N, minor), 
42.9 (CH2, i-BuCH2, major), 38.9 (CH2, i-BuCH2, minor), 24.9 (CH, i-BuCH, minor), 24.5 (CH, 
i-BuCH, major), 23.5 (CH3, i-BuCH3, major), 23.0 (CH3, i-BuCH3, minor), 21.7 (CH3, i-BuCH3, 
minor), 21.3 (CH3, i-BuCH3, major) ppm. 
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(4S,5S)-4-benzyl-3-((4-nitrophenyl)sulfonyl)-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (41d): 
 
34% conversion. Product was isolated via column chromatography (EtOAc/hexane, 30:70) and 
reclaimed starting material was resubjected to the reaction conditions and purified separately. 
Brown gum, combined yield 70%, 2.2:1 dr (after purification). HRMS-ESI (m/z): [M+Na]+ calcd 
for C13H12N2O6SNa, 423.0621; found, 423.0616. FTIR v!max (cm-1): 3107 (w, C=CH), 3069 – 2868 
(w), 1955 (w), 1772 (s, CO), 1605 (w), 1527 (s), 1381 (s), 1167 (vs), 1116 (s), 1089 (s), 855 (s), 
737 (s), 612 (vs). 1H NMR (500 MHz, CDCl3): δ 8.40 (d, J = 8.5 Hz, 2H, NsCH, major), 8.30 (d, 
J = 8.9 Hz, 2H, NsCH, minor), 8.27 (d, J = 8.5 Hz, 2H, NsCH, major), 8.09 (d, J = 8.5 Hz, 2H, 
NsCH, minor), 7.42 – 7.15 (m, 5H, ArH, major and minor), 5.22 – 5.14 (m, 2H, =CH and CH-O, 
minor), 5.09 (app. q, J = 6.4 Hz, 1H, =CH, major), 5.00 – 4.94 (m, 1H, CH-N, minor), 4.87 – 
4.80 (m, 2H, =CH2, major and minor), 4.76 – 4.74 (m, 1H, CH-O, major), 4.65 – 4.62 (m, 1H, 
CH-N, major), 3.48 (dd, J = 13.6, 4.0 Hz, 1H, BnCH2, major), 3.21 (dd, J = 14.7, 5.6 Hz, 1H, 
BnCH2, minor), 3.12 (dd, J = 14.6, 8.4 Hz, 1H, BnCH2, minor), 2.94 (dd, J = 13.6, 9.8 Hz, 1H, 
BnCH2, major) ppm. 13C NMR (125 MHz, CDCl3): δ 210.0 (QC, =C=, minor), 207.8 (QC, =C=, 
major), 151.3 (QC, CO, minor), 150.93 (QC, CO, major), 150.89 (QC, NsC, major), 150.7 (QC, 
NsC, minor), 143.4 (QC, NsC, minor), 143.2 (QC, NsC, major), 135.2 (QC, ArC, minor), 133.8 
(QC, ArC, major), 129.9 (CH, 2´NsCH, major), 129.7 (CH, 2´NsCH, minor), 129.4 (CH, 
2´ArCH, major and minor), 129.1 (CH, 2´ArCH, major), 128.7 (CH, 2´ArCH, minor), 127.7 
(CH, ArCH, major), 127.2 (CH, ArCH, minor), 124.3 (CH, 2´NsCH, major), 124.2 (CH, 
2´NsCH, minor), 88.8 (CH, =CH, major), 84.8 (CH, =CH, minor), 80.1 (CH2, =CH2, major), 
78.7 (CH2, =CH2, minor), 78.0 (CH, CH-O, minor), 75.8 (CH, CH-O, major), 62.5 (CH, CH-N, 
major), 61.9 (CH, CH-N, minor), 39.7 (CH2, BnCH2, major), 36.0 (CH2, BnCH2, minor) ppm. 
 
2.4.4 Divergent, Pd(0)-Catalysed Synthesis of Chiral 1,3-Dienes or 5-Vinyloxazolidinones From 
5-Allenyloxazolidinones 
 
General procedure for the synthesis of chiral 1,3-dienes: 
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A solution of the allenyloxazolidinone (1.0 equiv.), boronic acid (1.5 equiv.), Pd2dba3×CHCl3 (5 
mol%), tris(2,4-di-tert-butylphenyl) phosphite (10 mol%) and K2CO3  (1.5 equiv.) in toluene (0.06 
mM with respect to the allenyloxazolidinone) was stirred under a nitrogen atmosphere for 24 
hours at room temperature. The reaction was quenched with saturated aqueous NH4Cl and the 
organic layer extracted with CH2Cl2. This was dried with MgSO4 and concentrated in vacuo to 
give the crude product, which was purified via column chromatography (Et2O/hexane, 50:50, 
unless otherwise specified).  
 
(S,E)-N-(6-(4-methoxyphenyl)-2-methylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52a): 
 
Yellow solid, 74%, > 95:5 (E/Z). The enantiopurity was determined via chiral HPLC using a 
Daicel CHIRALPAK IA-U column, hexane/isopropanol (97:3), 0.2 mL/min, 40 °C, 254 nm, 
single peak, tR = 41.06 min, > 99% ee. The racemic analogue, prepared from racemic N-Boc-
valinal, gave two peaks (tR = 41.41, 44.63 min, 1:1) under the same conditions. Mp 85.5 – 89.4 
°C. [α]D
22 +16.8 (c 0.73, CHCl3). HRMS-ESI (m/z): [M-H]- calcd for C21H23N2O5S, 415.1333; 
found, 415.1342. FTIR v!max (cm-1): 3255 (w, NH), 2965 (w), 1607 (m), 1526 (s), 1509 (s), 1346 
(s), 1247 (s), 1166 (s), 1030 (s), 84 (s), 736 (vs). 1H NMR (500 MHz, CDCl3): δ 8.26 (d, J = 8.9 
Hz, 2H, NsCH), 7.96 (d, J = 8.9 Hz, 2H, NsCH), 6.92 (d, J = 8.8 Hz, 2H, ArCH), 6.78 (d, J = 8.8 
Hz, 2H, ArCH), 6.07 (d, J = 15.6 Hz, 1H, =CH), 5.12 (dd, J = 15.6, 8.2 Hz, 1H, =CH-CH-N), 
5.03 (d, J = 1.5 Hz, 1H, =CH2), 4.99 (s, 1H, =CH2), 4.68 (d, J = 8.4 Hz, 1H, NH), 3.80 (s, 3H, 
OMe), 3.79 – 3.70 (m, 1H, CH-N), 1.76 (app. oct, J = 6.7 Hz, 1H, i-PrCH), 0.93 (d, J = 6.8 Hz, 
3H, i-PrCH3), 0.88 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 159.2 (QC, 
ArC), 149.8 (QC, NsC), 147.0 (QC, NsC), 145.9 (QC, C=CH2), 134.6 (CH, =CH), 131.5 (QC, 
ArC) 129.4 (CH, =CH-CH-N), 128.9 (CH, 2´ArCH), 128.5 (CH, 2´NsCH), 124.1 (CH, 
2´NsCH), 116.9 (CH2, =CH2), 113.5 (CH, 2´ArCH), 62.3 (CH, CH-N), 55.2 (CH3, OMe), 33.2 
(CH, i-PrCH), 18.6 (CH3, i-PrCH3), 18.5 (CH3, i-PrCH3) ppm.  
 
(S,E)-N-(6-(3-methoxyphenyl)-2-methylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52b): 
 
Yellow gum, 62%, > 95:5 (E/Z). [α]D
23 +11.6 (c 1.77, CHCl3). HRMS-ESI (m/z): [M+Na]+ calcd 
for C21H24N2O5SNa, 439.1298; found, 439.1320. FTIR v!max (cm-1): 3295 (br., w, NH), 2963 – 
2874 (w), 1595 (w), 1527 (s), 1345 (vs), 1162 (s), 854 (m), 748 (s), 737 (s), 616 (s). 1H NMR 
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(400 MHz, CDCl3): δ 8.27 (d, J = 9.0 Hz, 2H, NsCH), 7.97 (d, J = 9.0 Hz, 2H, NsCH), 7.17 (app. 
t, J = 7.9 Hz, 1H, ArCH), 6.79 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H, ArCH), 6.57 (ddd, J = 7.6, 1.5, 1.1 
Hz, 1H, ArCH), 6.51 (dd, J = 2.5, 1.6 Hz, 1H, ArCH), 6.07 (d, J = 15.7 Hz, 1H, =CH), 5.16 (dd, 
J = 15.7, 8.2 Hz, 1H, =CH-CH-N), 5.08 (d, J = 1.5 Hz, 1H, =CH2), 5.05 (s, 1H, =CH2), 4.77 (d, 
J = 8.5 Hz, 1H, NH), 3.77 (s, 3H, OCH3), 3.79 – 3.72 (m, 1H, CH-N), 1.76 (app. oct, J = 6.7 Hz, 
1H, i-PrCH), 0.92 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.87 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR 
(100 MHz, CDCl3): δ 159.4 (QC, C-OMe), 149.9 (QC, NsC), 147.0 (QC, NsC), 146.3 (QC, 
C=CH2), 140.7 (QC, ArC), 134.1 (CH, =CH), 129.7 (CH, =CH-CH-N), 129.2 (CH, ArCH), 128.4 
(CH, 2´NsCH), 124.1 (CH, 2´NsCH), 120.2 (CH, ArCH), 117.6 (CH2, =CH2), 113.9 (CH, 
ArCH), 112.7 (CH, ArCH), 62.3 (CH, CH-N), 55.2 (CH3, OMe), 33.2 (CH, i-PrCH), 18.6 (CH3, 
i-PrCH3), 18.5 (CH3, i-PrCH3) ppm.  
 
(S,E)-N-(6-(2-methoxyphenyl)-2-methylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52c): 
 
Corresponding 5-vinyloxazolidinone obtained as major product (83%, > 95:5, E/Z). Yellow gum, 
32%, 90:10 (E/Z). [α]D
23 +6.8 (c 0.34, CHCl3). HRMS-ESI (m/z): [M-H]- calcd for C21H23N2O5S, 
415.1333; found, 415.1319. FTIR v!max (cm-1): 3284 (br., w, NH), 2962 – 2837 (w), 1605 (w), 
1528 (s), 1347 (s), 1163 (s), 854 (m), 748 (s), 737 (vs), 612 (s). 1H NMR (500 MHz, CDCl3): δ 
8.27 (d, J = 9.0 Hz, 2H, NsCH), 7.94 (d, J = 9.0 Hz, 2H, NsCH), 7.30 – 7.19 (m, 1H, ArCH), 6.87 
(td, J = 7.4, 1.0 Hz, 1H, ArCH), 6.83 (d, J = 8.3 Hz, 1H, ArCH), 6.78 (dd, J = 7.4, 1.8 Hz, 1H, 
ArCH),  6.01 (d, J = 15.6 Hz, 1H, =CH), 5.14 (d, J = 1.7 Hz, 1H, =CH2), 5.02 (d, J = 1.7 Hz, 1H, 
=CH2), 4.76 (dd, J = 15.5, 8.2 Hz, 1H, =CH-CH-N), 4.50 (d, J = 8.5 Hz, 1H, NH), 3.76 – 3.66 
(m, 1H, CH-N), 3.70 (s, 3H, OMe), 1.72 (app. oct, J = 6.8 Hz, 1H, i-PrCH), 0.90 (d, J = 6.8 Hz, 
3H, i-PrCH3), 0.84 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 156.3 (QC, 
ArC), 149.8 (QC, NsC), 147.0 (QC, NsC), 144.4 (QC, C=CH2), 134.0 (CH, =CH), 130.5 (CH, 
ArCH), 129.1 (CH, =CH-CH-N), 128.6 (CH, ArCH), 128.5 (CH, 2´NsCH), 128.3 (QC, ArC), 
124.1 (CH, 2´NsCH), 120.5 (CH, ArCH), 119.1 (CH2, =CH2), 110.6 (CH, ArCH), 62.1 (CH, CH-
N), 55.3 (CH3, OMe), 33.2 (CH, i-PrCH), 18.4 (CH3, i-PrCH3), 18.3 (CH3, i-PrCH3) ppm.  
 
(S,E)-N-(2-methyl-6-(4-nitrophenyl)hepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52d): 
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Yellow gum, 79%, 90:10 (E/Z). [α]D
22 +16.8 (c 0.73, CHCl3). HRMS-ESI (m/z): [M-H]- calcd for 
C20H20N3O6S, 430.1078; found, 430.1067. FTIR v!max (cm-1): 3298 (br., w, NH), 2964 – 2874 (w), 
1593 (w), 1516 (s), 1343 (vs), 1163 (m), 854 (m), 738 (vs), 616 (m). 1H NMR (400 MHz, CDCl3): 
δ 8.31 (d, J = 9.0 Hz, 2H, NsCH), 8.15 (d, J = 8.9 Hz, 2H, ArCH), 8.01 (d, J = 9.0 Hz, 2H, NsCH), 
7.23 (d, J = 8.9 Hz, 2H, ArCH), 6.17 (d, J = 15.8 Hz, 1H, =CH), 5.23 (s, 1H, =CH2), 5.19 (s, 1H, 
=CH2), 5.16 (dd, J = 15.8, 7.8 Hz, 1H, =CH-CH-N), 4.77 (d, J = 8.4 Hz, 1H, NH), 3.85 – 3.54 
(m, 1H, CH-N), 1.75 (app. oct, J = 6.7 Hz, 1H, i-PrCH), 0.89 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.84 
(d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 149.9 (QC, NsC), 147.4 (QC, 
ArC), 146.9 (QC, NsC), 146.0 (QC, C=CH2), 144.8 (QC, ArC), 133.1 (CH, =CH), 130.9 (CH, 
=CH-CH-N), 128.8 (CH, ArCH), 128.5 (CH, 2´NsCH), 124.1 (CH, 2´NsCH), 123.6 (CH, 
ArCH), 119.6 (CH2, =CH2), 62.0 (CH, CH-N), 33.1 (CH, i-PrCH), 18.6 (CH3, i-PrCH3), 18.4 
(CH3, i-PrCH3) ppm.  
 
(S,E)-N-(2-methyl-6-(3-nitrophenyl)hepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52e): 
 
Pale yellow gum, 80%, > 99:1 (E/Z). [α]D
23 –10.3 (c 4.03, CHCl3). HRMS-ESI (m/z): [M-H]- 
calcd for C20H20N3O6S, 430.1078; found, 430.1079. FTIR v!max (cm-1): 3287 (br., w, NH), 2964 – 
2874 (w), 1527 (s), 1347 (s), 1309 (m), 1161 (s), 854 (m), 748 (vs), 614 (s). 1H NMR (400 MHz, 
CDCl3): δ 8.31 (d, J = 9.0 Hz, 2H, NsCH), 8.13 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H, ArCH), 8.02 (d, J 
= 9.0 Hz, 2H, NsCH), 7.88 (app. t, J = 1.9 Hz, 1H, ArCH), 7.47 (app. t, J = 7.9 Hz, 1H, ArCH), 
7.38 (app. dt, J = 7.6, 1.3 Hz, 1H, ArCH), 6.17 (d, J = 15.8 Hz, 1H, =CH), 5.22 (s, 1H, =CH2), 
5.19 (s, 1H, =CH2), 5.15 (dd, J = 15.8, 7.9 Hz, 1H, =CH-CH-N), 4.87 (d, J = 8.5 Hz, 1H, NH), 
3.84 – 3.66 (m, 1H, CH-N), 1.75 (app. oct, J = 6.7 Hz, 1H, i-PrCH), 0.90 (d, J = 6.8 Hz, 3H, i-
PrCH3), 0.85 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 149.9 (QC, NsC), 
148.1 (QC, ArC), 146.9 (QC, NsC), 144.4 (QC, C=CH2), 140.9 (QC, ArC), 134.0 (CH, ArCH), 
133.2 (CH, =CH), 130.7 (CH, =CH-CH-N), 129.4 (CH, ArCH), 128.5 (CH, 2´NsCH), 124.2 (CH, 
2´NsCH), 122.8 (CH, ArCH), 122.7 (CH, ArCH), 119.4 (CH2, =CH2), 62.0 (CH, CH-N), 33.1 
(CH, i-PrCH), 18.5 (CH3, i-PrCH3), 18.4 (CH3, i-PrCH3) ppm.  
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(S,E)-N-(2-methyl-6-(2-nitrophenyl)hepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52f) + 
N,N'-((3S,4E,8E,10S)-2,11-dimethyl-6,7-dimethylenedodeca-4,8-diene-3,10-diyl)bis(4-
nitrobenzenesulfonamide) (43): 
 
Eluent: Et2O/hexane (60:40). Inseparable mixture (86:14) of 52f (47%, 90:10, E/Z) and 43 (> 
99:1, E/Z), respectively, obtained as a yellow gum. HRMS-ESI (m/z) (52f): [M-H]- calcd for 
C20H20N3O6S, 430.1078; found, 430.1079. HRMS-ESI (m/z) (43): [M-H]- calcd for 
C28H33N4O8S2, 617.1745; found, 617.1749. FTIR v!max (cm-1) (52f and 43): 3280 (br., w, NH, 52f 
and 43), 2960 – 2925 (w), 1716 (w), 1526 (s), 1347 (s), 1279 (s), 1162 (s), 853 (m), 735 (vs), 611 
(s). 1H NMR (500 MHz, CDCl3): δ 8.35 (d, J = 8.8 Hz, 4H, NsCH, 43), 8.31 (d, J = 8.9 Hz, 2H, 
NsCH, 52f), 8.06 (d, J = 8.9 Hz, 4H, NsCH, 43), 7.97 (d, J = 8.9 Hz, 2H, NsCH, 52f), 7.85 (dd, 
J = 8.1, 1.1 Hz, 1H, ArCH, 52f), 7.53 (td, J = 7.5, 1.2 Hz, 1H, ArCH, 52f), 7.45 (td, J = 8.0, 1.4 
Hz, 1H, ArCH, 52f), 7.05 (dd, J = 7.6, 1.3 Hz, 1H, ArCH, 52f), 6.15 (d, J = 15.6 Hz, 2H, =CH, 
43), 6.06 (d, J = 15.8 Hz, 1H, =CH, 52f), 5.64 (d, J = 9.1 Hz, 2H, NH, 43), 5.41 (dd, J = 15.5, 9.2 
Hz, 2H, =CH-CH-N, 43), 5.22 (s, 1H, =CH2, 52f), 5.11 (d, J = 2.0 Hz, 2H, =CH2, 43), 5.09 (s, 
1H, =CH2, 52f), 5.02 (d, J = 2.0 Hz, 2H, =CH2, 43), 4.72 (dd, J = 15.8, 7.7 Hz, 1H, =CH-CH-N, 
52f), 4.66 (d, J = 8.5 Hz, 1H, NH, 52f), 3.72 – 3.63 (m, 1H, CH-N, 52f and 2H, CH-N, 43), 1.73 
– 1.61 (m, 1H, i-PrCH, 52f and 2H, i-PrCH, 43), 0.84 (d, J = 6.8 Hz, 3H, i-PrCH3, 52f), 0.80 (d, 
J = 6.8 Hz, 3H, i-PrCH3, 52f), 0.77 (d, J = 6.7 Hz, 12H, i-PrCH3, 43) ppm. 13C NMR (125 MHz, 
CDCl3): δ 149.88 (QC, NsC, 52f), 149.85 (QC, 2´NsC, 43), 148.6 (QC, ArC, 52f), 147.2 (QC, 
2´NsC, 43), 146.9 (QC, NsC, 52f), 145.7 (QC, 2´=C, 43), 143.5 (QC, ArC, 52f), 134.0 (QC, =C, 
52f), 133.4 (CH, =CH, 52f), 133.02 (CH, 2´=CH, 43), 132.97 (CH, ArCH, 52f), 131.6 (CH, 
ArCH, 52f), 131.4 (CH, 2´=CH-CH-N, 43), 128.9 (CH, ArCH and =CH-CH-N, 52f), 128.4 (CH, 
2´NsCH, 52f), 128.0 (CH, 4´NsCH, 43), 124.3 (CH, 4´NsCH, 43), 124.2 (CH, 2´NsCH, 52f), 
124.1 (CH, ArCH, 52f), 119.4 (CH2, =CH2, 52f), 119.0 (CH2, 2´=CH2, 43), 63.3 (CH, 2´CH-N, 
43) 61.7 (CH, CH-N, 52f), 33.1 (CH, i-PrCH, 52f), 32.8 (CH, 2´i-PrCH, 43), 18.9 (CH3, 2´i-
PrCH3, 43), 18.7 (CH3, 2´i-PrCH3, 43), 18.3 (CH3, i-PrCH3, 52f), 18.1 (CH3, i-PrCH3, 52f) ppm.  
 
(S,E)-N-(6-(4-bromophenyl)-2-methylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52g): 
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Eluent: MeOH/CH2Cl2 (1:99). Yellow gum, 27%, > 95:5 (E/Z). [α]D
23 –4.8 (c 1.10, CHCl3). 
HRMS-ESI (m/z): [M-H]- calcd for C20H20N2O4SBr, 463.0333; found, 463.0344. FTIR v!max (cm-
1): 3280 (br., w, NH), 2961 – 2872 (w), 1716 (w), 1606 (w), 1527 (s), 1347 (s), 1309 (s), 1162 
(s), 1091 (m), 1010 (m), 853 (s), 735 (vs), 612 (s), 463 (s). 1H NMR (500 MHz,CDCl3): δ 8.28 
(d, J = 8.9 Hz, 2H, NsCH), 7.98 (d, J = 8.9 Hz, 2H, NsCH), 7.40 (d, J = 8.4 Hz, 2H, ArCH), 6.88 
(d, J = 8.4 Hz, 2H, ArCH), 6.09 (d, J = 15.7 Hz, 1H, =CH), 5.10 (dd, J = 15.7, 8.07 Hz, 1H, =CH-
CH-N), 5.07 (s, 2H, =CH2), 4.67 (d, J = 8.4 Hz, 1H, NH), 3.76 – 3.72 (m, 1H, CH-N), 1.75 (dq, 
J = 13.4, 6.7 Hz, 1H, i-PrCH), 0.90 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.85 (d, J = 6.8 Hz, 3H, i-PrCH3) 
ppm. 13C NMR (125 MHz, CDCl3): δ 149.9 (QC, NsC), 146.9 (QC, NsC), 145.5 (QC, ArC), 
138.1 (QC, C=CH2), 133.9 (CH, =CH), 131.4 (CH, 2´ArCH), 130.0 (CH, CH=CH-N), 129.5 
(CH, 2´ArCH), 128.5 (CH, 2´NsCH), 124.1 (CH, 2´NsCH), 121.8 (QC, ArC), 118.2 (CH2, 
=CH2), 62.2 (CH, CH-N), 33.1 (CH, i-PrCH), 18.6 (CH3, i-PrCH3), 18.5 (CH3, i-PrCH3) ppm.  
 
(S,E)-N-(6-(4-chlorophenyl)-2-methylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52h): 
 
Yellow gum, 66%, > 95:5 (E/Z). [α]D
23 +52.5 (c 0.89, CHCl3). HRMS-ESI (m/z): [M-H]- calcd 
for C20H20N2O4SCl , 419.0838; found, 419.0846. FTIR v!max (cm-1): 3283 (br., w, NH), 2963 – 
2873 (w), 1527 (s), 1347 (s), 1309 (s), 1162 (s), 1091 (s), 853 (m), 735 (vs), 611 (s), 463 (s). 1H 
NMR (400 MHz, CDCl3): δ 8.28 (d, J = 8.9 Hz, 2H, NsCH), 7.98 (d, J = 8.9 Hz, 2H, NsCH), 
7.24 (d, J = 8.5 Hz, 2H, ArCH), 6.94 (d, J = 8.4 Hz, 2H, ArCH), 6.09 (d, J = 15.7 Hz, 1H, =CH), 
5.10 (dd, J = 15.7, 8.1 Hz,  1H, =CH-CH-N), 5.07 (s, 2H, =CH2), 4.81 (d, J = 8.4 Hz, 1H, NH), 
3.76 – 3.71 (m, 1H, CH-N) 1.75 (app. oct, J = 6.7 Hz, 1H, i-PrCH), 0.90 (d, J = 6.8 Hz, 3H, i-
PrCH3 ), 0.85 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 149.9 (QC, 
NsC), 146.9 (QC, NsC), 145.4 (QC, ArC), 137.7 (QC, C=CH2), 133.9 (CH, =CH), 133.6 (QC, 
ArC), 129.9 (CH, =CH-CH-N), 129.2 (CH, 2´ArCH), 128.5 (CH, 2´ArCH), 128.4 (CH, 
2´ArCH), 124.1 (CH, 2´NsCH), 118.1 (CH2, =CH2), 62.2 (CH, CH-N), 33.1 (CH, i-PrCH), 18.54 
(CH3, i-PrCH3) , 18.46 (CH3, i-PrCH3) ppm. 
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Methyl (S,E)-4-(6-methyl-5-((4-nitrophenyl)sulfonamido)hepta-1,3-dien-2-yl)benzoate (52i): 
 
Brown solid, 34%, > 95:5 (E/Z). Mp 73.0 – 75.0 °C. [α]D
22 –4.7 (c 1.34, CHCl3). HRMS-ESI 
(m/z): [M-H]- calcd for C22H23N2O6S, 443.1282; found, 443.1277. FTIR v!max (cm-1): 3275 (br., 
w, NH), 2959 – 2923 (m), 1716 (m), 1527 (s), 1347 (s), 1278 (s), 1162 (s), 1107 (s), 1016 (m), 
853 (s), 736 (vs), 612 (s), 463 (s). 1H NMR (500 MHz, CDCl3): δ 8.28 (d, J = 9.0 Hz, 2H, NsCH), 
7.98 (d, J = 9.0 Hz, 2H, NsCH), 7.94 (d, J = 8.5 Hz, 2H, ArCH), 7.08 (d, J = 8.5 Hz, 2H, ArCH), 
6.12 (d, J = 15.7 Hz, 1H, =CH), 5.14 (s, 2H, =CH2), 5.10 (dd, J = 15.8, 8.0 Hz, 1H, =CH-CH-N), 
4.70 (d, J = 8.4 Hz, 1H, NH), 3.92 (s, 3H, CO2Me), 3.78 – 3.73 (m, 1H, CH-N), 1.75 (app. oct, J 
= 6.7 Hz, 1H, i-PrCH), 0.90 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.85 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 
13C NMR (125 MHz, CDCl3): δ 166.7 (QC, CO2Me), 149.9 (QC, NsC), 147.0 (QC, NsC), 145.7 
(QC, ArC), 143.9 (QC, C=CH2), 133.7 (CH, =CH), 130.2 (CH, CH-CH-N), 129.53 (CH, 
2´ArCH), 129.47 (QC, ArC), 128.4 (CH, 2´NsCH) , 127.9 (CH, 2´ArCH), 124.1 (CH, 2´NsCH), 
118.7 (CH2, =CH2), 62.1 (CH, CH-N), 52.2 (CH3, CO2Me), 33.1 (CH, i-PrCH), 18.54 (CH3, i-
PrCH3), 18.45 (CH3, i-PrCH3) ppm.  
 
(S,E)-N-(2-methyl-6-phenylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52j): 
 
Yellow gum, 61%, > 95:5 (E/Z). [α]D
23 +13.2 (c 1.89, CHCl3). HRMS-ESI (m/z): [M-H]- calcd 
for C20H21N2O4S, 385.1228; found, 385.1227. FTIR v!max (cm-1): 3287 (br., w, NH), 2963 – 2874 
(w), 1606 (w), 1527 (s), 1347 (s), 1310 (m), 1162 (s), 1092 (m), 854 (m), 752 (s), 736 (vs), 615 
(s). 1H NMR (400 MHz, CDCl3): δ 8.26 (d, J = 9.0 Hz, 2H, NsCH), 7.96 (d, J = 9.0 Hz, 2H, 
NsCH), 7.27 – 7.23 (m, 3H, ArCH), 7.06 – 6.85 (m, 2H, ArCH), 6.09 (d, J = 15.7 Hz, 1H, =CH), 
5.10 (dd, J = 16.1, 7.5 Hz, 1H, =CH-CH-N), 5.07 (d, J = 1.2 Hz, 1H, =CH2), 5.05 (s, 1H, =CH2), 
4.75 (d, J = 8.5 Hz, 1H, NH), 3.82 – 3.62 (m, 1H, CH-N), 1.76 (dq, J = 13.4, 6.7 Hz, 1H, i-PrCH), 
0.92 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.87 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, 
CDCl3): δ 149.8 (QC, NsC), 147.0 (QC, NsC), 146.5 (QC, C=CH2), 139.2 (QC, ArC), 134.3 (CH, 
=CH2), 129.6 (CH, =CH-CH-N), 128.4 (CH, 2´NsCH), 128.2 (CH, 2´ArCH), 127.8 (CH, 
2´ArCH), 127.7 (CH, ArCH), 124.1 (CH, 2´NsCH), 117.8 (CH2, =CH2), 62.3 (CH, CH-N), 33.1 
(CH, i-PrCH), 18.6 (CH3, i-PrCH3), 18.5 (CH3, i-PrCH3) ppm.  
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(S,E)-N-(6-(furan-3-yl)-2-methylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide (52k): 
 
Brown gum, 58%, > 95:5 (E/Z). [α]D
23 –11.1 (c 3.03, CHCl3). HRMS-ESI (m/z): [M-H]- calcd for 
C18H19N2O5S, 375.1020; found, 375.1004. FTIR v!max (cm-1): 3286 (br., w, NH), 2964 – 2874 (w), 
1527 (s), 1347 (s), 1309 (m), 1161 (s), 1091 (m), 854 (m), 735 (vs), 614 (s). 1H NMR (500 MHz, 
CDCl3): δ 8.26 (d, J = 9.0 Hz, 2H, NsCH), 7.99 (d, J = 9.0 Hz, 2H, NsCH), 7.33 (app. t, J = 1.7 
Hz, 1H, FurCH), 7.23 – 7.19 (m, 1H, FurCH), 6.23 (dd, J = 1.8, 0.9 Hz, 1H, FurCH), 6.02 (d, J = 
15.7 Hz, 1H, =CH), 5.39 (dd, J = 15.7, 8.1 Hz, 1H, =CH-CH-N), 5.11 (d, J = 1.4 Hz, 1H, =CH2), 
4.94 (s, 1H, =CH2), 4.90 (d, J = 8.4 Hz, 1H, NH), 3.76 – 3.72 (m, 1H, CH-N), 1.78 (dq, J = 13.5, 
6.8 Hz, 1H, i-PrCH), 0.92 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.88 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 
13C NMR (125 MHz, CDCl3): δ 149.8 (QC, NsC), 146.9 (QC, NsC), 143.0 (CH, FurCH), 139.5 
(CH, FurCH), 136.8 (QC, C=CH2), 133.4 (CH, =CH), 128.9 (CH, =CH-CH-N), 128.5 (CH, 
2´NsCH), 124.1 (CH, 2´NsCH), 123.9 (QC, FurC), 116.0 (CH2, =CH2), 109.7 (CH, FurCH), 62.3 
(CH, CH-N), 33.1 (CH, i-PrCH), 18.50 (CH3, i-PrCH3), 18.47 (CH3, i-PrCH3) ppm.  
 
(S,E)-N-(6-(benzo[b]thiophen-3-yl)-2-methylhepta-4,6-dien-3-yl)-4-nitrobenzenesulfonamide 
(52l): 
 
Yellow gum, 76%, > 99:1 (E/Z). [α]D
23 −20.4 (c 3.94, CHCl3). HRMS-ESI (m/z): [M-H]- calcd 
for C22H21N2O4S2, 441.0948; found, 441.0940. FTIR v!max (cm-1): 3283 (br., w, NH), 2964 – 2871 
(w), 1527 (s), 1346 (s), 1310 (m), 1163 (s), 1091 (m), 853 (m), 735 (vs), 616 (s). 1H NMR (500 
MHz, CDCl3): δ 8.24 (d, J = 8.9 Hz, 2H, NsCH), 7.94 (d, J = 8.9 Hz, 2H, NsCH), 7.83 (d, J = 7.5 
Hz, 1H, HetCH), 7.45 (d, J = 7.5 Hz, 1H, HetCH), 7.36 – 7.27 (m, 2H, HetCH), 7.03 (s, 1H, 
HetCH) 6.19 (d, J = 15.6 Hz, 1H, =CH), 5.31 (d, J = 1.3 Hz, 1H, =CH2), 5.22 (d, J = 1.6 Hz, 1H, 
=CH2), 5.01 (dd, J = 15.6, 8.0 Hz, 1H, =CH-CH-N), 4.66 (d, J = 8.6 Hz, 1H, NH), 3.76 – 3.71 
(m, 1H, CH-N), 1.70 (app. oct, J = 6.7 Hz, 1H, i-PrCH), 0.86 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.81 
(d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 149.8 (QC, NsC), 147.0 (QC, 
NsC), 140.6 (QC, C=CH2), 140.0 (QC, HetC), 137.9 (QC, HetC), 135.0 (QC, HetC), 134.0 (CH, 
=CH), 130.0 (CH, =CH-CH-N), 128.4 (CH, 2´NsCH), 124.5 (CH, HetCH) , 124.0 (CH, 
2´HetCH), 124.0 (CH, 2´NsCH), 122.9 (CH, HetCH), 122.7 (CH, HetCH), 120.1 (CH2, =CH2), 
62.0 (CH, CH-N), 33.0 (CH, i-PrCH), 18.5 (CH3, i-PrCH3), 18.3 (CH3, i-PrCH3) ppm.  
 
H
NS
O O
O2N
2k
O
H
NS
O O
O2N
2l
S
 173 
(S,E)-N-(2-methyl-6-methylene-7-phenylocta-4,7-dien-3-yl)-4-nitrobenzenesulfonamide (52m): 
 
Pale yellow solid, 43%, 85:15 (E/Z). Mp 75.0 – 79.0 °C. [α]D
22 +52.3 (c 0.81, CHCl3). HRMS-
ESI (m/z): [M-H]- calcd for C22H23N2O4S, 411.1384; found, 411.1376. FTIR v!max (cm-1): 3323 
(w, C=CH), 3266 (w, NH), 2958 – 2924 (m), 1673 (w), 1526 (s), 1348 (s), 1312 (m), 1168 (vs), 
1090 (s), 1015 (s), 851 (m), 736 (vs), 614 (vs). 1H NMR (400 MHz, CDCl3): δ 8.29 (d, J = 8.9 
Hz, 2H, NsCH), 7.94 (d, J = 9.0 Hz, 2H, NsCH), 7.26 – 7.18 (m, 5H, ArH), 5.87 (d, J = 15.7 Hz, 
1H, =CH), 5.37 (d, J = 1.6 Hz, 1H, Ph-C=CH2), 5.14 (d, J = 2.0 Hz, 1H, =CH2), 5.07 (d, J = 2.0 
Hz, 1H, =CH2), 5.00 (d, J = 1.6 Hz, 1H, Ph-C=CH2), 4.92 (dd, J = 15.7, 8.0 Hz, 1H, =CH-CH-
N), 4.54 (d, J = 8.5 Hz, 1H, NH), 3.64 – 3.58 (m, 1H, CH-N), 1.62 – 1.54 (m, 1H, i-PrCH), 0.69 
(d, J = 6.8 Hz, 3H, i-PrCH3), 0.58 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): 
δ 149.8 (QC, NsC), 147.9 (QC, Ph-C=CH2), 147.0 (QC, NsC), 146.6 (QC, C=CH2), 139.3 (QC, 
ArC), 132.9 (CH, =CH), 130.2 (CH, CH=CH-N), 128.4 (CH, 2´NsCH), 128.3 (CH, 2´ArCH), 
127.8 (CH, ArCH), 126.5 (CH, 2´ArCH), 124.0 (CH, 2´NsCH), 119.2 (CH2, =CH2), 114.8 (CH2, 
=CH2), 61.9 (CH, CH-N), 33.2 (CH, i-PrCH), 18.3 (CH3, i-PrCH3), 17.8 (CH3, i-PrCH3) ppm.  
 
(S,E)-N-(2-methyl-6-methylenedec-4-en-3-yl)-4-nitrobenzenesulfonamide (52n): 
 
67% conversion. Required resubjection to the reaction conditions to consume starting material 
and enable purification. Off-white needles, 30%, > 95:5 (E/Z). Mp 72.0 – 73.0 °C. [α]D
23 +52.5 (c 
0.89, CHCl3). HRMS-ESI (m/z): [M-H]- calcd for C18H25N2O4S, 365.1541; found, 365.1545. 
FTIR v!max (cm-1): 3277 (br., w, NH), 2956 – 2870 (w), 1606 (w), 1528 (s), 1348 (s), 1332 (s), 
1312 (s), 1161 (s), 1091 (s), 980 (s), 851 (s), 736 (vs), 631 (s), 462 (s). 1H NMR (500 MHz, 
CDCl3): δ 8.28 (d, J = 9.0 Hz, 2H, NsCH), 7.98 (d, J = 9.0 Hz, 2H, NsCH), 5.80 (d, J = 15.8 Hz, 
1H, =CH), 5.14 (dd, J = 15.8, 8.1 Hz, 1H, =CH-CH-N), 4.88 (d, J = 1.2 Hz, 1H, =CH2), 4.78 (s, 
1H, =CH2), 4.67 (d, J = 8.5 Hz, 1H, NH), 3.85 – 3.65 (m, 1H, CH-N), 1.92 – 1.73 (m, 2H, n-
BuCH2-C=CH2 and 1H, i-PrCH), 1.26 – 1.18 (m, 4H, n-BuCH2), 0.93 (d, J = 6.8 Hz, 3H, i-PrCH3), 
0.88 (d, J = 6.8 Hz, 3H, i-PrCH3), 0.87 – 0.80 (m, 3H, n-BuCH3) ppm. 13C NMR (125 MHz, 
CDCl3): δ 149.8 (QC, NsC), 147.0 (QC, NsC), 144.7 (QC, C=CH2), 135.3 (CH, =CH), 128.5 (CH, 
2´NsCH), 125.2 (CH, =C-CH-N), 124.1 (CH, 2´NsCH), 116.5 (CH2, =CH2), 62.5 (CH, CH-N), 
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33.2 (CH, i-PrCH), 31.4 (CH2, n-BuCH2-C=CH2), 30.2 (CH2, n-BuCH2), 22.5 (CH2, n-BuCH2), 
18.5 (CH3, 2´i-PrCH3), 13.9 (CH3, n-BuCH3) ppm.  
 
(S,E)-4-nitro-N-(5-(3-nitrophenyl)hexa-3,5-dien-2-yl)benzenesulfonamide (52o): 
 
Off-white gum, 47%, > 95:5 (E/Z). [α]D
22 –0.95 (c 2.19, CHCl3). HRMS-ESI (m/z): [M-H]- calcd 
for C18H16N3O6S, 402.0765; found, 402.0757. FTIR v!max (cm-1): 3238 (m, NH), 2963 (w), 1606 
(w), 1521 (s), 1345 (s), 1308 (s), 1171 (s), 1089 (s), 1065 (s), 985 (s), 850 (s), 804 (s), 734 (vs), 
683 (s), 604 (s), 570 (s). 1H NMR (500 MHz, CDCl3): δ 8.32 (d, J = 8.9 Hz, 2H, NsCH), 8.14 
(ddd, J = 8.1, 2.2, 1.2 Hz, 1H, ArCH), 8.03 (d, J = 8.9 Hz, 2H, NsCH), 7.91 (app. t, J = 1.9 Hz, 
1H, ArCH), 7.48 (app. t, J = 7.9 Hz, 1H, ArCH), 7.42 (app. dt, J = 7.6, 1.4 Hz, 1H, ArCH), 6.32 
(d, J = 15.8 Hz, 1H, =CH), 5.31 (s, 1H, =CH2), 5.23 (dd, J = 15.8, 7.0 Hz, 1H, =CH-CH-N), 5.23 
(s, 1H, =CH2), 4.79 (d, J = 7.6 Hz, 1H, NH), 4.17 – 4.10 (m, 1H, CH-N), 1.25 (d, J = 6.8 Hz, 3H, 
Me) ppm. 13C NMR (125 MHz, CDCl3): δ 150.0 (QC, NsC), 148.1 (QC, ArC), 146.9 (QC, NsC), 
144.4 (QC, =C), 141.0 (QC, ArC), 134.1 (CH, ArCH), 133.2 (CH, CH=CH-N), 131.8 (CH, =CH), 
129.3 (CH, ArCH), 128.4 (CH, 2´NsCH), 124.3 (CH, 2´NsCH), 122.9 (CH, ArCH), 122.7 (CH, 
ArCH), 119.8 (CH2, =CH2), 51.9 (CH, CH-N), 21.9 (CH3, Me) ppm. 
 
(S,E)-N-(2-methyl-7-(3-nitrophenyl)octa-5,7-dien-4-yl)-4-nitrobenzenesulfonamide (52p): 
 
Deep red gum, 58%, > 95:5 (E/Z). [α]D
22 –30.9 (c 2.66, CHCl3). HRMS-ESI (m/z): [M-H]- calcd 
for C21H22N3O6S, 444.1235; found, 444.1227. FTIR v!max (cm-1): 3284 (br., w, NH), 2957 – 2869 
(w), 1525 (vs), 1346 (vs), 1308 (s), 1162 (s), 1091 (m), 971 (m), 854 (m), 747 (m), 615 (s). 1H 
NMR (400 MHz,CDCl3): δ 8.30 (d, J = 8.9 Hz, 2H, NsCH), 8.12 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H, 
ArCH), 8.01 (d, J = 8.9 Hz, 2H, NsCH), 7.84 – 7.83 (m, 1H, ArCH), 7.46 (app. t, J = 7.9 Hz, 1H, 
ArCH), 7.35 (app. dt, J = 7.6, 1.2 Hz, 1H, ArCH), 6.24 (d, J = 15.7 Hz, 1H, =CH), 5.25 (s, 1H, 
=CH2), 5.19 (s, 1H, =CH2), 5.08 (dd, J = 15.7, 7.9 Hz, 1H, =CH-CH-N), 4.75 (d, J = 7.9 Hz, 1H, 
NH), 4.04 (app. p, J = 7.6 Hz, 1H, CH-N), 1.66 – 1.56 (m, 1H, i-BuCH), 1.44 – 1.25 (m, 2H, i-
BuCH2), 0.89 – 0.85 (m, 6H, i-BuCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 149.9 (QC, NsC), 
148.1 (QC, ArC), 147.1 (QC, NsC), 144.5 (QC, =C), 134.0 (CH, ArCH), 132.5 (CH, =CH-CH-
N), 132.4 (CH, i-BuCH), 129.4 (CH, ArCH), 128.5 (2´NsCH), 124.1 (2´NsCH), 122.8 (CH, 
ArCH), 122.6 (CH, ArCH), 119.6 (CH2, =CH2), 54.9 (CH, CH-N), 44.8 (CH2, i-BuCH2), 24.4 
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(CH, i-BuCH), 22.4 (CH3, i-BuCH3), 22.1 (CH3, i-BuCH3) ppm. NMR spectrum showed evidence 
of inseparable impurity, likely due to polymerization, despite efforts to purify under neutral 
conditions.  
 
(S,E)-4-nitro-N-(5-(3-nitrophenyl)-1-phenylhexa-3,5-dien-2-yl)benzenesulfonamide (52q): 
 
Yellow gum, 46%, > 95:5 (E/Z). [α]D
22 –29.8 (c 2.54, CHCl3). HRMS-ESI (m/z): [M-H]- calcd 
for C24H20N3O6S, 478.1078; found, 478.1074. FTIR v!max (cm-1): 3287 (br., w), 3104 – 2865 (w), 
1606 (w), 1524 (vs), 1346 (vs), 1309 (s), 1092 (m), 854 (m), 735 (s), 614 (s). 1H NMR (400 MHz, 
CDCl3): δ 8.18 (d, J = 8.8 Hz, 2H, NsCH), 8.15 (ddd, J = 8.0, 2.7, 1.7 Hz, 1H, ArCH), 7.98 (app. 
t, J = 2.0 Hz, 1H, ArCH), 7.79 (d, J = 8.9 Hz, 2H, NsCH), 7.49 (app. t, J = 7.8 Hz, 1H, ArCH), 
7.43 (app. dt, J = 7.6, 1.5 Hz, 1H, ArCH), 7.22 – 7.20 (m, 3H, BnCH), 7.02 – 7.0 (m, 2H, BnCH), 
6.32 (d, J = 15.7 Hz, 1H, =CH), 5.32 (dd, J = 15.7, 7.0 Hz, 1H, =CH-CH-N), 5.30 (s, 1H, =CH2), 
5.23 (s, 1H, =CH2), 4.72 (d, J = 7.4 Hz, 1H, NH), 4.18 (app. p, J = 6.7 Hz, 1H, CH-N), 2.87 (dd, 
J = 13.8, 5.9 Hz, 1H, BnCH2), 2.75 (dd, J = 13.8, 7.8 Hz, 1H, BnCH2) ppm. 13C NMR (100 MHz, 
CDCl3): δ 149.8 (QC, NsC), 148.1 (QC, ArC), 146.2 (QC, NsC), 144.5 (QC, =CH), 141.0 (QC, 
ArC), 135.6 (QC, BnC), 134.1 (CH, ArCH), 132.6 (CH, =CH), 132.1 (CH, =CH-CH-N), 129.4 
(CH, ArCH), 129.3 (CH, 2´BnCH), 128.8 (CH, 2´BnCH), 128.2 (CH, 2´NsCH), 127.3 (CH, 
BnCH), 124.1 (CH, 2´NsCH), 122.9 (CH, ArCH), 122.7 (CH, ArCH), 119.6 (CH2, =CH2), 57.2 
(CH, CH-N), 42.0 (CH2, BnCH2) ppm. 
 
Isolation of diphenyl (S,E)-(6-methyl-5-((4-nitrophenyl)sulfonamido)hepta-1,3-dien-2-
yl)phosphonate (56a): 
 
A solution of the allenyloxazolidinone (19.4 mg, 55.1 μmol, 1.0 equiv.), 4-methoxyphenylboronic 
acid (MIDA ester) (23.1 mg, 87.8 μmol, 1.5 equiv.), Pd2dba3×CHCl3 (5.8 mg, 5.6 μmol, 10 mol%), 
triphenyl phosphite (3.0 μL, 11.5 μmol, 20 mol%) and K2CO3  (14.5 mg, 104.9 μmol, 1.5 equiv.) 
in toluene (0.06 mM with respect to the allenyloxazolidinone) was stirred under nitrogen for 24 
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hours at room temperature. The reaction was quenched with saturated aqueous NH4Cl and 
extracted with CH2Cl2. The organic layer was dried with MgSO4 and concentrated in vacuo to 
give the crude material. Upon column chromatography (Et2O/hexane, 70:30), the phosphonated 
1,3-diene 56a was isolated as the major product, with no trace of the desired 4-methoxyphenyl 
substituted 1,3-diene. After recrystallisation in CH2Cl2 layered with hexane, the major product 
was obtained as black crystals (1.7 mg, 3.1 μmol, 27% with respect to 20 mol% P(OPh)3 as the 
limiting reagent, > 95:5, E/Z).  
 
Mp 76.1 – 79.6 ° C. [α]D
23 –26.7 (c 0.05, CHCl3). HRMS-ESI (m/z): [M-H]- calcd for 
C26H26N2O7PS, 541.1204; found, 541.1196. FTIR v!max (cm-1): 3151 (w, NH), 1588 (w), 1526 (s), 
1488 (s), 1346 (s), 1161 (vs, P=O), 934 (vs), 735 (s). 1H NMR (500 MHz, CDCl3): δ 8.18 (d, J = 
8.8 Hz, 2H, NsCH), 7.97 (d, J = 8.9 Hz, 2H, NsCH), 7.34 – 7.30 (m, 4H, ArCH), 7.20 – 7.17 (m, 
2H, ArCH), 7.12 – 7.09 (m, 4H, ArCH), 6.23 (d, J = 22.2 Hz, 1H, =CH2), 6.10 – 5.98 (m, 2H, 
=CH and 1H, CH-CH-N), 5.88 (d, J = 48.2 Hz, 1H, =CH2), 4.68 (d, J = 8.4 Hz, 1H, NH), 3.81 – 
3.76 (m, 1H, CH-N), 1.81 (app. sext, J = 6.7 Hz, 1H, i-PrCH), 0.91 (d, J = 6.8 Hz, 3H, i-PrCH3), 
0.87 (d, J = 6.8 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 149.96 (app. t, J = 7.6 
Hz, QC, 2´ArC-O), 149.8 (QC, NsC), 146.8 (QC, NsC), 134.6 (d, J = 177.8 Hz, QC, =C-P), 134.4 
(d, J = 8.7 Hz, CH2, =CH2), 133.0 (d, J = 4.6 Hz, CH, =CH-CH-N), 129.9 (d, J = 2.0 Hz, CH, 
4´m-ArCH), 128.7 (d, J = 12.8 Hz, CH, =CH), 128.3 (CH, 2´NsCH), 125.44 – 125.43 (m, 2´p-
ArCH), 124.2 (CH, 2´NsCH), 120.3 (dd, J = 7.9, 4.5 Hz, CH, 4´o-ArCH), 62.2 (CH, CH-N), 
33.2 (CH, i-PrCH), 18.5 (CH3, i-PrCH3), 18.3 (CH3, i-PrCH3) ppm. 31P NMR (200 MHz, 
(CD3)2CO): δ 9.08 (P(O)Ph2) ppm.  A crystal structure for this compound was obtained. 
 
General procedure for the synthesis of 5-vinyloxazolidinones: 
 
A solution of the allenyloxazolidinone (1.0 equiv.), boronic acid (1.5 equiv.), Pd2dba3×CHCl3 (2.5 
mol%), tris(2,4-di-tert-butylphenyl) phosphite (5 mol%) and AcOH  (1.5 equiv.) in toluene (0.06 
mM with respect to the allenyloxazolidinone) was stirred under a nitrogen atmosphere for 24 
hours at room temperature. The reaction was quenched with water and the organic layer extracted 
with CH2Cl2. This was dried with MgSO4 and concentrated in vacuo to give the crude product, 
which was purified via column chromatography (Et2O/hexane, 40:60, unless otherwise specified). 
 
N O
O
R ●
S
O
O
O2N
R'-B(OH)2 (1.5 equiv.)
L/Pd2dba3⋅CHCl3 (5/2.5 mol%)
AcOH (1.5 equiv.)
toluene, r.t. 24 h
3a-q1a-d
N O
O
R
S
O
O
O2N
R'
 177 
(4S,5S)-4-isopropyl-5-((E)-2-(4-methoxyphenyl)prop-1-en-1-yl)-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59a): 
 
Eluent: Et2O/hexane (50:50). Pale yellow solid, 93%, > 95:5 (E/Z). The enantiopurity was 
determined via chiral HPLC using a Daicel CHIRALPAK IA-U column, hexane/isopropanol 
(90:10), 0.2 mL/min, 40 °C, 254 nm, single peak, tR = 21.35 min, > 99% ee. The racemic analogue, 
prepared from racemic N-Boc-valinal, gave two peaks (tR = 21.45, 24.75 min, 1:1) under the same 
conditions. Mp 140.0 – 142.1 °C. [α]D
23 +4.42 (c 2.96, CHCl3). HRMS-ESI (m/z): [M+Na]+ calcd 
for C22H24N2O7SNa, 483.1196; found, 483.1207. FTIR v!max (cm-1): 2964 – 2837 (w), 1772 (s, 
CO), 1606 (m), 1531 (s), 1511 (s), 1350 (s), 1241 (m), 1168 (vs), 1121 (s), 1090 (s), 1030 (m), 
828 (s), 736 (s), 611 (vs), 564 (s). 1H NMR (500 MHz, CDCl3): δ 8.39 (d, J = 9.0 Hz, 2H, NsCH), 
8.30 (d, J = 9.0 Hz, 2H, NsCH), 7.27 (d, J = 8.9 Hz, 2H, ArCH), 6.87 (d, J = 8.9 Hz, 2H, ArCH), 
5.51 (dq, J = 9.2, 1.3 Hz, 1H, =CH), 5.13 (dd, J = 9.2, 2.5 Hz, 1H, CH-O), 4.18 (dd, J = 3.9, 2.5 
Hz, 1H, CH-N), 3.84 (s, 3H, OMe), 2.50 – 2.40 (m, 1H, i-PrCH), 2.12 (d, J = 1.3 Hz, 3H, CH3), 
1.03 (d, J = 7.0 Hz, 3H, i-PrCH3), 0.89 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, 
CDCl3): δ 160.0 (QC, ArC), 151.8 (QC, CO), 150.9 (QC, NsC), 143.3 (QC, NsC), 142.6 (QC, 
ArC), 133.4 (QC, =C), 129.9 (CH, 2´NsCH), 127.1 (CH, 2´ArCH), 124.3 (CH, 2´NsCH), 120.7 
(CH, =CH), 113.9 (CH, 2´ArCH), 73.1 (CH, CH-O), 68.5 (CH, CH-N), 55.4 (CH3, OMe), 30.5 
(CH, i-PrCH), 17.9 (CH3, i-PrCH3), 16.5 (CH3, CH3), 15.1 (CH3, i-PrCH3) ppm. A crystal 
structure for this compound was obtained (CCDC 1919154). 
 
(4S,5S)-4-isopropyl-5-((E)-2-(3-methoxyphenyl)prop-1-en-1-yl)-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59b): 
 
93% conversion. Starting material was removed via recrystallisation in CHCl3 layered with 
hexane, following column chromatography. Pale yellow crystals, 63%, > 95:5 (E/Z). Mp 116.5 – 
118.0 °C. [α]D
24 +8.4 (c 1.55, CHCl3). HRMS-ASAP (m/z): [M+H]+ calcd for C22H25N2O7S, 
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461.1377; found, 461.1380. FTIR v!max (cm-1): 2961 – 2839 (w), 1771 (s, CO), 1529 (s), 1375 (s), 
1349 (s), 1176 (vs), 1116 (s), 1045 (s), 856 (s), 739 (s), 680 (s), 615 (vs), 563 (vs). 1H NMR (500 
MHz, CDCl3): δ 8.39 (d, J = 9.0 Hz, 2H, NsCH), 8.30 (d, J = 9.0 Hz, 2H, NsCH), 7.28 (app. t, J 
= 8.0 Hz, 1H, ArCH), 6.91 – 6.86 (m, 2H, ArCH), 6.81 – 6.80 (m, 1H, ArCH), 5.55 (dq, J = 9.1, 
1.3 Hz, 1H, =CH), 5.12 (dd, J = 9.2, 2.4 Hz, 1H, CH-O), 4.18 (dd, J = 4.0, 2.4 Hz, 1H, CH-N), 
3.83 (s, 3H, OMe), 2.49 – 2.42 (m, 1H, i-PrCH), 2.13 (d, J = 1.3 Hz, 3H, CH3), 1.04 (d, J = 7.0 
Hz, 3H, i-PrCH3), 0.90 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 159.7 
(QC, ArC), 151.7 (QC, CO), 150.9 (QC, NsC), 143.3 (QC, NsC), 143.1 (QC, ArC), 142.7 (QC, 
=C), 129.8 (CH, 2´NsCH), 129.6 (CH, ArCH), 124.3 (CH, 2´NsCH), 122.5 (CH, =CH), 118.3 
(CH, ArCH), 113.3 (CH, ArCH), 112.3 (CH, ArCH), 72.9 (CH, CH-O), 68.5 (CH, CH-N), 55.3 
(CH3, OMe), 30.5 (CH, i-PrCH), 17.9 (CH3, i-PrCH3), 16.7 (CH3, CH3), 15.1 (CH3, i-PrCH3) ppm.  
 
(4S,5S)-4-isopropyl-5-((E)-2-(2-methoxyphenyl)prop-1-en-1-yl)-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59c): 
 
Yellow solid, 69%, > 95:5 (E/Z). Mp 122.2 – 123.8 °C. [α]D
24 +15.0 (c 2.63, CHCl3). HRMS-
ASAP (m/z): [M+H]+ calcd for C22H25N2O7S, 461.1377; found, 461.1370. FTIR v!max (cm-1): 2971 
– 2835 (w), 1789 (s, CO), 1521 (s), 1346 (s), 1164 (vs), 1133 (s), 1118 (s), 856 (m), 736 (vs), 684 
(s), 636 (s), 569 (vs). 1H NMR (400 MHz, CDCl3): δ 8.35 (d, J = 9.0 Hz, 2H, NsCH), 8.27 (d, J 
= 9.0 Hz, 2H, NsCH), 7.29 (ddd, J = 8.9, 7.8, 2.2 Hz, 1H, ArCH), 7.01 (dd, J = 7.4, 1.8 Hz, 1H, 
ArCH), 6.93 – 6.87 (m, 2H, ArCH), 5.34 (dq, J = 9.2, 1.4 Hz, 1H, =CH), 5.12 (dd, J = 9.2, 2.6 
Hz, 1H, CH-O), 4.19 (dd, J = 3.9, 2.6 Hz, 1H, CH-N), 3.80 (s, 3H, OMe), 2.50 – 2.42 (m, 1H, i-
PrCH), 2.08 (d, J = 1.3 Hz, 3H, CH3), 1.06 (d, J = 7.0 Hz, 3H, i-PrCH3), 0.91 (d, J = 6.9 Hz, 3H, 
i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 156.4 (QC, ArC), 151.8 (QC, CO), 150.9 (QC, 
NsC), 143.7 (QC, ArC), 143.3 (QC, NsC), 132.0 (QC, =C), 129.8 (CH, 2´NsCH), 129.4 (CH, 
ArCH), 128.9 (CH, ArCH), 124.3 (CH, =CH), 124.2 (CH, 2´NsCH), 120.6 (CH, ArCH), 110.9 
(CH, ArCH), 72.8 (CH, CH-O), 68.5 (CH, CH-N), 55.4 (CH3, OMe), 30.5 (CH, i-PrCH), 17.8 
(CH3, i-PrCH3), 17.8 (CH3, CH3), 15.1 (CH3, i-PrCH3) ppm.  
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(4S,5S)-4-isopropyl-5-((E)-2-(3-nitrophenyl)prop-1-en-1-yl)-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59e): 
 
Ligand/catalyst loading increased to 10/5 mol%, respectively. 84% conversion. Required 
resubjection to the reaction conditions to consume starting material and enable purification. 
Eluent: Et2O/hexane (50:50). Pale yellow solid, 62%, > 95:5 (E/Z). Mp 153.1 – 154.0 °C. [α]D
24 
+9.0 (c 2.44, CHCl3). HRMS-ESI (m/z): [M+Na]+ calcd for C21H21N3O8SNa, 498.0942; found, 
498.0952. FTIR v!max (cm-1): 2962 – 2853 (w),1779 (s, CO), 1524 (s), 1347 (vs), 1170 (vs), 1138 
(s), 1120 (s), 1088 (s), 854 (m), 736 (vs), 683 (s), 614 (vs), 561 (s). 1H NMR (500 MHz, CDCl3): 
δ 8.41 (d, J = 9.0 Hz, 2H, NsCH), 8.32 (d, J = 9.0 Hz, 2H, NsCH), 8.21 – 8.19 (m, 2H, ArCH), 
7.69 (ddd, J = 7.8, 1.8, 1.1 Hz, 1H, ArCH), 7.56 (dd, J = 8.8, 7.8 Hz, 1H, ArCH), 5.77 (dq, J = 
9.1, 1.3 Hz, 1H, =CH), 5.14 (dd, J = 9.1, 2.5 Hz, 1H, CH-O), 4.25 (dd, J = 3.8, 2.6 Hz, 1H, CH-
N), 2.52 – 2.46 (m, 1H, i-PrCH), 2.21 (d, J = 1.3 Hz, 3H, CH3), 1.04 (d, J = 7.0 Hz, 3H, i-PrCH3), 
0.87 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 151.5 (QC, CO), 160.0 
(QC, NsC), 148.4 (QC, ArC), 143.2 (QC, NsC), 142.9 (QC, =C), 141.2 (QC, ArC), 131.9 (CH, 
ArCH), 129.9 (CH, 2´NsCH), 129.7 (CH, ArCH), 124.7 (CH, =CH), 124.3 (CH, 2´NsCH), 123.3 
(CH, ArCH), 120.9 (CH, ArCH), 72.3 (CH, CH-O), 68.1 (CH, CH-N), 30.3 (CH, i-PrCH), 17.9 
(CH3, i-PrCH3), 16.7 (CH3, CH3), 14.9 (CH3, i-PrCH3) ppm.  
 
(4S,5S)-5-((E)-2-(4-bromophenyl)prop-1-en-1-yl)-4-isopropyl-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59g): 
 
Off-white solid, 73%, > 95:5 (E/Z). 129.4 – 132.8 °C. [α]D
24 +15.6 (c 0.85, CHCl3). HRMS-ASAP 
(m/z): [M+H]+ calcd for C21H22N2O6SBr, 509.0376; found, 509.0391. FTIR v!max (cm-1): 2963 – 
2853 (w), 1768 (s, CO), 1530 (s), 1365 (s), 1347 (s), 1170 (s), 1118 (s), 1008 (s), 800 (s), 736 (s), 
681 (s), 615 (vs), 555 (s). 1H NMR (500 MHz, CDCl3): δ 8.40 (d, J = 8.9 Hz, 2H, NsCH), 8.31 
(d, J = 8.9 Hz, 2H, NsCH), 7.49 (d, J = 8.5 Hz, 2H, ArCH), 7.21 (d, J = 8.5 Hz, 2H, ArCH), 5.64 
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(app. dd, J = 9.1, 1.2 Hz, 1H, =CH), 5.11 (dd, J = 9.2, 2.5 Hz, 1H, CH-O), 4.21 (dd, J = 3.7, 2.6 
Hz, 1H, CH-N), 2.49 – 2.43 (m, 1H, i-PrCH), 2.13 (d, J = 1.2 Hz, 3H, CH3), 1.02 (d, J = 7.0 Hz, 
3H, i-PrCH3), 0.86 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (100 MHz, CDCl3): δ 151.6 (QC, 
CO), 150.9 (QC, NsC), 143.2 (QC, Ns), 142.3 (QC, ArC), 140.1 (QC, ArC), 131.7 (CH, 
2´ArCH), 129.9 (CH, 2´NsCH), 127.5 (CH, 2´ArCH), 124.3 (CH, 2´NsCH), 122.8 (CH, =C), 
122.7 (QC, ArC), 72.6 (CH, CH-O), 68.2 (CH, CH-N), 30.3 (CH, i-PrCH), 17.8 (CH3, i-PrCH3), 
16.6 (CH3, CH3), 14.9 (CH3, i-PrCH3) ppm.  
 
(4S,5S)-5-((E)-2-(4-chlorophenyl)prop-1-en-1-yl)-4-isopropyl-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59h): 
 
Off-white solid, 81%, > 95:5 (E/Z). Mp 140.7 – 141.4 °C. [α]D
24 +15.4 (c 1.79, CHCl3). HRMS-
ESI (m/z): [M+Na]+ calcd for C21H21N2O6SCl, 487.0701; found, 487.0720. FTIR v!max (cm-1): 
2964 (w), 1779 (s, CO), 1526 (s), 1365 (m), 1348 (s), 1250 (m), 1168 (s), 1085 (s), 1012 (vs), 
797 (s), 614 (s), 550 (s). 1H NMR (500 MHz, CDCl3): δ 8.39 (d, J = 9.0 Hz, 2H, NsCH), 8.31 (d, 
J = 9.0 Hz, 2H, NsCH), 7.33 (d, J = 8.7 Hz, 2H, ArCH), 7.27 (d, J = 8.7 Hz, 2H, ArCH), 5.64 
(dq, J = 9.2, 1.3 Hz, 1H, =CH), 5.12 (dd, J = 9.2, 2.5 Hz, 1H, CH-O), 4.22 (dd, J = 3.8, 2.6 Hz, 
1H, CH-N), 2.49 – 2.43 (m, 1H, i-PrCH), 2.13 (d, J = 1.3 Hz, 3H, CH3), 1.02 (d, J = 7.0 Hz, 3H, 
i-PrCH3), 0.86 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 151.6 (QC, 
CO), 150.9 (QC, NsC), 143.3 (QC, NsC), 142.2 (QC, ArC), 139.6 (QC, =C), 134.5 (QC, ArC), 
129.9 (CH, 2´NsCH), 128.7 (CH, 2´ArCH), 127.2 (CH, 2´ArCH), 124.3 (CH, 2´NsCH), 122.7 
(CH, =CH), 72.6 (CH, CH-O), 68.2 (CH, CH-N), 30.3 (CH, i-PrCH), 17.8 (CH3, i-PrCH3), 16.6 
(CH3, CH3), 14.9 (CH3, i-PrCH3) ppm. 
 
Methyl 4-((E)-1-((4S,5S)-4-isopropyl-3-((4-nitrophenyl)sulfonyl)-2-oxooxazolidin-5-yl)prop-1-
en-2-yl)benzoate (59i): 
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71% conversion. Required resubjection to the reaction conditions to consume starting material 
and enable purification. Eluent: Et2O/hexane (50:50). Brown solid, 89%, > 95:5 (E/Z). Mp 167.0 
– 169.5 °C. [α]D
24 +19.6 (c 2.61, CHCl3). HRMS-ESI (m/z): [M+Na]+ calcd for C23H24N2O8SNa, 
511.1146; found, 511.1167. FTIR v!max (cm-1): 2962 – 2852 (w), 1768 (s, CO), 1713 (s, CO-OMe), 
1527 (s), 1348 (s), 1281 (s), 1173 (s), 1110 (s), 1087 (s), 1004 (s), 853 (s), 734 (s), 682 (s), 614 
(vs), 556 (vs). 1H NMR (500 MHz, CDCl3): δ 8.39 (d, J = 8.9 Hz, 2H, NsCH), 8.31 (d, J = 8.9 
Hz, 2H, NsCH), 8.02 (d, J = 8.5 Hz, 2H, ArCH), 7.40 (d, J = 8.5 Hz, 2H, ArCH), 5.73 (app. dd, 
J = 9.1, 1.3 Hz, 1H, =CH), 5.14 (dd, J = 9.1, 2.5 Hz, 1H, CH-O), 4.24 (dd, J = 3.7, 2.6 Hz, 1H, 
CH-N), 3.93 (s, 3H, CO2Me), 2.50 – 2.44 (m, 1H, i-PrCH), 2.17 (d, J = 1.2 Hz, 3H, CH3), 1.03 
(d, J = 7.0 Hz, 3H, i-PrCH3), 0.86 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): 
δ 166.5 (QC, ArC), 151.6 (QC, CO), 150.9 (QC, NsC), 145.6 (QC, =C), 143.2 (QC, NsC), 142.5 
(QC, ArC), 129.9 (CH, 2´ArCH), 129.8 (CH, 2´ArCH), 125.9 (CH, 2´ArCH), 124.3 (CH, 
2´NsCH), 123.9 (CH, =CH), 72.5 (CH, CH-O), 68.2 (CH, CH-N), 52.2 (CH3, CO2Me), 30.3 (CH, 
i-PrCH), 17.8 (CH3, i-PrCH3), 16.6 (CH3, CH3), 14.9 (CH3, i-PrCH3) ppm.  
 
(4S,5S)-4-isopropyl-3-((4-nitrophenyl)sulfonyl)-5-((E)-2-phenylprop-1-en-1-yl)oxazolidin-2-one 
(59j): 
 
Off-white solid, 75%, > 95:5 (E/Z). Mp 122.9 – 124.5 °C. [α]D
23 +9.6 (c 2.76, CHCl3). HRMS-
ESI (m/z): [M+Na]+ calcd for C21H22N2O6SNa, 453.1091; found, 453.1118. FTIR v!max (cm-1): 
2960 – 2851 (w), 1770 (s, CO), 1529 (s), 1374 (s), 1348 (s), 1167 (vs), 1108 (s), 1002 (m), 854 
(m), 753 (s), 740 (s), 615 (vs), 565 (vs). 1H NMR (500 MHz, CDCl3): δ 8.38 (d, J = 8.9 Hz, 2H, 
NsCH), 8.30 (d, J = 8.9 Hz, 2H, NsCH), 7.39 – 7.30 (m, 5H, ArCH), 5.59 (app. dd, J = 9.2, 1.3 
Hz, 1H, =CH), 5.14 (dd, J = 9.2, 2.5 Hz, 1H, CH-O), 4.20 (dd, J = 3.8, 2.6 Hz, 1H, CH-N), 2.49 
– 2.43 (m, 1H, i-PrCH), 2.15 (d, J = 1.2 Hz, 3H, CH3), 1.04 (d, J = 7.0 Hz, 3H, i-PrCH3), 0.89 (d, 
J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 151.7 (QC, CO), 150.9 (QC, 
NsC), 143.29 (QC, ArC), 143.26 (QC, ArC), 141.2 (QC, =C), 129.9 (CH, 2´NsCH), 128.6 (CH, 
ArCH), 128.5 (CH, 2´ArCH), 125.9 (CH, 2´ArCH), 124.3 (CH, 2´NsCH), 122.3 (CH, =CH), 
72.9 (CH, CH-O), 68.4 (CH, CH-N), 30.4 (CH, i-PrCH), 17.9 (CH3, i-PrCH3), 16.6 (CH3, CH3), 
15.0 (CH3, i-PrCH3) ppm.  
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(4S,5S)-5-((E)-2-(furan-3-yl)prop-1-en-1-yl)-4-isopropyl-3-((4-nitrophenyl)sulfonyl)oxazolidin-
2-one (59k): 
 
76% conversion. Required resubjection to the reaction conditions to consume starting material 
and enable purification. Eluent: Et2O/hexane (50:50). Off-white solid, 81%, > 95:5 (E/Z). Mp 
152.0 – 153.3 °C. [α]D
23 –5.4 (c 2.56, CHCl3). HRMS-ASAP (m/z): [M+H]+ calcd for 
C19H21N2O7S, 421.1064; found, 421.1057. FTIR v!max (cm-1): 2962 – 2876 (w), 1772 (s, CO), 1530 
(s), 1349 (s), 1170 (s), 1120 (s), 1088 (s), 737 (s), 615 (vs), 558 (s). 1H NMR (500 MHz, CDCl3): 
δ 8.41 (d, J = 8.9 Hz, 2H, NsCH), 8.32 (d, J = 9.0 Hz, 2H, NsCH), 7.50 (s, 1H, FurCH), 7.41 
(app. t, J = 1.7 Hz, 1H, FurCH), 6.44 (dd, J = 1.8, 0.8 Hz, 1H, FurCH), 5.60 (app. dd, J = 9.3, 1.1 
Hz, 1H, =CH), 5.13 (dd, J = 9.3, 2.5 Hz, 1H, CH-O), 4.20 (dd, J = 3.7, 2.7 Hz, 1H, CH-N), 2.48 
– 2.42 (m, 1H, i-PrCH), 2.03 (d, J = 1.2 Hz, 3H, CH3), 1.00 (d, J = 7.0 Hz, 3H, i-PrCH3), 0.84 (d, 
J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): δ 151.7 (QC, CO), 150.9 (QC, 
NsC), 144.0 (CH, FurCH), 143.4 (QC, NsC), 140.4 (CH, FurCH), 134.3 (QC, =C), 129.9 (CH, 
2´NsCH), 127.1 (QC, FurC), 124.3 (CH, 2´NsCH), 119.6 (CH, =CH), 107.1 (CH, FurCH), 72.5 
(CH, CH-O), 68.2 (CH, CH-N), 30.3 (CH, i-PrCH), 17.8 (CH3, i-PrCH3), 15.5 (CH3, CH3), 14.9 
(CH3, i-PrCH3) ppm.  
 
(4S,5S)-5-((E)-2-(benzo[b]thiophen-3-yl)prop-1-en-1-yl)-4-isopropyl-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59l): 
 
89% conversion. Required resubjection to the reaction conditions to consume starting material 
and enable purification. Eluent: Et2O/hexane (50:50). Brown solid, 98%, > 95:5 (E/Z). Mp 171.6 
– 174.5 °C. [α]D
24 –21.4 (c 1.91, CHCl3). HRMS-ASAP (m/z): [M+Na]+ calcd for 
C23H22N2O6S2Na, 509.0811; found, 509.0805. FTIR v!max (cm-1): 2963 – 2876 (w), 1776 (s, CO), 
1529 (s), 1363 (s), 1348 (s), 1169 (s), 1118 (s), 1085 (s), 752 (s), 736 (s), 615 (vs), 548 (s). 1H 
NMR (500 MHz, CDCl3): δ 8.31 (d, J = 9.0 Hz, 2H, NsCH), 8.26 (d, J = 9.0 Hz, 2H, NsCH), 
7.90 – 7.87 (m, 1H, HetCH), 7.72 – 7.69 (m, 1H, HetCH), 7.41 – 7.35 (m, 1H, HetCH), 7.31 (s, 
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1H, HetCH), 5.65 (dq, J = 9.3, 1.3 Hz, 1H, =CH), 5.22 (dd, J = 9.3, 2.6 Hz, 1H, CH-O), 4.23 (dd, 
J = 3.9, 2.6 Hz, 1H, CH-N), 2.54 – 2.47 (m, 1H, i-PrCH), 2.23 (d, J = 1.3 Hz, 3H, CH3), 1.09 (d, 
J = 7.0 Hz, 3H, i-PrCH3), 0.94 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): 
δ 151.7 (QC, CO), 150.9 (QC, NsC), 143.1 (QC, NsC), 140.6 (QC, HetC), 138.5 (QC, =C), 138.2 
(QC, HetC), 136.7 (QC, HetC), 129.8 (CH, 2´NsCH), 124.7 (CH, HetCH), 124.49 (CH, =CH or 
HetCH), 124.47 (CH, =CH or HetCH), 124.3 (CH, 2´NsCH), 124.0 (CH, HetCH), 123.2 (CH, 
HetCH), 122.6 (CH, HetCH), 72.6 (CH, CH-O), 68.5 (CH, CH-N), 30.5 (CH, i-PrCH), 18.3 (CH3, 
CH3), 17.9 (CH3, i-PrCH3), 15.1 (CH3, i-PrCH3) ppm.  
 
(4S,5S)-4-isopropyl-5-((1E,3E)-2-methyl-4-phenylbuta-1,3-dien-1-yl)-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59m): 
 
53% conversion. Required resubjection to the reaction conditions to consume starting material 
and enable purification. Eluent: Et2O/hexane (30:70). Yellow gum, 65%, > 99:1 (E/Z). [α]D
22 +24.1 
(c 1.86, CHCl3). HRMS-ESI (m/z): [M+Na]+ calcd for C23H24N2O6S, 479.1247; found, 479.1248. 
FTIR v!max (cm-1): 3106 (w), 3026 (w), 2964 – 2876 (w), 1773 (s, CO), 1531 (s), 1348 (s), 1170 
(vs), 1118 (s), 1088 (s), 960 (s), 855 (m), 747 (s), 682 (s), 613 (vs), 554 (s). 1H NMR (500 
MHz,CDCl3): δ 8.43 (d, J = 8.8 Hz, 2H, NsCH), 8.33 (d, J = 8.8 Hz, 2H, NsCH), 7.42 (d, J = 7.5 
Hz, 2H, ArCH), 7.36 (app. t, J = 7.5 Hz, 2H, ArCH), 7.28 (t, J = 7.3 Hz, 1H, ArCH), 6.71 (app. 
dd, J =  19.7, 16.2 Hz, 2H, styryl =CH), 5.52 (d, J = 9.4 Hz, 1H, =CH), 5.15 (dd, J = 9.4, 2.3 Hz, 
1H, CH-O), 4.21 – 4.20 (m, 1H, CH-N), 2.49 – 2.43 (m, 1H, i-PrCH), 1.98 (s, 3H, CH3), 1.00 (d, 
J = 7.0 Hz, 3H, i-PrCH3), 0.84 (d, J = 6.9 Hz, 3H, i-PrCH3) ppm. 13C NMR (125 MHz, CDCl3): 
δ 151.6 (QC, CO), 150.9 (QC, NsC), 143.2 (QC, NsC), 140.6 (QC, =C) 136.3 (QC, ArC), 131.5 
(CH, styryl =CH), 130.9 (CH, styryl =CH), 129.9 (CH, 2´NsCH), 128.8 (CH, 2´ArCH), 128.3 
(CH, ArCH), 126.7 (CH, 2´ArCH), 125.5 (CH, =CH), 124.3 (CH, 2´NsCH), 72.5 (CH, CH-O), 
68.2 (CH, CH-N), 30.2 (CH, i-PrCH), 17.8 (CH3, i-PrCH3), 14.8 (CH3, i-PrCH3), 13.1 (CH3, CH3) 
ppm.  
 
 
 
 
N O
O
S
O
O
O2N
3m
 184 
(4S,5S)-5-((E)-2-(4-methoxyphenyl)prop-1-en-1-yl)-4-methyl-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59o): 
 
Purified via recrystallization in CH2Cl2 layered with hexane. Yellow solid, 80%, 92:8 (E/Z). Mp 
153.4 – 153.8 °C. [α]D
23 +0.4 (c 1.54, CHCl3). HRMS-ESI (m/z): [M+H]+ calcd for C20H21N2O6S, 
433.1064; found, 433.1088. FTIR v!max (cm-1): 3108 9w), 1777 (s, CO), 1605 (m), 1529 (s), 1369 
(s), 1346 (s), 1170 (s), 1141 (s), 741 (s), 616 (vs), 560 (s). 1H NMR (400 MHz, CDCl3): δ 8.40 
(d, J = 9.0 Hz, 2H, NsCH), 8.28 (d, J = 9.1 Hz, 2H, NsCH), 7.29 (d, J = 8.9 Hz, 2H, ArCH), 6.87 
(d, J = 8.9 Hz, 2H, ArCH), 5.56 (dq, J = 8.9, 1.3 Hz, 1H, =CH), 4.95 (dd, J = 8.9, 5.2 Hz, 1H, 
CH-O), 4.28 – 4.22 (m, 1H, CH-N), 3.82 (s, 3H, OMe), 2.12 (d, J = 1.3 Hz, 3H, =C-CH3), 1.64 
(d, J = 6.2 Hz, 3H, Me) ppm. 13C NMR (125 MHz, CDCl3): δ 160.0 (QC, ArC), 151.6 (QC, CO), 
151.0 (QC, NsC), 144.3 (QC, =C), 143.2 (QC, NsC), 133.3 (QC, ArC), 129.9 (CH, 2´NsCH), 
127.1 (CH, 2´ArCH), 124.3 (CH, 2´NsCH), 119.2 (CH, =CH), 113.8 (CH, 2´ArCH), 79.2 (CH, 
CH-O), 60.2 (CH, CH-N), 55.3 (CH3, OMe), 19.9 (CH3, Me), 16.7 (CH3, =C-CH3) ppm.  
 
(4S,5S)-4-isobutyl-5-((E)-2-(4-methoxyphenyl)prop-1-en-1-yl)-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59p): 
 
Starting material 4.9:1 dr. 90% conversion. Required resubjection to the reaction conditions to 
consume starting material and enable purification. Yellow gum, 81%, 8.0:1 dr (crude), 15.3:1 dr 
(after purification), > 95:5 (E/Z). HRMS-ASAP (m/z): [M+H]+ calcd for C23H27N2O7S, 475.1533; 
found, 475.1531. FTIR v!max (cm-1): 2959 – 2839 (w), 1773 (s, CO), 1606 (m), 1531 (s), 1513 (s), 
1368 (s), 1247 (s), 1172 (vs), 1139 (s), 1120 (s), 1089 (s), 744 (s), 682 (s), 612 (vs), 561 (s). 1H 
NMR (400 MHz, CDCl3): δ 8.38 (d, J = 9.0 Hz, 2H, NsCH, major and minor), 8.32 (d, J = 9.0 
Hz, 2H, NsCH, minor), 8.28 (d, J = 9.0 Hz, 2H, NsCH, major and minor), 7.32 (d, J = 8.8 Hz, 
2H, ArCH, minor), 7.26 (d, J = 8.9 Hz, 2H, ArCH, major), 6.87 (d, J = 8.8 Hz, 2H, ArCH, major 
and minor), 5.70 (app. dd, J = 9.1, 1.2 Hz, 1H, =CH, minor), 5.51 (app. dd, J = 9.2, 1.2 Hz, 1H, 
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=CH, major), 5.07 (dd, J = 9.2, 2.9 Hz, 1H, CH-O, major and minor), 4.61 – 4.56 (m, 1H, CH-N, 
minor), 4.26 (app. dt, J = 10.2, 3.2 Hz, 1H, CH-N, major), 3.83 (s, 3H, OMe, major), 3.82 (s, 3H, 
OMe, minor), 2.11 (d, J = 1.2 Hz, 3H, CH3, major and minor), 2.05 – 1.90 (m, 1H, i-BuCH2, 
major), 1.83 – 1.60 (m, 2H, i-BuCH2, major and minor and i-BuCH, major and minor), 1.03 (d, 
J = 6.4 Hz, 3H, i-BuCH3, major), 1.00 (d, J = 6.4 Hz, 3H, i-BuCH3, major and minor), 0.91 (d, J 
= 6.2 Hz, 3H, i-BuCH3, minor) ppm. 13C NMR (100 MHz, CDCl3): δ 160.0 (QC, ArC, major and 
minor), 151.5 (QC, CO, major and minor), 150.9 (QC, NsC, major and minor), 143.59 (QC, =C, 
major), 143.56 (QC, =C, minor), 143.5 (QC, NsC, major and minor), 133.4 (QC, ArC, major and 
minor), 130.0 (CH, 2´NsCH, minor) 129.8 (CH, 2´NsCH, major), 127.06 (CH, 2´ArCH, major), 
126.98 (CH, 2´ArCH, minor), 124.30 (CH, 2´NsCH, major), 124.27 (CH, 2´NsCH, minor), 
120.0 (CH, =CH, major), 116.1 (CH, =CH, minor), 113.91 (CH, 2´ArCH, minor),  113.85 (CH, 
2´ArCH, major), 77.5 (CH, CH-O, major), 77.2 (CH, CH-O, minor), 62.6 (CH, CH-N), 59.96 
(CH, CH-N, minor), 55.33 (CH3, OMe, major), 55.31 (CH3, OMe, minor), 43.1 (CH2, i-BuCH2, 
major), 39.0 (CH2, i-BuCH2, minor), 25.0 (CH, i-BuCH, minor),  24.6 (CH, i-BuCH, major), 23.6 
(CH3, i-BuCH3, major), 23.0 (CH3, i-BuCH3, minor), 21.8 (CH3, i-BuCH3, minor), 21.4 (CH3, i-
BuCH3, minor), 16.8 (CH3, CH3, minor), 16.6 (CH3, CH3, major) ppm.  
 
(4S,5S)-4-benzyl-5-((E)-2-(4-methoxyphenyl)prop-1-en-1-yl)-3-((4-
nitrophenyl)sulfonyl)oxazolidin-2-one (59q): 
 
Starting material 2.2:1 dr. Pale yellow crystals, 79%, 3.2:1 dr (crude), 9.7:1 (after purification), 
> 95:5 (E/Z). Mp 68.9 – 72.4 °C. HRMS-ASAP (m/z): [M+H]+ calcd for C26H25N2O7SNa, 
509.1377; found, 509.1369. FTIR v!max (cm-1): 2959 – 2839 (w), 1774 (s, CO), 1606 (m), 1531 
(s), 1513 (s), 1369 (m), 1348 (s), 1246 (m), 1173 (s), 1124 (s), 736 (s), 612 (s), 559 (s). 1H NMR 
(500 MHz,CDCl3): δ 8.39 (d, J = 9.0 Hz, 2H, NsCH, major), 8.33 (d, J = 9.0 Hz, 2H, NsCH, 
minor), 8.31 (d, J = 9.0 Hz, 2H, NsCH, major), 8.16 (d, J = 9.0 Hz, 2H, NsCH, minor), 7.38 – 
7.19 (m, 5H, BnCH, major and minor), 7.14 (d, J = 8.9 Hz, 2H, ArCH, minor), 7.11 (d, J = 8.9 
Hz, 2H, ArCH, major), 6.84 (d, J = 8.9 Hz, 2H, ArCH, minor), 6.81 (d, J = 8.9 Hz, 2H, ArCH, 
major), 5.71 (app. dd, J = 8.4, 1.3 Hz, 1H, =CH, minor), 5.54 (dd, J = 8.5, 7.0 Hz, 1H, CH-O, 
minor), 5.35 (dq, J = 9.1, 1.3 Hz, 1H, =CH, major), 5.09 (dd, J = 9.1, 2.7 Hz, 1H, CH-O, major), 
5.03 (ddd, J = 8.9, 7.0, 5.1 Hz, 1H, CH-N, minor), 4.45 (ddd, J = 10.3, 4.0, 2.6 Hz, 1H, CH-N, 
major), 3.82 (s, 3H, OMe, minor), 3.80 (s, 3H, OMe, major), 3.57 (dd, J = 13.4, 4.0 Hz, 1H, 
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BnCH2, major), 3.18 (dd, J = 14.5, 5.1 Hz, 1H, BnCH2, minor), 3.05 (dd, J = 14.5, 8.8 Hz, 1H, 
BnCH2, minor), 2.92 (dd, J = 13.4, 10.3 Hz, 1H, BnCH2, major), 1.74 (d, J = 1.1 Hz, 3H, CH3, 
minor), 1.54 (d, J = 1.2 Hz, 3H, CH3, major) ppm. 13C NMR (100 MHz, CDCl3): δ 159.8 (QC, 
ArC, major), 159.7 (QC, ArC, minor), 151.6 (QC, CO, minor), 151.4 (QC, CO, major), 151.0 
(QC, NsC, major), 150.8 (QC, NsC, minor), 143.6 (QC, NsC, minor), 143.5 (QC, =C, minor), 
143.3 (QC, NsC, major), 142.6 (QC, =C, major), 135.5 (QC, BnC, minor), 134.2 (QC, BnC, 
major), 133.43 (QC, ArC, minor), 133.37 (QC, ArC, major), 129.9 (CH, 2´NsCH, major and 
minor), 129.5 (CH, 2´BnCH, major and minor), 129.3 (CH, 2´BnCH, minor), 129.2 (CH, 
2´BnCH, major), 128.7 (CH, BnCH, minor), 127.8 (CH, BnCH, major), 127.1 (CH, 2´ArCH, 
minor), 126.9 (CH, 2´ArCH, major), 124.4 (CH, 2´NsCH, major), 124.2 (CH, 2´NsCH, minor), 
119.8 (CH, =CH, major), 116.4 (CH, =CH, minor), 113.72 (CH, 2´ArCH, major), 113.67 (CH, 
2´ArCH, minor), 77.7 (CH, CH-O, minor), 76.2 (CH, CH-O, major), 64.6 (CH, CH-N, major), 
62.1 (CH, CH-N, minor), 55.3 (CH3, OMe, major and minor), 39.9 (CH2, BnCH2, major), 36.1 
(CH2, BnCH2, minor), 16.5 (CH3, CH3, minor), 15.7 (CH3, CH3, major) ppm. 
 
2.4.5 Intramolecular Diels–Alder Reactions of Chiral 1,3-Dienes to Give Isoindoline Scaffolds 
 
Synthesis of ethyl 2-(bromomethyl)acrylate (66):76 
 
A solution of the acrylate (0.47 mL, 3.86 mmol, 1.0 equiv.) in Et2O (8 mL) was cooled to –10 °C 
and PBr3 (0.15 mL, 1.60 mmol, 0.4 equiv.) added slowly with stirring. The reaction was allowed 
to warm to room temperature and stirred for 4 hours. The reaction was quenched at –10 °C by the 
addition of water and the organic layer extracted with hexane and dried with Na2SO4. After 
filtration and concentration in vacuo, the crude material was subjected to column chromatography 
(EtOAc/hexane, 5:95) to give the pure product as a colourless oil (0.629 g, 3.26 mmol, 85%).   
 
1H NMR (400 MHz, CDCl3): δ 6.31 (d, J = 0.9 Hz, 1H, =CH2), 5.93 (d, J = 0.9 Hz, 1H, =CH2), 
4.25 (q, J = 7.1 Hz, 2H, EtCH2), 4.16 (d, J = 0.9 Hz, 2H, CH2-Br), 1.31 (t, J = 7.1 Hz, 3H, EtCH3) 
ppm. 13C NMR (100 MHz, CDCl3): δ 164.8 (QC, CO), 137.5 (QC, =C), 128.8 (CH2, =CH2), 61.2 
(CH2, EtCH2), 29.3 (CH2, CH2-Br), 14.1 (CH3, EtCH3) ppm. The data match that previously 
reported.76  
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Synthesis of ethyl (1S,3aR,7aR)-6-(benzo[b]thiophen-3-yl)-1-isopropyl-2-((4-
nitrophenyl)sulfonyl)-1,2,3,4,5,7a-hexahydro-3aH-isoindole-3a-carboxylate (64a): 
 
To a solution of the 1,3-diene (20.6 mg, 46.6 μmol, 1.0 equiv.) and Et3N (8.0 μL, 57.4 μmol, 1.2 
equiv.)  in CH2Cl2 (0.7 mL) was added ethyl 2-(bromomethyl)acrylate (7.0 μL, 50.7 μmol, 1.1 
equiv.) and the reaction mixture stirred at room temperature with monitoring via TLC analysis 
(Et2O/hexane, 50:50). After 2 hours, additional portions of Et3N (1.8 equiv.) and ethyl 2-
(bromomethyl)acrylate (1.4 equiv.) were added and the reaction stirred for a further 1 hour. In 
order to push the reaction to completion, an additional portion of ethyl 2-(bromomethyl)acrylate 
(0.5 equiv.) was added after a further 1 hour and again after a further 2 hours, before leaving the 
reaction to stir for a further 12 hours at room temperature. After this time, the reaction was 
quenched with a saturated aqueous solution of NH4Cl and the organic layer extracted with 
CH2Cl2, dried with MgSO4, filtered and the filtrate concentrated in vacuo to give the crude 
product. This was subjected to column chromatography (Et2O/hexane, 30:70) to give the pure 
product as yellow crystals (12.3 mg, 22.2 μmol, 48% (60% conversion), 9:1 dr (after purification). 
The absolute stereochemistry was inferred to be as per the related product 64b (see Section 2.4.6). 
 
Mp 65.9 – 68.3 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C28H30N2O6S2Na, 577.1437; found, 
577.1469. FTIR v!max (cm-1): 2962 – 2873 (w), 1723 (s, CO-OEt), 1528 (s), 1347 (s), 1089 (s), 
1009 (s), 855 (m), 734 (vs), 617 (s). 1H NMR (400 MHz, CDCl3): δ 8.36 – 8.27 (m, 2H, NsCH, 
major and minor), 8.04 – 7.99 (m, 2H, NsCH, major and minor), 7.87 – 7.80 (m, 1H, HetCH, 
major and minor), 7.75 – 7.70 (m, 1H, HetCH, major and minor), 7.40 – 7.29 (m, 2H, HetCH, 
major and minor), 7.15 (s, 1H, HetCH, major), 7.13 (s, 1H, HetCH, minor), 6.15 (d, J = 2.1 Hz, 
1H, =CH, minor), 5.89 (d, J = 4.8 Hz, 1H, =CH, major), 4.36 (dd, J = 10.7, 4.1 Hz, 1H, CH-N, 
minor), 4.21 (qd, J = 7.1, 1.4 Hz, 2H, EtCH2, major), 4.06 (d, J = 11.3 Hz, 1H, CH2-N, minor), 
3.83 (dd, J = 6.8, 5.1 Hz, 1H, CH-N, major), 3.75 (d, J = 11.0 Hz, 1H, CH2-N, major), 3.63 (d, J 
= 11.0 Hz, 1H, CH2-N, major), 3.31 (app. t, J = 5.8 Hz, 1H, CH-CH-N, major), 3.21 (d, J = 11.3 
Hz, 1H, CH2-N, minor), 2.80 (dd, J = 11.3, 2.1 Hz, 1H, CH-CH-N, minor), 2.70 – 2.61 (m, 2H, 
CH2 and i-PrCH, minor), 2.56 – 2.47 (m, 2H, CH2, minor), 2.43 – 2.31 (m, 2H, CH2, major), 2.30 
– 2.22 (m, 1H, i-PrCH, major), 2.08 (app. dt, J = 13.4, 4.4 Hz, 1H, CH2, major), 1.86 – 1.79 (m, 
1H, CH2, minor), 1.67 – 1.59 (m, 1H, CH2, major), 1.28 (t, J = 7.1 Hz, 3H, EtCH3, major), 1.16 
(t, J = 7.1 Hz, 3H, EtCH3, minor), 1.03 (d, J = 7.2 Hz, 3H, i-PrCH3, minor), 0.99 (d, J = 7.0 Hz, 
3H, i-PrCH3, major), 0.86 – 0.82 (m, 3H, i-PrCH3, major and minor) ppm. 13C NMR (100 MHz, 
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CDCl3): δ 173.2 (QC, CO, major), 172.3 (QC, CO, minor), 149.8 (QC, NsC, major and minor), 
146.3 (QC, NsC, minor), 146.0 (QC, NsC, major), 140.5 (QC, HetC, major), 140.4 (QC, HetC, 
minor), 138.0 (QC, HetC, major), 137.8 (QC, HetC, minor), 137.6 (QC, HetC, minor), 137.4 (QC, 
HetC, major), 132.8 (QC, CH=C, major), 132.5 (QC, CH=C, minor), 128.12 (CH, 2´NsCH, 
minor), 128.07 (CH, 2´NsCH, major), 126.4 (CH, =CH, minor), 125.8 (CH, =CH, major), 124.4 
(CH, HetCH, major), 124.30 (CH, 2´NsCH, major and minor), 124.27 (CH, HetCH, minor), 
124.2 (CH, HetCH, major), 124.1 (CH, HetCH, minor), 123.0 (CH, HetCH, major), 122.9 (CH, 
HetCH, minor), 122.83 (CH, HetCH, minor), 122.77 (CH, HetCH, major), 122.4 (CH, HetCH, 
major), 122.1 (CH, HetCH, minor), 71.9 (CH, CH-N, major), 67.5 (CH, CH-N, minor), 61.5 
(CH2, EtCH2, major), 61.0 (CH2, EtCH2, minor), 57.2 (CH2, CH2-N, minor), 56.3 (CH2, CH2-N, 
major), 52.9 (QC, C-CO2Et, minor), 50.0 (QC, C-CO2Et, major), 45.8 (CH, CH-CH-N, minor), 
41.6 (CH, CH-CH-N, major), 31.9 (CH, i-PrCH, major), 30.9 (CH, i-PrCH, minor), 29.6 (CH2, 
CH2, minor), 28.1 (CH2, CH2, minor), 26.9 (CH2, CH2, major), 26.2 (CH2, CH2, major), 19.3 
(CH3, i-PrCH3, major and minor), 16.1 (CH3, i-PrCH3, major), 15.1 (CH3, i-PrCH3, minor), 14.2 
(CH3, EtCH3, major), 14.0 (CH3, EtCH3, minor) ppm. 
 
Synthesis of ethyl (1S,3aR,7aR)-1-isopropyl-6-(4-methoxyphenyl)-2-((4-nitrophenyl)sulfonyl)-
1,2,3,4,5,7a-hexahydro-3aH-isoindole-3a-carboxylate (64b): 
 
To a solution of the 1,3-diene (50.3 mg, 0.12 mmol, 1.0 equiv.) and Et3N (36.0 μL, 0.26 mmol, 
2.1 equiv.) in CH2Cl2 (2 mL) was added ethyl 2-(bromomethyl)acrylate (34 μL, 0.25 mmol, 2.0 
equiv.) and the reaction mixture heated at reflux with stirring. After 24 hours, the reaction mixture 
was concentrated in vacuo and subjected to column chromatography (EtOAc/hexane, 20:80) to 
give the pure product as deep yellow crystals (35.3 mg, 66.8 μmol, 55%, 10:3:1 dr). The absolute 
stereochemistry was determined via 1D NOE experiments performed using a derivative of 64b 
and justified by computational methods (see Section 2.4.6). 
 
Mp 60.6 – 63.1 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C27H32N2O7SNa, 551.1822; found, 
551.1813. FTIR v!max (cm-1): 2957 – 2855 (s), 1725 (s, CO-OEt), 1607 (m), 1530 (s), 1512 (s), 
1463 (s), 1347 (s), 1160 (vs), 1089 (s), 1033 (s), 735 (s), 685 (s), 615 (vs). 1H NMR (500 MHz, 
CDCl3): δ 8.32 (d, J = 9.0 Hz, 2H, NsCH, minor), 8.14 (d, J = 8.8 Hz, 2H, NsCH, major), 7.97 
(d, J = 8.8 Hz, 2H, NsCH, minor), 7.93 (d, J = 8.7 Hz, 2H, NsCH, major), 7.19 (d, J = 8.8 Hz, 
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2H, ArCH, minor), 6.81 – 6.78 (m, 2H, ArCH, major and minor), 6.06 – 6.05 (m, 1H, =CH, 
minor), 5.66 – 5.65 (m, 1H, =CH, major), 4.27 – 4.14 (m, 1H, CH-N, minor and 2H, EtCH2, 
major), 3.98 (d, J = 11.4 Hz, 1H, CH2-N, minor), 3.84 (d, J = 11.0 Hz, 1H, CH2-N, major), 3.81 
(s, 3H, OMe, major), 3.78 (s, 3H, OMe, minor), 3.70 – 3.65 (m, 2H, EtCH2, minor), 3.56 (dd, J 
= 6.8, 4.8 Hz, 1H, CH-N, major), 3.48 (d, J = 11.0 Hz, 1H, CH2-N, major), 3.30 – 3.28 (m, 1H, 
CH-CH-N, major), 3.20 (d, J = 11.3 Hz, 1H, CH2-N, minor), 2.73 (dd, J = 10.8, 2.7 Hz, 1H, CH-
CH-N, minor), 2.69 – 2.64 (m, 1H, i-PrCH, minor), 2.63 – 2.57 (m, 1H, CH2, minor), 2.50 (dd, J 
= 12.4, 7.9 Hz, 1H, CH2, minor), 2.46 – 2.32 (m, 1H, CH2, minor), 2.27 – 2.21 (m, 1H, CH2, 
major), 2.13 (dt, J = 17.4, 5.8 Hz, 1H, CH2, major), 2.05 – 1.96 (m, 2H, i-PrCH and CH2, major), 
1.81 – 1.71 (m, CH2, minor), 1.63 – 1.58 (m, 1H, CH2, major), 1.29 – 1.25 (m, 3H, EtCH3, major 
and minor), 1.08 (d, J = 7.6 Hz, 3H, i-PrCH3, minor), 1.06 (d, J = 7.0 Hz, 3H, i-PrCH3, major), 
0.88 (d, J = 6.7 Hz, 3H, i-PrCH3, major), 0.86 (d, J = 6.8 Hz, 3H, i-PrCH3, minor) ppm. 13C NMR 
(100 MHz, CDCl3): δ 174.0 (QC, CO, major), 172.3 (QC, CO, minor), 159.1 (QC, ArC, major), 
159.0 (QC, ArC, minor), 149.5 (QC, NsC, major and minor), 146.0 (QC, NsC, minor), 145.0 
(QC, NsC, major), 136.4 (QC, =C, minor), 135.4 (QC, =C, major), 133.4 (QC, ArC, minor), 132.5 
(QC, ArC, major), 128.23 (CH, 2´NsCH, major), 128.18 (CH, 2´NsCH, minor), 126.32 (CH, 
2´ArCH, minor), 125.8 (CH, 2´ArCH, major), 124.1 (CH, 2´NsCH, major and minor), 122.1 
(CH, =CH, minor), 122.0 (CH, =CH, major), 113.71 (CH, 2´ArCH, major), 113.66 (CH, 
2´ArCH, minor), 72.7 (CH, CH-N, major), 67.6 (CH, CH-N, minor), 61.5 (CH2, EtCH2, major), 
60.7 (CH2, EtCH2, minor), 57.28 (CH3, OMe, minor), 55.3 (CH3, OMe, major), 54.4 (CH2, CH2-
N, major), 52.7 (CH2, CH2-N, minor), 50.9 (QC, C-CO2Et, minor), 50.2 (QC, C-CO2Et, major), 
46.1 (CH, CH-CH-N, minor), 42.8 (CH, CH-CH-N, major), 32.2 (CH, i-PrCH, major), 30.9 (CH, 
i-PrCH, minor), 29.6 (CH2, CH2, minor), 27.1 (CH2, CH2, major), 26.1 (CH2, CH2, minor), 23.5 
(CH2, CH2, major), 19.8 (CH3, i-PrCH3, major), 19.3 (CH3, i-PrCH3, minor), 17.4 (CH3, i-PrCH3, 
major), 15.2 (CH3, i-PrCH3, minor), 14.1 (CH3, EtCH3, major), 14.0 (CH3, EtCH3, minor) ppm. 
NMR data for the second minor isomer has not been reported.  
 
Synthesis of ethyl (1S)-1-isopropyl-6-(4-methoxyphenyl)-2-((4-nitrophenyl)sulfonyl)-3-oxo-
2,3,3a,4,5,7a-hexahydro-1H-isoindole-4-carboxylate (64c): 
 
The required acyl chloride was freshly prepared by heating a solution of monoethyl fumarate in 
SOCl2 (0.4 M) at reflux for 2 hours and removing excess SOCl2 in vacuo. This was dissolved in 
THF (1.0 mL) to give a 0.63 M stock solution. To a stirring solution of the 1,3-diene (50.6 mg, 
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0.12 mmol, 1.0 equiv.) in THF (1.0 mL) was added pyridine (21.0 μL, 0.26 mmol, 2.1 equiv.) 
under a nitrogen atmosphere. Under a nitrogen atmosphere, the acyl chloride (0.24 mmol of a 
0.63 M solution in THF, 2.0 equiv.) was added dropwise to the reaction mixture at room 
temperature, before heating at reflux. After 4 hours, further portions of the acyl chloride (1.0 
equiv.) and pyridine (1.0 equiv.) were added in order to drive the reaction to completion, and the 
reaction heated at reflux for an additional 20 hours before quenching with an aqueous 1.0 M 
solution of HCl. The organic layer was extracted with CH2Cl2 and dried with MgSO4, filtered and 
concentrated in vacuo to give the crude material. Upon column chromatography (EtOAc/hexane, 
40:60) the product was isolated as pale yellow crystals (41.2 mg, 75.9 μmol, 63%, 13:2:1 dr). The 
absolute stereochemistry of the major isomer has not been determined. 
 
Mp 111 – 114 °C. HRMS-ESI (m/z): [M+Na]+ calcd for C27H30N2O8SNa, 565.1615; found, 
565.1624. FTIR v!max (cm-1): 1730 (s, CO-OEt), 1607 (w), 1531 (w), 1512 (w), 1349 (m), 1172 
(s), 1086 (s), 736 (s), 604 (s). 1H NMR (500 MHz, CDCl3): δ 8.37 – 8.35 (m, J = 8.9 Hz, 2H, 
NsCH, major and minor), 8.27 – 8.23 (m, 2H, NsCH, major and minor), 7.27 – 7.23 (m, 2H, 
ArCH, major and minor), 6.88 – 6.85 (m, 2H, ArCH, major and minor), 6.12 (d, J = 1.9 Hz, 1H, 
=CH, major), 5.95 – 5.94 (m, 1H, =CH, minor), 4.42 – 4.38 (m, 1H, CH-N, major and minor), 
4.28 – 4.16 (m, 2H, EtCH2, major), 4.15 – 4.05 (m, 2H, EtCH2, minor), 3.85 (s, 3H, OMe, minor), 
3.81 (s, 3H, OMe, major), 3.43 – 4.39 (m, 1H, CH-CH-N), 3.07 – 2.94 (m, 1H, CH-CO, major 
and minor and 1H, CH-CH-N, major), 2.88 – 2.80 (m, 1H, CH(CO2Et), minor and 1H, CH2, major 
and minor), 2.76 – 2.54 (m, 1H, CH(CO2Et), major and 1H, CH2, major and minor), 2.51 (app. 
sext, J = 7.0 Hz, 1H, i-PrCH, minor), 2.29 (app. sext,, J = 6.8 Hz, 1H, i-PrCH, major), 1.29 (t, J 
= 7.1 Hz, 3H, EtCH3, major), 1.25 (t, J = 7.1 Hz, 3H, EtCH3, minor), 1.20 – 1.18 (m, 3H, i-Pr, 
major and minor), 1.13 (d, J = 6.8 Hz, 3H, EtCH3 major), 1.05 (d, J = 6.8 Hz, 3H, EtCH3, minor) 
ppm. 13C NMR (125 MHz, CDCl3): δ 173.2 (QC, CO-N, major), 173.1 (QC, CO-N, minor), 
172.19 (QC, CO2Et, major), 172.17 (QC, CO2Et, minor), 159.5 (QC, C-OMe, major), 159.4 (QC, 
C-OMe, minor), 150.70 (QC, NsC, minor), 150.68 (QC, NsC, major), 144.30 (QC, NsC, major), 
144.0 (QC, NsC, minor), 138.7 (QC, =C, major), 137.9 (QC, =C, minor), 133.1 (QC, ArC, minor), 
132.3 (QC, ArC, major), 129.9 (CH, 2´NsCH, minor), 129.8 (CH, 2´NsCH, major), 126.5 (CH, 
2´ArCH, major), 126.4 (CH, 2´ArCH, minor), 124.1 (CH, 2´NsCH, major), 124.0 (CH, 
2´NsCH, minor), 118.9 (CH, =CH, major), 118.0 (CH, =CH, minor), 113.9 (CH, 2´ArCH, 
major), 113.8 (CH, 2´ArCH, minor), 68.7 (CH, CH-N, minor), 68.1 (CH, CH-N, major), 61.3 
(CH2, EtCH2, minor), 61.2 (CH2, EtCH2, major), 55.3 (CH3, OMe, major and minor), 46.9 (CH, 
CH-CO, minor), 44.30 (CH, CH-CH-N, major or CH-CO, major), 44.25 (CH, CH-CH-N, major 
or CH-CO, major), 42.8 (CH-CO, minor), 40.6 (CH, CH(CO2Et), major), 40.3 (CH, CH(CO2Et), 
minor), 36.8 (CH, CH-CH-N, minor), 32.7 (CH2, CH2, major), 29.8 (CH, i-PrCH, minor), 29.1 
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(CH, i-PrCH, major), 28.5 (CH2, CH2, minor), 21.0 (CH3, i-PrCH3, major), 20.8 (CH3, i-PrCH3, 
major), 19.7 (CH3, i-PrCH3, minor), 19.20 (CH3, i-PrCH3, minor), 15.3 (CH3, EtCH3, minor), 15.1 
(CH3, EtCH3, minor) ppm. NMR data for the second minor isomer has not been reported. 
 
2.4.6 Determination of the Absolute Stereochemistry of the Isoindoline Scaffolds 64a and 64b 
 
Reduction and O-tosylation of product 64b to give ((1S,3aR,7aR)-1-isopropyl-6-(4-
methoxyphenyl)-2-((4-nitrophenyl)sulfonyl)-1,2,3,4,5,7a-hexahydro-3aH-isoindol-3a-yl)methyl 
4-methylbenzenesulfonate (64g): 
 
To an oven-dried Schlenk flask was added LiAlH4 (6.1 mg, 0.16 mmol, 2.0 equiv.) and the vessel 
cooled to 0 °C, before THF (1 mL) was added. To the resulting solution was added the isoindoline 
(35.3 mg, 66.8 μmol, 1.0 equiv.) in THF (0.5 mL) dropwise with stirring and the reaction mixture 
warmed to room temperature. The reaction was stirred overnight, after which a Fieser workup 
was employed in which the reaction was diluted with Et2O and quenched by adding water (1 
drop), followed by an aqueous 15 % wt. solution of NaOH (1 drop), then further water (3 drops). 
MgSO4 was then added and the mixture was stirred before filtration of the resulting white solid. 
The filtrate was washed with brine and extracted with EtOAc before being dried with MgSO4 and 
concentrated in vacuo. The crude residue was subjected to column chromatography 
(EtOAc/hexane, 60:40, pre-washed with Et3N) to give the alcohol as a yellow solid (Rf = 0.49, 
EtOAc/hexane, 60:40, 10.6 mg, 21.8 μmol, 33%). The alcohol was dissolved in CH2Cl2 (0.75 
mL) in an oven-dried reaction vial and a molar excess of pyridine (0.1 mL) added. Tosyl chloride 
(14.2 mg, 74.5 μmol, 3.0 equiv.) was then added and the mixture stirred at room temperature. 
After 18 hours, the reaction was diluted with CH2Cl2 and washed with an aqueous 10% wt. 
solution of CuSO4, then water. The organic layer was dried with MgSO4, filtered and the filtrate 
concentrated in vacuo to give the crude product, which was subjected to column chromatography 
(CH2Cl2/hexane, 40:60), through which the major isomer of the O-tosyl derivative was able to be 
isolated as a yellow solid (3.1 mg, 4.8 μmol, 22%).  
 
HRMS-ESI (m/z): [M+Na]+ calcd for C32H36N2O8S2Na, 663.1805; found, 663.1808. 1H NMR 
(400 MHz, (CD3)2CO): δ 8.41 (d, J = 8.9 Hz, 2H, NsCH), 8.15 (d, J = 8.8 Hz, 2H, NsCH), 7.81 
(d, J = 8.4 Hz, 2H, TsCH), 7.47 (d, J = 8.0 Hz, 2H, TsCH), 7.18 (d, J = 8.9 Hz, 2H, ArCH), 6.85 
(d, J = 8.9 Hz, 2H, ArCH), 5.73 (d, J = 5.1 Hz, 1H, =CH), 3.99 (app. q, J = 10.1 Hz, 2H, CH2-
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OTs), 3.78 (s, 3H, OMe), 3.63 (dd, J = 7.4, 4.8 Hz, 1H, CH-N), 3.56 (d, J = 11.3 Hz, 1H, CH2-
N), 3.35 (d, J = 11.3 Hz, 1H, CH2-N), 2.54 (app. t, J = 6.3 Hz, 1H, CH-CHN), 2.44 (s, 3H, TsCH3), 
2.39 – 2.31 (m, 1H, i-PrCH), 2.13 – 1.92 (m, 2H, CH2), 1.62 – 1.57 (m, 1H, CH2), 1.20 – 1.12 (m, 
1H, CH2), 0.99 (d, J = 7.1 Hz, 3H, i-PrCH3), 0.82 (d, J = 6.7 Hz, 3H, i-PrCH3) ppm. This product 
was regarded as a derivative for the purpose of stereochemical determination and therefore full 
characterisation was not carried out.  
 
Computational modelling of O-tosyl derivative 64g in order to justify 1D NOE data: 
 
As discussed in Section 2.2.6, the 1D NOE data obtained for the O-tosyl derivative 64g was used 
to determine the absolute stereochemistry of the parent compound 64b (see appendix for 1D NOE 
spectra). From this, as well as the similarity in NMR data, it was inferred that the related system 
64a also exhibited the same absolute stereochemistry. The 1D NOE data was justified by 
comparing key interproton distances of possible stereoisomers of 64g (64g and 64g'), which were 
modelled computationally by Assoc Prof Haibo Yu (UOW). An exhaustive conformational 
sampling of compounds 64g and 64g' was carried out with the MMFF force field and RDkit as 
implemented in the script genConf.py.77a, b Both the energy-based (< 5.0 kcal/mol) and root-mean-
square deviation (RMSD)-based (> 0.5 Å) cleaning were applied. Only those conformers, which 
differed from the others by more than 0.5 Å RMSD and had an energy less than 5 kcal/mol higher 
than the lowest energy, were kept for further analyses. In total, 52 and 108 conformers were 
generated for 64g and 64g', respectively. Those conformers were subjected to geometry 
optimization in the gas phase with B3LYP/6-31G(d) and the optimized structures were verified 
with vibrational frequency calculations.77c The lowest energy conformers were used to extract key 
interproton distances. 
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   Chiral HPLC Data (see Section 2.2.3):  
 
Conditions: Daicel CHIRALPAK IA-U column, hexane/isopropanol (95:5), 0.2 mL/min, 40 °C. 
 
 
 
 
 
 
 
 
 
 
 
 
41a 
(racemic) 
41a 
(chiral) 
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Conditions: Daicel CHIRALPAK IA-U column, hexane/isopropanol (97:3), 0.2 mL/min, 40 °C. 
 
 
 
 
 
 
 
 
 
 
 
 
52a 
(chiral) 
52a 
(racemic) 
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Conditions: Daicel CHIRALPAK IA-U column, hexane/isopropanol (90:10), 0.2 mL/min, 40 °C. 
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(chiral) 
59a 
(racemic) 
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1D NOE Spectra (see Section 2.2.6): 
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Ha irradiated: 
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NMR Spectra for Novel Compounds (Part I): 
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NMR Spectra for Novel Compounds (Part II): 
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